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wt%  Drug loading in weight percent  
2TP 2-thiopyridine  
4HPR N-(4-hydroxyphenyl) retinamide 
α-mPNL α-methylprednisolone 
aa Amino acid 
AA Amino acid analysis 
Ab   Antibody  
Ach Acetylcholine 
AchE Acetylcholinesterase 
ACN  Acetonitrile  
AD Alzheimer’s disease 
AGM Aminoglutethimide 
AH Aminohexanoic acid 
AH-GDM 17-(6-aminohexylamino)-17-
demethoxygeldanamycin 
AHPP 4-amino-6-hydroxypyrazolo[3,4-D]pyrimidine 
AIC  Akaike information criterion  
AIDS Acquired immunodeficiency syndrome 
Ala Alanine 
ALL Acute lymphoblastic leukemia 
ALN Alendronate 
AM Activated monomer 
AMD Age-related macular degeneration 
AML Acute myeloid leukemia   
AMM  Activated monomer mechanism 
Amph B Amphotericin B 
ANG-2 Angiopep2 
Anh   Anhydrous 
APAF-1 Apoptotic protease activating factor 1  
ApoE4 Apolipoprotein E4 
APP Amyloid precursor protein 
Ar Argon 
ATP Adenosine triphosphate 
ATRP   Atom transfer free-radical polymerization  
AUC  Area under the curve  
[Abbreviations] 
24 
AuNP Gold nanoparticles 
Aβ Amyloid beta protein 
BACE1 β-site APP-cleaving enzyme 1 
BBB Blood brain barrier 
BDMC Bisdemethoxycurcumin 
Boc  Tertiary-butyloxycarbonyl  
BSA  Bovine serum albumin  
BTA 1,3,5-benzene tricarboxamide 
BTB Blood tumor barrier 
Bz Benzyloxycarbonyl 
CAA Cerebral amyloid angiopathy 
CAC Critical aggregation concentration 
CD Circular dichroism 
CDCl3 Deuterated chloroform 
CDP Linear cyclodextrin polymer (β-ciclodextrin + 
PEG) 
CED Convention-enhanced delivery  
CKD Chronic kidney disease 
CMC   Critical micelle concentration  
CNS Central nervous system 
COSY Correlated spectroscopy 
cPEP Cyclic peptide  
CPT Camptothecin 
Cu Copper  
CuAAC  Copper catalyzed azide/alkyne cycloaddition 
Cy Cyane 
Cys Cysteine 
Đ Dispersity 
Da Dalton 
DACH 1,2-diaminocyclohexane 
D-Asp8 D-aspartic acid octapeptide 
DB Di-block  
DCC N,N´-dicyclohexylcarbodiimide  
ddH2O Deionized water  
DDS Drug delivery system 
DEPT Distortionless enhancement by polarization 
transfer 
DIC N,N’-Diisopropyl carbodiimide 
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DIEA N,N-Diisopropylethylamine 
DLS Dynamic light scattering  
DMC Demethoxycurcumin 
DMEM Dulbecco’s modified eagle’s medium  
DMF N,N'-Dimethyl formamide 
DMSO Dimethyl sulphoxide 
DMSP Dimethylsphingosine 
DMTMM 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-
methylmorpholinium 
DNA Deoxyribonucleic acid 
DO3A-tBuNH2   tert-butyl 2,2´,2´´-(10-(2-(2aminoethylamino)-
2oxoethyl)- 1,4,7-tetrazacyclododecane-1,4,7-
triyl)triacetate  
DOOA 3,6-dioxa-octanediamine  
DOSY Diffusion-ordered spectroscopy 
DOTA 1,4,7-tetrazacyclododecane-1,4,7-10-tetraacetic 
acid  
DOX Doxorubicin 
DP Degree of polymerization 
DPPC Dipalmitoylphostotidyl choline 
DSPC-Chol 1,2-distearoyl-sn-glycerol-3-phosphatidylcholine 
and choline 
DTPA Diethylene triamine pentaacetic acid 
DTT  1,4-dithiothreitol  
DXM Dexamethasone 
EA Elemental analysis 
EC European commission 
EDC 1-Ethyl-3-(-3-dimethylaminopropyl) 
carbodiimide hydrochloride 
EDTA Ethylenediaminetetraacetic acid 
EG Ethylene glycol 
E° Standard reduction potential 
EPI Epirubicin 
EPO Epoetin beta 
EPR Enhanced permeability and retention 
eq Equivalents 
ESF European science foundation 
FA Fluocinolone acetonide  
Fab Fragment antigen-binding 
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FACS Fluorescence activated cell sorting 
FBS  Fetal bovine serum  
FCS Fluorescence correlation spectroscopy 
FDA Food and drug administration 
FDC Free drug content 
Fmoc Fluorenylmethyloxycarbonyl 
FRET Fluorescence resonance energy transfer 
FT-IR Fourier transform infrared spectroscopy  
G6S Glucosamine-6-sulphate 
Ga Gallium  
GA Geldanamycin 
GAU Glutamic acid units 
Gd  Gadolinium  
Gem Gemcitabine 
GFLG Gly-Phe-Leu-Gly 
gHSQC Gradient heteronuclear single quantum 
coherence 
GI Gastro-intestinal 
GLFG Gly-Leu-Phe-Gly 
Glu Glutamic acid 
Gly Glycine  
GPC Gel permeation chromatography 
GSH Glutathione 
HBr Hydrobromide Acid 
HCl Hydrochloride Acid 
HCN-1A Human cortical neuronal cells 
HDL High Density Lipoprotein 
HES Hydroxyethylstarch 
HEWL Hen egg white lysozyme  
HFIP 1,1,1,3,3,3-Hexafluoroisopropanol  
HGH Human growth hormone 
HMDS Hexamethyldisilazane 
HOBt Hydroxybenzotriazole 
HPLC High pressure liquid chromatography  
HPMA N-(2’-Hydroxypropyl)methacrylamide 
hrGCSF Human recombinant granulocyte-colony 
stimulating factor 
HSP Heat-shock protein 
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HTV High vacuum techniques 
HUVEC  Human umbilical vein endothelial cells  
i.m. Intramuscular 
i.p.  Intraperitoneal  
i.v.  Intravenous  
ID  Injected dose  
IHC  Immunohistochemistry  
IL Interleukin 
In Indium 
K8-ELP Lysine-8-elastin-like polypeptides 
KDa Kilodalton 
keV Kiloelectron Volts 
LAM Lamivudine 
LE Linking efficiency 
Leu Leucine 
LiBr Lithium bromide 
LiOH Lithium hydroxide 
LRP1 Low-density lipoprotein receptor-related protein-
1  
LSGS Low serum growth supplement  
M/I Monomer/initiator ratio 
m/z    Mass/charge 
mAb Monoclonal antibody 
MAEHP 2-methyl-N-(2’-aminoethyl)-3-hydroxyl-4-
pyridinone  
MAO Monoamine oxidase 
MBq Mega Becquerel 
MCDK Madin-Darbycanine kidney 
MCR Mean Count Rate 
MDR Multidrug resistance 
ME Macrophage elastase 
MFI Maximum fluorescence intensity 
MMP Matrix metalloproteinase 
Mn Number average molecular weight 
MOPS  3-(N-morpholino)propanesulfonic acid  
MRI Magnetic resonance imaging 
MS Mass spectrometry  
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-
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carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium 
MTT 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide  
MTX Methotrexate 
MW Weight average molecular weight 
MWCO Molecular weight cut off 
N2 Nitrogen 
NA Normal amine 
NAC N-acetyl cysteine   
NAM Normal amine mechanism 
NaOH Sodium hydroxide 
nBu N-Butylamine 
NCA N-Carboxyanhydride 
NCE New chemical entity 
NCS Neocarzinostatin 
NGS  Normal goat serum 
NHS N-Hydroxysuccinimide  
NIR Near InfraRed  
NIRF Near InfraRed Fluorophores 
NMDA N-methyl-D-aspartate  
NMR Nuclear Magnetic Resonance 
NO Nitric oxide 
NOESY Nuclear Overhauser Effect Spectroscopy 
NOTA 1,4,7-triazacyclododecane-1,4,7-tetraacetic acid  
NPs Nanoparticles 
Npt Neopentylamine 
NSAIDs Non-steroidal antiinflamatory drugs 
NSCLC Non-small cell lung cancer 
OBzl(Glu) NCA y-Benzyl L-glutamate N-carboxyanhydride 
OG Oregon green cadaverine 
PAH Poly(aspartate hydrazide) 
PAMAM Poly(amido amine) 
PB Phosphate buffer  
PBLG  poly(γ-benzyl L-glutamate)   
PBS Phosphate buffer saline  
PC-DCP Phosphocholine-dihexadecyl phosphate 
cholesterol 
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PCS Photon correlation spectroscopy  
PD Pharmacodynamics 
PDC Polymer drug conjugate   
PDEPT Polymer-directed enzyme prodrug therapy  
PDGF Platelet derived growth factor 
PDI Polydispersity index 
pDMAEMA Poly(dimethylamino)ethylmethacrylate 
PEA β-phenylethylamine  
PEG Poly(ethylene glycol) 
PEI Poly(ethylene imine) 
PELT Polymer-enzyme liposome therapy  
PEO Poly(ethylene oxide) 
PET Positron emission tomography  
PGA Poly(L-glutamic acid) 
PGE1 Prostaglandine E1 
P-gp Glycoprotein P 
PGSE Pulse-field gradient Spin-Echo 
Phe Phenylalanine 
PHF Polyacetal 
PI-3 kinase Phophoinositide 3-kinase 
PK   Pharmacokinetics  
PLA Polylactic acid 
PLL Poly(L-Lysine) 
PLMA Poly(L-maleic acid) 
PMDTA N,N,N',N',N"-pentamethyldiethylenetriamine  
PMMA Poly(methyl methacrylate) 
PMS Phenazine methyl sulfate 
PNS Peripheral nervous system  
POM Polyoxometalate  
PPC  Polymer protein conjugate  
PPO Poly(propylene oxide) 
PS Presenilin 
PSS Polymer standards service 
Pt Platinate 
PT  Polymer therapeutics 
PTX Paclitaxel 
RAFT   Reversible addition-fragmentation chain-transfer  
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RES Reticulum endothelium system  
rf  radio-frequency 
RFU Relative fluorescence units 
Rg Gyration radius 
Rh Hydrodynamic radius 
RI Refractive index 
RMT Receptor mediated transport 
RNP  Radionuclide purity  
ROCK Rho associated kinase 
ROP Ring opening polymerization 
ROS Reactive oxygen species. 
r.t. Room temperature 
RY  Radiochemical yield  
s.c Subcutaneous 
SALP Sulphate alkyl laminaripentaoside 
SANS  Small angle neutron scattering  
SAS Small angle scattering 
SAXS Small angle X-ray scattering  
SD Standard deviation 
SD Sprague-Dawley 
SEC Size exclusion chromatography 
SEM Standard error of the mean 
siRNA Silence interfering ribonucleic acid 
SMA Copoly(styrene-maleic acid) 
SMANCS Styrene maleic acid neocarzinostatin 
SPECT    Single photon emission computed tomography  
SPPS Solid phase peptide synthesis 
TAMRA Tetramethyl-6-carboxyrhodamine 
TDC Total drug content 
TEM Transmission electron microscopy 
Tf  Transferrin  
TFA Trifluoroacetic acid 
TfR  Transferrin receptor  
THF Tetrahydrofuran 
ThT Thioflavin T 
TIPS Triisopropylsilane 
TJ   Tight junction 
[Abbreviations] 
31 
TNF Tumor necrosis factor 
tr  Retention time  
Tyr Tyrosine 
UV  Ultraviolet  
v/v Volume/volume  
VEGF Vascular endothelial growth factor 
WHO World health organization 
WSTs Water soluble tetrazolium salts 
XTT 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide 
Y Yield 
ZVD Zidovudine 
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Alzheimer’s disease (AD) is a neurodegenerative multiple 
process of the central nervous system, which currently represents the 
most common cost of Dementia. The already high incidence of AD is 
predicted to dramatically increase over the years. In fact, the experts 
claim that it will become a global epidemy by 2050. Consequently, 
direct and indirect costs related to AD are doomed to dramatically 
increase. For instance, only in America, AD related burden will 
overcome the trillion of dollars by 2050. Moreover, available 
medication (Exelon®, Namenda®, Aricept®, and Razadyne®) produce 
moderate symptomatic benefits, but do not stop disease progression. 
Hence, AD, among other neurodegenerative disorders, can be 
considered an unmet medical need. Neuroprotective drugs, such as, 
curcuminoids are been taking in high consideration in order to approach 
these fatal disorders from a protective and preventive point of view. In 
this context, nanomedicine and, in particular, Polymer Therapeutics 
(PT) emerge as a powerful alternative to overcome the limitations of 
low MW drugs including their poor pharmacokinetic and 
pharmacodynamic profiles and low solubility in aqueous solvents, 
required for i.v. administration. 
Nonetheless, in the PT field, there is a need to develop new and 
innovative polymer carriers to be used as drug delivery systems and/or 
imaging agents owing to the fact that there is no universal polymeric 
system that can be used in the treatment of all diseases. Apart from 
biodegradability, the development of novel well-defined architectures with 
higher MW (in order to increase passive targeting provided by the EPR 
effect), predictable structure and conformation (defined three-dimensional 
architecture in solution), higher homogeneity, greater drug loading 
capacity and increased multivalency is considered crucial. To this respect, 
polypeptides are envisaged to achieve a major impact on a number of 
different relevant areas including nanomedicine. Thus, new PT based 
on amino acids are excellent candidates for drug delivery, as they do 
not suffer from the previously mentioned limitations. Concretely, 
polyglutamates constitute a versatile platform, which has been 
effectively used as building blocks in polymer drug conjugates and 
polymeric micelles for various medical applications ranging from 
cancer to regenerative medicine. Moreover, it is expected its FDA 
approval after approval of PGA-paclitaxel conjugate, OpaxioTM for the 
treatment of various cancers alone or in combination (OpaxioTM has 
been recently designated as orphan drug in combination with 
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radiotherapy and temozolomide for the treatment of glioblastoma 
multiforme). Nevertheless, control on polymer chain length, 
polydispersities and stereochemistry has been the major challenge in 
the development of synthetic polypeptides over the past years. Besides, 
the use of branched polymers is emerging in order to accomplish the 
previously described requisites. They exhibit special properties when 
compared to their linear counterparts. As a result of their different 
architectures, solution conformation, size and shape as well as greater 
multivalency, different therapeutic outputs could be gained. Due to their 
compact and globular shapes they are postulated to perform better 
regarding to overcome biological barriers, a pre-requisite in 
neurodegenerative disorders treatment as well as diagnostics due to the 
presence of the blood-brain barrier (BBB), one of the most challenging to 
surpass. 
Therefore, the main aim of this thesis was the design of new 
versatile polyglutamate-based nanotherapeutics to be used in the treatment 
and/or diagnosis of devastating neurodegenerative pathologies such as AD. 
In order to accomplish our final goal, firstly, we report the 
development of synthetic pathways to a plethora of functional 
polyglutamates with well-defined structure, adjustable MW and low 
polydispersities (Đ <1.2) applying the ring opening polymerization 
(ROP) of N-Carboxyanhydrides (NCA) with novel initiators. 
Furthermore, this methodology has been extended to reach a number of 
architectures based on PGA, including stars, grafts, and hybrid di-block 
copolymers. In addition, a versatile post-polymerization modification 
method to introduce a variety of functionalities such as alkyne, azides, 
reactive disulfides, maleimide groups or protected amines has been 
developed, yielding a set of orthogonal reactive attachment sites 
suitable for further bioconjugations. The physico-chemical properties of 
the obtained polyglutamates have been exhaustively investigated, in 
terms of size and solution conformation by the use of a battery of 
complex techniques including DLS, DOSY-NMR, CD, TEM and 
SANS. Furthermore, we have developed a novel PGA-based family of 
systems that, according to their physico-chemical characterization, 
underwent a self-assembly process where it did exist a 
structure/conformation-concentration dependency encountering at low 
concentrations “unimers” of 5-10 nm size, whereas bigger structures of 
around 100-180 nm were formed at high concentrations. After covalent 
entrapment of these bigger structures by means of click chemistry, the 
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concentration dependence conformation was clearly eliminated. We 
have taken profit from that special behavior to develop a strategy in 
order to reach complex polypeptide based architectures through 
bottom-up approaches 
Preliminary in vitro evaluation in selected cell models in terms 
of biodegradability, biocompatibility and cellular uptake is presented. 
Furthermore, after an adequate labeling with fluorescence/NIR probes 
or/and cation complexing moieties towards the use of MRI and/or PET 
techniques, the in vivo fate (pharmacokinetics and biodistribution) of 
our polyglutamates is also described. Preliminary results suggest that 
they were non-toxic entities, validating them as possible carriers for 
drug delivery.  
The covalently entrapped unique architectures have been 
ultimately used to reach carriers for BBB crossing by means of surface 
modifications with targeting units and imaging agents. Their BBB 
crossing properties have being explored in vivo, reaching at least 1.2 % 
of injected dose in the brain. Thus, those results make them optimal 
candidates to be used in AD treatment.  
Among all the biological hallmarks of AD, we are centering our 
efforts in the amyloid pathway, by the use of curcuminoids and with a 
neuroprotective approach by combining them with the presence of 
propagyl moieties within the construct. Their biological output 
regarding cellular uptake, cell viability, drug release profile and 
biodistribution has been investigated. Moreover, proof of concept of 
their activity was achieved in vitro, in organotypic hippocampal 
cultures and is currently being validated in vivo. 
Finally, the potential of PGA-based conjugates as tissue-
specific smart imaging probes is also explored within the frame of the 
European consortium LIVIMODE. The combination of NIRF enzyme 
specific smart probes together with the tissue specificity provided by 
PGA as carrier is explored to be applied in the early detection of 
disease-related events in vitro as well as in vivo. This strategy could be 
used for the development of theranostics towards the early detection 
and treatment of neurodegenerative disorders. 
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 The present thesis dissertation is focused on the design of a new 
versatile polymeric platform to be used as carrier in the development of 
nanomedicines for the treatment and/or diagnosis of devastating 
pathologies, such as, neurodegenerative diseases.  
Such general objective, encompasses several specific pyramidal 
tasks that can be summarize as follows: 
(i) Design and tune up of a new controlled and versatile 
polymerization methodology to yield novel biocompatible, 
biodegradable and multifunctional polymeric carriers based on 
polyglutamic acid (PGA). An exhaustive carrier characterization will be 
followed by means of a battery of physico-chemical techniques. Once 
established, the mentioned polymerization strategy will allow the 
achievement of the subsequent aims. 
(ii) Design, synthesis, exhaustive physico-chemical 
characterization and biological evaluation in adequate cell and in vivo 
models of complex PGA-based macromolecular architectures obtained 
by controlled NCA polymerization techniques and bottom up 
approaches. This includes to fully understand the solution conformation 
behavior inherent to such architectures with the purpose of unravel the 
structure underlying self-assembly processes 
(iii) Development of a new and versatile methodology for 
post-polymerization modification of polyglutamates allowing 
orthogonal reactive attachment sides, highly suitable for further 
conjugations of bioactive agents of different nature as well as imaging 
probes.  
(iv) Synthesis, characterization and biological evaluation of 
PGA-based constructs capable to promote active transport through the 
Blood-Brain Barrier (BBB) by covalent binding of known targeting 
vectors.  
(v) Synthesis, characterization as well as validation of the 
novel platforms for its use in targeted drug delivery and/or molecular 
diagnostic tools in neurodegenerative disorders, such as Alzheimer’s 
disease. The main goal for this part of the project is to obtain PGA-
based combination conjugates using the neuroprotective-neurorescuer 
propargyl moieties and the neuro-antiinflamatory curcuminoids.  
(vi) Development of an in vivo imaging polymeric platform 
based on protease-activated smart ligands that allow non-invasive 
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quantitative assessment of target expression in diseased tissue 
(diagnosis) and monitoring of disease progression (staging). These tools 
are of high relevance for disease detection, monitoring of disease 
progression, developing animal models of human disease and 
evaluating novel therapies. This part of the thesis is included on the 
frame of a European FP7 Project (LIVIMODE Light-based Functional 
In Vivo Monitoring of Disease-related Enzymes).  
With all that objectives in mind, the long-term goal is the 
establishment of different versatile building blocks: BBB crossing 
nanovectors, polymer-based combination conjugates for AD treatment, 
and smart imaging macromolecular probes. The combination of such 
building blocks would ideally be the base of a novel theranostic 
platform for effective monitoring and treatment of neurodegenerative 
diseases.  
 
  
 
 
 
 
 
 
                                   Chapter 1 
General Introduction 
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Statistics provided by the World Health Organization (WHO) 
reveal that every 4 seconds a person dies of cancer, every 11 seconds 
from AIDS and every 86 seconds of Alzheimer's disease (AD). Thus, 
for these and other degenerative, chronic or chemo-resistant diseases, 
an urgent need for better therapies arises.  
Currently, the development of new therapies is approached by 
two different trends. In the first approach, research in genomics and 
proteomics is enabling the identification of new specific molecular 
targets.1 However, in practice it is still nearly impossible to find or 
synthesize such a "perfect" drug for any given target. This line of 
research is being conducted mainly through (i) screening of natural 
products, (ii) the synthesis of compounds of low molecular weight 
(Mw) via traditional medicinal chemistry or through combinatorial 
approaches,2, 3 and (iii) by the identification of natural macromolecules, 
including antibodies,4 proteins5 and oligonucleotides6-8 with inherent 
biological activity. The limited progress made by this strategy is mainly 
attributed to (i) the use of non-adequate preclinical models, which 
resulted to be poorly predictive,9 (ii) the lack of drug specificity in 
clinical practice, and (iii) the problem of acquired resistance.  
The second approach, in many ways complementary to the first 
one, is focused on the use of drug delivery systems (DDS), in particular 
in the design of innovative carriers,10, 11 developed to precisely guide the 
bioactive agent(s) to the site of action. DDS have been developed to 
accomodate the transfer of a lead compound from “bench to bedsite” 
which is often limited by the lack of systems or technologies suitable 
for specific molecular transport.12 Concretely, the full therapeutic 
potential of a bioactive agent requires a specific molecular delivery, as 
the specific localization of therapeutics to the diseased cell promotes 
the efficient delivery to a precise intracellular compartment and ensures 
availability within the required timeframe. 
In this context, nanoscience and nanotechnology provide the 
basis for the development of innovative delivery strategies and have 
enormous potential to improve human health, particularly in serious 
chronic diseases like cancer or neurodegeneration,13 and are opening 
new markets to the pharmaceutical industry. The “nanomedicine” field 
is distinguishable as it uniquely focuses on medically related, patient-
centric nanotechnologies.14 In the words of the European Science 
Foundation’s (ESF) Forward Look Nanomedicine15 “Nanomedicine 
uses nano-sized tools for diagnosis, prevention and treatment of disease 
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and to gain increased understanding of the complex underlying 
pathophysiology of disease. The ultimate goal is improved quality-of-
life”. The European Commission’s (EC) Joint Research Centre Report 
“Nanomedicine; Drivers for development and possible impacts” 
classifies Polymer Therapeutics as nanomedicines. 
With 40 products already in the market and more than 70 in 
cancer clinical trials,14 the nanomedicine field has experienced a 
notably exponential growth within the last decade. This fact is due to its 
potential to serve as a candidate solution for the urgent requirement of 
dealing with unsolved pharmaceutical and clinical needs in life-
threating diseases.16 In the recent years, nanomedicine has gained 
special attention in different research areas, especially for drug and 
gene delivery, in diagnostics and molecular imaging as well as in tissue 
repair and engineering17 amongst other uses. 
1.1. POLYMER THERAPEUTICS. 
Polymer therapeutics (PT) can be underlined as one of the most 
successful first generation of nanomedicines, with 15 products in 
routine clinical use. Furthermore, 2 of them are within the US Top 10 
selling drugs, the polymeric drug glatiramer acetate for the treatment of 
multiple sclerosis (Copaxone®, Teva Pharm; $3.7 billion), and the 
polymer conjugate polyethylene glycol (PEG)-filgrastim for the 
treatment of neutropenia (Neulasta®, Amgen; $3.6 billion).18 
1.1.1. Concept and Classification. 
The term “polymer therapeutics” was firstly introduced by Ruth 
Duncan to describe hybrid nanoconstructs that combine a bioactive 
agent with a polymer by either covalent or electrostatic interactions.19 A 
bioactive compound is described as a substance able to produce a 
biological response. The expression “Polymer Therapeutics” is then 
used to describe polymeric drugs,20-22 polymer-drug conjugates,23, 24 
polymer-protein conjugates,25-27 polymeric micelles where the drug is 
attached by covalent bonding,28-30 and multicomponent polyplexes 
(polyelectrolyte complexes) which are being developed as non-viral 
vectors31-35 (Figure 1.1). Polymeric micelles are self-assembling 
colloidal aggregates of polymeric block copolymers (amphipathic 
molecules), while polyplexes are polyelectrolyte complexes usually 
formed by a polycation and an anionic oligonucleotide or plasmid. 
These nano-sized medicines (5-100 nm in diameter) are considered as 
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new chemical entities (NCEs) from an industrial standpoint, whose 
versatility in the synthetic chemistry used, the possibility of addition of 
biomimetic features, and even the addition of bioresponsive units, make 
them one of the most versatile nanotechnologies currently available.19  
 
Figure 1.1. Schematic representation of the Polymer Therapeutics 
family. Redrawn from Duncan.19 
Through clinical use of polymer–protein conjugates (Table 1.1), 
and clinical development of polymer–anticancer drug conjugates (Table 
1.2), PT is already well established as a new therapeutic class not only 
for cancer treatment,36-38 but is also expanding its use to treat diseases 
other than cancer (i.e. PEG–interferon  conjugate known as Pegasys® 
or Peg-intron® can be used to cure hepatitis). Besides, many recent 
studies using polymer-drug conjugates have embraced a broad number 
of pathologies, including tissue regeneration.39 Furthermore, acquired 
knowledge based on the development of this first generation of PT has 
helped to inform on the improved design of second generation products. 
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Drug delivery concept from PT point of view, encompasses two 
important concepts; (i) targeting, what refers to the release of 
therapeutics at a desired body site (tissue, cell, cellular compartment), 
and (ii) controlled drug release, to ensure appropriate bioactive agent 
concentrations within the suitable therapeutic window for a desired 
duration. As it can be observed from the examples listed in the Tables 
1.1 and 1.2, intravenous injection (i.v.) is the preferred administration 
route for polymer-drug conjugates, owing to allow bioavailability in the 
bloodstream in a faster way, when compared to other routes, and 
avoidance of specific biological barriers (i.e. oral, which encounters the 
problem of poor penetration into the intestinal mucosa).41, 42 
Drug conjugation to a polymer chain offers many advantages, 
including (i) enhanced water solubility (relevant for poorly soluble 
drugs such as camptothecin (CPT) or platinate (Pt) derivatives or taxol 
(PTX)); (ii) increased plasma half-life by means of a higher 
hydrodynamic volume that presumably decreases kidney clearance; (iii) 
protection against proteolytic enzymes, or unspecific cellular uptakes; 
(iv) prevention or reduction of aggregation, immunogenicity and 
antigenicity. Polymer chains can prevent systemic generation of 
antibodies (complement activation), which is particularly relevant in 
polymer-protein design; and (v) changed pharmacokinetics (PK) at 
whole body as well as at cellular and even subcellular level. It is 
possible to achieve specificity due to passive targeting based on disease 
related vasculature abnormalities (EPR effect 'enhanced permeability 
and retention effect')43-47 and, therefore, lower systemic toxicity and 
may even overcome chemoresistant mechanisms (i.e. multidrug 
resistance (MDR) induced by glycoprotein P (P-gp) overexpression in 
plasma membrane) and thereby, restricting cellular uptake to endocytic 
pathway (lysosomotropic intracellular drug delivery).38  
The EPR effect phenomenon was firstly described by 
Matsumura and Maeda46 and is based on the unique pathophysiological 
features of most solid tumors: extensive angiogenesis, defective 
capillaries and impaired lymphatic drainage. Hence, after intravenous 
(i.v.) administration, the ‘leakiness’ of the angiogenic tumor 
vasculature allows selective extravasation of the conjugate into tumor 
tissue. Additionally, tumor tissue lacks of an effective lymphatic 
drainage, which subsequently promotes polymer retention. 
Combination of these two factors leads to the accumulation of the 
conjugate in tumor tissue (Figure 1.2). Thus, due to their size, PT (as 
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other nanomedicines), take advantage from passive targeting provided 
by EPR effect. Moreover, such effect is also present in inflamed areas, 
opening the window for the design of nanovectors towards infectious 
and inflammatory diseases.48 EPR-mediated targeting is ultimately 
driven by circulating plasma concentration of the polymer conjugate.37 
Nevertheless, the strength of the EPR effect differs on tumor type, 
tumor region, inflamed area, etc., being highly dependent on tumor 
vascularization. Hence, poor-vascularized damaged tissues are less 
susceptible to therapies based on nanosystems that rely solely on such 
effect,49 exposing the need for active targeting strategies in order to 
approach all possible scenarios.  
 
Figure 1.2. Enhanced permeability and retention (EPR) effect and 
passive targeting. Nanocarriers can extravasate into the tumors or 
inflamed areas through the fenestrations between endothelial cells and 
accumulate there due to poor lymphatic drainage. Adapted from ref.50 
Once accumulated in tumor or target tissue, the conjugates are 
generally internalized into cells by endocytic mechanisms driven by 
interactions with proteins and receptors on the cell surface. Drug 
conjugation to a water-soluble polymer platform restricts cellular 
uptake to the endocytic pathway and hence, bypasses mechanisms of 
resistance such as MDR induced by P-gp overexpression in plasma 
membrane. Indeed, phase I/II clinical trials with 2-N-(Hydroxypropyl 
methacrylamide) (HPMA) copolymer-Doxorubicin (DOX) (PK1, FCE 
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28068) demonstrated clear therapeutic responses in breast cancer 
patients resistance to standard DOX treatment. 
Macromolecules are captured by invaginations of cell plasma 
membrane forming vesicles named endosomes. Such vesicles undergo a 
complex sequence of fusion events directing the substances to the right 
compartment. In this process, the endosomal compartment pH drops 
down from the early to late endosome to values around 5.5.51 Moreover, 
at the end of the fusion process, the formed lysosomes host a battery of 
enzyme machinery utilized to degrade complex molecules such as 
lipids or proteins. Most of polymer-drug conjugates rely on the 
lysosomotropic drug delivery pathway, where either proteolytic 
enzymes or acidic pH triggers drug release. However, the hostile 
environment of lysosomes must be avoided if the presence of 
hydrolytic enzymes and acidic pH drives to inactivation/degradation of 
the bioactive agent. This issue is particularly important in 
peptide/protein and nucleic acid delivery. To circumvent that, pH-
responsive endosomolytic carriers are developed in order to promote 
endosomal escape upon pH stimuli. Several examples of such systems 
can be found in literature.52-56  
 
Figure 1.3. Lysosomotropic intracellular drug delivery process 
followed by Polymer-Drug conjugates. 
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1.1.2. Rational design of polymer conjugates. 
The previous section regarding the use of different endocytic 
pathways highlights the need for a rational design of nanosystems, 
given a selected molecular target and a chosen therapeutic agent. 
Polymer conjugates can be separated into two groups: polymer-
protein and polymer-drug conjugates. The biological purpose or the 
rational pursued in each case is different and, therefore, so are the 
parameters to be considered for its construction. While protein 
conjugation seeks to promote greater stability in serum and decreased 
immunogenicity, polymer-drug conjugates are designed to influence 
low Mw drug pharmacokinetics at whole organism and at cellular level, 
allowing also to cross biological barriers, improving cellular specificity, 
controlling drug release rate and consequently, decreasing non-specific 
toxicities and enhancing its therapeutic value. 
Thus, all that aspects include the choice of an appropriate 
polymeric carrier, suitable linker(s) or spacer(s), depending on the 
bioactive agent(s) to deliver and the molecular target to approach.  
1.1.2.1. Polymer-Protein Conjugates. 
Many of the limitations of peptide/protein/antibody therapies 
deal with low stability, short circulation times, poor therapeutic outputs 
as well as possible immunogenic responses. Polymer-protein 
conjugates emerge as a potential solution to circumvent these 
limitations.57 Although this family started in the early 90s with the 
development of SMANCS (poly-styrene-co-maleic acid, SMA 
conjugate of neocarzinostatin NCS),58 the most popular technique by 
far to reach polymer-protein conjugates is PEGylation.59, 60 PEGylation 
is an FDA (Food and Drug Administration) approved technology61 
based on the use of PEG to build polymer-protein conjugates with 
various examples already in the market (Table 1.1). PEG conjugated to 
a protein increases its solubility and plasma stability, reduces 
immunogenicity and prolongs plasma half-life by avoiding rapid 
excretion through reticulum endothelium system (RES), overall 
yielding to a better patient compliance. The PEG-L-asparaginase 
(Oncaspar®) was the first anticancer conjugate to get approval from the 
FDA in 1994 (used for the treatment of acute lymphoblastic leukemia), 
while the PEGylated enzyme PEG-Uricase (Pegloticase®) approved for 
the treatment of gout in 2010 was the last one to follow (see Tables 1.1 
and 1.2). It is important to mention the exponential growth of PEG-
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Aptamer conjugates after the approval of Macugen in 2004 for 
intraocular administration in the treatment of macular degeneration,62 as 
well as, Cimzia, an immunoconjugate where site-specific conjugation 
through bioresponsive linkers was a major achievement.63 
Regarding their design, site-specific and reproducible protein 
conjugation is a desired feature. Therefore, the use of semi-telechelic 
polymers and site-specific conjugation chemistries are preferred to 
avoid cross-linking reactions and provide a specific point of linkage. In 
most of polymer-protein conjugates already found in the market or 
currently in clinical practice, protein release is not desired, therefore 
non-biodegradable bonds are usually applied (i.e. Oncaspar®, 
NeulastaTM or PEG-Asys®).1 On the contrary, if an intracellular 
transport is pretended, endosomotropic transport is indispensable and 
biodegradable linkers are essential. Importantly, the polymer carrier to 
be used should present such endosomolytic properties to enhance 
cytosolic delivery.60 As this thesis focuses on the use of polymer-drug 
conjugates/imaging agents, detailed examples of polymer-protein 
conjugates are out of the scope and plenty of such constructs can be 
found in literature.25, 64-70 
1.1.2.2. Polymer-Drug Conjugates. 
The rational design of a polymer drug conjugate for systemic 
administration following Ringsdorf’s traditional model71 is based on a 
three component design: a water-soluble polymer, a bioresponsive 
linker and a bioactive agent. Nonetheless, due to polymer multivalency 
more than one compound can easily be introduced into the polymer 
main chain allowing the introduction of targeting residues (in order to 
trigger active targeting-receptor-mediated endocytosis)72 or more than 
one drug (polymer-based combination therapy),73-76 as well as imaging 
agents for theranostic purposes,77 which could enhance conjugate 
therapeutics value. 
The choice of an appropriate polymer carrier is a key step in the 
design of polymer-drug conjugates. It is currently accepted that an ideal 
polymer carrier should be characterized by (i) biodegradability or 
adequate MW, to avoid progressive accumulation in vivo; (ii) low 
polydispersity, to ensure an acceptable homogeniecity of the final 
conjugates allowing to adjust PK; (iii) longer body circulation time, in 
order to extend conjugate activity and to promote adequate 
biodistribution and accumulation in body compartments of interest; and 
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(iv), multivalency: multiple reactive groups to achieve a satisfactory 
drug loading.  
Traditionally, linear polymers with random-coil conformations 
have been used to synthesize most PT already in the clinics. These 
include natural polymers (dextran (α-1,6 polyglucose), dextrin (α-1,4 
polyglucose), hyaluronic acid, cyclodextrin); and synthetic polymers, 
such PEG, HPMA copolymers, polyacetals and poly-L-glutamic acid 
(PGA).14, 78  
Because of their nature, polymers present specific challenges 
for pharmaceutical development. A manufactured drug substance 
should be homogeneous and composed of a single, defined species. By 
contrast, all synthetic polymers are inherently heterogeneous and, as 
macromolecules, they can bear special challenges for characterization. 
Total control of crucial parameters such as chain length, MW, 
polydispersity (Đ), microstructure, final conformation as well as 
localization of charge or hydrophobic-hydrophilic balance are key to 
adequately tailor conjugate body distribution, fate, biological activity 
and toxicity.44 79-82 Relative stereochemistry of polymeric chains 
(tacticity) is been now considered of major importance since it modifies 
secondary structures and can directly influence polymer degradation 
profile, which is particularly relevant when using polypeptides as 
carriers.73 Surface charge is also important in some biological aspects, 
including celullar trafficking and biodistribution profile. For instance, 
neutral or negatively charged surfaces usually avoid non-specific 
uptakes and possitively charged surfaces are prone to tubular 
reabsorption in the kidneys. All these issues must be considered when 
chosing the appropriate polymer carrier for the desired application.83 
The average molecular weight is described by the “weight 
average molecular weight” (MW) and “number average molecular 
weight” (Mn) and the ratio MW/Mn gives a measure of the 
polydispersity Đ. For instance, polysaccharides extracted from natural 
sources are particularly disperse (Đ > 2) and normally have high MW 
(>200 kDa). New polymer chemistry approaches depending on the 
polymerization strategy used provide with synthetic polymers with 
narrow dispersities. For example, PEG has been synthesized by anionic 
polymerization yielding polymers with Đ ~ 1.01, which can be 
considered as almost monodisperse.  
Besides, design of bioresponsive polymer-drug linkers stable 
during blood circulation and capable of triggering drug release under 
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specific conditions is another key feature to achieve an effective 
intracellular drug release by lysosomotropic delivery.38 As previously 
mentioned, after being internalized by an endocytic mechanisms, 
polymer-drug conjugates travel through the endosomal pathway until 
reaching the lysosome, where in presence of proteolytic enzymes 
and/or acidic pH, degradation of the carrier and/or the biodegradable 
polymer-drug linkers occurs allowing drug release. Most drugs used in 
these constructs are hydrophilic/lipophilic, therefore once released, the 
drugs diffuse out to cytosol to achieve the desired molecular target.10 
Different types of linkers are already under use. These include: 
(i) Linkers that respond to pH changes, mainly used for small drugs 
conjugation as acid-labile spacers, such as acetal, ester bonds, N-cis-
aconityl acid, or hydrazone linkage.84, 85 (ii) Linkers susceptible to 
lysosomal enzymes, (exclusively for small drugs), usually oligopeptides 
specifically designed to be stable in blood but fast cleaved by lysosomal 
enzymes (i.e. Cathepsin B or D, and other metalloproteinases), allowing 
a lysosomotropic drug delivery. Examples of such oligopeptide linkers 
include GFLG (Gly-Phe-Leu-Gly) and GLFG (Gly-Leu-Phe-Gly).86-88 
(iii) Self-inmolative linkers.89 Among then, coiled coil linkers represent 
an example, where the cargo is attached to a polymer backbone via a 
non-covalent, biologically inspired coiled coil linker. This linker 
consists of a pair of complementary peptides that are bound around 
each other in a superhelical fashion to form a tertiary structural motif 
that is referred as a coiled coil. 90-92 (iv) Reductive-sensitive linkers that 
trigger drug release upon reductive environments mainly due to 
gluthatione.93 (v) Drug release by anchimeric-assisted hydrolysis, 
where the drug-linker is first released from the polymer by hydrolysis 
(first prodrug), which triggers the linker (second prodrug) that finally 
releases the free and active drug. Examples of this include the 1,6-
elimination reaction or trimethyl lock lactonization.94, 95 
Importantly, the chemistry used in conjugate synthesis must not 
generate toxicity or immunogenicity in biological systems, and of 
course, will not modify the active properties of the conjugated element. 
1.2. FROM THE VERY BEGINNING TILL THE CURRENT 
STATE OF THE ART. 
Although the first polymer anticancer -drug conjugate entered 
clinical trials in 1994 and was followed by more than 17 polymer-
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anticancer drug conjugates.73 Their way to become a real product on the 
market has been slowed down due to some initial setbacks. This 
included rational design errors that yielded an unspecific drug release 
for MAG-CPTTM (HPMA copolymer-CPT conjugate) and 
PNU166945TM (HPMA copolymer-PTX conjugate),96, 97 commercial 
issues in the case of FCE 28068 and FCE 2806996, 97 and the lack of 
activity found in early Phase III trials with OpaxioTM due to the use of 
non-suitable clinical models.98 
HPMA copolymer-DOX conjugate (PK1, FCE 28068), 
developed by Kopecek and Duncan was the first anticancer drug 
conjugate to be clinically evaluated in 1994. After PK1, other six 
HPMA conjugates have been clinically evaluated with HPMA 
copolymer-DACH-platinate (AP5306, Prolindac®)97 being the most 
advanced in Phase III clinical trials for ovarian cancer treatment. It is 
important to note, that the only targeted polymer-drug conjugate in 
clinical trials so far is also an HPMA conjugate (PK2, CF28069, 
HPMA copolymer-DOX-galactosamine). This conjugate is used for 
hepatocellular carcinoma treatment, using galactosamine as targeting 
residue, which recognizes the asialoglycoprotein receptor in the liver 
(see Tables 1.1 and 1.2). In the case of PGA as platform, OpaxioTM 
(PGA-paclitaxel (PGA-PTX) conjugate formerly known as XyotaxTM, 
(developed by Cell Therapeutics Inc.) is the most clinically advanced in 
phase III-IV, mainly for ovarian, prostate and esophageal cancer alone 
or in combination with cisplatin or radiotherapy. In 2012, orphan drug 
designation was granted to OpaxioTM for the treatment of glioblastoma 
multiforme in combination of temozolomide and radiotherapy.99 Unlike 
HPMA-PTX conjugate, OpaxioTM contains a greater drug loading (37 
wt% vs 5 wt%) that confers stability in blood (PTX is linked through an 
ester bond that should be shielded during blood circulation in order to 
avoid release triggered by plasma esterases). Important to note, the 
therapeutic value of OpaxioTM as anticancer agent has been found to be 
gender-dependent, with increased survival in women but not in men. 
The accepted hypothesis for this relates to the correlation between 
estrogen levels and cathepsin B activity, responsible of PTX release as 
PGA is susceptible to degradation in the presence of this serine 
protease. For that reason, cathepsin B is now used as a clinical 
biomarker guiding ongoing trials that only enroll chemotherapy-naïve 
advanced NSCLC female patients with estradiol levels greater than 25 
pg.mL-1.73 This finding is in consonance with novel strategies for the 
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near future based on the design of nanopharmaceutics for their clinical 
use in personalized therapy,100 allowing the selection of patients who 
will benefit more from therapy and suffer less side-effects. Apart from 
OpaxioTM, the conjugate CT-2106, PGA-CPT, is also in Phase II trials.  
Tables 1.1 and 1.2 summarize current efforts done in the field 
of PT up to date, including the screening of the first generation of 
marketed PT (Table 1.1) and those currently under clinical evaluation 
(Table 1.2). Certain notable advances include PEGylated products 
NKTR-102 (in advanced Phase III trials for metastatic breast cancer, 
and Phase II trials in ovarian and colorectal cancers),101, 102 and NKTR-
181, an orally administered conjugate for opioid-induced constipation 
developed by Nektar Therapeutics;103 XMT-1001 (Fleximer1-CPT) and 
the potent anti-angiogenic conjugate XMT-1107 (Fleximer1-
fumagillin) in Phase I developed by Mersana;104 and the first conjugate 
administered as a supramolecular assembled particle of 30 nm, 
CRLX101 (formerly IT-101) a cyclodextrin-CPT nanoparticle 
advancing in Phase III developed by Cerulean Pharma Inc.105  
Polymer conjugates have been also used in diagnostics by 
means of a large variety of imaging agents proposed as nanoprobe 
candidates. Nanosystems are commonly labeled with reported tracer 
probes for in vivo and ex vivo monitoring of pharmacokinetic profiles, 
biodistributions (clearance), targeting cellular and subcellular 
localizations. The first imaging agents in the clinics were 125I-labeled 
PK1 and PK2 used to monitor conjugate biodistribution in patients.97 
Since then, several imaging techniques have been approached, 
encompassing MRI, PET or optical imaging using near infra-red (NIR) 
fluorescent and luminescent probes.106-112 Following these approaches, 
an intravascular contrast agent, Gadomer® based on a dendrimeric 
polymer containing 24 gadolinium ions was transferred into clinics, but 
was soon retired due to poor pharmacokinetics.113 Nevertheless, there 
are plenty of examples of polymeric probes under development in 
literature, due to several inherent advantages including enhance 
circulation times and tissue targeting.114 Indeed, this thesis deals with 
the development of smart activatable polymeric probes in Chapter 8. 
Furthermore, the concept “theranostics” was recently born as a 
promising and feasible approach to combine therapeutic and diagnostic 
capabilities within the same polymeric platform offering the possibility 
of not only diagnosis but also monitoring of disease evolution upon 
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treatment using only one construct. Many relevant examples of 
theranostic approaches can be found in literature.14, 77, 115-117 
1.3. WHAT’S NEXT? CHALLENGES, NEW TRENDS AND 
OPPORTUNITIES. 
Lessons learned from the development of the first generation of 
polymer conjugates have facilitated the development of an improved 
second generation of PT. These improvements encompass the 
optimization of polymerization techniques and linking chemistry, as 
well as data gained in efficacy profiles, clinical toxicities and side 
effects. Current efforts are directed towards practical and cost-effective 
designs for specific targets with defined routes of administrations and 
dosage in order to reach personalize medicine as the ultimate goal. 
Towards this aim, four major research lines are now being explored 
including: (i) the synthesis of novel well-defined polymeric 
architectures as carriers, (ii) the search for suitable potent and reliable 
characterization techniques, (iii) the use of polymer-based combination 
therapy, and (iv) their application towards new molecular targets. All 
these strategies are summarized in Figure 1.4 and discussed below. 
 
Figure 1.4. Current research lines in PT field: novel molecular targets 
in cancer as well as other disease, polymer-based combination therapy, 
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new architectures and polymeric systems, and an exhaustive physico-
chemical characterization essential to clinical translation following 
regulatory indications. Redrawn from ref24. 
1.3.1. Use of novel well-defined polymeric carriers and 
adequate physico-chemical characterization techniques. 
As previously mentioned, there is a growing interest in novel 
biodegradable polymeric systems with new well-defined homogeneous 
architectures (to enhance passive accumulation by EPR effect), with 
low polydispersities, higher possibility for multivalency and greater 
drug loading capacity. Their potential advantages include a more 
defined chemical composition, tailored surface multivalency, and 
creation of a defined three-dimensional architecture in solution. 
The use of less heterogeneous systems in combination with 
their characterization by means of novel sophisticated physico-chemical 
techniques, will ultimately allow a better understanding of structure-
activity relationships, key to define safety and efficacy parameters set 
by regulatory demands.118  
Non-biodegradable polymers such as HPMA or PEG have been 
widely used in PT with some examples already in the clinics. 
Nevertheless, such polymeric carriers are limited in terms of MW, in 
order to allow renal elimination, and to avoid lysosomal accumulations 
that could lead to lysosomal storage diseases. Biodegradable polymers 
allow the utilization of higher MW platforms to optimize 
pharmacokinetics and higher dose administrations.19, 78 These systems 
are essential for the treatment of diseases that require chronic 
administration, such as tissue repair, and neurodegenerative 
disorders,119-121 and so the development of better polymeric carriers is 
ongoing. Cathepsin B degradable PGA,122 dextrins degradable by 
amylase,120, 123, 124 polyacetals125-127 that display pH-dependent 
degradation, degradable polysaccharide polysialic acids128, 129 and 
hydroxyethyl starch (HES)130, 131 are interesting options. 
As already mentioned, advances in organic and polymer 
chemistry, including the use of click chemistry132 and optimization of 
controlled and scalable polymerization techniques (Reversible 
Addition-Fragmentation chain Transfer (RAFT) polymerization, Atom 
Transfer Radical Polymerization, (ATRP) or Ring Opening 
Polymerization (ROP) among others)133-136 is allowing to reach novel 
and well-defined polymeric carriers from different architectures 
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including multi-block copolymers and branched systems such as 
hyperbranched, stars, brush-like, dendrons and dendrimers.137, 138 These 
new polymeric platforms possess inherent characteristics and 
sometimes, unexpected properties derived from their nature and 
structures what can be translate into different mechanism to cross 
biological barriers and cellular trafficking.  
The development of complex architectures must however be 
accompanied by the development of appropriate techniques for their 
characterization. Sophisticated novel physico-chemical techniques 
include SANS (small-angle neutron scattering),126, 139, 140 SAXS (small-
angle X-ray scattering), wide angle X-ray scattering (WAXS), PGSE-
NMR (pulse-field gradient spin-echo nuclear magnetic resonance),127 
and novel electron microscopies, such as Cryo-TEM (Transmission 
Electron Microscopy).141, 142 Their combination is contributing to 
increase knowledge regarding size, morphology, conformations in 
solution as well as the establishment of accurate structure-activity 
relationships. Furthermore, improved bio-physical techniques (mostly 
imaging techniques) are making possible in vitro an in vivo monitoring 
of biological outputs.143 
1.3.2. Polymer-based combination therapy. 
The use of polymer–drug conjugates in combination therapy 
can be also seen as an important opportunity to enhance therapeutic 
value provided that there is no disease characterized only by single 
molecular events. The polymeric carrier itself can provide an ideal 
platform for the simultaneous delivery of a cocktail of drugs 
simultaneously.76 To this respect, four types of polymer-based 
combination therapy have been proposed (Figure 1.5). These 
encompass the administration of (i) polymer-drug conjugate + free 
drug(s) (Type I), (ii) polymer-drug conjugate + polymer-drug conjugate 
(Type II), (iii) single polymeric carrier bearing the combination of 
drugs (Type III), and (iv) polymer-directed enzyme prodrug therapy 
(PDEPT) or polymer-enzyme liposome therapy (PELT).76 PDEPT is 
based on the combination of polymer-drug conjugate together with a 
polymer carrying the enzyme responsible for the release the drug at the 
target site, whereas PELT relies on a liposome encapsulated drug 
delivery system together with a polymeric carrier bearing the enzyme to 
degrade the liposome for drug release.  
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Figure 1.5. Polymer-based combination therapy strategies. 
The first endocrine-chemotherapy combination reported, 
HPMA copolymer-aminoglutethimide-DOX,144 (HPMA-AGM-DOX) 
revealed that conjugates containing both drugs showed markedly 
enhanced cytotoxicity compared with the single counterpart HPMA 
copolymer–DOX, a conjugate which has already shown clinical activity 
in breast cancer patients.145 Mixtures of polymer conjugates containing 
only AGM or only DOX did not show a synergistic benefit. Other drug 
cocktails using HPMA as polymeric platform for cancer treatment, 
have been used in combination therapy, including the antiangiogenic 
TNP-470 + alendronates or the two drugs gemcitabine and DOX.76  
Combination therapy is currently being pursued for the 
treatment of many different pathologies, including cancer, infectious 
diseases and neurological disorders with high expectations and with 
examples appearing in an exponential manner.76, 146 However, many 
aspects still require refinement, related to the rational design of 
combination systems (drug selection and drug ratios in the 
combinations). For instance, the study of release profiles in Type III 
combination therapies is vitally important as the presence of one drug 
can hindered or delay the release of the other. This influences drug 
concentrations at the target site in a given moment and so modifies their 
synergistic properties. 
1.3.3. Approaching novel molecular targets. 
Novel sophisticated strategies in cancer therapy are currently 
under intense development thanks mainly to advances in genomics and 
proteomics regarding molecular mechanisms in tumorigenesis. Polymer 
conjugates containing drugs directed against novel anticancer targets 
are also emerging, including the first anti-angiogenic conjugate, HPMA 
copolymer–TNP-470.147 There are also preliminary attempts to develop 
therapies that target the apoptotic signaling cascade at molecular level 
with promising in vivo results in ovarian cancer.148 Specific inhibition 
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of kinases and heat-shock proteins are also targeted.149, 150 while a 
combination of chemotherapy and photodynamic therapy 
(chemoradiotherapy) is also being explored.151, 152 A summary of these 
novel approaches in cancer treatment is shown in Table 1.3.  
Table 1.3. New molecular targets in cancer therapy using Polymer-drug 
conjugates. Adapted from Sanchis et al.39 
Molecular Target Polymer Drug Ref 
PI-3 kinase HPMA copolymer Wortmannin 153 
 PEG-PAH Wortmannin 154 
Sphingosine kinase PGA DMSP 150 
HSP-90 K8-ELP(1-60) GA 155 
 HPMA copolymer AH-GDM 149 
Jab1 PEG Curcumin 156 
Bcl-2 HPMA copolymer HA14-1 157 
Angiogenesis 
inhibitors 
HPMA copolymer TNP-470 147, 158, 159 
mPEG-PLA TNP-470 160 
HPMA copolymer TNP-470 161 
 HPMA copolymer PTX 162 
Aromatase inhibitors HPMA copolymer DOX,AGM 144, 163, 164 
DNA alkylating, ROS HPMA copolymer Gem, DOX 165 
PEG  EPI, NO 166 
Chemoradiotherapy PGA 4-HPR 167 
 HPMA copolymer Mesochlorin e6 152 
 HPMA copolymer DOX, Gem 151, 168 
 PEG Psolaren 169 
*4HPR: N-(4-hydroxyphenyl) retinamide; AH: Aminoihexanoic acid, AH-
GDM: 17-(6-aminohexylamino)-17-demethoxygeldanamycin; ALN: 
Alendronate; DMSP: Dimethylsphingosine; EPI: Epirubicin; 
GA:Geldanamycin; Gem: Gemcitabine; HSP: heat-shock protein; K8-ELP: 
Lysine-8-elastin-like polypeptides; NO: Nitric oxide; PAH: Poly(aspartate 
hydrazide); PI-3 kinase: Phosphoinositide 3-kinase; PLA: Polylactic acid; 
ROS: Reactive oxygen species. 
Advances in drug discovery have expanded the identification of 
new drugs with relevant activities in different human pathologies, 
encouraging the development of new polymer therapeutic families 
targeting many other diseases beyond cancer. Some examples already 
present in clinics include Cimzia® for rheumatoid arthritis (RA), 
Macugen® for age-related macular degeneration and Krystexxa® for 
chronic gout. Diabetes, hypertension, infectious diseases, digestive tract 
diseases or RA, are also being currently targeted (See Table 1.4). 
Additionally, PT have emerged as useful tools to promote tissue repair, 
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applications in wound healing, bone resorption or ischemia/reperfusion 
injuries are promising strategies. Some of the ongoing examples are 
extensively reviewed by Sanchis et al,39 and summarized in Table 1.4. 
Table 1.4. Polymer-drug conjugates in the treatment of diseases other 
than cancer. Adapted from Sanchis et al.39 
Disease Polymer Drug Ref 
Diabetes PGA Phloridzin 170, 171 
Hypertension SMA AHPP 172 
HIV PEG Saquinavir 173 
 SALP ZVD 174 
 k-carrageenan ZVD 175 
 Dextrin ZVD 176 
 PHEA ZVDe 177 
Hepatitis Dextran LAM 178 
Fungal infection PEG Amph B 179, 180 
Leishmaniasis Arabino-galactan Amph B 181, 182 
HPMA copolymer Amph B 183 
 HPMA copolymer NPC1161 184 
Sepsis PEG Peptoid 7 185 
Bowel constipation PEG Naxolol* 69 
Ulcerative colitis Dextran Budesonide 186, 187 
Inflammatory bowel  pDMAEMA DXM 188 
Rheumatoid arthritis HPMA copolymer DXM 189 
CDP α-mPNL 190 
Neuroinflammation PAMAM NAC 191 
Wound healing PAMAM G6S 119 
 Dextrin rhEGF 120, 192 
Ischemia/ 
reperfusion injury 
PGA APAF-1 inh.  121, 193-
195 
Modified dextran 17β-estradiol 196 
SMA AHPP 197 
PEG NO 198 
Osteoporosis HPMA copolymer PGE1 189 
 HPMA copolymer ALN 189 
 HPMA copolymer D-Asp8 189 
Rare disease (FAP) PGA 
PEG 
Doxycycline 
RAGE peptide 
199 
200 
*PEG-Naxolol (NKTR-118); α-mPNL: α-methylprednisolone; AHPP: 4-
amino-6-hydroxypyrazolo[3,4-D]pyrimidine; Amph B: Amphotericin B; 
APAF-1 inh.: Apoptotic protease activating factor 1 inhibitors; CDP: linear 
cyclodextrin polymer (β-cyclodextrin + PEG); D-Asp8: D-aspartic acid 
octapeptide; DXM: Dexamethasone; G6S: Glucosamine-6-sulphate; LAM: 
Lamivudine; NAC: N-acetyl cysteine; PAMAM: Poly(amidoamine); 
pDMAEMA: Poly(dimethylamino)ethylmethacrylate; PGE1: Prostaglandin E1; 
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SALP: Sulfate alkyl laminaripentaoside; SMA: Copoly(styrene-maleic acid); 
ZVD: Zidovudine. FAP: Familial Amyloidotic Polyneuropathy 
PT are also expanding to areas of neurodegenerative disorders 
treatment and diagnosis, and will be addressed in more detail in the 
following section.  
In conclusion, the PT sector is a growing field with many 
challenges but with many opportunities for improvement. Conjugates 
for the treatment of diseases other than cancer are still at an early stage 
of preclinical development, however, these underlie a strong research 
base for future PT that will hopefully reach clinical use in the next 
decade.  
Overall, a new golden era for PT is just beginning driven by the 
growing acceptance of PT as clinically important agents, continued 
search for innovation in big Pharma, and the rapid convergence of 
interests of many scientific disciplines arising from the increased 
popularity of nanomedicine. Over the last decade, new hybrid 
nanotechnologies have emerged, i.e. polymer combination therapies, 
theranostics, complex polymer conjugates assembled into 
nanoparticles, new polymer chemistries and compositions trying to 
capitalize on the unique physico-chemical behavior of nanomaterials. 
Indeed, investments in nanomedicine is increasing and as a 
consequence, the number of publications related to PT/polymer-drug 
conjugates has increased 10-folds since 1996, highlighting the 
relevance of this relatively new area (Figure 1.6). 
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a) Published elements                  b) Citations 
  
Figure 1.6. Published elements (a) and citation number (b) from 1996 
to 2015 related to the key words “polymer therapeutics” and “polymer 
drug conjugates” acquired from Web of Science. 
1.4. POLYMER THERAPEUTICS FOR THE TREATMENT OF 
NEURODEGENERATIVE DISORDERS. 
Nanomedicine offers an opportunity to overcome problems 
related to neurodegenerative disorders treatment mainly related with 
passage through the blood-brain barrier (BBB) (extensively explained 
in Chapter 6). Most drugs under development and the strategies used to 
reach the central (CNS) or peripheral (PNS) nervous systems lack of 
optimal therapeutic efficacy due to poor pharmacokinetics, high 
toxicities and low BBB penetration. Drug concentrations within the 
therapeutic window needed to effectively treat most of the CNS 
disorders are difficult to reach at the desired target site inside brain. In 
this respect, PT are promising candidates for the treatment and 
diagnosis of CNS related diseases (including brain tumor) since they 
hold key characteristics to surpass main limitations from low MW 
tracers/drugs. Those features include (i) changed pharmacokinetic 
profiles and enhanced plasma half-life necessary to promote specific 
tissue/organs accumulations (ii) the possibility to include targeting 
moieties for specific active targeting strategies in order to increase 
brain accumulation by selective ligands or monoclonal antibodies; (iii) 
controlled and sustained drug release of conjugated drugs using 
cleavable linkers under specific environments; (iv) stability and 
reduced immunogenicity of the bioactive compound and possess 
optimal size to allow better penetration (when compared with other 
nanoconstructs such as liposomes).201 
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FDA approval of Gliadel® wafer (MGI Pharma, Bloomington, 
USA) implants for brain therapy in malignant gliomas has made real 
the possibility of using polymeric systems to reach CNS.202, 203 
Nonetheless, implants in deep brain regions are required for an 
effective drug delivery, and so represent a highly aggressive treatment. 
Consequently, research is currently focused on the development of non-
invasive methods based on different administration routes, all 
attempting to avoid brain tissue disturbance where risks could 
frequently be higher than benefits. The main strategies pursued for CNS 
delivery in the PT field involve systemic administrations with the use of 
the commonly known “Trojan Horses” to cross the BBB.204-206 These 
strategies are based on the conjugation of targeting ligands of specific 
receptors present in BBB. Although some systems have already 
demonstrated some translocation across BBB,207, 208 the vast majority 
only achieve about 1 % of the administered dose, with 4 % the 
maximum obtained.14  
Pluronic® block copolymers consisting on hydrophilic 
poly(ethylenoxide) (PEO) and hydrophobic poly(propylene oxide) 
(PPO) blocks (PEO-b-PPO-b-PEO) are promising drug delivery 
systems that can act as polymeric drugs themselves or be used as 
polymeric micelles for imaging probes/drug delivery.209-211 This 
technology is already in Phase III clinical trials (Pluronic®-DOX, 
SP1049C, Supratek Pharma) for the treatment of highly resistant 
tumors) and is being highly explored for CNS delivery due to their 
inherent ability to interact with hydrophobic surfaces and so improved 
capability to cross biological barriers. For instance, conjugation of 
polyclonal antibodies against brain α2-glycoprotein or insulin, allowed 
Pluronics® bearing drugs or fluorescence probes via receptor mediated 
transport (RMT) to cross the BBB. This technology has also been 
applied for peptide/protein delivery to the CNS carrying opioid 
peptides,212 horseradish peroxidase213 or leptin.214, 215  
The biodegradable PLMA (poly-β-L-malic acid) has been used 
for the development of PT to treat glioma via i.v. administration 
achieving specific accumulation in brain tumors and the suppression of 
intracranial glioma growth by the administration a complex PLMA 
conjugate. These conjugates combine targeting vectors for the BBB and 
the blood-tumor barrier (BTB), the endosomal disrupting unit 
trileucine, and the delivery of the antisense oligonucleotide laminin-411 
for tumor inhibition.216-218  
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PEG based PT are also under investigation for CNS treatment 
strategies including PEG as carrier itself or as extra unit to provide 
stealth properties to the final construct. Examples include the 
PEGylation of several growth factors for neuroprotective purposes,219-
225 or OX26 antibody conjugation.226, 227  
The globular structure of PAMAM dendrimers, together with 
their cationic surfaces, make them suitable systems due to their higher 
diffusivity in brain parenchyma after convention-enhanced delivery 
(CED).228, 229 Plentiful examples of the use of these systems can be 
found in literature, mainly for glioma treatments and 
neuroinflammation. For instance, PAMAM-Methotrexate (MTX) 
dendrimers bearing the targeting antibody Cetuximab (ICM-C225) 
demonstrated tumor accumulation after CED administration.230 
Additionally, intravitreal administration of PAMAM dendrimers 
demonstrated novel, intrinsic targeting properties by selectively 
localizing in activated microglia and astrocytes in the brain and 
retina.231-234 A clinically used steroid, fluocinolone acetonide (FA), has 
also been conjugated to the hydroxyl-functionalized; G4; PAMAM 
dendrimer, producing a nanodevice with sustained drug release for up 
to 90 days.231 A single systemic dose of hydroxyl terminated; 
PAMAM-G4 conjugated to N-acetyl cysteine (D-NAC) also produced 
dramatic improvements in motor function, neuronal counts and 
myelination, and reduced neuroinflammation.232 Overall, these 
PAMAM dendrimer–drug conjugates have shown promising preclinical 
efficacy in the alleviation of neuroinflammation associated with both 
ocular and brain diseases.233 PAMAM dendrimers have been also 
exploited in combination with Pluronics for small interfering (si)RNA 
brain delivery by means of polyplexes. For instance, radio-labeled 
siRNA-PAMAM-G7 dendriplexes incorporated in poloxamer 407 
(Pluronic® F127) and chitosan gels were shown to cross the BBB 
following intranasal administration.235 Apart from their intrinsic 
properties to cross barriers, the targeting vectors Angiopep-2 
(ANGIO1005, Angiochem Inc., Canada) and Transferring have been 
efficiently conjugated to PAMAM dendrimers improving their brain 
accumulation.236, 237 Nevertheless, PAMAM dendrimers have safety 
issues for systemic administration that have to be still solved. 
The examples listed are just a few and further nanosystems for 
CNS delivery are currently under development.238 Despite the fact that 
those systems are still in early stages, results obtained are encouraging 
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the use of PT as promising and exciting candidates for CNS drug 
delivery and molecular diagnostics. Nevertheless, further investigations 
in respect to the intrinsic barrier crossing properties of new and existing 
polymeric carriers (prioritizing vesicular and globular shapes) as well 
as the development of new targeting vectors and in deep exploration of 
the already discovered is in high demand in order to achieve effective 
treatments.  
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The work presented within this thesis chapter was carried out in 
tight collaboration with Dr. Inmaculada Conejos Sánchez, who also 
presented part of it in her thesis dissertation. As a result both of us are 
co-first authors of the publication in the journal Polymer Chemistry, 
Volume 4, Issue 11, Pages 3182-3186 (“A controlled and versatile 
NCA polymerization method for the synthesis of polypeptides”). 
2.1. INTRODUCTION AND BACKGROUND. 
The development of more defined architectures with higher 
MW (to enhance passive targeting), predictable structure and 
conformation, lower heterogeneity, higher drug loading capacity and 
greater multivalency are main research lines in nanomedicine.  
Polypeptides are envisaged to achieve a major impact on a 
number of different relevant areas such as biomedicine and 
biotechnology. Acquired knowledge and the increasing interest on 
amino acids, peptides and proteins is establishing a large panel of these 
biopolymers whose physical, chemical and biological properties are 
ruled by their controlled sequences and composition. Polymer 
therapeutics has helped to establish these polypeptide-based constructs 
as polymeric nanomedicines for different applications, such as disease 
treatment and diagnostics among others. 
Indeed, routine clinical use of copaxone1, 2 and the promising 
phase III clinical results including the recent designation as orphan drug 
of the polymer drug conjugate OpaxioTM (polyglutamic acid (PGA) 
paclitaxel conjugate, formerly Xyotax, PPX, CT-2103)3 have 
underlined the high potential of synthetic polypeptides within 
nanomedicine, in particular polyglutamic acid (PGA)4.  
2.1.1. Polypeptide Design and Synthesis. 
Polypeptides belong to a family of macromolecules diverse 
both in applications and structural features. As a result, there are several 
strategies for their synthesis and preparation. In general, the methods for 
the design of polypeptides can be divided in two main different 
methodologies: the synthetic techniques, and the recombinant DNA 
techniques. 
In the synthetic approaches, stepwise solid-phase polypeptide 
synthesis (SPPS),5, 6 native chemical ligation (NCL)7 or ring opening 
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polymerization of α-amino-N-carboxyanhydrides (NCAs)8-10 can be 
included. Those techniques are mainly based on the use of amino acids 
or their derivatives as monomers and are particularly useful in the 
design of hybrid architectures that combine sequences of peptidic and 
non-peptidic nature.  
Recombinant DNA techniques can be seen as an alternative 
genetically encoded approaches for the synthesis of polypeptides. The 
main advantage of this technique is the inherent accuracy of the 
methodology, which includes high specificity in the sequence and 
stereochemistry of the newly synthesized polypeptide. On the other 
hand, not all polypeptides can be properly expressed in a heterologous 
host, and non-peptidic moieties cannot be included unless post-
expression modification techniques are applied. 
2.1.1.1. Recombinant DNA Expression of Proteins. 
Recombinant DNA expression of proteins is often used for the 
synthesis of proteins with different purposes.11 One of the most relevant 
is protein and peptide engineering and design, which is the one that will 
be reviewed herein. 
 
Figure 2.1. Recombinant DNA technique for protein synthesis. 
Redrawn from Rhodes et al.12 
In recombinant techniques (genetically encoded synthesis) 
three steps can be described. First of all, the creation of a recombinant 
gene segment that encodes for the protein of interest: a protein target is 
identified and translated into the corresponding genetic code. Then, the 
target oligonucleotide is synthesized; secondly, the insertion of this 
segment into a DNA vector, which is classically a plasmid from 
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bacteria to produce a recombinant DNA molecule; and finally, 
transformation of this recombinant DNA molecule into a host cell. Cells 
that are successfully transformed with the recombinant DNA molecule 
are grown in culture. This gene produces large amounts of the desired 
protein, which is later isolated from cells (Figure 2.1). Due to low cost 
and convenience, bacteria (such as Escherichia coli (E. coli) or Bacillus 
subtilis) are the most frequently used. It is important to mention that 
achievement of recombinant genes is the rate-limiting step, in particular 
if the polypeptidic product of interest is based on a large number of 
repeats. 
This technique presents several advantages over synthetic 
methods: (i) It produces polypeptides with defined sequence, 
stereochemistry, and MW based on a genetic template; (ii) Continuous 
supply of polypeptide can be achieve after optimization (iii) The in vivo 
folding machinery of cells can assist to ensure the correct secondary or 
tertiary structures and conformations of the peptides. 
However, it also present some drawbacks that must be 
mentioned: (i) Is time and effort consuming, mainly due to synthesis 
optimization of the gene (especially if large MW are desired); and to 
optimization of the expression levels in the host cell; (ii) Only short 
sequences up to 100 nucleotides can be produced by chemical synthesis 
using an automated solid phase DNA synthesizer. For larger sequences, 
combination with other techniques is needed (concatenation of 
oligonucleotides,13 recursive directional ligation (RDL),14 and 
mutagenesis or amplification of existing gene segments using 
polymerase chain reaction (PCR);15 (iii) Multi-domain proteins are 
much more challenging to express than proteins smaller than 30 kDa; 
(iv) Incompatibility between protein and bacteria leads to toxicity, 
reducing protein production; (v) Only the 20 natural L-amino acids can 
be incorporated using standard cellular components. Although, this 
problem is slowly being surpassed.16  
2.1.1.2. Synthetic Approaches. 
The majority of limitations of genetically encoded synthesis to 
produce polypeptides can be surpassed with the use of synthetic 
techniques. Among the advantages of synthetic approaches, the following 
can be pointed out: (i) Unnatural amino acids can be used to produce a 
vast number of novel architectures with different properties and 
structure-function relationships; (ii) It enables combination of 
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polypeptides with other synthetic polymers such as PEG, (iii) They are 
an easier and faster methodologies compared with genetically encoded 
techniques; (iv) Higher yields and large scale synthesis. 
Nevertheless, controlled chain length and stereochemistry have 
represented an issue over the past years. 
2.1.1.2.1. Solid-Phase Peptide Synthesis (SPPS). 
Stepwise Solid-Phase Peptide Synthesis (SPPS) was first 
reported by Merrifield in 1963.5 In his protocol, Merrifield attached the 
first N-protected amino acid group through an ester bond to a 
polystyrene resin partially chlorinated. After that, the protecting group 
was removed yielding a free amino group ready to react with the next 
N-protected amino acid. Thus, the general principle of SPPS consists 
on repeating cycles of coupling-wash-deprotection-wash. The peptide is 
‘immobilized’ onto the solid-phase and can be retained during a filtration 
process, whereas liquid-phase reagents and synthesis by-products are 
flushed away. Finally, the resin can be removed and the peptide isolated 
(Figure 2.2). The main amino protecting groups usually used are 9-
fluorenylmethyloxycarbonyl (FMOC) and t-butyloxycarbonyl (BOC), 
and each of them requires different resins and amino acid side-chain 
protection and, consequently, different cleavage/deprotection steps.  
The main advantages of this approach can be summarized as: 
(i) It allows the synthesis of natural peptides as well as incorporation of 
unnatural amino acids, D-amino acids, and peptide/protein backbone 
modification; (ii) Total control over peptide composition is achieved; 
(iii) Clean method due to the possibility to perform wash cycles after 
each reaction; (iv) Process can be automated using a peptide 
synthesizer. 
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Figure 2.2. Schematic representation of Merrifield solid-phase peptide 
synthesis (SPPS). 
On the other hand, some drawbacks must also be taken into 
account: (i) Large, complex polypeptides/proteins cannot be prepared, 
due to a low coupling efficiency as the length of the peptide increases; 
(ii) High purity is not usually obtained when large polypeptides are 
synthesized; (iii) It is necessary to use an excess of amino acids and 
coupling reagents; (iv) solubility of protected peptide segments is 
sometimes challenging. 
Due to all these drawbacks, SPPS is typically restricted to the 
synthesis of polypeptides of less than 50 amino acid residues in order to 
not compromise purity. 
2.1.1.2.2. Native Chemical Ligation (NCL). 
Chemical ligation can be considered as a simple technique 
based on the chemoselective reaction of two unprotected peptide 
segments that will react exclusively among them diminishing potential 
side reactions and generation of undesirable by-products.17 This 
methodology was first introduced in 1991 by Schnölzer and co-
workers18 which consisted on the formation of a non-amide bond at the 
ligation site (i.e. thioester-linked products). Although introduction of a 
non-native linker within the protein was well-tolerated in folded 
proteins, it is always better if possible, the use of peptidic bonds as 
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linkers in order to mimic natural enzymes/proteins. This problem was 
solved by Dawson and co-workers7, 19 with the introduction of native 
chemical ligation (NCL) approach (Figure 2.3). It is based on the 
formation of an unstable covalent bound thioester-linked intermediate 
that spontaneously rearranges forming the most thermodynamically 
favored amide bond at the ligation site. This robust approach has been 
widely used to produce a series of model peptides,20 protein 
inhibitors,21 and a vast variety of other proteins.22 
 
Figure 2.3. Native chemical ligation. (a) Water, pH= 7; (b) 
rearrangement of thioester intermediate amide linked product. 
The main advantage of this strategy is the absence of complex 
combinations of protecting groups as unprotected amino acids can be 
directly linked. However, its use is restricted to link peptide segments, 
therefore, is necessary to synthesize those segments using other 
alternative techniques.  
2.1.1.2.3. Ring-Opening Polymerization (ROP) of α-
Amino Acid N-Carboxyanhydrides (NCAs).  
The ring-opening polymerization (ROP) of amino acid-N-
carboxyanhydrides (NCA) is the most commonly applied 
polymerization technique to produce polypeptides and polypeptide-
based block copolymers on a multigram scale (Scheme 1.1). Although 
the obtained polymers are less defined than natural peptides, the 
polymerization method enables access to polypeptidic architectures, 
which are beyond nature’s possibilities. The ROP of NCAs has already 
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been used for the synthesis of polypeptides with various applications 
that range from drug delivery systems,23 tissue engineering,24 sensing25 
to catalysis.26 The first NCA27 were synthesized by Leuchs in 1906. 
Since then, a plethora of polypeptides has been created due to the 
variety of natural and non-natural amino acids and the versatility of the 
polymerization method, as it has been reviewed in the following 
excellent literature.9, 10, 28, 29. 
 
Scheme 1.1. Ring-opening polymerization (ROP) of α-amino acid N-
carboxyanhydrides (NCAs). 
The opportunity to use functional non-natural polymers in 
combination with the scalable synthesis makes the ROP of NCA a great 
choice to reach well-defined polypeptides. Polypeptides produced from 
the NCAs possess the ability (as natural proteins) to form secondary 
structures e.g., α-helixes and β-sheets. Moreover, their multiple 
functionalities, adjustable MWs (1-1000 kDa) and structural 
homogeneity favor self-assembly into defined supramolecular 
nanostructures with potential biomedical and pharmaceutical 
applications.  
One of the trends in the development of polymeric based 
nanomedicines is the building of well-defined, reproducible and 
homogenous architectures. Although NCA polymerization can never 
provide perfect control in polypeptide synthesis, the living character of 
the polymerization allows to get close to it. Synthesis of narrowly 
distributed polypeptides for their potential use in biomedicine is a 
desirable goal, which turned out to be rather demanding. Furthermore, 
the characterization of such synthetic proteins remains a challenge, 
mainly due to the fact that standard methods for polymer 
characterization are based on mathematical models for random coiled 
architectures. In addition, standard protein analytics cannot be applied 
to samples disperse in sequence as well as MW. 
In principle, every NCA can be polymerized by a nucleophile 
or a base. Both initiation steps lead to a different propagation 
mechanism. But it has to be kept in mind that, in aprotic solvents, every 
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nucleophile can also act as a base leading to the coexistence of both 
mechanisms. This fact can be considered to be one of the main reasons 
for rather undefined polypeptides. Therefore, the ROP of NCAs can 
proceed via two mechanisms: normal amine mechanism (NAM, 
induced by nucleophilic substitution) and activated monomer 
mechanism (AMM, induced by deprotonation). 
As mentioned above, NAM is based on the nucleophile attack 
of the initiator. The intermediate formed is an unstable carbamic acid 
that decarboxylates yielding a new free amino group, thus, propagating 
the polymerization. Therefore, mainly primary amines can be used to 
polymerize NCAs. A proof of this mechanism was demonstrated 
independently by Peggion et al.30 and Goodman et al.31 by confirming 
the incorporation of the initiator fragment in the final polymer. Scheme 
2.2 summarizes initiation and propagation steps. 
 
Scheme 2.2. Initiation and propagation steps according to NAM. 
In contrast, AMM (first proposed by Ballard et al.)32, 33 is based 
on the basic character of the initiator and its ability to subtract the 
proton of the 3-N of NCA in a preinitiation step leading to the “real 
initiator”. This real initiator attacks the 5-CO to give a tadpole dimer, 
followed by reaction with another NCA, creating a new anion with the 
simultaneous release of CO2. This tadpole dimer is attacked by a new 
anion, to give a tadpole trimer, and so on, followed by the creation of 
NCA anion at each reaction step (see Scheme 2.3). For that reason this 
latter mechanism is attributed to tertiary amines or metal alkoxide, 
stronger basic than nucleophile initiators. In the cases of secondary 
amine, as well as of alkali halide-initiated polymerizations, it is 
believed that AMM and NAM coexist.34 Whereas NAM is valid for N-
unsubstituted NCAs and N-substituted NCAs, AAM mechanism is only 
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for N-unsubstituted NCAs (due to the preinitiation step). Furthermore it 
should be noticed, that NCA anion itself can rearrange into an α-
isocyanatocarboxylate (See Scheme 2.5). 
 
Scheme 2.3. Preinitiation, initiation and propagation steps in AMM. 
Moreover, in NAM initiation rate is faster than propagation, 
since primary amines are more nucleophilic than the ω-amino groups. 
A fast initiation is one of the key requirements for a controlled 
polymerization, leading to MW control and additionally polypeptides 
with low dispersities due to the fact that every initiator is supposed to 
start a polymer chain. On the contrary, as AMM proceeds via anion, it 
is expected that the propagation rate is faster than in NAM leading to 
higher MWs. Nonetheless, polypeptides with high polydispersity 
indices (Ɖ) are obtained.34 Due to this, AMM should be avoided in 
order to achieve control polymerizations. Since amines can act as both 
a nucleophile and a base, polymerization will always switch back and 
forth between “amine” and “activated monomer” mechanisms. 
Especially, the use of secondary amines is unfavorable, because such 
compounds are sterically more hindered and have a more basic 
character. In summary, primary amines with reduced basic character 
seemed to be the key to a polymerization of NCA following just NAM. 
Besides both mentioned polymerization mechanisms, a number 
of unwanted side reactions exist destroying the living nature of ROP of 
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NCAs. It is important to take into account all factors hindering the 
controlled polymerization such as purity of NCAs as well as reaction 
system (purity of solvents…),35 presence of water or moisture,36 CO2 
pressure,37, 38 pH, temperature), presence of salts,39 cleavage of 
protecting groups,37, 40 and undesired termination processes (carbamate 
mechanisms or reaction with α-isocyanatocarboxylates).33, 41 The 
carbamate mechanism is based on the nucleophilic attack of the 
intermediate carbamate to another NCA leading to the formation of 
urea groups within the polymer and termination of the chain growth 
reaction itself (see Scheme 2.5). On top of all this, most oligopeptides 
tend to form secondary structures even at very low degrees of 
polymerization, most notably α-helices and β-sheets. Both forms differ 
strongly in solubility and reactivity towards further polymerization. To 
conclude, AMM should be diminished to yield well-defined homo and 
block copolymers as control over polymer end groups is essential for 
the synthesis of multiblock architectures or end group functionalization. 
Classic NCA polymerization tends to be very problematic, even when 
initiated by primary amines leading in most cases to reduced control 
about polymerization process itself. Especially whenever a higher 
degree of polymerization or complex architectures are desired, the 
occurring side reactions interfere.  
For those reasons, efforts have been devoted to develop new 
approaches in order to overcome these drawbacks, such as, the use of 
heavy metal catalysts,42 high vacuum techniques (HVT),43 primary 
amine hydrochloride salts,44 the combination of low temperature with 
primary amines,45 the use of silazane derivatives as initiators46 or the 
optimization of reaction conditions (pressure, temperature, etc.).47, 48 
Unfortunately, all methods present limitations: 
In 1997 Deming,42 developed a new class of NCA-initiators 
based in organickel and cobalt (0) compounds, able to overcome 
termination reaction and leading to homo and block copolypeptides 
with narrow Ɖ (<1.2), controlled MW (500-500.000 Da), preserving the 
original chirality of NCA monomer and useful for a wide range of 
NCAs.49, 50 The main drawback is the fact that heavy metal catalysts 
must be carefully removed to avoid non-specific toxicity in biomedical 
applications. Besides, some other disadvantages are initiating complex 
synthesis and requirement of an hydrogen atom at the 3-N of the 
NCA.50 Schlaad et al. in 2003.44 reported the use of primary amine 
hydrochloride salts as macroinitiators in order to avoid AMM 
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mechanism. The nucleophilic amine terminus is transferred into a 
dormant (i.e. protonated) state. Reactivity of primary amine 
hydrochlorides toward NCAs was first investigated by Knobler et al.51 
in the 1960s. Main drawbacks are that polymerization time increases 
due to reduced reactivity of the active sites leading to incomplete 
monomer conversion and presence of nucleophilic chloride anions 
which can act as initiators of NCA polymerization as well. Therefore, 
remaining monomer has to be removed before a second block can be 
synthesized. In their work Schlaad and co-workers reported Ɖ < 1.1 and 
Mn not higher than 22 kDa.44 
 
Scheme 2.4. Hydrochloric salt of a primary amine reaction with NCA. 
The use of primary amines and High Vacuum Techniques 
(HVT) for the living polymerization was also proposed by 
Hadjichristidis et al. in 2004.47 According to the authors, HVT enables 
the synthesis of well-defined, homo, copolypeptides with complex 
macromolecular architectures and are also valid for polypeptides 
hybrids. However, HVTs require complex and expensive experimental 
setup, complicating synthesis. In addition, the closed system generates 
a pressure gradient during polymerization, which may influence 
polymerization kinetics. The use of low temperatures with primary 
amines was reported by Vayaboury et al in 2004,48 decreasing 
termination reactions. At 0 °C, activation energy barrier for chain 
propagation becomes lower than that of side reactions. The main 
disadvantage of this methodology is that reaction times increase about 
2-4 times while yields decrease. And finally, the use of silazane 
derivatives as initiators was carried out by Lu et al. in 2007,46, 52 leading 
to low Ɖ, the expected MWs and almost quantitative yields. The weak 
point of this approach is that is not general since it cannot be used for 
polymerization of N-unsubstituted NCA and Hexamethyldisilazanes 
(HMDS) amines are sensitive to hydrolytic reactions. Scheme 2.5 
represents the complexity involved in the chemistry of NCA 
polymerizations.  
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2.1.2. Polypeptides as Polymer Therapeutics. 
The use of amino acids as building blocks offers the 
opportunity to reach different polymeric systems (homo, or hybrid 
block copolymers) with diverse macromolecular architectures and a 
variety of possibilities for many therapeutic applications (Figure 2.4).  
 
Figure 2.4. Schematic representation of the possibilities offered by the 
used of amino acids as building blocks. 
Some of the inherent characteristics of polypeptides make them 
excellent candidates for drug delivery, such as presence of functional 
groups in their sequence that provide specific sites for direct attachments 
or charged-induced interactions with different biomolecules. 
Furthermore, polypeptides are susceptible to enzymatic degradation 
within a safe profile and the generation of non-toxic metabolites. All 
together stand for remarkable properties to turn them into marketed 
products. The importance and potential of polypeptides in the 
development of drug delivery systems have been clearly proven. In 
fact, it must be noticed that, the most successful first generation 
polymer therapeutics introduced in Chapter 1, is mainly represented by 
homopolymers, di-block or tri-block copolymers formed overall by 
PGA, poly(L-lysine) (PLL) or poly(L-aspartate).  
[Chapter 2] 
102 
 
Figure 2.5. Examples of polypeptide-based Polymer Therapeutics in 
the clinics. 
2.1.2.1. Current Applications of Polypeptides in Drug 
Delivery. 
Polypeptides have demonstrated their potential as drug delivery 
systems (DDS) with enough examples in literature of their use in 
Polymer Therapeutics. There are indeed successful products from all 
categories listed in the introduction highlighting its relevance. 
Polymeric drugs. The already mentioned random copolymer 
Copaxone® (glatiramer acetate) was the first polymeric drug reaching 
the market for the treatment of multiple sclerosis53, 54 and it was 
considered one of the top 10 selling drugs worldwide in the first quarter 
of 2013 (Figure 2.5). In early 90s, the use of poly(Arg-Gly-Asp) 
demonstrated to inhibit lung metastasis and migration of B16-BL6 
melanoma in mice.55 Finally, the multivalent lysine-dendrimer 
VivaGel® is another example of a polymeric drug under clinical 
development for topical applications as a vaginal virucide to prevent 
HIV-1 infection.56 
Polymer-drug conjugates. As stated in the introductory chapter, 
the initial steps of polymer-drug conjugates were focused on anticancer 
agent development57 that were able to favor tumor accumulation, 
facilitated by the EPR effect and demonstrated tissue penetration.58 To 
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this respect, the already mentioned OpaxioTM,59 represents one of the 
best examples of the potential of polypeptides as drug delivery systems. 
Indeed, polyglutamates are highly biocompatible, biodegradable and 
multifunctional polymers, which have been successfully for various 
medical applications.1, 60 In the body, such degradability is triggered by 
cysteine proteases (particularly cathepsin B), which play a key role in 
lysosomal degradation of this polymer.61 Many worth mentioning 
examples of PGA use as polymeric carriers can be found in literature. 
For instance, the also mentioned PGA-camptothecin (CPT)62 (formerly 
CT-2106) is in Phase II for colorectal and ovarian cancers, although the 
company Cell Therapeutics Inc. (CTI, Seattle, WA, USA) has no 
immediate plans to conduct any further clinical studies.63 Eldar-Boock 
et al. have designed a PGA-PTX conjugate which incorporates an 
integrin-targeted moiety: a cyclic RGD peptidomimetic which 
significantly improved tumor accumulation and increased anti-tumor 
efficacy in an orthotopic murine 4T1 metastatic breast cancer model.64 
PGA-Dopamine conjugate represents another example. This conjugate 
has significantly increased the short half-life of dopamine, 
indispensable in the regulation of angiogenesis, opening up a door for 
possible treatments of angiogenesis-dependent diseases.65 It is also worth 
mentioning the PGA conjugate of a hydrophobic pro-apoptotic 
sphingolipid: N,N-dimethylsphingosine (DMSP) linked through an ester 
bonding. This drug induces apoptosis competing with sphingosine 
kinase (SpK), a key regulator of tumor angiogenesis.66 
When talking about combination therapy approaches for cancer 
treatment, there are also several examples of PGA use as efficient 
carrier. Deladriere et al. have designed and evaluated a family of PGA-
AGM-DOX conjugates with demonstrated activity in an orthotopic 4T1 
breast cancer mouse model.67 In recent years, several studies have 
confirmed the therapeutic potential of this application68 and, as expected, 
polypeptides have followed this trend. For instance, Wadhwa et al. have 
conjugated D-penicillamine and idarubicin to PGA, proving in vivo 
longer residence time in blood and a significant enhancement in 
survival of athymic mice bearing NCI-H460 tumor xenografts.69  
Although pro-apoptotic approaches are related with cancer 
therapy, anti-apoptotic strategies have also applications in regenerative 
medicine.70 Vicent and coworkers designed a PGA-based Apaf-1 
inhibitor conjugate,71 which represented the first anti-apoptotic 
polymeric nanomedicine. This conjugate has efficiently shown to 
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promote regeneration in the course of inflammation-induced tissue 
injury.72 More recently, in the same group, PGA-doxycycline (DOXY) 
conjugates as fibril disrupters where developed as an approach towards 
the treatment of the rare amyloidotic disease FAP (Familial 
Amyloidotic Polyneuropathy).73 Moreover, PGA can act as an adjuvant 
itself making appealing its application in vaccinations by the simple 
antigen presentation within the polymer to generate a directed immune 
response.74 
Apart from homo-polyamino acids, engineering of elastin-like 
peptides (ELPs) has also been explored for drug delivery. ELPs are 5-
1500 amino acids in length based on the pentamer sequence Val-Pro-
Gly-X-Gly, where X represents any amino acid.75 Synthesis is achieved 
through recombinant DNA techniques (Section 2.1.2). Their most 
significant property relies on a temperature-conformation relationship 
going from unordered structures to ordered β-turns when surpassing 
their temperature transition. Exploiting this property and by means of 
the application of local hyperthermia, these carriers have been targeted 
to solid tumors. This feature from ELP carriers classifies them as 
promising candidates for thermally responsive polymer-drug conjugates 
in cancer treatment. For instance, Geldanamycin has been conjugated to 
the block polymer lysine 8-elastin-like polypeptides (K8-ELP) showing 
higher cytotoxicity combining heat and K8-ELP-GA in cell cultures.76 
DOX has been also conjugated to ELPs77 alone or in combination with 
cell penetrating peptides.78 Chilkoti et al. have reviewed multiple 
alternatives for these systems.79  
Polymeric micelles. The majority of these micellar systems 
include a biodegradable polypeptide block, such as poly(aspartic acid) 
(PAA), PGA or PLL and a variety of hydrophilic polymers, mostly 
PEG.80 The first example was reported by Ringsdorf et al. by 
conjugating cyclophosphamide (CP) sulfide in PEG-PLL copolymer.81 
Kataoka and co-workers are pioneers in this area with several block co-
polypeptide micelles in clinical trials as anticancer agents,82 and many 
similar analogues in preclinical evaluation, i.e., NC-6301 (analogue of 
NK911 with docetaxel) and NC-4016 [analogue of NC-6004 with 
oxaliplatin (DACH-platinate)].83 Inoue and co-workers developed a 
PEG-block-poly(aspartic acid)-DOX copolymer forming polymeric 
micelles that were delivered intravenously to the brain through 
conventional-enhanced delivery (CED), resulting in prolonged median 
survival compared with free DOX.84 With the same polymeric structure 
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and under the same concept, NC-6300/K-912 releases epirubicin at low 
pHs and is currently in phase I clinical trials.85  
Once again, under the concept of combination therapy and 
including pH-response stimuli, PEG-poly(aspartate-hydrazide) (PEG-
PAH) block copolymers have been conjugated to DOX and 
wortmannin, alone or in combination to achieve pH-sensitive polymeric 
micelles.86 Nevertheless, wortmannin is not a FDA approved drug and 
its synergistic activity with DOX was not fully demonstrated in this 
work. 
There also many examples of the use of polypeptides to form 
polyplexes (especially PLL) for gene delivery applications87 as well as 
their use in protein delivery.88 For the purposes of this thesis 
dissertation, those systems will not be reviewed.  
2.1.2.2. Applications in Molecular Imaging and 
Theranostics. 
As cited in Chapter 1, polymer conjugates have been also 
proposed as nanoprobes for disease monitoring by means of tracer 
probe labeling.89, 90 Even more interesting is the concept of 
“theranostics” based on the “find, fight and follow approach” that offers 
the possibility of an early detection, disease targeting and treatment.4, 91 
As example Li et al. have carried out biodistribution studies in solid 
tumor models using PGA-DTPA-Gd by MRI that allowed them to 
observe localization of the PGA-based probe in the necrotic zone of 
tumors.92 Recently, they have added a second label for multi-modal 
imaging by incorporating the near-infrared dye NIR813.93 The authors 
were able to ratify an increased uptake of PGA-Gd-NIR813 into tumor 
and a selective accumulation into the necrotic/apoptotic region of the 
tumor. In addition, polypeptide-based micellar MRI contrast agents are 
under current development ensuring the validity of these constructs for 
imaging purposes.94 Furthermore, there are plenty of studies of HPMA 
polymer in combination with diagnostic agents. For instance, HPMA-
DOX conjugate labeled with 131I was considered in Phase I clinical 
trials.90 In another study, HPMA with Gadolinium was prepared by 
copolymerization method, including RGD moieties and labeled with 
111In as diagnostic agent.95 Recently HPMA labeled with 64Cu and 
loaded with RGD moieties was evaluated as targeted system of tumor 
angiogenesis in prostate cancer xenografts by PET (positron emission 
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tomography) showing increased accumulation when compared with 
non-targeted control.96  
2.2. RESULTS AND DISCUSSION. 
As stated in the introduction, PGA can be synthesized by 
controlled ROP of NCAs.10, 23, 97 Control on polymer chain length and 
stereochemistry have been one of the major challenges in synthetic 
approaches and all of the techniques developed up to know to surpass 
all the problems derived from the inherent characteristics of NCA 
polymerization have their own limitations. Herein, a versatile and 
simple methodology for the preparation of well-defined polyglutamate 
nanocarriers, overcoming those limitations, is described. 
2.2.1. Monomer synthesis and stability. Synthesis of γ-benzyl 
L-glutamate NCA (OBzl(Glu) NCA) (1). 
α-Amino acid N-carboxy anhydrides (NCAs) synthesis can be 
divided into two groups depending on the nature of the amino acid 
substrate (Scheme 2.6). The first is Leuchs method and is based on the 
cyclization of N-alkoxycarbonyl amino acid halides to form α-amino 
acid N-carboxy anhydride. The second is called Fuchs-Farthing 
method, and involves direct phosgenation of unprotected α-amino acids 
Scheme 2.6. N-α-carboxyanhydrides synthesis described by (1) Leuchs 
and (2) Fuchs-Farthing. 
We adapted the protocol from N.M.B Smeets et al.,98 a 
variation of Fuchs-Farthing method (Scheme 2.7). In addition, some 
variations were also implemented such as removal of remaining 
phosgene or HCl by nitrogen flow prior to precipitation followed by 
recrystallization and filtration under Schlenk conditions to avoid 
impurities and enhance storage stability. 
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Scheme 2.7. γ-benzyl L-glutamate NCA (OBzl(Glu) NCA) (1) 
synthesis. 
Phosgene was avoided due to the lack of stoichiometric control 
in its use that can result in the formation of several impurities. Such as 
the amino acid chloride hydrochloride formed by HCl cleavage of the 
NCA ring, which can be phosgenated in a second step to form α-
isocyanate acid chlorides (Scheme 2.8). Both byproducts are critical in 
NCA polymerization and will lead to a broad or even multimodal Ɖ. 
Hence, trichloromethyl chloroformate was used instead, which 
decomposes by temperature yielding phosgene. Due to the need for 
thermal decomposition higher temperatures than in conventional Fuchs-
Farthing method (40-50 °C) are mandatory. 
 
Scheme 2.8. Byproduct formation due to excess of phosgene and HCl. 
Reaction mechanism is shown in the Scheme 2.9 and involves 
the direct phosgenation of unprotected α-amino acids. Cyclization 
proceeds through the formation of N-chloroformyl amino acid 
intermediates and loss of a second HCl molecule completes the NCA. 
 
Scheme 2.9. Monomer synthesis mechanism. 
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The reaction generates 2 equivalents (eq.) of HCl per molecule 
of NCA capable to initiate NCA self-degradation. To avoid that 
process, limonene was used to scavenge HCl by addition to its double 
bonds (Scheme 2.10). Amines or other strong bases cannot be used due 
to the fact that they would attack the formed NCA and lead to its 
decomposition. In contrast limonene acts as an almost non-nuclephilic/-
basic HCl scavenger. In addition to limonene, a N2 or Ar stream was 
applied for 2-4 hours after reaction time to remove the excess of HCl. 
 
Scheme 2.10. Mechanism of action of Limonene. 
The white solid obtained after precipitation was then 
recrystallized several times. The presence of HCl impurities can be 
identified by precipitation of silver chloride when some drops of a 
solution 1 M of AgNO3 are added to a solution of monomer. NCA 
purity is the main criteria to ensure long term storage. This issue was 
corroborated with stability studies of the NCA under different storage 
conditions. Results are shown in Table 1.1 where a “-“symbol means 
that monomer was found already polymerized. 
Table 1.1. Stability of NCA under different storage conditions. 
Conditions Storage Time (days) 
5  6  7  8  10  11  20  50  
r.t. - - - - - - - - 
r.t./Ar +/- - - - - - - - 
4°C + + +/- - - - - - 
4°C/Ar + + + + + + +/- +/- 
-23°C + + + + + + + + 
-23°C/Ar + + + + + + + + 
*r.t.: room temperature. Ar: storage under Argon. 
Thus, monomers were stored at -23°C under inert atmosphere. 
It must be mentioned that, prior polymerization, monomer integrity was 
always checked by (i) its solubility in tetrahydrofurane (THF) 
(polymerized monomer is only partially soluble whereas monomer is 
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completely soluble), (ii) its melting point (93.4 °C), (iii) the already 
mentioned AgNO3 test, and (iv) its 1H-NMR spectra in CDCl3.  
1H-NMR and 13C-NMR spectra with corresponding 
assignments are depicted in Figure 2.6. 
a) 
 
b) 
 
Figure 2.6. NMR spectra in CDCl3 of OBzl(Glu) NCA (1). a) 1H-
NMR, b) 13C-NMR. 
2.2.2. Exploration of NCA polymerization techniques using 
novel initiators. 
2.2.2.1. Exposing the need for novel methods. 
As stated in the introduction, the wide range of reaction 
pathways that can occur during polymerization process, make 
controlled polymerization of NCAs a challenging task. For that reason, 
reaction conditions were optimized by using sophisticated and ultra-
dried Schlenk equipment, freshly dried and distilled solvents as well as 
well-dried reagents. Under these conditions, and as a starting point in 
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
f1 (ppm)
1.
08
1.
11
2.
02
1.
00
2.
00
4.
76
1
2
3
4
5
67
8
91 2
3
45-9
δ(ppm)
7.5    7.0     6.5     6.0    5.5     5.0    4.5     4.0     3.5    3.0     2.5    2.0     1.5     1.0    0.5
O
NH
O
O
O
O
1
2
3 4
6
7
8
9
11 10
5
12
13
1 2
3 4
6
7
8
9,13
5
10,12
11
δ(ppm)
170   160  150  140  130  120  110   100   90    80    70     60    50     40    30    20     10
[Chapter 2] 
110 
order to address the degree of control and weak points of most applied 
methodologies of NCA polymerization techniques such as the use of 
primary amines and hydrochloride salts (Schlaad methodology). 
Several attempts varying monomer/initiator (M/I) ratio were carried out 
in N,N’-dimethylformamide (DMF) as a solvent, at 40 °C during three 
days by using n-butylamine and n-butylammonium hydrochloride salt 
(Scheme 2.11). 
 
Scheme 2.11. General scheme for polymerizations using initiators 
based in n-butylamine and its derivatives salts. 
Several conclusions can be drawn from the obtained results 
(Table 2.2). In the case of NA initiated polymerizations, degree of 
polymerization (DP) obtained is, apparently, independent of the M/I 
above a DP of 100, which make this methodology invalid when high 
MW are required. In the case of polymerizations initiated by 
hydrochloride salts, it can be observed that MW obtained increases as 
the ratio M/I increases, however, is still far lower from the theoretically 
expected. In both methodologies, Ɖ increased when higher MW were 
pursued. In conclusion, although both methods are easy to apply 
without sophisticated equipment or complex synthesis they are invalid 
whenever DP above 100 is desired. Hence, there is a need for a 
different approach. 
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Table 2.2. NCA Polymerization in DMF with n-butylamine and n-
butylammonium hydrochloride salt as initiators at 40 °C during 3 days 
at a monomer concentration of 0.38 mol∙L-1.  
Initiator DPtheo Y (%) Mna (kDa) DPa Ɖa DPb 
n-Bu-NH2 100 77 20.3 93 1.25 41 
400 75 22.4 103 1.43 59 
1600 83 20.5 94 1.42 60 
n-Bu-NH3Cl 
 
100 60 4.4 20 1.35 36 
400 72 18.1 83 1.56 55 
1600 73 20.7 95 1.52 90 
a. Data obtained by SEC in DMF; b. Data obtained by 1H-NMR. DP= 
degree of polymerization, DPtheo= [M]/[I]= Monomer Concentration/ 
Initiator Concentration, n-Bu-NH2= n-butylamine, n-Bu-NH3Cl= n-
butylammonium hydrochloride salt, Ɖ= dispersity, Mn= apparent, Y= 
Yield. 
DP by 1H-NMR was calculated by comparison of the integral of 
the corresponding signals of the n-butyl initiator at low shifts (between 
0.8-1.5 ppm), which can be assigned to the seven protons CH3CH2CH2 
of the molecule; and the corresponding signal of the CHα of the 
polypeptide chain (Figure 2.7). 
 
Figure 2.7. Typical 1H-NMR spectrum of poly(γ-benzyl L-glutamate) 
(PBLG) (2) in DMF-d7. 
From the previous results, it could be concluded that there is a 
clear need for new approaches to reach living defined polypeptides with 
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control over chain length. Herein, a novel synthetic approach which 
uses, for the first time, ammonium salts with non-nucleophilic counter 
ions such as tetrafluoroborate (BF4) was proposed as an alternative. The 
BF4 ammonium salts as initiators combine the advantages of primary 
amine hydrochloride salts repelling AMM mechanism and reducing the 
reactivity of the amine (<nucleophilic, << basic); and the use of a 
counterion in the salt without nucleophilic character, correcting the 
main drawback of the Schlaad methodology. Its inert character is based 
on the symmetry of the ion leading to an equal charge distribution and 
its composition of highly electronegative fluorine atoms, which 
diminish the basicity of the anion. For this reason, a more controlled 
polymerization is expected with these initiators. However, remaining 
drawbacks still are that AMM mechanism is only suppressed and the 
influence of secondary structure remains untouched. 
Based on the advantages listed above, a whole study of this 
hypothesis was planned. Thus, a screening of NCA polymerization of 
OBzl(Glu) NCA (1) using tetrafluoroborate salts as initiators was 
designed (Scheme 2.12). Within this screening, several parameters were 
varied, such as solvents (THF, DMF, dimethyl sulphoxide (DMSO), 
and dioxane), temperature (0, 25, 40, 60 and 80 °C) and initiators (n-
butylammonium (3), neopentylammonium (4), PEG-ammonium (5), as 
well as functionalized initiators such as propargylammonium (6), (N3-
EG(2) ammonium (7)) BF4.  
Scheme 2.12. Synthesis of PBLG (2) through the different ammonium 
tetrafluoroborate initiators. 
2.2.2.2. Initiators. 
Apart from initiating the polymerization process, due to the 
versatility of this polymerization methodology that includes the initiator 
within the C-terminus polymer backbone, the initiator can be used to: 
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(i) Introduce C-terminus end functionalities that can serve 
as linkage points or reactive sites for further conjugations or 
polymerization processes respectively. This was demonstrated herein 
with the use of propargylammonium (6), (N3-EG(2) ammonium) (7) 
BF4 initiators to introduce alkyne and azide moieties, respectively. The 
presence of an end alkyne or azide functionality allows site-specific 
conjugation of antibodies, proteins or imaging probes at the same time 
that side chain multivalency enables the design of advanced 
theranostics or polymer-based combination nanopharmaceutics, a hot 
topic in this area due to current clinical needs.68, 991 
(ii) Synthesize hybrid di-block copolymers when macro-
initiators consisting on polymeric chains are used. This was also 
demonstrated by the use of MeO-PEG- NH3BF4 as macroinitiator to 
lead PEG-PGA hybrid di-block copolymers (8). These hybrid di-block 
copolymers might offer different properties due to differences in 
hydrophilicity of the blocks leading to amphiphilic polymers whose 
properties might be tunable by controlling the blocks size.  
(iii) Quantify by proton NMR the DP obtained during 
polymerization process. To this respect, in this work, n-butylamine was 
initially used to determine DP. Nevertheless, this initiator was later on 
substituted by neopentylamine in order to increase signal-to-noise ratio 
due to the 9 equivalent protons of neopentyl group.  
The initiators based on tetrafluoroborate ammonium salts can 
be easily prepared by reaction of the corresponding amine with HBF4 
diethyl ether complex or by ion exchange using ammonium chloride 
and tetrafluoroborate Meerwein salt (BF4- OEt3+) (Scheme 2.13)100 
purified by recrystallization and stored without detected decomposition 
or impurities (Figure 2.8).  
 
Scheme 2.13| Synthetic route for BF4 salts obtaining. 
  
R1
Homopolymer Di-block copolymer C-terminus functionalized polymers
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a) 
 
b) 
 
Figure 2.8. a) 1H-NMR in DMSO-d6 of nBu-NH3BF4 initiator (3). b) 
19F-NMR example in DMSO-d6 of nBu-NH3BF4 initiator (3). The rest 
can be found at Supplementary Information (SI) in Appendix III. 
2.2.2.3. NCA polymerization optimization. 
First, variation of solvent conditions was performed using in all 
cases n-butylammonium BF4 (3) as initiator of the polymerizations as 
well as MeO-PEG(2000)ammonium BF4 (5) at 40 °C during three days. 
Then, several studies using freshly distilled solvents such as THF, 
DMSO, dioxane, and DMF were carried out in order to select an 
appropriate solvent. All solvents have been carefully purified according 
to literature.101 From these experiments, it could be clearly concluded 
that DMF as solvent in polymerizations leads to acceptable yields, 
controlled MW with narrow Ɖ as determined by GPC. This is not an 
unexpected result since in DMF, formation of the salt between the 
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intermediate of the carbamic acid and the amino groups of the 
propagating chains can be avoided, which leads to higher than the 
normal first order kinetics. 29, 102 DMSO was the second choice in the 
ranking, because performed polymerizations yielded defined systems, 
but the lower yields and the fact that work up is much more 
complicated since DMSO is not miscible with apolar organic solvents 
required in precipitation. Polymers synthesized in dioxane or THF were 
found to show bi/trimodal distributions as shown by gel permeation 
chromatography (GPC). Moreover, their MW did not correlate with the 
expected by 1H-NMR.  
Following with the optimization process, the effect of 
temperature was also studied. From the literature mentioned in the 
introduction, it is already known that lower temperatures suppress some 
side reactions but elongates reaction times. As in the process of 
optimization, time was kept as a constant parameter, when reactions 
were done at lower temperature, lower yields were obtained (20-30 %). 
Higher temperatures (60, and 80 °C) resulted in slightly yellow colored 
reactions in the case of 60 °C, and strong yellow colored with 80 °C, 
which can be explained by decomposition of DMF into dimethylamine 
and cleavage of the protecting group at high temperatures, leading to 
benzyl alcohol, which is yellow colored. In conclusion, a lack of 
control is present when high temperatures like 60 °C or above are 
applied in polymerizations. When low temperatures are applied, very 
poor yields were obtained (when 3 days of reaction time are kept), 
which is non-tolerable for the production of polypeptides on large scale.  
With DMF established as solvent, and 40 °C as the appropriate 
temperature for a 3 days reaction, effect of monomer concentration was 
studied. When higher dilutions were used, less defined polymers (in 
terms of Ɖ and expectable MW) were obtained. This fact can be related 
to secondary structure formation, which depends on polypeptide 
concentration in solution. Hence, 0.1 g∙mL-1 monomer concentration 
was established as optimal according to results from Table 2.3. 
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Table 2.3. NCA polymerization in DMF with different monomer 
concentrations. 
Initiator [C] 
g∙mL-1 
[C] 
M 
DPtheo 
 
Y 
(%) 
Mna 
(kDa) 
DPa Ɖa DPb 
n-Bu 
NH3BF4  
0.1 0.38 200 85 13.9 65 1.28 112 
0.05 0.19 200 60 10.6 48 1.27 70 
0.025 0.09 200 60 2.43 11 2.71 57 
a. Data obtained by SEC in DMF; b. Data obtained by 1H-NMR. 
DPtheo= [M]/[I]= [Monomer]/[Initiator], n-Bu-NH3BF4= n-
butylammonium BF4 salt, Mn= apparent, Y= yield. 
The versatility of this method was explored by polymerization 
of OBzl(Glu) NCA (1) with BF4 salts of neopentyl amine (4), n-
butylamine (3), propargylamine (6), azide amine (7) as well as MeO-
PEG amine (MW 2000, Ɖ. 1.03) (5) yielding controlled block 
copolymers. Some results are summarized in Table 2.4. 
Table 2.4. Demonstration of the versatility of the technique by 
preparation of a variety of functional end groups with different DPs. 
Initiator DPtheo Y(%) Mn (kDa)a Ɖa DPa DPb 
Npt- 
NH3BF4 
50 73 10.5 1.15 48 40 
100 70 16.4 1.10 75 73 
200 75 22.5 1.13 103 197 
400 85 44.2 1.08 202 405 
1200 80 156.3 1.19 715 * 
n-Bu- 
NH3BF4 
50 64 6.8 1.11 31 29 
100 64 13.8 1.09 63 60 
200 63 16.2 1.12 74 107 
400 72 31.5 1.18 144 212 
800 53 48.4 1.19 221 * 
1200 51 94.4 1.21 431 * 
MeO-PEG(2000)- 
NH3BF4 
50 73 6.9 1.17 23 38 
100 81 13.9 1.19 55 79 
200 80 17.7 1.19 72 149 
propargyl-NH3BF4 200 84 16.4 1.21 75 * 
N3-EG(2)-NH3BF4 200 77 18.2 1.19 83 * 
a. Data obtained by SEC in DMF b. Data obtained by 1H-NMR, 
*Values below the detection limit. 
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IR was used to monitor monomer conversion with reaction time 
as a general tool to identify the end of polymerization. DMF strongly 
absorbs in IR region, therefore suitable peaks to follow the reaction had 
to be found. Figure 2.9 shows IR spectra of OBzl(Glu) NCA (1) DMF 
and PBLG (2) in DMF. Peaks corresponding only to monomer were 
localized at 1857, 1785 and 920 cm-1. Peaks at 1785 and 920 cm-1 were 
selected due to their higher signal-to-noise ratio. 
 
Figure 2.9. Polymerization monitoring through FT-IR. Spectra of 
PBLG (2) in DMF solution over reaction time.  
In all cases, polymers were characterized by 1H-NMR and GPC 
analysis (DMF and/or 1,1,1,3,3,3-hexafluoroisopropanol, HFIP). Some 
examples are given in Figures 2.10 and 2.11. Additionally, Circular 
Dichroism (CD) was used to confirm secondary structure showing α 
helix formation in all cases for benzyl protected polymers (Figure 2.11). 
 
Figure 2.10. 1H-NMR spectra of polymerizations carried out with n-
butyl BF4 salts at different [M]/[I] ratio of polymerization in DMF-d7. 
      δ(ppm) 
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a)                                                b) 
 
Figure 2.11. NCA-ROP. Representative data of PBLG series (2b) 
prepared via Npt-BF4 initiator are compiled in (a) GPC traces in DMF. 
(b) CD spectra in HFIP at 20 °C. 
For polymerization kinetics, reaction was performed under 
nitrogen flow and at 40 °C using neopentylammonium BF4 salt as 
initiator. Each point of kinetics was took from one Schlenk tube, thus, 
system was not opened while polymerization was running in order to 
not perturb kinetics. As expected, reaction follows a first order kinetics 
and Ɖ increases as reaction time does when higher chains are 
generated. Results are summarized in Figure 2.12. 
 
Figure 2.12. Kinetics of NCA polymerization of OBzl(Glu) NCA (1) 
with neopentyl ammonium BF4 salt as initiator [M]/[I]= 100. 
For further confirmation of the advantages of our novel 
methodology over the use of primary amines, neopentyl ammonium 
BF4 salt was compared to its analogous amine form (Table 2.5). NCA 
polymerization with primary amine initiator was performed at 4 °C and 
25 °C. However, BF4 salt initiation was carried out only at 25 °C due to 
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the fact that reaction time was considerable increased at low 
temperatures (because of the dormant amine species).  
Table 2.5. Summary of results from NCA-ROP through NA and BF4 
initiators in DMF, at different temperatures. 
I DPthe 
T 
°C 
Y 
% 
Mna 
kDa 
Ɖa DPa 
Mnb 
kDa 
Ɖb DPc 
N
pt
-N
H
2 50 4 74 9.4 1.13 43 9.7 1.10 57 
100 64 27.8 1.06 127 22.2 1.11 144 
200 68 28.7 1.10 131 23.6 1.14 202 
400 90 15.7 1.14 72 29.5 1,10 190 
N
pt
-N
H
2 50 25 74 9.6 1.21 44 9.3 1.11 47 
100 80 11.9 1.17 54 11.0 1.14 78 
200 79 13.9 1.14 64 12.1 1.16 114 
400 78 16.4 1.16 75 12.5 1.16 121 
N
pt
-B
F
4 
50 25 73 10.5 1.15 48 7.9 1.22 40 
100 70 16.4 1.10 75 15.1 1.17 73 
200 75 22.5 1.13 183 20.4 1.15 197 
400 85 44.2 1.08 202 35.8 1.16 405 
a. Data obtained by SEC in DMF. b Data obtained by SEC in HFIP. c. 
Data obtained by 1H-NMR. I= Initiator, Npt= neopentylamine, Mn= 
apparent Mn, Y= yield. 
HFIP was used as alternative solvent to DMF to ratify an 
adequate MW, and Ɖ data determination. DMF is usually effective 
enough in disrupting hydrogen bonds, nevertheless, secondary 
structures cannot be neglected in GPC measurements even at 70 °C 
(temperature in the GPC).103, 104 For that reason, HFIP was proposed 
expecting absence of secondary structures. However, comparison of 
polymer MW obtained showed not significant differences for both 
solvents. Looking at GPC graphs, slight tailing can be observed for 
PBLGs (2) bearing 50-100 glutamic acid units (GAU), since in this 
range a small amount of polymers are too short to form helical 
structures and therefore a mixture of random coils and helical structures 
is present within the same polymer sample. This can be confirmed by 
CD spectroscopy and NMR (4.8 ppm, alpha proton) applying GPC 
conditions. Indeed, this was observed in neopentyl initiator peak which 
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was divided into two signals (0.83 and 0.79 ppm), none of which comes 
from the free initiator (0.93 ppm), when low MW polymers were 
analyzed by NMR. As in nature, low MW PGAs display a more 
pronounced contribution of random coil structures. However, those 
effects are absent for higher MW PGAs and therefore are not attributed 
to undefined polypeptides but to the nature of the polypeptide itself. 
After the study, it was concluded that both, the use of NH2 at 
low temperature or BF4 at 25 °C lead to MW control of the polymers, 
up to a DP of 200, with low Đ (1.05-1.20) which pointed out the living 
character of the polymerization process. Nevertheless, and as expected, 
when higher MW were required, only BF4 achieved the desired DP.  
In conclusion, MW of polymers can be precisely controlled up 
to a DP of 800 without the use of complex initiators or demanding 
experimental setup. The derived polymers have low Đ (<1.2) indicating 
the well-controlled character of the polymerization. The use of these 
novel initiators provided reproducibility batch-to-batch as well as 
enabled scalability of the synthesis, from 100 mg to 10 g of starting 
NCA monomer. Indeed, a spin-off company was grown up from the 
laboratory, which applies the above described methodology. 
2.2.3. Optimization of the deprotection protocols of PBLG (2). 
Once synthesized and properly characterized, removal of the 
protecting groups from PBLG (2) is necessary in order to obtain free 
carboxylic groups for further bioconjugations. Due to the presence of 
functional groups, glutamic acid based NCAs must be polymerized 
using protecting groups in order to avoid undesired side reactions and 
benzyloxycarbonyl (Bz) is the most widely used protecting group. 
There are different protocols for the removal of these protecting groups, 
such as strong acidic conditions, aqueous basic conditions or catalytic 
hydrogenation. However, in respect to deprotection of polypeptidic 
chains there are some issues that must be considered prior deprotection: 
(i) Harsh acidic conditions can lead to chain cleavage from 
protonation of side-chain ester groups which react with the amide 
backbone. TFA/HBr or acetic acid/HBr is known to lead to 
deprotection in the absence of racemization,105 however, these 
conditions are not suitable for sensitive functional end groups derived 
from functional initiators, e.g. alkyne or biotin moieties as well as PEG 
based block copolymers (i.e. PEG is rapidly degraded under those 
conditions);106  
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(ii) Catalytic hydrogenation might lead to reduced yields 
caused by purification steps need which usually involve the use of 
resins that can interact within the polypeptide backbone. Furthermore, 
is ineffective for MW higher that 10 kDa (the helical conformation 
impedes access of the catalyst)107 and as in the case of acidic 
conditions, it can be used for functional end groups derived from 
functional initiators that can be hydrogenated such as alkynes, azides, 
vinyl moieties, etc. 
(iii) Basic conditions might solve the problem of chain 
cleavage caused by acidic conditions, nevertheless, racemization can 
occur due to deprotonation of α protons of the polymeric chains. 
Hence, the final PGA homo (9) and di-block polymers (10) 
must be obtained using a deprotection method that ensures full removal 
of protecting groups with acceptable yields to be scalable, without 
damaging the polymer chains and without racemization; an issue, 
which is often not considered carefully and could induce important 
changes in nanomedicine behavior in a clinical setting. Changes in 
secondary structure due to polypeptide racemization will potentially 
alter immunological properties, degradation profile, and secondary 
structure. Consequently drug release, the pharmacokinetics profile and 
biodistribution might be unpredictable upon polypeptide-drug 
conjugation.  
The aim of this study was then to establish an optimal 
deprotection conditions for all different polymeric architectures based 
on PBLG. As depicted in Scheme 2.14, three methodologies were 
tested either for homopolymers or di-block copolymers: acidic or basic 
media and catalytic hydrogenation. 
 
Scheme 2.14. Deprotection protocols. (i) Acidic method: HBr (2 
eq.)/TFA, 5 h, 25 °C; (ii) Catalytic hydrogenation: H2/Pd(OH)2, 16 h, 
25 °C; (iii) Basic method: NaOH aq. (1.5 eq.)/THF (1:8 (v/v)), 16 h, 4 
°C. R represents Npt- or nBu-, MeO-PEG(2000)-, propargyl, or azide 
initiators, n is the number of repeating units of the glutamic block and 
m the ethylene glycol units. 
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2.2.3.1. Classic conditions. Catalytic hydrogenation vs. 
Acidic conditions. 
To begin with, two methodologies for the removal of benzyl 
groups for homopolymers synthesis were studied. First, the use of 
acidic media with HBr/TFA and second, catalytic hydrogenation with 
the use of H2 atmosphere with Pd(OH)2/C as catalyst. Both of them lead 
to complete removal of benzyl groups, however, HBr/TFA was chosen 
due to simplicity of reaction conditions, higher yields obtained 
(quantitative versus 40 %) and the easier work up. As mentioned 
before, catalytic hydrogenation presents the handicap of the removal of 
Carbon afterwards using specific purification methods (celite columns), 
which can be the cause of the poor yield obtained.  
Standard acidic conditions (HBr/TFA) were optimized for the 
deprotection of homopolymers. In order to avoid polymer damage, 
different eq. of HBr as well as different reaction times were evaluated 
to establish the minimum amounts and reaction time to yield complete 
deprotection. Classical use of 4 eq. of HBr per carboxylic group in TFA 
solution were reduced to 2 eq. and complete removal of protecting 
groups was observed after 5 hours reacting at r.t.. Polymers were 
obtained in quantitative yields, after purification by precipitation into a 
large excess of cold diethyl ether leading to a white solid that was 
recovered after centrifugation. After washing with diethyl ether, the 
product was then purified by acid-base precipitation (NaHCO3 /HCl 6 
M). Dialysis, ultrafiltration or Sephadex G25 columns were done 
leading to the sodium salt form. Once purified, polymers were 
characterized by 1H-NMR. In Figure 2.13 it is shown the characteristic 
1H-NMR spectrum of α-polyglutamic acid (PGA) (9). Figure 2.14b 
shows the typical random coil conformation obtained in CD of 
deprotected PGAs of different MW ranging from 50-400 GAU.  
Importantly, longer reaction times (up to 16 h) are required 
when undertaking large scale deprotection at acidic conditions to ensure 
full benzyl group removal and polypeptide stability.  
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Figure 2.13. 1H-NMR spectrum in D2O of nBu initiated PGA 
deprotected (9a). 
a)                                                b) 
 
Figure 2.14. a) 1H-NMR (D2O) analysis of PGAs (9b) with different 
DP (50, 100, 200 and 400). In red is pointed out the signal of the 
initiator used (neopentyl) indicating polymer integrity after 
deprotection. b) CD spectra in ddH2O at 20 °C. 
Thus, it was demonstrated that HBr/TFA acidic method lead to 
well-defined PGA polymer chains with complete removal of benzylic 
groups without chain cleavage, avoiding racemization processes. 
Nonetheless, is not a suitable method for deprotection of hybrid di-
block copolymers PEG-PBLG, since HBr is a common reagent used for 
ethers cleavage. To confirm the damage produced to the PEG block, 
PEG stability studies under acidic and basic conditions were performed 
obtaining the GPC profiles (Figure 2.15). This study clearly showed 
that HBr/TFA deprotection is not applicable for PEG-PBLG. 
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Figure 2.15. PEG exposure to deprotection conditions: GPC traces 
(refractive index). Red: HBr/TFA treatment, blue: Pd/C, black: LiOH, 
green: non-treated. 
2.2.3.2. Basic conditions optimization. 
In respect to the exposed need for a suitable method to 
deprotect polypeptides bearing sensitive groups to both acidic and 
catalytic hydrogenation conditions, a basic deprotection protocol was 
developed. 
First of all, and in order to validate the possible use of basic 
deprotections, different assays using LiOH and NaOH were carried out 
by subjecting PEG to different conditions summarized in Table 2.6. 
The resulting polymers were analyzed by GPC and proton NMR to 
check PEG integrity after exposure time and purification. Within this 
first study, it was concluded that PEG chains did not resulted damaged 
with the use of sodium hydroxide solutions. This encouraged us to 
continue with the optimization of basic conditions.  
Kataoka’s protocol for PEG-poly(β-benzyl L-aspartate) 
deprotection108 was proposed as a first approach. Within this method, 
benzyl groups from aspartate units are easily removed by using a 
solution of NaOH at 0 °C during 10 minutes. However, when those 
conditions were applied to the deprotection of PBLG, using mixtures of 
THF/H2O in order to solubilize the products, deprotection did not 
occur. For that reason, longer reaction times, as well as control over the 
eq. of NaOH added were studied to achieve our purpose. In a first trial 
showed in Table 2.6, 2 eq. of NaOH and 5 h at 25 °C were used to 
deprotect PEG-PBLG (8), resulting in complete deprotection as 
analyzed by 1H-NMR in order to estimate the deprotection efficacy. 
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Table 2.6. Evaluation of different basic conditions. 
 
Method eq. t (h) 
Bz 
removal 
PEG 
integritya 
PEG 
integrityb 
PEG2000-PGA71 LiOH 4 24 √ X - 
PEG2000-PGA71 NaOH 4 24 √ X - 
MeO-PEG2000 LiOH 4 24 - X - 
MeO-PEG2000 NaOH 4 24 - X - 
MeO-PEG2000 LiOH 2 7 - X 
 
MeO-PEG2000 NaOH 2 7 - X - 
MeO-PEG20000 NaOH 2 5 - - √ 
PEG2000-PGA71 NaOH 2 5 √ √ - 
a. 1H-NMR data, b. GPC data, eq.: eq. GAU 
2.2.3.2.1. Optimization with/for homopolymers. 
With 2 eq. of NaOH, at 25 °C and 5 hours as a starting point, 
conditions were optimized using homopolymers, in order to assess the 
balance between complete deprotection and avoidance of racemization 
processes. This basic deprotection study of polyglutamates was carried 
out varying parameters such as reaction time, NaOH eq. and 
THF/ddH2O ratio.  
In all cases, 50 mg of polymer were dissolved in THF at r.t. 
Then, solution was cooled down and maintained under stirring at 4 °C. 
Finally NaOH solution was added drop wise. Turbidity was found in all 
cases once NaOH was added. Solutions were left under vigorous 
stirring the desire time. The organic solvent was removed under 
vacuum, and the aqueous phase was purified by ultracentrifugation 
using a Vivaspin® (MWCO 3000 Da).  
The study was monitored by polarimeter measurements to 
evaluate α coefficient as a measure of the rotation angle of polarized 
light. Each sample was dissolved in ddH2O at 10 mg∙mL-1 concentration 
and average data was obtained after 20 measurements. The obtained 
products were analyzed by 1H-NMR to prove complete deprotection. 
The alpha carbon of the amino acids is a chiral carbon that 
provides optical activity to the molecule. Amino acids in nature have an 
L configuration, which is related to rotation of the plane of polarized 
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light to the left giving negative α values. The rotation degree of 
polarized light depends on the number of chiral molecules that it 
encounters through the polarimeter cell. In this study, the synthesized 
glutamic acid NCA possess an L conformation that it must be retained 
during polymerization process if polymerization is initiated by a 
nucleophile, and not a base. This is the case of the described 
methodology within this work. L configuration must be also retained 
after deprotection to ensure biocompatibility of the polymeric carriers 
synthesized. 
As the purpose of the study was to find appropriate basic 
conditions were racemization does not occur, each deprotected polymer 
was evaluated to determine its specific rotation ([α]Tλ), value that was 
calculated according to the literature with the formula in Equation 1.1. 
 
cL
T

 100   
Equation 1.1. Formula of the specific rotation [α] of the polypeptide 
chain. α= observed rotation, L= polarimeter cell length (dm), c= 
concentration (g∙100∙mL-1) and T= temperature. 
As strong basic conditions can damage the stereochemistry of 
glutamic acid units by deprotection of alpha proton and subsequent 
reprotonation, the protocol was modified to find softer conditions. For 
that reason, a whole studied was carried out at 4 °C. In a first approach, 
THF/ddH2O ratio was varied, using a decreased amount of NaOH eq. 
(1.2) and 24 hours as reaction time (Table 2.7). The best THF/ddH2O 
ratio value found so far, according to α measurements was 8:1.  
Table 2.7. Optimization of THF/ddH2O (v/v) ratio and concentration 
with 1.2 eq., 24 hours. 
 
eq. 
GAU 
eq. 
NaOH 
THF: 
H2O  
αav SD 
%s2 
coeff 
[α]25λ 
PBLG  
(45 GAU) 
 
1 1.2 4:1 -0.146 0.001 -0.727 -1.46 
1 1.2 5.3:1 -0.283 0.001 -0.473 -2.83 
1 1.2 8:1 -0.311 0.001 -0.428 -3.11 
Reaction time was still too long in order to prevent 
racemization, nevertheless, when reaction time was decreased to 16 
hours using only 1.2 eq. of NaOH per carboxylic group, complete 
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deprotection was not achieved. For that reason, the study was repeated 
using 1.5 eq. and a reaction time of 16 hours. Results validated as 
optimum THF/ddH2O ratio the founded before (8:1). Interestingly, 
when higher ratios of THF/ddH2O were used, deprotection did not 
occurred, probably due to limited accessibility of NaOH to the polymer 
chains (Table 2.8). 
Table 2.8. Optimization of the THF/ddH2O ratio and concentration 
with 1.5 eq., 16 hours. 
 
eq. 
GAU 
eq. 
NaOH 
THF: 
H2O 
αav SD %s2 coeff [α]25λ 
PBLG 
(45 GAU) 
1 1.5 64:1 * 
1 1.5 32:1 * 
1 1.5 16:1 -0.466 0.002 -0.330 -4.66 
1 1.5 8:1 -0.479 0.002 -0.345 -4.79 
1 1.5 4:1 -0.237 0.001 -0.598 -2.37 
Once the optimal ratio THF/ddH2O was established, reaction 
time was varied by using 1.5 eq. of NaOH. Results summarized in 
Table 2.9 lead to the conclusion that, although 8 hours were enough 
time (and minimum needed) to achieve complete PBLG deprotection, 
the best α value was obtained for 16 hours reaction time. Reduced 
reaction times did not end up in deprotection. 
Table 2.9. Time optimization using 8:1 THF/ddH2O and 1.5 eq. NaOH. 
 
eq. 
GAU 
eq. 
NaOH 
t 
(h) 
αav SD %s2 coeff [α]25λ 
PBLG 
(45 GAU) 
1 1.5 2 * 
   
1 1.5 4 * 
   
1 1.5 6 * 
   
1 1.5 8 -0.484 0.002 -0.758 -4.84 
1 1.5 16 -0.615 0.002 -0.287 -6.15 
As conclusion, it can be said that the use of 1.5 eq. NaOH, 16 
hours and THF/ddH20 8:1 efficiently deprotected PBLG, with the 
highest negative α value that we could obtained, being around -0.6. To 
our knowledge, there was no information available on literature to 
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assess whether those values are enough to undoubtedly claim that 
racemization processes are not occurring. For that reason, α values of 
comparable polymers with well-known L configurations were studied: 
(i) In one hand, L-polyglutamates obtained by solid phase 
peptide synthesis (SPPS). (ii) On the other hand, HBr deprotected 
polyglutamates obtained by our methodology. As mentioned before, 
acid deprotection has been demonstrated not to affect the 
stereochemistry of the initial polymer. (iii) A commercial deprotected 
PGAn with different GA units (n= 100, 200 and 300). 
Comparison with SPPS polymers will allow us to confirm that 
racemization processes did not occur either during polymerization, 
ratifying nucleophilic initiation of the methodology described as above 
mentioned. Results obtained after measuring α values are summarized 
in Table 2.10 
Table 2.10. Observed rotation for SPPS synthesized PGA in 
comparison with commercial (Com.) PGAs and ROP-NCA synthesized 
PGA (9). 
 
αav SD %s2 coeff. [α]25λ 
Com. PGAn (n= 100) -0.567 0.001 -0.224 -5.67 
Com. PGAn (n= 200) -0.545 0.001 -0.243 -5.45 
Com. PGAn (n= 300) -0.485 0.002 -0.315 -4.85 
PGA20 HBr dep. (SPPS) -0.555 0.001 -0.210 -5.55 
PGA15 (SPPS) -0.512 0.002 -0.357 -5.12 
PGA15 (SPPS) NaOH 2 M 0.007 0.001 18.470 0.07 
As it can be extracted from Table 2.10, α values of SPPS PGA, 
commercial PGA and PGA HBr deprotected are on the same range that 
the ones achieved with the optimized basic deprotection methodology. 
Moreover, damage on stereochemistry and therefore optical activity 
caused by the use of strong basic conditions was proven by exposing 
PGA15 to concentrated NaOH (2 M) during 16 hours. This gave a 
positive α value (0.007) of complete racemization. 
Finally, the versatility of the method was validated by studying 
the deprotection of different MW polymers with the optimized 
conditions (Table 2.11). In all cases, according to α coefficients, optical 
activity remained untouched. 
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Table 2.11. Comparison of observed rotation from PGAs (9) with 
different DP after deprotection with the optimal basic protocol. 
PBLGn αav SD %s2 coeff. [α]25λ 
n= 100 -0.654 0.002 -0.331 -6.55 
n= 200 -0.659 0.002 -0.287 -6.59 
n= 400 -0.664 0.002 -0.285 -6.64 
2.2.3.2.2. Optimization with/for hybrid DB PEG-PGA. 
Once the conditions were established, the study was then 
conducted on hybrid di-block copolymers PEG-PBLG (3). 
Nevertheless, when polymers were evaluated under the same optimized 
methodology, incomplete reactions took place due to the use of 1.5 eq. 
of NaOH. For that reason, the procedure was re-optimized to deprotect 
di-block copolymers. Products were purified as for homopolymers and 
analyzed by 1H-NMR to check complete deprotection (Figure 2.16). 
Figure 2.16. 1H-NMR spectrum in D2O of di-block PEG-PGA (10) 
with the signals assigned. 
Variation of NaOH eq. was first carried out by using 16 hours 
and the ratio THF/ddH2O as fixed parameter. From the results obtained 
(Table 2.12), it was concluded that although yield was slightly 
increased, the use of more than 2 eq. NaOH began to cause changes on 
stereochemistry of the polymer chains as seen by less negative α values. 
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Table 2.12. Optimization of NaOH eq. for di-block deprotection using 
the same conditions of time and THF/ddH2O ratio (16 h, 8:1). 
 
eq. 
NaOH 
αav SD %s2 coeff. [α]25λ 
PEG-PGAn 
(50 GAU) 
2 -0.551 0.002 -0.294 -5.51 
3 -0.510 0.001 -0.292 -5.10 
4 -0.440 0.005 -0.325 -4.40 
Reaction time was varied in order to achieve higher yields 
(Table 2.13). However, longer reaction times did not improve 
significantly those yields and α values were on detriment upon 
increasing reaction time. Therefore, 16 hours was established as the 
optimal time frame. 
Table 2.13. Optimization of reaction time for di-block deprotection 
using the same conditions of NaOH eq. and THF/ddH2O ratio (2, 8:1). 
 
eq. NaOH t (h) αav SD %s2 coeff. [α]25λ 
PEG-PGAn 
50 GAU 
2 16 -0.535 0.003 -0.468 -5.35 
2 21 -0.517 0.001 -0.283 -5.17 
2 24 -0.494 0.003 -0.648 -4.94 
Summarizing, complete deprotection without deviations in 
specific rotation ([α]Tλ) value of deprotected PGA was achieved. 
Moreover, the [α]Tλ values were on the range of PGA 15mers prepared 
by solid phase peptide synthesis (SPPS) independent from the 
optimized acidic or basic methodology. 
A summary of results obtained for homo and di-block 
copolymers regarding acid basic deprotection are represented in Figure 
2.17. 
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Figure 2.17. Comparison between in specific rotation ([α]Tλ) was 
performed analyzing a PGA15 synthesized by SPPS, PGA50 after acidic 
(1) and basic deprotection and PEG-PGA50 after basic deprotection as it 
is reflected in the diagram.  
The deprotection protocol enabled acidic as well as basic 
deprotection of PBLG allowing the synthesis of PEG based block 
copolymers and the incorporation of sensitive functional groups. As 
conclusions, it can be said, that, for homopolymers deprotection, 
HBr/TFA optimized method was preferred since quantitative yields 
were always obtained without chain cleavage as well as without 
changes on stereochemistry of α carbons of the polymer chain. 
Moreover, for low scale reactions, reaction time is much lower when 
compared to basic protocol. For large scale reactions, the optimal 
reaction time was set as 16 hours. In the case of di-block copolymers, 
the basic protocol was always preferred in order to avoid chain 
cleavage of PEG block. In addition, this protocol was also used for the 
deprotection of PBLG bearing functional groups at the chain end 
sensitive to acidic and hydrogenation conditions. 
To draw to a close with this part, it is worth mentioning that, 
although BF4 salts have been reported to be safe,100, 109 BF4 traces have 
never been detected in 19F-NMR after removal of protection groups 
either by acidic or basic methodologies and workup (Figure 2.18). 
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a)    b) 
 
Figure 2.18. a) 19F-NMR of PBLG (2) before benzyl deprotection in 
DMSO-d6, b) 19F-NMR of PGA (8), after benzyl deprotection in 
DMSO-d6. Explanation of chemical shifts: B has two isotopes with 
spin > ½ and because the ion is symmetric one can observe quadrupole 
splitting rather than quadrupole broadening. For [(10B)F4]- 10B (19.58 % 
abundance) has spin (I) 3 so (2nI +1), n= 1 resonance will be split into 
seven lines of equal intensity (19.58/7). On top of this (chemical shift 
probably but not necessarily the same) [(11B)F4] 11B (80.42 % abundant) 
has spin 3/2 so (2nI +1) resonance will be split into 4 lines of equal 
intensity so about 20 % (80/4) with a different B-F coupling. 
2.3. CONCLUSIONS. 
Summarizing the above results, a new methodology for NCA 
polymerization was applied to enable easy, multigram scale synthesis 
of narrowly distributed PGA. The optimization of the monomer 
synthesis, as well as its storage was studied in a first place following a 
modification of the Fuchs-Farthing method. As every impurity with 
nucleophilic or basic character can initiate the polymerization, careful 
recrystallization and purification under dry atmosphere is necessary to 
store and to apply NCAs to reach controlled ring opening 
polymerization. Once that step was optimized, various polymerization 
parameters where adjusted such as solvent used, temperature and 
concentration in order to get well-defined polymers. Moreover, DP 
could be adjusted precisely over a long range of MWs. In addition, the 
deprotection protocol enabled acidic as well as basic deprotection of 
PBLG allowing the synthesis of PEG based block copolymers and the 
incorporation of sensitive functional groups.  
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Conformation and polydispersity are relevant parameters in the 
described methodology. Recently, Huesmann et al. have addressed both 
topics in poly(L-lysine) synthesis.104  
It has to be mentioned that large scale PGA synthesis under 
GMP conditions are currently being implemented ratifying the 
feasibility of the described methodology to enable a rapid clinical 
transfer of our PGA-based nanomedicines. Importantly, these methods 
are more widely applicable to other synthetic polypeptides or 
polypeptide-based constructs which ratifies the broad interest of this 
approach. 
 
Figure 2.19. Schematic representation of NCA polymerization 
methodology developed within this chapter.  
2.4. MATERIALS AND METHODS. 
2.4.1. Materials. 
All chemicals were reagent grade, obtained from Aldrich and 
used without further purification, unless otherwise indicated. MeO-
PEG(2000)-NH2 and H-L-Glu(OBzl)-OH were obtained from Iris 
Biotech. All solvents were of analytical grade and were dried and 
freshly distilled. Deuterated chloroform-d1, DMSO-d6, DMF-d7 and 
D2O were purchased from Deutero GmbH. Preparative SEC was 
performed using Sephadex G-25 superfine from GE as well as PD 
MiniTrap G-10 ™ columns containing 2.1 mL of Sephadex™ G-10. 
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Dialysis was performed in a Millipore ultrafiltration device fitted with a 
1, 3, or 10 kDa MWCO (Vivaspin®) regenerated cellulose membrane. 
2.4.2. Characterization techniques. 
2.4.2.1. NMR spectroscopy. 
1H and 13C-NMR spectra were recorded on a Bruker AC 300 at 
r.t. and at a frequency of 300 and 75 MHz respectively and analyzed 
using the MestreNova 6.2 software. 
2.4.2.2. DMF GPC.  
For SEC measurements in DMF containing 1g∙L-1 of lithium 
bromide as an additive, an Agilent 1100 series system was used with a 
flow rate of 1 mL∙min-1 at 30 °C as an integrated instrument, including 
three HEMA-based columns (105/103/102 Å porosity) from MZ-
Analysentechnik GmbH, a UV (275 nm) and an RI detector. Calibration 
was achieved with well-defined PEG/DMF or poly(methyl 
methacrylate) (PMMA)/DMF standards, provided by Polymer 
Standards Service (PSS)/Mainz Germany. 
2.4.2.3. HFIP GPC. 
GPC was performed with HFIP containing 3 g∙L-1 potassium 
trifluoroacetate as eluent at 40 °C. The columns were packed with 
modified silica (PFG columns particle size: 7 µm, porosity: 100 & 1000 
Å. A refractive index detector (G 1362A RID) was used to detect the 
polymer. Molecular weights were calculated using a calibration 
performed with PMMA standards (Polymer Standards Services GmbH) 
and toluene as internal standard. 
2.4.2.4. Circular Dichroism (CD).  
CD Spectroscopy was performed with a J-815 CD 
Spectrometer (JASCO Corporation) using a Peltier thermostated cell 
holder (PTC-423, JASCO Corporation) with a recirculating cooler 
(JULABO F250, JASCO Corporation). A nitrogen flow (~2.7 L∙min-1) 
was lead through the spectrometer and controlled with a nitrogen flow 
monitor (Afriso Euro-Index). Samples were dissolved in HFIP for 
protected and ddH2O for deprotected samples and diluted to a 
concentration of 0.25 mg∙mL-1. Samples were measured repeatedly (n= 
3) in a quartz cuvette with d= 0.1 cm at 20 °C. Obtained molar 
ellipticities were plotted as mean residue ellipticity. 
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2.4.2.5. Infrared (IR) spectroscopy analysis for 
polymerization monitoring.  
IR spectra were recorded using thermo scientific Nicolet 380 
FT-IR spectrometer with a spectral range 7800-350 cm-1, optical 
resolution (apodized) < 0.9 cm-1 resolution (standard) and peak-to-peak 
noise < 2.2∙10-5 abs. (> 22000:1) (1 minute scan). All samples analyzed 
were under solution or previously dissolved in DMF. Analysis was 
carried out at 25 ˚C.  
2.4.2.6. Polarimetry.  
Chirality of deprotected polymers was checked using the 
automatic polarimeter Jasco P1020 measuring 3 times x20 scans each. 
Solutions were all prepared in ddH2O at 10 mg∙mL-1. Analysis were 
carried out at 25 °C. 
2.4.3. Protocols. 
2.4.3.1. NCA monomer synthesis. Synthesis of γ-benzyl L-
Glutamate N-carboxyanhydride (NCA) (1). 
H-L-Glu(OBzl)-OH (17 g, 71.66 mmol, 264 g∙mol-1) was added 
to a two-neck 250 mL round bottom flask fitted with a stirrer bar, reflux 
column, dropping funnel and an argon in and outlet. The apparatus was 
purged with Ar for 5 min. Afterwards anhydrous (anh.) THF (120 mL) 
was added and the contents were heated to 60 °C. Limonene (11.6 mL, 
71.66 mmol, 1 eq.) was added to the stirring suspension before 
diphosgene (5.2 mL, 8.5 g, 43 mmol, 0.6 eq.) dissolved in THF (10 mL, 
anh.) was added via a dropping funnel over a period of 10 min. The 
reaction was left stirring for 3 hours at 60 °C whilst purging with Ar 
leading to a clear solution. The reaction mixture was bubbled with Ar to 
aid the removal of remaining HCl for 2 hours whilst the Ar outlet was 
directed through an aqueous 1 M sodium NaOH to neutralize the gas. 
The reaction solvent was reduced to a quarter of the original volume by 
rotary evaporation and ethyl acetate (32 mL) was added. The contents 
were added to ice cold hexane (200 mL) to form a white precipitate, 
which was isolated by vacuum filtration and washed with cold hexane. 
The solid was recrystallized from toluene (50 mL, anh.) and THF (30 
mL, anh.) under inert atmosphere (N2 or Ar) by using a 250 mL two 
neck-flask 250 round bottom flask fitted with a stirrer bar, reflux 
column and an argon inlet and outlet where crystallization was induced 
by a drop wise addition of cold hexane (27 mL). Finally the white 
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crystals were filtered under Ar conditions by using Schlenk techniques, 
and stored at -20 °C. 
To ensure that residual HCl had been successfully remove, 
NCA (2-4 mg) was dissolved in THF (0.5 mL) and added to a 0.1 mmol 
silver nitrate solution (1 mL) where the solution remained clear. When 
Ag+ and Cl- ions meet they form the colorless insoluble AgCl salt, 
which can be easily detected. Another test is checking the solubility in 
THF. The NCA is soluble in THF, if turbidity is seen in the solution, 
can be due to the presence of remaining hexane and should disappear 
by heating the solution, but if precipitation is seen is due to the 
presence of polymer or starting material (both not soluble in THF). 
Yields: 70-80 %. mp: 93.4 °C. 1H-NMR: δH (300 MHz, CDCl3): 
2.00-2.30 (2H, m, CH2), 2.52-2.60 (2H, m, CH2), 4.30-4.34 (1H, t, CH), 
5.09 (2H, s, OCH2), 6.40 (1H, s, NH), 7.30 (5H, m, Ph).13C-NMR: δC 
(75 MHz, CDCl3) 27.5, 30.6, 57.6, 67.8, 129.2, 129.4, 129.5, 135.9, 
152.4, 170.2, 173.3. 
2.4.3.2. General method for the preparation of 
Hydrochloride salts. 
In a one-neck 100 mL round bottom flask, 10 mL (7.4 g, 101 
mmol) n-butylamine were added to 20 mL of dichloromethane. The 
mixture was cooled in an ice bath and 8.43 mL (101 mmol) of 
concentrated hydrochloric acid was slowly added. The mixture was 
concentrated in vacuo until white crystals started to precipitate. The 
crystals were filtrated and recrystallized from dichloromethane.  
Yield: 87 % of white needles. 1H-NMR: δH (300 MHz, DMSO-
d6) 8.13 (3H, s), 2.72 (2H, t), 1.53 (2H, quint), 1.31 (1H, sext), 0.86 
(1H, t). 
2.4.3.3. General method for the preparation of BF4 salts. 
These salts were easily prepared by reaction of the 
corresponding amine with tetrafluoroboric acid diethyl ether complex, 
HBF4∙Et2O, and posterior purification by recrystallization. 
2.4.3.3.1. Synthesis of tetrafluoroborate n-
butylammonium salt (3). 
Butylamine (200 mg, 2.7 mmol) was dissolved in 1 mL diethyl 
ether, and 442 mg (2.7 mmol) of HBF4∙Et2O, was added to the solution 
leading to the formation of a white solid salt in a quantitative yield. The 
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product was filtered off and recrystallized two times from ethyl acetate. 
The product was then dried under high vacuum and stored at -20 °C.  
Yield: 50 % of a white solid. 1H-NMR δH (300 MHz, DMSO-
d6) 7.58 (3H, s), 2.84-2.71 (2H, m), 1.56-1.43 (2H, m), 1.39-1.25 (2H, 
m), 0.89 (3H, t) 13C-NMR δC (75 MHz, DMSO-d6) 38.64, 29.09, 19.08, 
13.49. EA: C: 29.61 % (calc.: 29.85 %), H: 7.27 % (calc.: 7.51 %), N: 
8.60 % (calc.: 8.70 %). 
2.4.3.3.2. Synthesis of tetrafluoroborate 
neopentylammonium salt (4). 
To 5 mL (5.59 g, 36.74 mmol) of HBF4∙Et2O, 4.31 mL (3.20 g, 
36.74 mmol) of neopentylamine were slowly added. The addition 
resulted in the precipitation of a white solid. The solvent was removed 
under vacuum and the solid was recrystallized twice from ethyl acetate 
and washed with cyclohexane. The product was dried under vacuum.  
Yield: 42 % of a white solid. 1H-NMR δH (300 MHz, DMSO-
d6) 7.58 (3H, s), 2.63 (2H, s), 0.93 (9H, s) (Fig. 5S). 13C-NMR δC (75 
MHz, DMSO-d6) 49.94, 30.21, 26.78 EA: C: 34.35 % (calc.: 34.43 %), 
H: 7.99 % (calc.: 8.06 %), N: 8.07 % (calc.: 8.00 %).  
2.4.3.3.3. Synthesis of tetrafluoroborate PEGammonium 
salts (5). 
MeO-PEG(2000)-amine (600 mg, 0.3 mmol, 1892 g∙mol-1) was 
dissolve in 3 mL of THF, and 53.4 mg (0.3 mmol, 45 µL) of 
HBF4∙Et2O, was added to the solution leading to the formation of a faint 
yellow salt in a quantitative yield. The solvent was removed in a rotary 
evaporator. Solvent was evaporated and the solid residue was washed 
three times with hexane (washes were repeated until pH was not 
acidic). The product was then dried under high vacuum and stored at -
20 °C.  
Yield: Quantitative.1H-NMR δH (300 MHz, DMSO-d6) 7.69 
(3H, s), 3.78-3.70 (2H, m), 3.52 (139H, d), 3.47-3.39 (6H, m), 3.24 
(3H, s), 3.06-2.91 (2H, m) 
2.4.3.4. General procedure for NCA polymerization. 
Synthesis of poly(γ-benzyl L-Glutamate) (PBLG) (2) under N2 
conditions by using Schlenk techniques. 
OBzl(Glu) NCA (0.5 g, 1.9 mmol, 264 g∙mol-1) was added to a 
Schlenk tube fitted with a stirrer bar, a stopper and purged with 3 cycles 
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of vacuum/Ar, under Ar flow and dissolved in 5 mL of solvent (freshly 
purified). Afterwards the initiator was added and the mixture was left 
stirring at 40 °C in an oil bath for 3 days under Ar/N2 atmosphere with 
constant pressure. After 3 days reacting, the solution was poured into 40 
mL of cold diethyl ether leading to a white suspension that was 
centrifuged at 4.000 rpm during 10 minutes. Supernatant was removed 
and the white solid was then suspended in ddH2O and freeze-dried.  
Yield: 70-90 %. 1H-NMR δH (300 MHz, DMF-d7) 8.58 (1H, s), 
7.42 (5H, s), 5.19 (2H, s), 4.21 (1H, s), 2.81 (2H, s), 2.45 (2H, s). 13C-
NMR δC (75 MHz, DMF-d7) 175.94 (s), 172.26 (s), 162.77-162.18 (m), 
161.98 (s), 136.76 (s), 128.87 - 127.75 (m), 66.05 (s), 57.13 (s), 35.41-
34.17 (m), 32.48 (s), 30.84, 30.30-29.04 (m), 27.28 (s), 25.99 (s). 
*Note: the corresponding signals of initiator depend on the 
initiator used: n-butyl ammonium; neopentyl ammonium or methoxy 
polyethylene glycol ammonium. 
2.4.3.5. NCA polymerization kinetics. 
OBzl(Glu) NCA (0.6 g, 2.27 mmol, 264 g∙mol-1) was dissolved 
in 6 mL of previously purified DMF. The content was split into 6 
Schlenk tubes fitted with a stirrer bar, a stopper, and under N2 
atmosphere. Afterwards, a solution in DMF of initiator was prepared, 
and the corresponding amount was added to each tube. The mixtures 
were left stirring at 40 °C in an oil bath for 4 days under Ar/N2 
atmosphere with constant pressure. Time points of kinetics were 
collected each 14, 22, 38, 46, 70, and 96 hours, by precipitation of the 
polymers into diethyl ether tree times, freeze-dry of the sample in 
ddH2O and GPC analysis of the MW eluting with DMF/LiBr.  
2.4.3.6. Deprotection of PBLG. 
2.4.3.6.1. Deprotection of PBLG under catalytic 
hydrogenation with Pd(OH)2 Charcoal in DMF. 
100 mg (0.0035 mmol, 28251 g∙mol-1) of PBLG was dissolved 
in 15 mL DMF absolute, in a round bottom flask fitted with a septum 
and a stirring bar. Then Pd(OH)2 Charcoal was added and the flask was 
purged with N2 in order to remove air and afterwards N2 was removed 
by purging with H2. The reaction was left stirring for two days under H2 
atmosphere (with a balloon full of H2). Purification was carried out 
pouring the solution into a large excess of diethyl ether. Centrifugation 
leads to a mixture of a white solid with palladium/charcoal. The solid 
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was re-dissolved in acidic water and filtered through a celite column in 
a syringe and a filter. As a result, PGA (9) was obtained as a white 
powder. 
Yield: 40 %. 1H-NMR δH (300 MHz, D2O) 4.31-4.26 (1H, m), 
2.38-2.14 (2H, m) 2.10-1.80 (2H, m) 2.10-1.80 (2H, m). 
2.4.3.6.2. Deprotection of PBLG with HBr in 
trifluoroacetic acid. Optimal conditions. 
In a round bottom flask fitted with a glass stopper and a stirrer 
bar, 100 mg of PBLG (0.0035 mmol) were dissolved in 3 mL TFA. 
Once dissolved, 2 eq. of HBr (48 % v/v, 1.49 g∙cm-3, 81 g∙mol-1) per 
carboxylic group were added drop wise, and the yellow mixture was 
left stirring for 5 hours. *Note: For big scale deprotection of PBLG (> 
600 mg), 16 hours were needed in order to achieve full deprotection. 
Then, the solution was poured into a large excess of cold diethyl ether 
leading to a white solid that was recovered after centrifugation (2600 
rpm, 4 °C, 10 minutes). The product (9) was washed per triplicate with 
diethyl ether and dried over high vacuum. After that, the product was 
then purified by acid-base precipitation (NaHCO3 /HCl 6 M). Dialysis 
or ultrafiltration was done leading to the sodium salt form.  
Yield: 75-86 %. 1H-NMR δH (300 MHz, D2O) 4.31-4.26 (1H, 
m), 2.38-2.14 (2H, m) 2.10-1.80 (2H, m) 2.10-1.80 (2H, m). 
2.4.3.6.3. Basic deprotection with NaOH aq./THF 
mixture. Optimal conditions. 
HOMOPOLYMER (9): In a round bottom flask, PBLG (5.1 
μmol, 9760 g∙mol-1, 50 GAU) was dissolved in THF (16 mL) at r.t. 
Then, the solution was cool down up to 4 °C and kept under stirring. In 
a vial, 1.5 eq. of NaOH per carboxylic group (7.7 μmol, 40 g∙mol-1) 
were dissolved in 2 mL of ddH2O and then added to the main solution 
drop wise. Turbidity was found after NaOH addition. The solutions 
were left under vigorous stirring for 16 h. Afterwards, THF was 
removed by evaporation. The residue was diluted with ddH2O, 
concentrated and purified by ultrafiltration (Vivaspin®, MWCO 3000 
Da). Upper part of the tube was freeze dried and the obtained white 
solid was analyzed by NMR (D2O). 
Yield: 40-60 %. 1H-NMR δH (300 MHz, D2O) 4.31-4.26 (1H, 
m), 2.38-2.14 (2H, m) 2.10-1.80 (2H, m) 2.10-1.80 (2H, m). 
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DI-BLOCK (10): In a 50 mL round bottom flask, protected di-
block (0.184 mmol, 12208 g∙mol-1, 50 GAU) was dissolved in 16 mL of 
THF at r.t. Then, the solution was cooled down up to 4 °C and kept 
under stirring. In a vial, 2 eq. of NaOH per carboxylic group of the 
polypeptide block (0.369 mmol, 40 g∙mol-1) were dissolved in 2 mL of 
ddH2O and then added to the main solution drop wise. Turbidity was 
found after NaOH addition. The solutions were left under vigorous 
stirring for 16 h. Afterwards, THF was removed under evaporation and 
the residue was diluted with ddH2O, concentrated and purified by 
ultrafiltration (Vivaspin®, MWCO 3000 Da). Upper part of the tube 
was freeze dried and the obtained white solid was analyzed by NMR 
(D2O). 
Yield: 40-70 %. 1H-NMR δH (300 MHz, D2O) 4.16 (1H, m), 
3.45 (xH, m), 2.13 (2H, m), 1.76-1.89 (2H, m). i.e. DB50 (δ) 1.76-1.89 
(100H, m), 2.13 (100H, m), 3.45 (172H, m), 4.16 (50H, m). 
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3.1. INTRODUCTION AND BACKGROUND. 
As stated in Chapter 1, there is still an urgent need for the 
development of new and smart polymeric systems. Key desirable 
characteristics of these new upcoming systems are higher MW and 
degree of homogeneity, predictable conformations in solution, 
multivalency and increased drug loading capacity among others.  
Recent efforts in the field are devoted towards novel 
biodegradable polymers as they allow utilization of higher MW 
platforms to optimize PK, essential for the treatment of diseases that 
require chronic administration, such as neurological disorders or tissue 
regeneration.1 Apart from biodegradability, the development of novel 
well-defined architectures with higher MW, predictable structure and 
conformation, higher homogeneity, greater drug loading capacity and 
increased multivalency is considered crucial. In this context, the use of 
branched polymers is emerging in order to accomplish the previously 
described requisites. They exhibit special properties when compared to 
the linear analogues as a result of their different architectures, solution 
conformations, sizes and shapes as well as greater multivalency, what 
could yield to different therapeutic output.2, 3 Branched polymers 
include star,4 hyperbranched and dendritic-like polymers,5 dendrimers,6 
graft, brush and comb-like polymers7 as well as polymer networks.8 
(Figure 3.1). 
 
Figure 3.1. Examples of branched architectures. 
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3.1.1. Star polymers definition.  
Star polymers are branched polymers consisting on several 
linear chains attached to a central core. They can be sub-classified 
depending on the nature of the different branches: if the branches are 
identical linear chains they are named “Symmetric Stars”, if the branches 
have different MW or topology they are considered as “Asymmetric 
Stars”, and as “Miktoarm Stars” if the branches are chemically different. In 
all cases, these arms can be constituted by one-block or multi-block 
copolymers. 
This special category of polymers has become popular in different 
research areas (chemistry, physics, biochemistry and engineering) due to 
the unique mechanical, rheological, as well as biomedical properties that 
are unreachable for linear polymers.9-11  
As general basis, star polymers are characterized by a compact 
structure, presumably with globular shape, and have large surface areas, 
increased concentrations of end groups with functionalities, when 
compared to polymers with similar MW. Moreover, they offer unique 
rheological properties which make them optimal platforms for drug 
delivery12 among other biological applications.13 Furthermore, multi-arm 
stars as well as hyperbranched polymers show enhanced solubility, lower 
melt viscosity, different thermal and physical properties in general, in 
comparison to their corresponding linear structures.14 Viscosity and other 
properties depend more on arm MW than on the total MW of the star 
polymer.15 If compared to dendrimers, star polymers offer the advantages 
of feature accelerated and tunable methods of synthesis. Apart from bio-
applications, these unique materials are being considered of growing 
interest in other areas as thermoplastics,16 nanoelectronics17 and many other 
applications.10, 11 
As stated before, star polymers are defined by a smaller size and 
therefore higher segment density as judged against to linear polymers with 
the same MW. One of the most appealing properties, apart from their 
rheological characteristics and thermoplastic character, is their self-
assembly behavior. Nonetheless, it must be said that reports up to date 
suggest that macromolecular architecture is a key parameter for the tuning 
of micellar behavior and properties, and thus, it must be well-considered 
for the design of new materials and their potential biological applications, 
in particular as drug delivery systems.  
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3.1.2. Synthetic approaches. 
The first attempt to synthesize star polymers was in 1948 by 
Schaefgen and Flory18 who, by using the core first approach with 
multifunctional initiators such as cyclohexanenetetrapropionic or 
dicyclohexaneneoctacarboxylic acid, polymerized ε-caprolactam to give 
rise to tetra- and octa-arm star-like polyamides. Later on, Morton et al.19 
used the so-called arm first approach for the synthesis of 4-arm star 
polystyrene by neutralizing polystyryllithium living chains with 
tetrachlorosilane. From that period plentiful efforts have been done to build 
novel star-shaped architectures as well as to understand from a theoretical 
and experimental point of view,20 their unique properties arising from their 
intrinsic nature. Advances in modern polymer chemistry, especially with 
the introduction of controlled/living radical polymerizations in the 1990s, 
made possible the exponential growth of these complex materials. The 
most important polymerization techniques used comprise anionic, cationic, 
controlled radical, ring opening, ring-opening metathesis, group transfer, 
step-growth polycondensation, metal template-assisted, and electrostatic 
self-assembly and covalent fixation methods. The advances in “click 
chemistry” represented an important contribution especially when the 
strategy followed is the arm first approach. Nevertheless, the synthetic 
methods for the development of star-related architectures are out of the 
scope of this thesis and detailed information could be obtained from 
literature.10, 11  
For the synthesis of star polymers, two major strategies have been 
widely applied: the core-first approach (divergent approach) and the arm-
first approach (convergent approach).10 
The core-first approach (or divergent approach) is anchored in 
the use of a multifunctional initiator as core that initiates the 
polymerization of several arms on a simultaneous way (Figure 3.2a). In 
order to achieve control in polymerization for the synthesis of 
homogenous constructs, it is crucial to have equally reactive initiating 
sites. Moreover, initiation step must be always faster than propagation. 
Historically, the major disadvantage of this methodology is the 
difficulty in the characterization of the polymers obtained as arm MW 
cannot be directly measured. Nevertheless, advances in characterization 
techniques are progressively solving the problem and this strategy is the 
most widely used in the synthesis of star polypeptides.21 
On the other hand, the arm-first approach (or convergent 
approach), consists on the reaction of living macromolecular chains 
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previously synthesized, with a multifunctional reagent that serves as 
core (Figure 3.2b). Two main strategies can be followed in this case; 
either by using a multifunctional molecule that will neutralize linear 
living chains (use of “multifunctional linking agents”) or can be based 
on the covalent attachment of telechelic linear polymers to a 
multifunctional central core (“coupling onto”). The main advantage of 
the “arm first” approach is that characterization should be easier since 
the living arms can be characterized in a previous step before linking. 
Nevertheless, the main disadvantage of this methodology is the steric 
hindrance component which could limit the number of arms linked. 
Moreover a large excess of living chains is always a requisite. For that 
reason, and in order to get star polymers with high purity, purification-
fractionation steps are unavoidable. 
 
Figure 3.2. Synthetic approaches for the preparation of peptide-based 
star polymers via (a) core-first or divergent approach; b) arm first or 
convergent approach; c) core-cross linked stars. 
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Besides these two widely used approaches, a latest 
classification takes into account a new synthetic strategy (Figure 3.2c). 
This approach consists on the reaction of living macroinitiators (MI) 
(also named macromonomers) with multifunctional molecules acting as 
cross-linkers giving rise to star-shaped architectures known as core 
cross-linked star (CCS) polymers.22  
3.1.3. Drug delivery applications. 
There are plenty of examples of drug encapsulations within these 
unique architectures due to their inherent nature.23 However, only few 
examples can be found in literature on their use as polymer-drug 
conjugates and they are still far to enter any clinical stage. Most of 
them are based on the use of the well-known HPMA copolymers.24 For 
instance, in 2000 Wang et al.25 reported the synthesis of star-like 
HPMA by conjugating semitelechelic HPMA macromolecules to 
PAMAM dendrimers from generations G2 to G4 as core. DOX was 
then conjugated to HPMA chains. Jelínková et al.26 compared two 
different antibody-targeted HPMA copolymers of -GlyPheLeuGly-
DOX (star-like vs. linear HPMA). The star-like conjugate consisted on 
30 to 40 copolymer chains of HPMA bearing DOX linked to the central 
antibody molecule via an amide bond between the end of each 
backbone chain and the lysine ε-amino groups of the antibody. Whereas 
binding affinity was independent from the polymer architecture, the 
star-like conjugate exhibited 10-fold higher cytotoxic effect in vitro in 
different cancer cell lines and 6.5-fold higher concentration in blood in 
biodistribution studies in mice, as compared to their linear counterparts. 
Both types of anti-Thy-1.2 targeted conjugates cured all mice bearing 
T-cell lymphoma EL4, however, the star-like conjugates containing 
anti-CD71/A or B antibodies performed better than classic linear ones 
in colorectal cancer SW 620. 
Then, Etrych et al.27 described the synthesis of a family of new 
biodegradable star polymer-DOX conjugates based also on a 
macromolecular core formed by PAMAM dendrimers from which 
semitelechelic HPMA copolymer DOX conjugates (hydrazone linked) 
were grafted. They were able to synthesize different MW constructs 
from 200 to 1000 g.mol-1 with relatively low Đ (~1.7). The star 
conjugates exhibited higher in vivo anti-tumor activities when 
compared to the free DOX or linear polymer conjugates in a EL4T-cell 
lymphoma mouse model.28 Previously, the same group has developed 
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star-shaped immunoglobulin-containing HPMA-based conjugates29 
with hydrazone-DOX, that showed comparable cytostatic activity as for 
free DOX.HCl in several cancer cell lines, and significantly higher 
antitumor activity in vivo in mice bearing EL4 T-cell lymphoma than 
immunoglobulin free conjugates. 
Another example of hybrid dendritic-star like polymers is the 
work of Cao et al.30 who reported the synthesis of a dendrimer-like star 
polymer based on well-defined poly(L-lactic acid) (PLLA) star polymer 
with six carboxylic acid-terminated polyester dendrons of 2,2-
bis(hydroxymethyl)propionic acid. Amine-functionalized folic acid 
moieties were effectively conjugated and uptake of those constructs 
was much higher than for non-targeted ones against mouth epidermal 
carcinoma (KB) cells (overexpressing folate-receptor). 
Kowalczuk et al.31 described the synthesis of star-shaped 
cysplatin nanoconjugates (12-14 nm radii) based on a highly branched 
poly(styrene) core and poly(tert-butyl acrylate) arms. They were able to 
achieve a high cysplatin loading (45 wt %) and their in vitro evaluation 
showed a sustained drug release, an endocytic mechanism of uptake, 
and a lower cytotoxic effect when compared to the free drug.  
Very recently, Li et al.32 published nanoparticle systems (~15 
nm radii) based on star polymers as theranostic vectors bearing 
aldehyde groups for the covalent conjugation of DOX and activated 
esters for the 1-(5-amino-3-aza-2-oxypentyl)-4,7,10-tris(tert-
butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane (DO3A-tBu-
NH2)—a Gadolinium (Gd3+) chelating agent. Among other results, they 
found that the DOX/Gd-conjugated nanoparticles yielded a similar IC50 
to free DOX for breast cancer cell lines, confirming DOX integrity after 
nanoparticle conjugation. Moreover, relaxivity of Gd loaded in star-
shaped polymers was found to be 3 times higher than conventional 
organic non-polymeric Gd/DO3A complexes. 
Navath et al. reported the synthesis and biological evaluation of 
N-Acetyl cystein (NAC) conjugated to 6, and 8 PEG star-shaped 
polymers via disulfide bonds for applications in neuroinflammation.33 
Conjugates diameter sizes were between 21-28 nm and 34-43 nm for 6 
arm an 8 arm, respectively. The two synthesized constructs showed a 
release of NAC of 74 % in 2 hours when exposed to glutathione (GSH) 
at intracellular concentrations (2-10 mM) whereas no release was 
observed with extracellular concentrations of GSH (2 µM). The 
conjugates showed 2-fold increased antioxidant activity compared to 
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free drug when they were tested by monitoring cytokine release in 
lipopolysaccharide (LPS) induced inﬂammatory response in microglial 
cells looking at the ROS (reactive oxygen species), NO (free radical 
nitrile), anti-inﬂammatory activity and GSH depletion.  
There are also some examples of star-polymer-drug conjugates 
for antifungal applications. Sedlák et al., in 2008 reported the synthesis 
of β-glucosidase-sensitive star-PEG-Amphotericin B (AmB) 
conjugates. Amphotericin B is a powerful antifungal drug.34 By the use 
of the linker β-D-glucopyranoside (molecular switch sensitive to β-
glucosidases), the release of AmB is ensured to occur only in parasital 
fungal pathogens that have specific hydrolase β-glucosidases, and not 
in healthy human tissues where these enzymes are not present. Their 
preliminary studies showed an efficient targeted delivery at the areas of 
activity of pathogens. The same group has used the star-shaped PEG 
platform described before as drug delivery carrier for the antifungal 
agent nystatin, with similar results.35  
3.1.4. Star polypeptides. Antecedents. 
Various polypeptide-based star polymers have been synthesized 
over the years. For example, Klok et al.36 used perylene derivatives 
with four primary amine groups as initiators to lead 4-arm PBLG and 
PZLL and Inoue et al.9 used hexafunctional initiators for the synthesis 
of 6-arm PBLG star polymers both taking profit of the NCA 
polymerization techniques. Other examples are provided from the work 
of Aliferis et al.37 who used 2-(aminomethyl)-2-methyl-1,3-
propanediamine as a trifunctional initiator for the synthesis of P(BLL-
b-BLG)3 3-arm star-block co-polypeptides; or the studies of Karatzas et 
al.38 in the synthesis of 4-arm (PEO-b-PBLG)4 hybrid star block co-
polymers using four-arm PEO stars end-functionalized with primary 
amines as initiators to polymerize OBzl(Glu) NCA among others. 
More recent examples include the use of dendritic cores as 
initiators such as of poly(ethylene imine) (PEI),39 poly(propylene 
imine) (PPI),40, 41 or poly(amidoamine) (PAMAM).42 The examples 
listed are all based on the use of amine initiation in NCA 
polymerization techniques with the inherent limitations of the 
mentioned methodology, either leading to low MW, or star polymers 
with very broad Đ. The use of HVT from Hadjichristidis group can be 
seen as a suitable solution,37, 38 however, requirement of complex 
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equipment is always a disadvantage in order to develop a versatile 
synthetic procedure. 
Despite the fact that there is a growing interest in the 
development of hybrid and peptide-based star polymers as prospective 
advanced materials for biological applications in the field of 
nanomedicine, most of the studies undertaken to date have been 
focused on the synthesis of new and varied star polymers and their 
study in terms of self-assembly under a variety of conditions.43 Only 
recently, peptide-based star polymers have been considered and 
explored as drug delivery systems. Sulistio et al.44 synthesized peptide-
based CCS polymers composed entirely of amino acid building blocks. 
These constructs were composed of PLL arms emerging from a poly(L-
cysteine) (PLC) core and could be core-functionalized via reaction with 
primary amines bearing different functional groups (e.g., pyrene, 
alkyne). These types of stars were able to entrap hydrophobic drugs, 
such as the anti-cancer drug pirarubicin, through physical interactions 
with pyrene moieties of the core. Moreover, due to the presence of 
disulfide bonds at the core, the stars could also be cleaved by reducing 
agents such as dithiothreitol, yielding redox-sensitive polymers. Apart 
from that, the same group developed CCS polymers with PLL arms, 
PLC cores and peripheral allyl functionalities by using an allylamine 
initiator, allowing the conjugation of targeting moieties such as folic acid 
moieties for cancer cell targeting. Their in vitro studies against breast 
cancer cells showed absence of toxicity and an enhanced cell uptake for 
those CCS bearing folic acid residues. Xing et al.45 prepared CCS 
polymers using MeO-PEG1900-NH2 as a macroinitiator for ROP cysteine 
and OBzl(Glu) NCA derivatives which resulted in the formation of 
nanogels where the polymers had 9700 PEG arms and a Mw of 4.2 × 107 
Da. Those nanogels were tested in vitro in terms of cytotoxicity, being 
non-toxic and biocompatible. The hydrophobic drug indomethacin, was 
encapsulated and efficiently released using gluthathione in 
physiological media. Byrne et al. have reported the synthesis of multi-
arm star polypeptides by NCA polymerization from dendritic initiators 
based on PPI. Such systems were loaded with rhodamine B and showed 
and enzyme controlled payload release when incubated with 
thermolysin.41 The same group have recently published the 
glycosylation of those star shaped polymers and found selective binding 
to lectin ConA as a function of degree of branching and glycosylation.46 
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The examples presented are based on the encapsulation of 
hydrophobic drugs and not on a chemical conjugation, since there are 
not yet examples on literature (as far as our knowledge). Nonetheless, 
they represent good examples to point out the possible use of star-
shaped polypeptides in drug delivery applications. 
Summing up, branched polymers are outstanding aspirants as 
carriers due to their unique rheological, mechanical and biomedical 
properties derived from their structure, inaccessible for linear polymers. 
There is a wide range of opportunities in the field of PT for these 
relatively new and interesting architectures. Preliminary results suggest 
that they are non-toxic entities, validating them as possible carriers for 
drug delivery among other applications. However, there is still a long 
way to go in this respect and the true potential of these constructs has 
not yet been realized. In addition, in vivo studies must be accomplished 
in order to confirm the absence of an immunogenic response and an 
adequate fate. Furthermore, many other possible architectures, with the 
use of natural and unnatural amino acids, are yet to be unexplored, 
which may increase the versatility and applicability of these 
nanostructures.  
For that reason, one step further was taken in this work and the 
BF4 methodology for NCA polymerization was used to synthesize well-
defined branched polymers, in a divergent method from novel 
multifunctional initiators. In addition, their exhaustive physicochemical 
characterization and preliminary in vitro evaluation is also presented as 
it is considered compulsory data in the process towards their validation 
as nanocarriers. 
3.2. RESULTS AND DISCUSSION. 
The previously described methodology based on the use of BF4 
salts as initiators for NCA polymerization47 have been extended to 
synthesize well-defined 3-arm star polyglutamates (Scheme 3.1). 
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Scheme 3.1. Schematic representation of the NCA polymerization 
using star-shaped initiators. 
Control in the initiation step that this newly described 
methodology offers is key to the synthesis of branched polymers with 
predictable MW and low Đ. The use of a variety of multifunctional 
amine initiators in their BF4 salt form to ring-open polymerize 
OBzl(Glu) NCA (1), results in a fast and homogeneous initiation and 
efficient propagation to achieve well-defined architectures.  
To this aim we synthesized four different multifunctional 3-arm 
initiators, including one that contained disulfide bonds within the arms. 
In the presence of a reducing agent (Glutathione GSH, or 1,4-
dithiothreitol DTT) the star could then be disassembled into the 
individual arms. This novel initiator for polypeptide synthesis enables 
characterization of the individual arms to ensure similar chain length 
resulting from a living polymerization and efficient initiation.  
3.2.1. Initiator synthesis. 
In all cases, the synthesis of initiators was carried out starting 
from the multifunctional core 1,3,5-benzenetricarbonyl thricloride, to 
which, the mono-Boc protected diamines, N-Boc-ethylendiamine N-
Boc-1,6-hexanediamine, 1-(t-Butyloxycarbonyl-amino)-3,6-dioxa-8-
octaneamine (N-Boc-DOOA), and N-Boc-cysteamine were efficiently 
coupled in a simple and clean reaction. Briefly, reactions took place 
under inert conditions (N2 flow) where 1 eq of 1,3,5-benzenetricarbonyl 
thricloride in dried THF was reacted with 3.3 eq. of the corresponding 
Boc protected amine in the presence of N,N’,N’’-
diisopropylethylendiamine for 2 hours. Then, the dried product was 
obtained pure after several purification steps including washing and 
recrystallization (See Materials and Methods, M&M). In general, the 
mono-Boc protected 3-arm initiator precursors were carefully purified 
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to avoid di- or mono-functional cores that would lead to unwanted 
mixtures of 1- and 2-arm star polymers. 
In the case of cysteamine based initiator, a previous step for the 
synthesis of mono-Boc cysteamine (11) from cysteamine 
dihydrochloride was carried out using a general method taken from 
Girgenti et al.48 with slight modifications (Scheme 3.2). Briefly, a 
suspension of 3 eq. cysteamine dihydrochloride in chloroform was 
treated with 6 eq. of triethylendiamine and stirred for 20 minutes at r.t. 
A solution of 1 eq. di-tert-butyldicarbonate in anh. chloroform was 
added drop wise and left reacting for 16 hours more. After that, the 
product was purified according to M&M and characterized by 1H-NMR 
(Figure 3.3). 
S
SH2N NH2
O
OO
O O
S
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Scheme 3.2. Synthesis of mono-Boc cysteamine (11) from cysteamine 
dihydrochloride. 
 
a) 
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b) 
 
Figure 3.3. NMR spectra in DMSO-d6 of tert-butyl (2-((2-
aminoethyl)disulfanyl)ethyl)carbamate (mono-Boc-cysteamine) (11). a) 
1H-NMR; b) 13C-NMR. 
Once purified, the identity of the mono-Boc protected initiators 
(12) was assessed by 1D NMR (1H-NMR, 13C-NMR), with the aid of 
DEPT-135 and 2D NMR spectra (gHSQCED and COSY) for 
assignments. An example of NMR spectra and assignments is given in 
Figure 3.4 for the initiator 12a. The rest can be found in SI (Appendix 
III). 
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b) 
 
Figure 3.4. NMR spectra of 1,3,5-Tri-tert-butyl 
((benzenetricarbonyltris(azanediyl)) tris(ethane-2,1-diyl))tricarbamate 
(12a). a) 1H-NMR in DMSO-d6; b) 13C-NMR in CDCl3. 
Then, the BF4 ammonium salt initiators (13) were obtained 
simply by removal of Boc groups using tetrafluoroboric acid. Once 
more, identity of the compounds was investigated by 1H-NMR, 13C-
NMR, and 19F-NMR in this case. An example of NMR set is given for 
the initiator 13a. Other NMR spectra can be found in SI. 
a) 
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b) 
 
c) 
 
Figure 3.5. NMR spectra in D2O of 1,3,5-
(benzenetricarbonyltris(azanediyl)) triethanammonium BF4 salt (13a). 
a) 1H-NMR; b) 13C-NMR; c) 19F-NMR 
3.2.2. Synthesis of 3-arm star shaped polyglutamates through 
NCA polymerization techniques. 
Using the newly synthesized initiators, several polymerizations 
of OBzl(Glu) NCA (1) were carried out in order to prove the versatility 
of the BF4 salts based methodology in the synthesis of star-shaped 
architectures. In all cases, reactions yield 3-arm star shaped 
polyglutamates (St-PBLG) (14) with different MW ranging from 15.0-
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60.0 kDa (Table 3.1, Figure 3.6) and Đ in the range of 1-1.2 
independently of the initiator used. This fact suggests that a large 
spacer between the initiator core and the initiation site is not necessary, 
despite concerns over steric hindrance.  
Table 3.1. Variety of initiators used in the polymerization processes 
and different DPs obtained, demonstrating the versatility of the 
technique. 
Star I DPtheo 
Mna 
(kDa) 
Mnb 
(kDa) 
DPa DPb Ð 
14a_1 
Ethyl 
based 
100 21.3 21.0 97 96 1.26 
14a_2 150 24.1 27.6 110 126 1.22 
14a_3 250 50.3 51.5 229 235 1.09 
14a_4 300 59.2 60.9 270 278 1.19 
14b_1 
Hexyl 
based 
75 16.4 - 75 - 1.25 
14b_2 150 23.9 23.7 109 108 1.23 
14b_3 250 51.5 52.6 235 240 1.17 
14c_1 
DOOA 
based 
75 15.8 16.9 72 77 1.13 
14c_2 100 22.2 24.1 101 110 1.23 
14c_3 150 33.2 31.1 152 142 1.10 
14c_4 200 40.5 41.6 185 190 1.12 
14d_1 Cyst based 200 43.1 - 196 - 1.22 
a) Data obtained by SEC in DMF. b) Data obtained by 1H-
NMR, I= initiator DP= degree of polymerization, Ɖ= polydispersity. 
a)                                              b) 
 
Figure 3.6. a) Selected GPCs from St-PBLG (14a) in DMF (1 % LiBr) 
at 8 mg∙mL-1. b) CD of St-PBLG (14) at 20 °C in HFIP at 0.1 mg∙mL-1. 
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Polymers were characterized using a number of physico-
chemical analytical techniques, yielding the desired MW by GPC and 
1H-NMR. Data obtained from GPC and 1H-NMR was, in general, 
consistent with the feed ratios for polymer synthesis thus, obtaining the 
desired MW even up to 60 kDa. This is a highly significant fact and a 
major benefit offered by the technology we are describing herein, since 
most star polypeptides described in literature have not achieved high 
MW with narrow Đ.36-38, 43-45, 49 All data obtained so far indicates an 
excellent control over polymerization using these initiators, however, to 
fully demonstrate this fact, we endeavored to prove the homogeneity 
achieved on the arms MW. To do that, we employed the above-
mentioned initiator bearing disulfide bonds. The polymer synthesized 
was efficiently reduced by means of DTT, releasing the individual arms 
and allowing monitoring by SEC. Remarkably, we were able to almost 
perfectly disassemble the star polymers to yield linear chains of 1/3 
MW of the original star and with low Đ (<1.25) (Figure 3.7).  
 
Figure 3.7. GPC traces in DMF/LiBr of cysteamine initiated St-PGA 
(14d_1) before and after treatment with DTT 1 M during 72 hours. 
This evidence, in addition to the expected MW of stars from 
GPC and 1H-NMR fully demonstrate that star polymers synthesized 
have very similar length arms resulting from fast and efficient initiation 
and controlled propagation. Knowing that this synthesis of St-PBLG 
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leads to homogenous material, makes them much more favorable 
candidates to be used as drug delivery carriers or imaging probes.  
3.2.3. Deprotection of St-PBLG. 
In order to have a full understanding on the quality of the star 
polymers synthesized, the analysis of the deprotected polymers had to 
be also performed. Benzyl protecting groups were removed using 
conventional methods already reported for linear polymers.47 
Nevertheless, it was important to choose the correct deprotection 
approach depending on the initiator used. For example, to maintain the 
integrity of the DOOA core, a procedure using NaOH with previously 
optimized conditions was used.47 Standard HBr/TFA acidic conditions 
were used in all other cases. Complete removal of benzyl protecting 
groups was certified by 1H-NMR (7.4 ppm and 5.3 ppm) and the 
remaining aromatic signal observed, therefore, were assigned to the 
benzylic core of the star at 8.2 ppm (3 protons). Integration of this 
signal against those of glutamic acid provided the average number of 
units per chain and consequently, MW. After deprotection, the expected 
random coil conformation of polyglutamate chains was observed in all 
samples when analyzed using Circular Dichroism (CD) (Figure 3.8). 
Finally, DLS (Dynamic Light Scattering) at 0.2 mg∙mL-1showed 
particle sizes between 4-8 nm in all measurements (Figure 3.9).  
a)                                                    b) 
 
Figure 3.8. a) 1H-NMR of St-PGA (15c) of different MW. The red 
square is surrounding benzyl core signals. b) CD of St-PGAs (15) in PB 
at 37 °C showing typical random coil conformation of PGAs. 
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Figure 3.9. Example of particle size obtained by DLS from St-PGA 
(15) at 0.2 mg∙mL-1 in PBS 7.4 at 25 °C. 
3.2.4. In vitro biological characterization of the synthesized 
polyglutamate based architectures. 
 Key features for the validation of the newly synthesized 
polymers as potential carriers for drug delivery or imaging probes are 
their biodegradability, their toxicity in cell cultures and the way cells 
are taken them up. For that purpose, the present chapter is also devoted 
to the biological characterization of these architectures, where 
preliminary in vitro evaluation in selected cell models is described. 
3.2.4.1. In vitro Biodegradability. 
As mentioned before, PGA is a biodegradable polymer carrier. 
The degradation of poly(L-glutamic acid) by lysosomal enzymes has 
been extensively studied in vitro using purified enzymes and cell 
lysates.50, 51 These studies showed that poly(L-glutamic acid) is more 
susceptible to lysosomal degradation than poly(aspartic acid) and 
poly(D-glutamic acid),52 and that cysteine proteases, particularly 
cathepsin B, play key roles in the lysosomal degradation of poly(L-
glutamic acid).50 
To ensure that enzyme-dependent biodegradability of St-PGA 
had not been compromised by the architecture, all synthesized 
polymers were incubated in presence of lysosomal enzyme cathepsin B 
(at pH 6 in acetate buffer and EDTA, under reductive conditions by 
using DTT in order to favor the enzyme activity). The degradation rate 
was monitored by GPC under aqueous conditions. As expected, 
polymers were degraded in presence of cathepsin B but following 
different kinetics upon the polymerization initiator used (Figure 3.10). 
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a) Star ethyl initiated                   b) Star hexyl initiated 
 
Figure 3.10. Example of degradation profiles by cathepsin B of two St-
PGA initiated by a) Ethyl based initiator (15a) and b) Hexyl based 
initiator (15b). GPC traces in PBS at different time points. 
3.2.4.2. Cell viability assays. 
Another key feature for the validation of the newly synthesized 
polymers as potential carriers for drug delivery or imaging probes is 
their toxicity in cell cultures. 
Cell-based assays are often used in order to screen collections 
of compounds with the purpose of determining possible cytotoxic as 
well as cell proliferation effects. This kind of assays are also commonly 
used for receptor binding measuring, trafficking of cellular 
components, or monitoring organelle function. It is important to know 
how many viable cells are remaining at the end of the experiment 
independently on the type of assay used. There are currently a wide 
variety of methods that can be used to estimate the number of viable 
eukaryotic cells. Most of them are based on multi-well formats where 
data are recorded using a plate reader, due to their facile preparation, 
less cost-effective and the needless of sophisticated equipment, in 
contrast to methods by flow cytometry and high content imaging. These 
methods include tetrazolium reduction, resazurin reduction, protease 
markers, and ATP (Adenosine Triphosphate) detection. The first three 
methods measure some aspect of general metabolism or an enzymatic 
activity as a marker of cell viability. All of them are based on the 
incubation of a specific reagent with a population of viable cells to 
convert a substrate to a colored or fluorescent product, generating a 
signal that is proportional to the number of viable cells present. This 
signal can be detected with a plate reader. The ATP assay is also based 
on the measurement of a fluorescent signal produced, although in this 
case no incubation period is needed since the addition of assay reagent 
immediately ruptures the cells. 
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Within this project, tetrazolium reduction assays have been 
applied in order to validate the different polymeric carriers synthesized. 
The reduction of tetrazolium salts is currently a reliable process and can 
be directly correlated to the number of viable cells since this process 
only occurs when mitochondrial reductase enzymes are active. In 
general, the most commonly tetrazolium compounds used include: 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), 
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium), XTT (2,3-bis-(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide), and WSTs (water 
soluble tetrazolium salts) family  that can be classified in two categories 
due to their mechanism of action. On one hand, MTT which is 
positively charged and readily penetrates viable eukaryotic cells and; on 
the other hand MTS, XTT, and WST-1 which are negatively charged 
and do not readily penetrate cells. For that reason, the latest are usually 
applied in combination with an intermediate electron acceptor that can 
penetrate viable cells where is reduced in the cytoplasm or at the cell 
surface and exit the cells where they can convert the tetrazolium to the 
soluble formazan product53 (Figure 3.11). A common electron acceptor 
used is PMS (phenazine methyl sulfate). One of the advantages of the 
tetrazolium assays that produce an aqueous soluble formazan is that 
absorbance can be recorded form the assay plates periodically during 
early stages of incubation. In contrast to MTT reagent, the more recent 
developed MTS, XTT and WST series can be reduced by viable cells to 
generate formazan products that are directly soluble in cell culture 
medium.54 Therefore, a liquid handling step during the assay procedure 
as required for MTT is not further needed making the protocols more 
convenient and reliable. In contrast to XTT, MTS exhibits a greater 
concentration range with linearity in the absorbance (comparable to 
MTT) what makes this reagent optimal for cell viability determination. 
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Figure 3.11. Intermediate electron acceptor PMS transfers electron 
from NADH in cytoplasm to reduce MTS in culture medium into an 
aqueous soluble formazan. 
Within this project, combination of MTS/PMS was used to 
assess cell viability after treatments. In brief, after cell incubations, 10 
µL of manufacturer solution of MTS/PMS (20:1) was added to each 
well, and the cells were incubated for a further 2 hours. Mitochondrial 
dehydrogenase enzymes of viable cells indirectly converted MTS 
tetrazolium into a colored formazan product. Optical density of each 
well was measured at 490 nm. 
Two different cell lines where used in order to determine the 
cytotoxicity of selected polymers from the family synthesized: 
SHSY5Y human derived neuroblastoma cell line and HUVEC human 
umbilical vein endothelial cells. Those two cell lines where rationally 
selected, as one of the main aims of this dissertation was the evaluation 
of the ability of the synthesized compounds to cross biological barriers, 
and more concretely, the BBB where endothelial cells plays a major 
role. HUVEC cell line was an established cell line in the laboratory, 
and all the parameters such as cell density where optimized for 
compound testing. However, this fact was not true for SHSY5Y cell 
line, and therefore, it had to be set by cell growing curves starting from 
different seeding densities up to 1 week. These curves where obtained 
by MTS assays to cells incubated in 96-well plates over different 
periods of time and maintained at 37 °C in an atmosphere of 5 % 
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carbon dioxide and 95 % air. Experiments were done with 6 replicates 
and per triplicate. 
 
Figure 3.12. SHSY5Y cell line growing curves obtained by MTS 
assays. n> 3, mean ± SEM. 
According to the results obtained from the growing curves, 
12000 cell/well (in 96-well microtitre plates, 35000 cell∙cm-2) for 
SHSY5Y, was established as a proper seeding density in order to 
maintain the cells under exponential growth during the treatments (72 
hours). Hence, for cell viability experiments, 72 hours MTS assays 
against SHSY5Y and HUVEC where then performed. Firstly, different 
architectures where compared: linear-PGA, PEG-PGA hybrid di-block 
copolymer, and 3-arm St-PGA (ethyl based initiated). As it can be 
observed from Figure 3.13a, no toxicity was observed against SHSY5Y 
cell line up to 3 mg∙mL-1 (higher concentrations were not tested). 
Afterwards, several 3 arm St-PGAs with different MW and 
core due to the use of different initiators were also evaluated, this time 
against HUVEC cell line. As it can be seeing from Figure 3.13b, all 
polymeric structures tested where non-toxic against HUVEC cell line 
up to 3 mg∙mL-1 (higher concentrations were not tested). 
  
[Chapter 3] 
173 
a) 
 
b) 
 
Figure 3.13. Cell viability assay of a) 3 different PGA architectures 
against SHSY5Y cell line, 72 hours of treatments. b) Different 3-arm 
St-PGAs against HUVEC cell line, 72 hours of treatments. n> 3, mean 
± SEM. 
3.2.4.3. Cellular uptake. 
Understanding of cellular internalization mechanisms used by 
nanopharmaceuticals has become a key player in the field of drug 
delivery. Nanomedicines mainly use endocytic vesicles or endosomes, 
which in turn employ a complex mechanism to address the different 
molecules to specific intracellular locations. It can be said that charge, 
shape, material composition, and surface functional groups are basic 
physico-chemical parameters that determine cell entry of 
nanomedicines by endocytic pathway.55  
Confocal microscopy techniques and flow cytometry are 
routinely used with fluorescence-labeled polymers in order to evaluate 
their uptake by cells. Live-cell confocal imaging, allows visualizing 
trafficking between multiple compartments within individual living 
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cells over time, avoiding any possible artifacts derived from fixation 
protocols.56 On the other hand, flow cytometry give us semi-
quantitative information about the mechanism of internalization. 
3.2.4.3.1. Fluorescence labeling of PGA-based 
architectures with Oregon Green Cadaverine. 
Thus, after evaluation of degradation kinetics and 
biocompatibility of the systems, different PGA architectures were 
fluorescently labeled for in vitro evaluation.  
For macromolecular therapeutics and nano-sized drug delivery 
systems, fluorescent labeling is commonly applied to allow intracellular 
trafficking studies, conjugate cell-specific localization and/or in vivo 
fate and PK. Probes such as the fluorophore Oregon Green (OG) have 
been extensively reviewed for cellular studies to determine cell uptake 
and binding.3, 56, 57 To this aim, the conjugated probe must fulfill some 
requirements such as high stability of the probe itself as well as stability 
of the linkage to ensure adequate carrier monitoring. On the other hand, 
a minimal percentage of probe loading is desirable in order to avoid 
data misinterpretation due to changes in polymer conformation 
resulting from changes in charge and solubility. In order to fulfill all 
that criteria, less than 1 mol% of OG was conjugated through a non-
biodegradable amine bond. In the case of linear PGACOOH and St-
PGACOOH, conjugation was carried out by using diisopropylcarbodimide 
(DIC) / Hydroxybenzotriazole (HOBt) as carboxylic acid activators in 
organic solvents. On the other hand, for OG labeling of PEG-
PGACOONa, hybrid di-block copolymer, DMTMM∙Cl was used. The 
protocol of OG conjugation was previously established and routinely 
used with DIC/HOBt in Dr Vicent laboratory, ensuring 80-90 % 
conjugation efficiency of the fluorescence dye. A schematic 
representation of polymers labeling is depicted in Scheme 3.3. 
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Scheme 3.3. Synthesis of OG 488 labeled products (21). 
The formation of amide bonds by condensation of carboxylic 
acids with amines in presence of carbodiimides is one of the most 
common synthetic procedures.58 DIC is a carbodiimide used in peptide 
synthesis. As a liquid, it is easier to handle than the commonly used 
N,N′-dicyclohexylcarbodiimide DCC and EDC (N',N'-dicyclohexyl 
carbodiimide and 1-ethyl-3-(-3-dimethylaminopropyl) carbodiimide 
hydrochloride respectively) especially since its urea is soluble in most 
organic solvents, facilitating work up processes. To optimize the 
couplings, additives such as HOBt are widely used for the generation of 
active esters able of efficient acylation of amino groups, especially in 
the case of amino acids and peptides.59 Furthermore, HOBt is well 
known to act as racemization suppression agent. 
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Scheme 3.4. DIC/HOBt detail reaction mechanism. 
The use of different carboxylic acid activators responds to 
practical and technical reasons, since the hybrid di-block copolymer is 
obtained directly as sodium salt form after deprotection (see Scheme 
3.4), in contrast to linear and St-PGAs. The acid form conversion of 
PEG-PGA was avoided in order to not compromise PEG block 
integrity.47 In any case, OG labeling was successfully accomplished 
independently of the selected PGA derivative and methodology. The 
labeled polymers where always converted into sodium salt form, and 
purified by Sephadex G25 using commercial PD10 columns. The 
fractions containing OG labeled polymer where selected after 
measuring their fluorescence at 485 nm in the plate reader Victor 
WallacTM, collected and re-purified by dialysis using Vivaspin® 
MWCO 3000 Da, in order to avoid any trace of free OG which would 
lead to interference and different mechanisms of uptake. A typical 
curve obtained after fluorescence measuring of the fractions from PD10 
columns is shown in Figure 3.14. After purification, dye loading was 
calculated by (i) the fluorescence associated with the polymer 
containing fractions related to the total fluorescence output coming 
from all the fractions after PD10 column (Figure 3.14) and by (ii) 
recording a calibration curve of the labeled polymeric architecture as 
well as the free OG. 
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Figure 3.14. Example of a typical curve obtained after fluorescence 
measuring of 1 mL fractions collected from PD10 columns. 
In order to properly quantify the OG content of every 
conjugate, a calibration curve was recorded. It has to be taken into 
account that quenching phenomena are obtained at high OG 
concentrations (Figure 3.15). Hence, it is necessary to be in the proper 
fluorescence range for an accurate estimation of OG content. 
 
Figure 3.15. OG fluorescence calibration curve in PBS pH 7.4 with 
increasing concentrations showing quenching phenomena. 
Moreover, it is has to be also mentioned that slight changes in 
fluorescence intensity could be found when using different pH buffers 
to dissolve the polymeric conjugates as well as free OG. Figure 3.16 
represents OG calibration curve obtained at different pHs highlighting 
the importance of controlled pHs during the OG loading estimations as 
well as during uptake experiments.  
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Figure 3.16. OG calibration curve at pH 5.5 and pH 7.4. 
3.2.4.3.2. Cellular uptake study by Flow Cytometry. 
The experiments carried out were pursuing different answers: 
(i) On one hand, the effect of MW on cellular uptake was studied by 
using different linear PGA-OG and hybrid DB PEG-PGA-OG of 
different number of GAU. (ii) On the other hand, the new architectures 
star-shaped polymers where characterized in terms of cellular uptake 
for the first time. (iii) Finally, the three different architectures with 
similar MW were compared to assess the effect of polymeric structure 
on uptake mechanisms. 
Flow cytometry (cell uptake and binding) together with live-
cell confocal microscopy analysis (subcellular fate and pathway) in 
SHSY5Y human derived neuroblastoma cell line, were used to study 
cellular trafficking of the OG-labeled polymers. Uptake experiments 
were carried out at different temperatures, 37 °C (total uptake) and 4 °C 
(binding) in order to determine the presence of energy dependent or 
non-dependent internalization mechanisms, such as endocytosis or 
diffusion, respectively. It is worth mentioning that all experiments were 
done in the presence of cathepsin B inhibitor CA-047 in order to avoid 
possible degradation of PGA chains along the incubation periods. 
Results were represented by means of cell associated fluorescence 
(CAF) over incubation time. CAF represents the percentage of positive 
cells multiplied by fluorescence intensity and divided by 100, always 
removing CAF of control cells (without treatments) in order to avoid 
any artifacts from autofluorescence phenomena.  
Results clearly showed energy-dependent mechanisms of 
internalization (endocytosis) in all the cases due to absence of uptake at 
4 °C as observed by flow cytometry. Figure 3.17 shows an example of 
the uptake profile of a 3 arm St-PGA (250 GA units). Energy dependent 
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uptake represents the result of subtracting uptake at 4 °C from uptake at 
37 °C. 
 
Figure 3.17. Uptake study by flow cytometry of St-PGA fluorescently 
labeled in SHSY5Y cell line as example. n> 3, mean ± SEM. 
When different linear PGA homopolymers of different number 
of GAU (80, 180, and 250) where compared, no significant differences 
in cellular uptake profiles were observed. In the case of DB, although 
CAF at 5 hours was comparable to that of PGA homopolymers, its 
uptake kinetics was slower (Figure 3.18). 
 
Figure 3.18. Uptake profile (energy dependent only) of different OG-
labeled polymers against SHSY5Y cell line including different MW 
linear PGAs and one DB PGA. n> 3, mean ± SEM. 
Then, linear homopolymer and star structures with greater MW 
(with potential to increase EPR effect) were compared. Interestingly, 
St-PGA-OG showed a significant increase (about 3-fold) in CAF at 5 h 
time point when compared with linear-PGA-OG conjugate of similar 
MW (~250 GAU). (Figure 3.19).  
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b)…………………………….c) 
 
d) 
 
Figure 3.19. Uptake study against SHSY5Y cell line of St-PGA-OG in 
comparison with linear PGA of similar MW (around 250 GAU). a) 
CAF of both polymers over time. b) CAF of both polymers at 5 hour 
showing significant differences when statistics was performed using 
one-way ANOVA. ρ*< 0.05. c) % of positive (+) cells to OG 
fluorescence, comparison of both polymers at 5 hours showing 
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statistical differences. ρ*< 0.05. d) % of positive cells representation 
comparing both polymers together with the control used (cell 
autofluorescence). n> 3, mean ± SEM. 
This finding might be attributed to the inherent properties of the 
different architectures. As general basis, star polymers have a more 
compact structure, presumably with globular shape, and have large 
surface areas, increased concentrations of functional end groups for 
polymers with equal molecular weight, and unique rheological 
properties which make them optimal platforms for drug delivery and 
imaging among other biological applications10, 11  
3.2.4.3.3. Cellular uptake by Live-Cell Confocal Imaging.  
As mentioned before, live-cell confocal imaging, allows 
visualizing trafficking between multiple compartments within 
individual living cells over time. Results obtained by flow cytometry 
were further confirmed with confocal microscopy experiments at 2 
hours post-treatment with OG labeled polymers in SHSY5Y cells 
following a pulse-chase experiment. Co-localization in lysosomes was 
observed upon the use of lysosomal marker Lysotracker Red (Figure 
3.20). 
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Figure 3.20. Confocal image of uptake at 2 hours post-treatment of 
OG-labeled polymers in SHSY5Y cell line following a pulse-chase 
experiment. Co-localization with lysosomal marker Lysotracker Red 
was observed. 
A co-localization histogram can be built by using Leica 
Software (Figure 3.21), confirming a high degree of co-localization in 
lysosomes for all polymers. 
 
Figure 3.21. Representative co-localization histogram of St-PGA-OG 
as example. In red, fluorescence intensity corresponding to Lysotracker 
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Red Channel; in green, fluorescence intensity corresponding to OG 488 
Channel; in Blue, fluorescence intensity of DAPI channel (for Hoetch). 
3.3. CONCLUSION. 
In summary, herein, a controlled living polymerization 
approach to obtain polyglutamate-based star shaped polymers have 
been described based on our recently developed ROP of NCAs with 
novel non-nucleophilic initiators (Chapter 2).47 This fact represents a 
sign of its versatility. Our approach does not require of neither complex 
and expensive equipment nor low temperatures, but is capable to yield 
star-shaped polypeptides with low Đ (< 1.2) in a relatively short time 
and in a variety of MW including high and adjustable molecular mass. 
Moreover, it has been also described a method that gives very 
convincing evidence that the arms on stars were of equal MW by using 
reducible initiators containing disulfide bonds. This has been 
highlighted as a highly significant result when considering new 
polymer carriers as drug delivery systems or imaging probes due to the 
need for homogeneity in these materials. 
In vitro biocompatibility (MTS assays) was not compromised 
with the use of different polymeric architectures according to results 
obtained from the polymers tested. Regarding uptake profiles, all 
polymers tested (independently of MW or architecture) followed an 
energy-dependent mechanism of uptake, presumably through endocytic 
mechanism due to the absence of uptake at 4 °C. MW of the polymers 
(at least in linear structures) did not significantly affect the degree of 
internalization. Nonetheless, this degree of internalization was highly 
increased when star-shaped polymers where used, highlighting the 
importance of the architecture in the biological output. 
3.4. MATERIALS AND METHODS. 
3.4.1. Materials. 
All chemicals were reagent grade, obtained from Aldrich and 
used without further purification, unless otherwise indicated. H-L-
Glu(OBzl)-OH, was obtained from Iris Biotech. Phenazinemethosulfate 
(PMS) was supplied by Sigma (Sp). Dulbecco’s Modified Eagle’s 
Medium (DMEM), Leibovitz, Phosphate buffer saline (PBS), Foetal 
bovine serum (FBS) Medium 200, Low Serum Growth Supplement 
(LSGS) and Trypsin, were provided from Gibco. (3-(4,5-
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dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) (MTS) was supplied by Promega (Sp).  
All solvents were of analytical grade and were dried and freshly 
distilled. Deuterated chloroform-d1, DMSO-d6, DMF-d7 and D2O were 
purchased from Deutero GmbH. 
Preparative SEC was performed using Sephadex G-25 
superfine from GE as well as PD MiniTrap G-10 ™ columns 
containing 2.1 mL of Sephadex™ G-10. Dialysis was performed in a 
Millipore ultrafiltration device fitted with a 1, 3, or 10 kDa MWCO 
regenerated cellulose membrane (Vivaspin®). 
3.4.2. Characterization techniques. 
NMR spectroscopy was performed as for section 2.4.2.1 from 
Chapter 2. 
3.4.2.1. GPC in DMF. 
For SEC measurements in DMF containing 1g∙L-1 of lithium 
bromide as an additive, an Agilent 1100 series system was used with a 
flow rate of 1 mL∙min-1 at 70 °C as an integrated instrument, including 
three HEMA-based columns (105/103/102 Å porosity) from MZ-
Analysentechnik GmbH, Viscoteck TDATM 302 triple detector 87 with 
UV detection coupled, and Calibration was achieved with well-defined 
poly(methyl methacrylate) (PMMA)/DMF standards, provided by 
Polymer Standards Service (PSS)/Mainz Germany. 
3.4.2.2. Circular Dichroism (CD).  
CD Spectroscopy was performed with a J-815 CD 
Spectrometer (JASCO Corporation) using a Peltierthermostated cell 
holder (PTC-423, JASCO Corporation) with a recirculating cooler 
(JULABO F250, JASCO Corporation). A nitrogen flow (~2.7 L∙min-1) 
was lead through the spectrometer and controlled with a nitrogen flow 
monitor (Afriso Euro-Index). The samples were dissolved in HFIP for 
protected and PBS pH 7.4 for deprotected samples and diluted to a 
concentration of 0.1 mg∙mL-1. Samples were measured repeatedly (n= 
3) in a quartz cuvette with d= 0.1 cm at 20 °C for HFIP samples and 37 
°C for PBS dissolved samples. Obtained molar ellipticities were plotted 
as mean residue ellipticity. 
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3.4.2.3. Dynamic Light Scattering (DLS). 
DLS measurements were performed at 25 °C using a Malvern 
ZetasizerNanoZS instrument, equipped with a 532 nm laser at a fixed 
scattering angle of 173°. Polymer solutions (0.2 mg∙mL-1) were 
prepared in PBS pH 7.4. Solutions were sonicated for 10 min and 
filtered through a 0.45 μm cellulose membrane filter. Size distribution 
by volume was measured (diameter, nm) for each polymer per triplicate 
with n> 3 measurements. 
3.4.2.4. UV-VIS.  
UV-VIS measurements were performed using JASCO V-630 
spectrophotometer at 25 °C with 1.0 cm matched quartz cells and with 
spectral bandwidth of 0.5 nm. 
3.4.2.5. Victor2 WallaceTM.  
Percentage of OG 488 loading in different polymers was 
determined by fluorescence measurements using Multilabel HTS 
counter Wallac Victor2 1420 + software Wallac 1420 workstation from 
Perkin Elmer. Dark 96-Well Multiwell Plates will 100 μL where used 
for that purpose. Fluorescence was measured using 490 filter for 
excitation and 535 for emission wavelengths. 
3.4.3. Protocols. 
Monomer synthesis was performed as for Section 2.4.3.1. 
3.4.3.1. Initiators Synthesis. 
3.4.3.1.1. Ethyl-based initiator synthesis. 
a. Synthesis of 1,3,5-Tri-tert-butyl ((benzenetricarbonyltris (azanediyl)) 
tris(ethane-2,1-diyl))tricarbamate (12a).  
In a two-neck round bottom flask fitted with a stirrer bar, and a 
N2 inlet and outlet, 1,3,5-benzenetricarbonyl thricloride (1.88 mmol, 1 
eq.) was dissolved in 12 mL of anh. THF. N,N’,N’’-
diisopropylethylendiamine (DIEA) (6.22 mmol, 3.3 eq.) was added to 
the reaction mixture followed by drop wise addition of N-Boc-
ethylendiamine (6.22 mmol, 3.3 eq.) over a period of 10 minutes. 
Reaction was then left to proceed for 2 hours. After that time, solvent 
was completely removed under vacuum. The product was re-dissolved 
in chloroform and washed (3x) with ddH2O, and (3x) with acidic water 
(pH~3). Finally, the organic phase was isolated under vacuum and the 
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product was recrystallized from THF/Methanol/Hexane yielding a 
white crystalline solid. The product was then dried under high vacuum 
and stored at -20 °C. 
Yield: 82 %. δH (300 MHz, DMSO) 8.68-8.65 (m, 3H), 8.41 (s, 
3H), 6.92-6.88 (m,3H), 3.34-3.31 (m, 6H), 3.16-3.13 (m, 6H), 1.37 (s, 
27H).13C NMR (75 MHz, CDCl3) 166.80 (C=O), 156.84 (C=O), 134.58 
(CAr quaternary), 128.47 (CHAr), 79.57 (C quaternary), 40.93 (CH2), 
40.43 (CH2), 28.45 (CH3). 
b. Synthesis of 1,3,5-(benzenetricarbonyltris(azanediyl)) 
triethanammonium BF4 salt (13a).  
In a round bottom flask fitted with a stirrer bar and a stopper, 
compound 12a (1 eq.) was dissolved in dichloromethane. Afterwards, 
3.3 eq. of tetrafluoroboric acid diethyl ether complex, HBF4∙Et2O, was 
added to the solution leading to the instantaneous formation of a white 
solid. The precipitate was filtered off and recrystallized (3x) from 
THF/methanol/hexane. The product was then dried under high vacuum 
and stored at -20 °C. 
Yield: 98 %. δH (300 MHz, D2O) 8.32 (s, 3H), 3.72-3.68 (m, 
6H) 3.25-3.21 (m, 6H).13C NMR (75 MHz, D2O) 169.45 (C=O), 134.38 
(CAr quaternary), 129.36 (CAr), 39.23(CH2), 37.52 (CH2).19F-NMR: -
150.48 (BF4). MALDI-TOF: 337.1709 [M+1]. 
3.4.3.1.2. Hexyl-based initiator synthesis. 
a. Synthesis of 1,3,5-tri-tert-
butyl((benzenetricarbonyltris(azanediyl)tris(hexane-1,6-
diyl))tricarbamate (12b). 
In a two-neck round bottom flask fitted with a stir bar, and a N2 
inlet and outlet, 1,3,5-benzenetricarbonyl thricloride (1.88 mmol, 1 eq.) 
was dissolved in 12 mL of dried THF. After that, DIEA (6.22 mmol, 
3.3 eq.) was added to the reaction mixture followed by the drop wise 
addition of N-Boc-1,6-hexanediamine (6.22 mmol, 3.3 eq.) over a 
period of 10 minutes. Reaction was then left to proceed for 2 hours. 
After that time, solvent was completely removed under vacuum. The 
product was re-dissolved in chloroform and washed (3x) with ddH2O, 
and acidic water (3x). Finally, the organic phase was isolated under 
vacuum and the product was recrystallized from THF/Methanol/Hexane 
yielding a white crystalline solid. The product was then dried under 
high vacuum and stored at -20 °C.  
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Yield: 72 % δH (300 MHz, DMSO) 8.37 (s, 3H), 6.75 (m, 3H), 
3.30-3.24 (m, 6H), 2.91-2.87 (m, 6H), 1.55-1.51 (m, 6H), 1.37-1.29 (m, 
45H). δC (75 MHz, CDCl3) 166.28 (C=O), 156.49 (C=O), 134.93 (CAr 
quaternary), 128.68 (CAr), 79.34 (C quaternary), 40.33 (CH2), 39.92 
(CH2), 29.89 (CH2), 29.19 (CH2), 28.42 (CH3), 26.19 (CH2), 25.90 
(CH2).  
b. Synthesis of 1,3,5-(benzenetricarbonyltris(azanediyl))trishexan-1-
ammonium BF4 salt (13b). 
In a one-necked round bottom flask fitted with a stir bar and a 
stopper, compound 12b (1 eq.) was dissolved in dichloromethane. 
Afterwards, 3.3 eq. of HBF4∙Et2O, was added to the solution leading to 
the formation of a white solid salt in almost quantitative yield. The 
product was then filtered off and recrystallized (3x) from 
THF/methanol/hexane. The product was then dried under high vacuum 
and stored at -20 °C. 
Yield: 90 %. δH (300 MHz, D2O) 8.12 (s, 3H), 3.37-3.32 (m, 
6H), 2.96-2.91 (m, 6H), 1.61-1.57 (m, 12H), 1.39-1.34 (m, 12H). δC (75 
MHz, D2O) 168.92 (C=O), 135.00 (CAr quaternary), 128.49 (CAr), 39.97 
(CH2), 39.42 (CH2), 28.10 (CH2), 26.60 (CH2), 25.57 (CH2), 25.23 
(CH2).19F-NMR-150.41. MALDI-TOF: 505.3563 [M+] 
3.4.3.1.3. DOOA-based initiator synthesis. 
a. Synthesis of 1,3,5-tri-tert-butyl 
((((((benzenetricarbonyltris(azanediyl))tris(ethane-2,1-
diyl))tris(oxy))tris(ethane-2,1-diyl))tris(oxy))tris(ethane-2,1-
diyl))tricarbamate (12c). 
In a two-neck round bottom flask fitted with a stir bar, and a N2 
inlet and outlet, 1,3,5-benzenetricarbonyl thricloride (0.75 mmol, 1 eq.) 
was dissolved in 12 mL of dried THF After that, DIEA (6.22 mmol, 3.3 
eq.) was added to the reaction mixture followed by the drop wise 
addition of N-Boc-DOOA (2.49 mmol, 3.3 eq.) over a period of 10 
minutes. Reaction was then left to proceed for 2 hours. After that time, 
solvent was completely removed under vacuum. The product was re-
dissolved in chloroform and washed with ddH2O, and acidic water (3x 
each). Finally, the organic phase was isolated under vacuum and the 
product was recrystallized (3x) from THF/Methanol/Hexane yielding a 
white crystalline solid. The product was then dried under high vacuum 
and stored at -20 °C. 
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Yield: 70 %. δH (300 MHz, CDCl3) 8.35 (s, 3H), 3.62-3.58 (m, 
24H), 3.51-3.48 (m, 6H), 3.24-3.20 (m, 6H), 1.34 (s, 27H). δC (75 MHz, 
CDCl3) 165.99 (C=O), 156.19 (C=O), 135.05 (CAr quaternary), 128.55 
(CAr), 79.42 (Cquaternary), 79.32 (CH2), 77.22 (CH2), 70.20 (CH2), 
69.66 (CH2), 40.51 (CH2), 40.09 (CH2), 28.39 (CH3). 
b. Synthesis of 1,3,5'-(((((benzenetricarbonyltris(azanediyl))tris(ethane-
2,1-diyl))tris(oxy))tris(ethane-2,1-diyl))tris(oxy))triethanammonium 
BF4 salt (13c). 
In a one-necked round bottom flask fitted with a stir bar and a 
stopper, compound 12c (1 eq.) was dissolved in dichloromethane. 
Afterwards, 3.3 eq. HBF4∙Et2O, was added to the solution leading to the 
formation of a white solid salt in almost quantitative yield. The product 
was then filtered off and recrystallized (3x) from 
THF/methanol/hexane. The product was then dried under high vacuum 
and stored at -20 °C. 
Yield: 85 %. δH (300 MHz, D2O) 8.24 (s, 3H), 3.74-3.67 (m, 
30H), 3.61-3.58 (m, 6H), 3.14-3.10 (m, 6H). δC (75 MHz, D2O) 168.95 
(C=O), 134.86 (CAr quaternary), 128.89 (CAr), 69.56 (CH2), 69.49 
(CH2), 68.78 (CH2), 66.37 (CH2), 39.56 (CH2), 39.08 (CH2).19F NMR:-
150.48. MALDI-TOF: 601.3354 [M+]. 
3.4.3.1.4. Cysteamine-based initiator synthesis. 
a. Synthesis of tert-butyl (2-((2-aminoethyl)disulfanyl)ethyl)carbamate 
(mono-Boc-cysteamine) (11). 
General method from Girgenti et al.48 with slight modifications. 
Briefly, a suspension of cysteamine dihydrochloride (15 mmol) in 100 
mL of anh. chloroform was treated with triethylamine (30 mmol) and 
stirred for 20 minutes at r.t.. A solution of di-tert-butyldicarbonate (5 
mmol) in another 50 mL of anh. chloroform was added drop wise over 
a period of 1.5 hours, keeping the reaction at 0 °C. The reaction mixture 
was warmed to r.t. and stirred for 16 hours more. After that time, 20 
mL of ddH2O were added and the organic layer was washed with 
ddH2O (3x). A colorless oil was obtained as a pure compound after 
removal of the solvent under high vacuum  
Yield: 50 %. 1H-NMR δH (300 MHz, DMSO-d6) 6.97-6.96 
(1H, d), 3.23-3.17 (2H, q), 2.81-2.68 (6H, m), 1.50 (1H, s), 1.38 (9H, 
s). 13C-NMR δC (75 MHz, DMSO-d6) 155.94 (C=O), 78.21 (C 
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quaternary), 42.57 (CH2), 41.40 (CH2), 39.90 (CH2), 38.13 (CH2), 28.67 
(CH3). 
b. Synthesis of 1,3,5-tri-tert-butyl ((((benzenetricarbonyltris(azanediyl) 
)tris(ethane-2,1-diyl))tris(disulfanediyl))tris(ethane-2,1-
diyl))tricarbamate (12d). 
In a two-neck round bottom flask fitted with a stir bar, and a N2 
inlet and outlet, 1,3,5-benzenetricarbonyl trichloride (0.38 mmol, 1 eq.) 
was dissolved in 12 mL of dried THF. After that, DIEA (1.24 mmol, 
3.3 eq.) was added to the reaction mixture followed by the drop wise 
addition of N-Boc-cysteamine (1.24 mmol, 3.3 eq.) over a period of 10 
minutes. Reaction was then left to proceed for 2 hours. After that time, 
solvent was completely removed under vacuum. The product was re-
dissolved in chloroform and washed with ddH2O, and acidic water (3x 
each). Finally, the organic phase was isolated under vacuum and the 
product was obtained by column chromatography on silica gel using 
CH2Cl2:MeOH (90:10). Rf= 0.5. The product was then dried under high 
vacuum and stored at -20 °C. 
Yield: 70 %. 1H-NMR δH (300 MHz, Acetone-d6) 8.21 (3H, 
m), 8.43 (3H, m), 6.17 (3H, s), 3.73-3.67 (6H, m), 3.37-3.30 (6H, m), 
2.98-2.94 (6H, m), 2.84-2.79 (6H, m), 1.32 (27H, s). 13C-NMR δC (75 
MHz, CDCl3) 165.87 (C=O), 156.21 (C=O), 135.45 (CAr quaternary), 
129.06 (CAr), 78.16 (Cquaternary), 39.87 (CH2), 39.31 (CH2), 38.07 
(CH2), 37.43 (CH2), 28.68 (CH3). 
c. Synthesis of 1,3,5-(((benzenetricarbonyltris(azanediyl))tris(ethane-
2,1-diyl))tris(disulfanediyl))triethanaminium BF4 (13d). 
In a one-necked round bottom flask fitted with a stir bar and a 
stopper, compound 12d (1 eq.) was dissolved in dichloromethane. 
Afterwards, 3.3 eq. of HBF4∙Et2O, was added to the solution leading to 
the formation of a white solid salt in almost quantitative yield. The 
product was then filtered off and washed (3x) with ether. For further 
purification, the product is recrystallized from THF/methanol/hexane 
and then dried under high vacuum and stored at -20 °C. 
Yield: 80 %. 1H-NMR δH (300 MHz, D2O) 8.08 (3H, s), 3.62-
3.57 (6H, m), 3.23-3.18 (6H, m), 2.86-2.84 (12H, m). 13C-NMR δC (75 
MHz, DMSO-d6) 165.47 (C=O), 134.55 (CAr quaternary), 128.06 (CAr), 
39.77 (CH2), 39.31 (CH2), 38.28 (CH2), 37.65 (CH2). 19F-NMR: -
148.31. 
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3.4.3.2. Synthesis of St-PBLG (14).  
As described in Section 2.4.3.4. 23 
Yield: 70-90 %. 1H-NMR δH (300 MHz, DMF-d7) 8.58 (xH, s), 
7.42 (5H, s), 5.19 (2H, s), 4.21 (1H, s), 2.81 (2H, s), 2.45 (2H, s). 13C-
NMR δC (75 MHz, DMF-d7) 175.94 (s), 172.26 (s), 162.77-162.18 (m), 
161.98 (s), 136.76 (s), 128.87-127.75 (m), 66.05 (s), 57.13 (s), 35.41 - 
34.17 (m), 32.48 (s), 30.84, 30.30-29.04 (m), 27.28 (s), 25.99 (s). x: DP 
obtained/3 arms 
3.4.3.3. Deprotection of St-PBLG.  
Different methods were followed depending on the initiator 
used: acid conditions (described in Section 2.4.3.6.2.) were applied 
when ethyl and hexyl based initiators were used. On the other hand, 
basic conditions (described in Section 2.4.3.6.3.) were applied for 
DOOA, and cysteamine based initiator synthesis.  
3.4.3.4. Kinetics of polymer degradation in presence of 
Cathepsin B. 
Several PGA-based polymers were degraded in vitro in 
presence of lysosomal enzyme cathepsin B. To test their degradation 
kinetic profile by cathepsin B, the different polymer solutions (3 
mg∙mL-1) were prepared. Exactly 3 mg were weighed and 700 µL of 
acetate buffer 20 mM, pH 6, 100 µL of EDTA 2 mM, 100 µL of DTT 5 
mM were added. Finally, 6.25 units of Cathepsin B (100 µL of a 
solution of 25 units of cathepsin B in 400 µL of acetate buffer pH 6 20 
mM) were added. Cathepsin B needs acidic pH (5-6) to be active as 
well as reductive environment, therefore a DTT solution was also added 
together with EDTA in order to complex possible free cations that can 
inactivate cathepsins (mainly Ca2+). 
Once solutions were prepared, aliquots of 100 µL were picked 
at different time points after homogenization. Meanwhile, samples were 
kept at 37 °C under stirring. Aliquots at different time points (0, 0.5, 1, 
2, 4, 8, 24, 48, 72, 96, 120, 144, 168 hours) were taken, frozen and later 
analyzed by GPC. To evaluate the mass of the polymers, 100 μL of 3 
mg mL-1 polymer solution in PBS was injected in GPC using two TSK 
Gel columns in series G2500 PWXL and G3000 PWXL with a 
Viscotek TDATM 302 triple detector 87 with UV detection coupled. The 
mobile phase used was PBS 0.1 M, flow 1 mL min-1. 
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3.4.3.5. Fluorescence labeling with Oregon Green 488 
Cadaverine. 
3.4.3.5.1. Protocol to label linear and St-PGA. 
In a round two necked bottom flask fitted with a stirrer bar and 
two septums, 29 mg of St-PGA (0.225 mmol GAU, 1 eq.) was 
weighted and dissolved in 1.5 mL of dry DMF under N2 flow. Then, 
1.12 μL of DIC (0.85 mg, 0.00674 mmol, 0.03 eq.) were added and the 
reaction was left to proceed for 5 minutes at r.t. Afterwards, HOBt (1 
mg, 0.00674 mmol, 0.03 eq.) was added directly. Reaction was then left 
to proceed for 10 minutes before OG (1 mg, 2.25·10-3 mmol, 0.01 eq.) 
was added. The pH was adjusted to 8 by adding ~100 μL of DIEA. The 
mixture was left stirring overnight at r.t. and protected from light. 
Finally, solvent was removed under vacuo and the product was 
dissolved in 300 μL of water and then adding ~50 μL of NaHCO3 1 M. 
The solution was purified by Sephadex PD10 column eluting with 
ddH2O. OG loading was calculated by fluorescence using a 
Victor2Wallac™ plate reader with excitation filter of 490 nm and 
emission filter of 535 nm. A calibration curve with OG was first 
performed. Yields: 95 %. OG loadings: 0.8-0.95 mol GAU. 
3.4.3.5.2. Protocol to label DB PEG-PGA. 
In a one neck round bottom flask fitted with a stir bar and a 
stopper, 50 mg of DB PEG-PGA (0.36 mmol GAU, 1 eq.) were 
suspended in 5 mL of ddH2O. Afterwards 2.1 mg of DMTMM∙Cl were 
added dissolved in 2 mL of ddH2O (7.1·10-3 mmol, 0.02 eq.). After 10 
minutes OG (1.5 mg, 3.36 10-3 mmol 0.01 eq.) was added and the pH 
was adjusted to 8 by adding some drops of 1 M NaHCO3 solution. 
Reaction was allowed to proceed 16 hours stirring at r.t. The solution 
was then concentrated in the freeze-dryer and purified by Sephadex 
PD10 column eluting with ddH2O. OG was calculated by fluorescence 
using a Victor2Wallac™ plate reader with excitation filter of 490 and 
emission filter of 535. A calibration curve with OG was first performed. 
Yields: 95 %. OG loadings: 0.7-0.8 mol GAU. 
3.4.3.6. Cell Culture protocols. 
HUVEC cells were cultured in Medium 200 supplemented with 
Low Serum Growth Supplement (LSGS). SHSY5Y cells were cultured 
in DMEM media supplemented with Foetal Bovine Serum (FBS). Cells 
were maintained at 37 °C in an atmosphere of 5 % carbon dioxide and 
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95 % air. Medium was replaced every 2-3 days and underwent passage 
once weekly when 80 % of cell confluence was reached. 
3.4.3.7. MTS assay for cell viability. 
MTS cell viability assay (72 h incubation). Cells were seeded in 
sterile 96-well microtitre plates at a cell density of 35000 cell∙cm-2 for 
SHSY5Y and 1260 cell∙cm-2 for HUVEC. Plates were incubated for 24 
hours and compounds (0.2 μm filter sterilized) were then added to give 
a final concentration of 0-3 mg∙mL-1. After 72 h of incubation, 
MTS/PMS (20:1) (10 μL of manufacturer solution) was added to each 
well, and the cells were incubated for a further 2 hours. Optical density 
of each well was measured at 490 nm. Plates were read 
spectrophotometrically using Victor2 Wallac plate reader. The 
absorbance values were represented as the percentage of cell viability 
taken as 100 % cell viability of untreated control cells.  
3.4.3.8. Cellular uptake by flow cytometry of OG-labeled 
polymers in SHSY5Y cells.  
SHSY5Y cells were seeded in 6-well plates at a density of 
35000 cell∙cm-2 (1 mL cell suspension per well) and allowed to adhere 
for 24 hours. In binding experiments conducted at 4 °C, cells were pre-
incubated at this temperature for 30 min prior to start the experiment. 
For both experiments, 4 °C and 37 °C, the cathepsin B inhibitor CA-
074 (0.4 μL from a solution of 5 μM to reach a final concentration of 2 
μM) was added 30 min before the addition of the conjugate. Then, 10 
μL of OG-labeled polymer (0.01 mg OG∙mL-1) were added at different 
time points from 0 to 300 min meanwhile cells were incubated either at 
37 °C or 4 °C for each experiment. Finally, cells were placed on iced in 
order to stop energy dependent mechanisms and washed twice with 
cold PBS-BSA 0.1 %. (PBS supplemented with Bovine Serum Albumin 
(BSA)). Then cells were suspended in 0.5 mL of cold PBS by the use of 
a scrapper. Finally, the cell pellet was placed in flow cytometer tubes. 
Cell-associated fluorescence was then analyzed using a Becton 
Dickinson FACS Calibur cytometer (California, USA) equipped with 
an argon laser (488 nm) and emission filter for 550 nm. Data collection 
involved 10,000 counts per sample, and data were analyzed using 
CELLQuestTM version 3.3 software. Data are expressed by plotting the 
cell-associated fluorescence, which is the result of the % of positive 
cells by multiplied by the mean fluorescence. CAF= % positive 
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cells*mean fluorescence/100. Cells incubated without polymer were 
used to account for the background fluorescence. 
Statistical Analysis. Data from the experiments was analyzed 
using one-way ANOVA. In all cases, we considered differences to be 
significant when p***<0.001; p**<0.01; p*<0.05; ns: non-significant. 
3.4.3.9. Confocal fluorescence microscopy: Live-cell 
imaging. 
For live-cell imaging, SHSY5Y cells were seeded at a density 
of 35000 cell∙cm-2, on glass bottom culture dishes (1 cm2 Petri plate) 
and allowed to seed for 24 hours at 37 °C. The experiment was 
performed following a pulse-chase mode at 37 °C. First, the cathepsin 
B inhibitor CA-074 (0.4 μL from a solution of 5 μM to reach a final 
concentration of 2 μM) was added 30 min prior the addition of the St-
PGA-OG. Then, 10 μL of OG-labeled polymer (0.01 mg OG∙mL-1) 
were added and the cells were incubated for 2 hours at 37°C (pulse). 
The medium was removed and cells were washed twice with PBS. 1 
mL of medium containing 2 μM of the CA-074 inhibitor was then 
added, and cells were incubated for 4 hours at 37 °C (chase). 30 min 
before washing the cells with PBS-BSA 0.1 %, the nuclear marker 
Hoetch (1 μL from a solution 5 mM), and the lysosomal marker 
Lysotracker Red (0.75 μL from a solution of 100 μM) were added in 
order to identify possible co-localizations and therefore establish an 
endocytic pathway. Finally, cells were washed with PBS-BSA 0.1 %. 
Then, the glass was removed and placed on the microscope chamber 
with fresh media containing 2 μM of CA-074 inhibitor. Samples were 
analyzed under the microscope. Images were captured with an inverted 
DM IRE2 microscope equipped with a λ-blue 60 x oil immersion 
objective and handled with a TCS SP2 system, equipped with an 
Acoustic Optical Beam Splitter (AOBS). Excitation was performed 
with an argon laser ((OG 496 nm) and HeNe laser (Lysotracker Red 
594 nm), and blue diode (Hoetch 405 nm). Images were captured at an 
8-bit grey scale and processed with LCS software (version 2.5.1347a, 
Leica Germany) containing multicolor, macro and 3D components. 
Control cells that followed the same incubation time were also analyzed 
to establish the autofluorescence, as well as cells treated only with 
Hoetch or Lysotracker Red.  
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4.1. INTRODUCTION AND BACKGROUND. 
As stated in Chapter 1, the choice of an appropriate polymer to 
serve as drug delivery system/imaging agent is key for an adequate 
biological output. Besides, the chemistry for the attachment of bioactive 
molecules must be seriously considered. To this respect, conjugation 
chemistry of polymers to natural or non-natural agents is of major 
importance. The incorporation of reactive sites becomes even more 
demanding whenever orthogonal reactive groups are mandatory for 
site-specific conjugation of bioactive compounds (i.e. peptides, 
proteins, antibodies) (Figure 4.1). 
There are two main approaches to introduce reactive groups for 
later bioconjugations, into polymers: the (co)polymerization of reactive 
monomers1 and the post-polymerization modification techniques.2 
Recent advances in synthetic polymer chemistry have made possible 
the construction of complex macromolecules with control over many 
parameters such as functionality, topology, MW and Đ. While co-
polymerization may offer a certain control about distribution of reactive 
groups among the polymer chain, post-polymerization modification is 
usually much easier to perform, since the synthesis of monomer bearing 
sterically bulky, highly aggregating or reactive groups can be avoided. 
Moreover, post-polymerization modification can be a powerful and 
attractive approach for the synthesis of functional polymers overcoming 
the limited functional group tolerance of many controlled 
polymerization techniques.2, 3 
The concept of post-polymerization modification was 
developed by Hermann Staudinger in the 1920s who laid down the 
foundation to use this approach to fabricate functional materials.4 Since 
then, the scope of post-polymerization modification reactions has 
suffered a great expansion, especially in the 1990s due to the re-
discovery of highly efficient coupling chemistries that allow 
quantitative, chemoselective and orthogonal functionalization of 
reactive polymer precursors.1 
For all that reasons, a new and versatile post-polymerization 
modification methodology allowing to introduce a series of 
functionalities into PGA polymer backbone is described within this 
chapter. Part of this work was published in the journal Polymer 
Chemistry, year 2013, volume 4, issue 10, pages 2980 - 2994 (A 
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versatile post-polymerization modification method for polyglutamic 
acid: Synthesis of orthogonal reactive polyglutamates and their use in 
"click chemistry"). 
 
Figure 4.1. Schematic representation of the versatility of the strategy 
pursued within this chapter in the development of methods for efficient 
introduction of orthogonal reactive sites into PGA polymeric chains for 
further bioconjugations. 
4.2. RESULTS AND DISCUSSION. 
4.2.1. Direct post-polymerization modification of PBLG (2) by 
aminolysis. 
As a starting strategy for the direct post-polymerization 
modification of PBLG one could think in direct aminolysis reaction. 
Aminolysis is any type of reaction in which a molecule is split into two 
parts by reacting with a molecule of ammonia or an amine. In the case 
of this particular aminolysis reaction, is a nucleophilic acyl substitution 
where the benzylic esters (protective benzyl groups) of the polymer 
backbone of PBLG will be substituted by the attack of an amine to the 
C=O group resulting in the amide formation.5 As the polymer is 
entirely composed of amide bonds due to the nature of PBLG, this kind 
of substitution could be dangerous for the integrity of the polymer 
backbone. This will depend on the aminolysis reaction conditions as 
well as the basicity of the amine used. To reduce the risks of backbone 
damage produce by aminolysis, 2-hydroxypyridine was used as 
catalyst. The use of 2-hydroxypyridine will presumably speeds up 
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reaction time, and will allow the use of less harsh reaction conditions.6  
The mechanism of action of this catalyst is not fully elucidated, 
and there are different theories. One of them claims that an 8-
membered-ring transition state is created with the involvement of three 
molecules which entropically is not very favorable. The other one 
claims that the protecting group is first substituted by the catalyst and 
subsequently the catalyst is substituted by the reacting amine. Those 
mechanisms are depicted in Scheme 4.1. 
 
Scheme 4.1. Different possible mechanisms of the aminolysis reaction 
catalyzed by 2-hydroxypyridine. A) With an 8-membered-ring 
transition state; B) With an intermediated resulting from the 
substitution of the benzyl group for the catalyst. 
To test the versatility and possible risks of this approach within 
polyglutamate backbone, we used a Boc end capped PBLG (16) (MW= 
18177 g∙mol-1, Ð: 1.14). The use of Boc end capped polymers responds 
to the need of monitoring backbone integrity which could be easily 
observed by the end cap group signals in 1H-NMR. For that purpose, 
first PBLG was end capped by using 5 eq. of trimethylacetylchloride as 
a capping agent and DIEA as a base to activate the N-terminus of the 
backbone nucleophilicity. Reaction was carried out in DMF, during 4 
hours under nitrogen atmosphere leading to complete conversion of the 
end group according to the 1H-NMR spectrum. (Scheme 4.2, Figure 
4.2)  
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Scheme 4.2. Synthesis of end capped PBLG (16). 
 
Figure 4.2. 1H-NMR in CDCl3 of end capped poly(γ-benzyl L-
glutamate) (16) with corresponding assignments. Signal 5 (CH2) was 
integrated by 186 protons, since the polymer used was of ~83 GAUs 
according to GPC results. Signal 5 was compared with signal 1 
(corresponding with three CH3 groups from end capping group) to 
confirm complete conversion as it can be seen from the integrations. 
Once end capping was complete, the polymer backbone was 
modified by the use of three different mono-Boc protected diamines: N-
Boc-DOOA, N-Boc-hexaneamine and N-Boc-ethylenediamine 
(Scheme 4.3). These amines are not much different in their pKb values 
(pKb N-Boc-DOOA: 9.4; N-Boc-hexaneamine: 10.2 and N-Boc-
ethylenediamine: 9.2 according to ref7). However, they differ in their 
hydrophobic character. The use of mono-Boc protected amines could 
be interesting to build complex architectures based on polyglutamates 
such as graft, brush and comb-like polypeptides, due to the creation of 
different reactive sites, in this case randomly distributed, which can be 
used for later polymerization processes in order to grow branches. 
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Scheme 4.3. General reaction scheme of the synthesis of modified 
PBLG via aminolysis, with different amines Boc protected amines. 
Different percentages of modifications with the three different 
amines were aimed (5, 10, 20 mol% GAU). Reactions were always 
carried out in DMF as a solvent, under nitrogen atmosphere and at 50 
°C during 48 hours. The reagents ratio was optimized as follows. The 
use of 2 eq. of the desired modification of the amines (X, i.e., 0.1 for 10 
% modification), and 1 eq. of catalyst (ratio 1:2X:1X) did not lead to 
any modification. Then, the use of 1:20X:5X ratio worked for the 
reaction with N-Boc-DOOA, but not for N-Boc-hexaneamine and N-
Boc-ethylendiamine modifications which could be explained due to the 
higher hydrophobicity of these two latest amines when compared to the 
N-Boc-DOOA. Finally, the use of the ratio 1:40X:5X, lead to 
successful results for N-Boc-DOOA as well as N-Boc-ethylendiamine. 
In the case of N-Boc hexaneamine, poor modifications were obtained in 
all reactions (never higher than 4 %). In fact, when the polymer 
backbone integrity was analyzed by GPC as well as by 1H-NMR 
(endcapping integrity), cleavage was observed in the ones modified 
with N-Boc-hexaneamine (Figure 4.3).  
 
Figure 4.3. GPC trace from the polymers modified with N-Boc-
hexaneamine through aminolysis reaction. 
Retention Volume (mL)
0.00 3.75 7.50 11.25 15.00 18.75 22.50 26.25 30.00 33.75 37.50 41.25 45.00
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The degree of modification can be calculated with the aid of 
1H-NMR spectra (Figure 4.4). It was calculated by comparison of the 
signal of the α-carbon of the polymer backbone and the signal of the 
Boc-group. The integral of the proton in CHα corresponds with one 
proton, while the integral of the Boc-group should correspond to 9 
protons for 100 %. Moreover, signals corresponding to OCH2C6H5 
decrease in comparison with CHα due to aminolysis substitution. 
Figure 4.4 shows an example of characterization performed and the rest 
can be found in SI. 
As mentioned before, GPC was used to check the integrity of 
polymer backbone after modification, as well as to ratify that Ð of 
polymers after modification remains constant, what suggests an 
homogeneous substitution during reaction. For modifications with N-
Boc-ethylendiamine (17a) as well as for N-Boc-DOOA (17c), results 
were consistent, the Ð’s were below 1.2 in all the cases (Table 4.1).  
 
Figure 4.4. Example of poly(γ-benzyl L-glutamate-co-N-Boc-
ethylendiamine glutamate) (17a) characterization. a) 1H-NMR spectrum 
in CDCl3 with corresponding assignments. b) GPC trace in DMF/LiBr. 
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Table 4.1. Overview of results obtained within aminolysis reactions. 
N-Boc protected 
amine 
% 
mod. 
(calc) 
% 
mod. 
(real) 
Y 
(%) 
Mnb 
kDa 
MWb 
kDa 
Ðb 
N-Boc-DOOA 
(17c) 
5 4.7 57 20.8 22.6 1.09 
10 8 76 21.0 23.5 1.12 
20 15 76 21.0 22.9 1.09 
N-Boc-
ethylendiamine 
(17a) 
5 3.3 86 18.4 20.9 1.13 
10 10 94 18.8 22.4 1.19 
20 21 75 19.6 22.8 1.16 
N-Boc-
hexaneamine 
(17b) 
5 3.6 47 Degradation observed 
10 3.4 47 Degradation observed 
20 3 42 Degradation observed 
a. Data obtained by 1H-NMR. b. Data obtained by GPC in DMF/LiBr. 
CD spectra were also recorded from the samples to examine the 
conformations of the modified polymers in HFIP 0.1 mg∙mL-1 at 20 °C 
(Figure 4.5). According to the CD spectra of modified polymers with 
N-Boc-DOOA (17c) and N-Boc-ethylendiamine (17a) with different 
percentages of modification, the α-helix is retained in both cases.  
 
Figure 4.5. CD spectrum of poly(γ-benzyl L-glutamate-co-N-Boc-
ethylendiamine glutamate) (17a) as example at 0.1 mg∙mL-1 in HFIP 
and 20 °C. Similar profiles where obtained for N-Boc-DOOA modified 
polymers. 
 Additionally, and as mentioned before, these modifications 
could be used to produce reactive sites for further polymerizations. The 
Boc groups can be easily removed with HBF4∙Et2O (Scheme 4.4) 
without damaging the end cap protecting group, neither the benzylic 
esters as confirmed by 1H-NMR (Figure 4.6). Although it might be 
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interesting to compare the structures produced by polymerization of 
these different polymers with potentially different degrees of branching 
due to the different percentages of modifications by aminolysis 
(reactive sites), the synthesis of graft co-polymers was not on the scope 
of this project. 
 
Scheme 4.4. Boc-deprotection of N-Boc amine modified PBLGs. 
 
Figure 4.6. 1H-NMR spectra in CDCl3 of poly(γ-benzyl L-glutamate-
co-ethylendiamine glutamate) (18a), overlapping with the protected 
polymer (17a). The red circle hightlights the disappearance of Boc 
signal. 
As conclusion, it can be stated that, aminolysis reaction is a 
very straightforward reaction which could be used for direct 
modification of benzyl protected polyglutamates, of particular interest 
when reactive sites for posterior polymerizations are required. 
Nevertheless, the lack of versatility of this reaction (it depends on 
polymer stability upon reaction conditions, as well as on the amine used 
for modifications), the need for harsh conditions and a large excess of 
reagents, and the restriction to organic solvents were polyglutamate 
chains will be solubilized, make it a non-suitable choice for the 
introduction of functional reactive groups for orthogonal 
bioconjugations. 
8.5    8.0   7.5   7.0    6.5    6.0    5.5    5.0   4.5    4.0    3.5   3.0    2.5    2.0    1.5    1.0    0.5
δ(ppm)
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For that reason, there was a need for a versatile methodology 
which must fulfill some requirements such as: (i) the use of mild 
reaction conditions in order to keep the polymer backbone, (ii) high 
versatility, making possible the use of aqueous and organic solvents as 
well as the introduction of hydrophobic and hydrophilic moieties. 
4.2.2. Post-polymerization modification of PGA with 
DMTMM. 
Taking into account the points above discussed, in this work we 
pursued the development of a versatile post-polymerization 
modification methodology allowing the introduction of different 
functionalities such as alkyne, azide, reactive disulfides, protected 
amines and protected alcohols, or PEG moieties into PGA. 
The selected strategy to achieve this goal was based on in situ 
activation of carboxyl functionalities of PGA by 4-(4,6-Dimethoxy-
1,3,5-triazin-2-yl)-4-methyl morpholinium (DMTMM) chloride 
(DMTMM∙Cl) (19a) in aqueous solution, and DMTMM∙BF4 (19b) salt 
for organic solvents.8 DMTMM∙Cl (19a) was synthesized according to 
literature.9 Briefly, 1 eq of 2-chloro-4,6-dimethoxy-1,3,5-triazine 
(CDMT), was reacted with 0.93 eq of N-methylmorpholine (NMM) at 
r.t. (Scheme 4.5). A white solid appeared within several minutes that 
can be easily isolated. In the case of the BF4 form (19b) for organic 
solvents, the chloride salt was displaced by the BF4 in situ by reacting 
CDMT and NMM in water, and addition of NaBF4.10 
 
Scheme 4.5. DMTMM∙Cl (19a) synthesis according to Kunishima et al. 
Therefore, modifications on the procedure reported by 
Michielsen and coworkers20 have been performed to adjust the protocol 
to PGA. Activation of the carboxylic acids within polymer backbone 
was carried out by using DMTMM∙Cl (19a) for aqueous solutions with 
PGA as a sodium salt, and DMTMM∙BF4 (19b) for organic solvents 
such as DMF with PGA as an acid (insoluble in aqueous media). The 
use of one or the other was based on different criteria such as the 
solubility of the selected amine, or taken into account practical reasons 
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depending on subsequent reaction needs (i.e. if PGA is needed as acid 
or as salt). Afterwards, the selected amine was added into the reaction 
mixture leading to the corresponding modified polymer. The reaction is 
described in Scheme 4.6. 
After the required optimization, this strategy has been 
implemented herein to accomplish direct bioconjugation of contrast 
agents (i.e. DO3A), imaging probes (Cy5.5, Oregon green), drugs and 
also PEGylation. PEGylation is well known as the process of covalent 
attachment of PEG chains to another molecule, normally a drug or a 
therapeutic protein. The covalent attachment of PEG to a drug or 
therapeutic protein can "mask" it from the host's immune system 
(reduced immunogenicity and antigenicity) and increase its 
hydrodynamic size which prolongs circulation time by reducing its 
renal clearance. PEGylation can also provide water solubility to 
hydrophobic drugs and proteins. Therefore, the introduction of 
PEGylated units into polymer backbone not only allowed us the 
inclusion of a spacer between the polymer and the corresponding 
bioactive compound, but also can modify the polymer in vivo fate, 
biodistribution and therefore, the possible therapeutic application.  
 
Scheme 4.6. Synthesis of reactive PGA derivatives (20) and their use 
for site-specific conjugation. 
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The mechanism of action of DMTMM∙Cl consists on the 
formation of an activated ester with the release of 4-methylmorpholine 
in a first step. This activated ester reacts with the corresponding amine 
compound. The pH of the reacting mixture is always adjusted to 8 in 
order to favor the amine form of the compound instead of the 
protonated one that coexist in equilibrium, with non nucleophilic 
character. In the case of DMTMM∙BF4 salt, the base DIEA was used 
for the same reasons. In Scheme 4.7, the mechanism of the reaction is 
depicted for the concrete case of the use of DMTMM∙Cl. 
 
Scheme 4.7. General scheme of post-polymerization modification of 
PGA sodium salt with DMTMM∙Cl as activator of the carboxylic 
groups of the polymer backbone. 
Once conversion was fully achieved (usually 16 hours), 
different procedures for purification of the resulting constructs were 
explored. In the case of reactions with DMTMM∙BF4 under organic 
solvents, a first step of ether precipitation was carried out. Then, 
polymer was suspended in an aqueous solution and dissolved by 
conversion into sodium salt form upon addition of sodium bicarbonate. 
After that, the aqueous solutions were purified using different methods. 
One of them was based on acid/base precipitation since PGA is 
insoluble as carboxylic acid but soluble as sodium salt. As all by-
products were water soluble, the resulting polymers could be easily 
purified by precipitation in acidic water (pH~3-4) and re-dissolved with 
sodium bicarbonate (3x). After freeze-drying pure colorless PGA 
modified polymers (20) as sodium salt could be collected. 
Additionally, ultrafiltration by using a membrane of MWCO 
3000 was also explored since polymers with a higher content of 
mEG(6) (>30 %) cannot be precipitated under the above described 
conditions. Likewise precipitation, ultrafiltration yielded pure colorless 
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PGA derivatives after freeze-drying. Finally, size exclusion 
chromatography (SEC) using Sephadex G25 columns was also 
investigated as alternative purification method. In all three cases, the 
product was obtained pure and in comparable yields (>80 %), but, it 
could be said that ultrafiltration was preferable at large scale whereas 
Sephadex G25 /PD10 columns were the preferred methodology at small 
scale. Once purified, percentages of modification achieved was 
determined by 1H-NMR. 
Table 4.2. Characteristics of the polymers synthesized using 
DMTMM∙Cl in aqueous solutions.  
PGA-prop 
(20a) 
% Alkyne  
(calc.) 
% Alkyne  
1H-NMR 
Mn 
kDa 
MW 
kDa 
Ð 
20a_1 50  31  19.5 22.0 1.13 
20a_2 30 18 18.8 21.3 1.13 
20a_3 20  11 18.5 20.9 1.13 
20a_4 10  6  18.2 20.6 1.13 
PGA-EG(2/6/9)N3 
(20b-d) 
% Azide  
(calc.) 
%Azide  
1H-NMR 
Mn 
kDa 
MW 
kDa 
Ð 
20b_1 (n=2) 60 30 26.2 29.6 1.13 
20b_2 (n=2) 20 15 22.3 25.2 1.13 
20b_3 (n=2) 15 11 21.0 23.7 1.13 
20c_1 (n=6) 50 34 33.6 38.0 1.13 
20c_2(n=6) 30 18 26.2 29.6 1.13 
20c_3 (n=6) 20 16 25.3 28.5 1.13 
20d_1 (n=9) 50 28 40.7 46.0 1.13 
20d_2 (n=9) 20 16 33.3 37.6 1.13 
20d_3 (n=9) 10 9 29.0 32.8 1.13 
PGA-mEG(6) 
(20e) 
% EG  
(calc.) 
% EG  
1H-NMR 
Mn 
kDa 
MW 
kDa 
Ð 
20e_1 200  87  56.7 64.0 1.13 
20e_2 140  73 50.4 57.0 1.13 
20e_3 100  49  39.7 45.0 1.13 
20e_4 60  30 31.3 35.3 1.13 
20e_5 20  8 21.5 24.3 1.13 
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PGA-SS-2TP 
(20f) 
% Cystea 
mine2TP 
(calc.) 
% Cystea 
mine2TP 
1H-NMR 
Mn 
kDa 
MW 
kDa 
Ð 
20f_1 50 32 23.6 27.2 1.15 
20f_2 35  30 23.4 26.9 1.15 
20f_3 10  9 23.0 26.5 1.15 
20f_4 5  4 23.0 26.3 1.15 
*PGA-prop (20a): poly(glutamic acid-co-propargyl glutamate); PGA-
EG(2/6/9)N3 (20b-d): poly(glutamic acid-co-EG(n)N3 glutamate); PGA-
mEG(6) (20e): poly(glutamic acid-co-EG(6)OMe glutamate); PGA-SS-2TP: 
poly(glutamic acid-co-cysteamine2TP glutamate) 
Table 4.3. Characteristics of the polymers synthesized using 
DMTMM∙BF4 in organic solutions (DMF).  
PGA-N-Boc-
ethylendiamine 
(20g) 
% N-Boc-
ethylendi-
amine  
(calc.) 
% N-Boc-
ethylendi-
amine 
1H-NMR 
Mn 
kDa 
MW 
kDa 
Ð 
20g_1 50  54  18.1 21.5 1.19 
20g_2 20 17 14.1 16.7 1.19 
20g_3 10  12 13.0 15.5 1.19 
PGA-N-Boc-DOOA 
(20h) 
% N-Boc-
DOOA  
(calc.) 
% N-Boc-
DOOA 
1H-NMR 
Mn 
kDa 
MW 
kDa 
Ð 
20h_1 50  62  13.4 16.0 1.19 
20h_2 20 17 12.8 15.2 1.19 
20h_3 10  5 12.5 14.8 1.19 
PGA-prop 
(20a) 
% Alkyne  
(calc.) 
% Alkyne  
1H-NMR 
Mn 
kDa 
MW 
kDa 
Ð 
20a_5 75 35 15.6 18.1 1.16 
20a_6 50  30 15.5 18.0 1.16 
20a_7 35  22  15.4 17.9 1.16 
20a_8 20 16 15.3 17.8 1.16 
20a_9 10 9 15.2 17.7 1.16 
*PGA-N-Boc-ethylendiamine (20g): poly(glutamic acid-co-N-Boc-
ethylendiamine glutamate); PGA-N-Boc-DOOA (20h): poly(glutamic acid-co- 
N-Boc-DOOA glutamate).
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Figure 4.7. 1H-NMR spectrum (D2O) of poly(glutamic acid-co-
propargyl glutamate) (20a). 
Figure 4.8. 1H-NMR spectrum (D2O) of poly(glutamic acid-co-
EG(n)N3 glutamate) (20b-d). 
Figure 4.9. 1H-NMR spectrum (D2O) of poly(glutamic acid-co-
EG(6)OMe glutamate) (20e). 
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Figure 4.10. 1H-NMR spectrum (D2O) of poly(glutamic acid-co-
cysteamine2TP glutamate) (20f). 
 
Figure 4.11. 1H-NMR spectrum (D2O) of poly(glutamic acid-co-N-
Boc-ethylendiamine glutamate) (20g). 
Figure 4.12. 1H-NMR spectrum (D2O) of poly(glutamic acid-co-N-
Boc-DOOA glutamate) (20h). 
[Chapter 4] 
216 
In PGA-prop (20a), alkyne content was quantified by 
integration of the signals from propargyl alkyne (3.81 ppm CH2- and 
2.48 ppm acetylenic proton) in relation to signals of PGA (2.40-1.52 
ppm PGA side chain and 4.01 ppm α-proton) from 1H-NMR spectra in 
D2O (see Figure 4.7). In the case of PGA-mEG(6) (20e), and PGA-
EG(2/6/9)N3 (20b-d), the oligoethylene glycol content was quantified 
by integration of the corresponding signals of ethylene glycol unit in 
1H-NMR spectra in D2O, in comparison with the corresponding signals 
of PGA (see Figure 4.8). The peaks at 3.26, 3.35 and 3.48 ppm 
correspond to -CH2- protons near to amide group and azide group. The 
big signal at 3.55 ppm belongs to -CH2- of oligoethylene glycol chain 
plus one of the triplet corresponding to terminal CH2 protons (Figure 
4.9). This latter signal changes in its integration whenever modification 
is done with EG2 (2 units of ethylene glycol in the inside chain which 
correspond with 10 protons) or EG6 (which corresponds with 50 
protons). In the case of modifications with the N-Boc-ethylendiamine, 
peaks at 3.21 ppm (-CH2-) and 3.11 ppm (-CH2-) chemical shifts and 
more precisely the peak of the Boc signal at 1.35 ppm (-CH3)3 were 
used for quantifications (Figure 4.11). Similarly, in the case of N-Boc-
DOOA modifications, the big signal at 3.52 ppm corresponds to the -
CH2- of the oligoethylene glycol unit, and peaks at 3.32 and 3.20 ppm 
were assigned to -CH2- close to amide groups (Figure 4.12). As for N-
Boc-ethylendiamine modified products (20g-h), Boc signal at 1.35 ppm 
was used for quantification of the percentage of substitution. Finally, in 
modifications with pyridyl dithiol cysteamine (cysteamine2TP) (20f), 
the ratio of the integrals of pyridine ring 8.4 ppm (CHaromat), 7.84 ppm 
(CHaromat), and 7.28 ppm (CHaromat) to the integral of -proton of PGA 
was used to calculate the percentage of derivatization. Peaks at 3.48 and 
2.95 ppm correspond to -CH2- of cysteamine as shown in Figure 4.10. 
Thus, in comparison with PGA signals, % of substitution of 
each polymer could be easily calculated. Characteristics of all PGA 
derivatives are displayed in Tables 4.2 and 4.3. 
Overall, linking efficiencies are comparable or even better than 
post-polymerization modification of poly(acrylic acid) PAA as reported 
by Michielsen and coworkers 20 and are around 60-80 % when low 
degrees of substitution are desired. Only in some cases of sterically 
demanding amines as well as for solubility reasons, reduced linking 
efficiency of 40-50 % at high degrees of substitution were obtained.  
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4.2.3. Study of the influence of the percentage of modification 
in polymer size and solution conformation.  
Once the protocol for post-polymerization modification 
reactions was optimized, the influence of different percentages of 
substitutions was tested in terms of size, solution conformation, and 
biodegradability of the newly synthesized constructs. Some 
representative examples will be illustrated in the following paragraphs. 
CD spectra in PB 0.1 M (phosphate buffer without saline) at 37 
°C and 0.1 mg∙mL-1 were recorded in order to assess changes (if they 
were) in secondary structures of modified polymers (Figure 4.13). PB is 
used in order to keep constant the pH avoiding problems caused in 
voltage when measurements are done in PBS buffer, due to salt content. 
As it can be seen in Figure 4.13, all polymers analyzed showed the 
typical random coil conformation as for linear PGA without significant 
changes in the secondary structure. 
 a)    b) 
 
Figure 4.13. CD spectra of a) Different PGA-prop (20a), b) PGA-N-
Boc-DOOA (20h), in PB at 37 °C and at [C] of 0.1 mg∙mL-1. 
The effect of polymer concentration and temperature of the 
analysis was also checked with some examples as it can be seen in 
Figure 4.14. From results obtained no big influence due to the 
temperature of the analysis was found. On the other hand, CD plots 
changed with the concentration used, being constant at concentrations 
from 0.05-0.5 mg∙mL-1. Above that concentration, a red shift could be 
observed for the negative band from 196 to 203, this might be due to 
partial transition of the polymeric backbone random coil to a more 
organized conformation, however, further studies on this regard should 
be done in the future to unravel this conformational issue. 
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  a)    b) 
 
Figure 4.14. CD spectra of A) PGA-EG(6)N3 (20c), in PB at [C] of 0.1 
mg∙mL-1 and different temperatures, B) PGA-N-Boc-DOOA (20h), in 
PB at 37 °C and at different concentrations. 
In the case of Boc protected amines, Boc groups were removed 
with a mixture of trifluoroacetic acid/dichloromethane TFA/CH2Cl2 
(40:60), in order to check the influence on secondary structure of the 
deprotected amines with the pH. For that purpose, CD spectra were 
recorded at different pHs using polymers with different percentage of 
modifications. In Figure 4.15, examples with DOOA modified PGAs 
are shown. As it can be seen in CD plots, pH influence on secondary 
structure seems to be slightly higher when amine percentage of 
modification is greater. However, no major changes in secondary 
structure are found at physiological pH, what is significantly relevant 
regarding their potential use for biomedical applications. 
 a)    b) 
 
Figure 4.15. CD spectra in PBS at [C] of 0.1 mg∙mL-1 at different pHs, 
of a) PGA-DOOA 10 % (20j), b) PGA-DOOA 20 % (20j), both 
polymers bearing free amine groups. 
The solution conformation of several PGA modified polymers 
was analyzed by Small Angle Neutron Scattering (SANS). From the 
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curve fitting obtained by means of FISH software, it could be 
concluded that solution conformation of all constructs corresponded to 
“capped rods” with two different radius (Ra and Rb). The values 
obtained for different PGAs bearing EG(n) azide groups with similar 
degree of modification but different EG length showed smaller rods 
(small Ra and Rb) for EG(6) when compared with EG(2) and EG(9). 
This could be in concordance with the degradation rate obtained, higher 
for EG(6) (see next section), and its posterior biological output (see 
Chapter 8). In the case of ethylendiamine and DOOA modified 
polymers, Ra, remained more or less constant independently of degree 
of modification. Nevertheless, longer rods (higher Rb) where obtained 
when the percentage of functionalization was increased. 
Table 4.4. Summary of the results obtained from SANS 
characterization. 
Compound % mod MW kDa 
SANS 
Ra (nm) Rb (nm) 
PGA-EG(2) (20b) 32 32.3 1.40 140 
PGA-EG(6) (20c) 27 36.4 1.00 94 
PGA-EG(9) (20d) 28 40.7 1.40 140 
PGA-ethylendiamine 
(20i) 
12 12.7 1.45 105 
54 13.4 1.40 155 
PGA-DOOA (20j) 
5 13.0 1.40 120 
17 14.1 1.32 150 
It has to be mentioned that the protocol of post-polymerization 
modification was successfully applied in the introduction of functional 
moieties in the case of hybrid di-block copolymers and star-shaped 
polymers as well, highlighting its versatility.  
4.2.4. Click Chemistry model couplings with small molecules. 
The purpose of the introduction of functional moieties into the 
polymer backbone was their posterior use for bioconjugations in 
orthogonal reactions. Conjugation strategies can be divided into two 
categories: chemical11, 12 and biological ligation.13 Among chemical 
strategies, Copper Catalyzed Azide/Alkyne Cycloaddition (CuAAC) 
formally known as CuI-mediated Huisgen 1,3-dipolar cycloaddition 
reaction has been widely applied14 since it is a versatile but easy to 
perform methodology for site-specific chemical ligation of complex 
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molecules to polymers. Moreover, this class of reaction is atom 
efficient, broad in scope, and it provides high yields under relatively 
mild conditions in aqueous as well as organic media; it presents high 
tolerance of functional groups (except for those that are self-reactive 
(e.g. azides and alkynes)); and in addition, reaction can be developed at 
various types of interfaces, such as solid/liquid, liquid/liquid, or even 
solid/solid interfaces. Therefore, the characteristics of this reaction 
completely fits with the definition of Barry Sharpless12:“ A click 
reaction must be modular, wide in scope, high yielding, create only 
inoffensive by-products (that can be removed without chromatography), 
are stereospecific, simple to perform and that require benign or easily 
removed solvent. ”  
Apart from the advantages pointed out, it has to be noticed that 
the process is thermodynamic and kinetically favorable (50 and 26 
kcal/mol, respectively), regiospecific (whereas the classic Huisgen 1,3-
dipolar cycloaddition often gives mixtures of regioisomers, the copper-
catalyzed reaction allows the synthesis of the 1,4-disubstituted 
regioisomers specifically), and chemoselective, with a 107 rate 
enhancement over non-catalyzed reaction. 
This type of reactions have been widely used for many 
applications of post-polymerization modification to couple telechelic 
polymers with differently functionalized chain ends (yielding di-and tri-
block copolymers), to prepare graft copolymers (by grafting from or to 
methods), to conjugate synthetic polymers to biomacromolecules, to 
cross-link polymers or to achieve complex architectures including 
dendrimers, hyperbranched polymers and core-cross-linked star 
polymers. 
These newly synthesized PGA derivatives have been used to 
develop a conjugation protocol for the attachment of either hydrophobic 
or hydrophilic molecules employing the CuAAC methodology (Scheme 
4.8). 
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Scheme 4.8. Click reactions toward PGA-prop copolymer and PEG-
EG(n)N3 as example. 
From the different catalyst known, the system CuSO4∙5 H2O/ 
sodium ascorbate is widely used when reaction takes places in aqueous 
solutions, and CuBr/ N,N,N',N',N"-pentamethyldiethylenetriamine 
(PMDTA) when organic solvents are used. The active specie is Copper 
(I), which is easily oxidized to Copper (II) in aqueous solutions as its 
potential of reduction predicts: 
ܱଶ + 2ܪଶܱ(݈) + 4݁
ି → 4ܱܪି(ܽݍ)       E°O2/OH= +0.40V 
ܥݑା → ܥݑଶା + 1݁ି                                    E°Cu2+/Cu+= 0.16V 
ET= E°O2/OH - E°Cu2+/Cu+= +0.24V (favorable reaction when the E 
is positive) 
For that reason, systems were always carefully degassed prior 
to addition of the catalyst and afterwards as well.  
In the case of the catalyst CuSO4.5 H2O/ sodium ascorbate, the 
active specie Cu (I) is formed “in situ” with the reductive power of 
ascorbate (known as a potent antioxidant). An excess of reductive agent 
is always added in order to prevent re-oxidation of the catalyst. In the 
case of CuBr/PMDTA, the active specie does not need to be formed in 
situ. PMDTA is a basic, bulky, and flexible, tridentate ligand which 
stabilizes Cu(I) in solution. Its basic character is required as a base is 
necessary in the first step to deprotonate the acetylene and generate a 
Cu acetylide intermediate. When reaction takes place in water, it is the 
water acting as a base. 
The coupling reaction was monitored by FT-IR by 
disappearance of the asymmetric vibration band. Figure 4.16 displays a 
representative FT-IR spectrum. Time zero represents the pure azide in 
absence of the corresponding alkyne reagent. As it can be seen, the 
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asymmetric vibration band was observed at 2485 cm-1, this band was 
disappearing with time up to 48 h when it was non-longer detectable. 
Finally, the polymers were purified according to the above-mentioned 
methodologies for post-polymerization modification. In all cases 
colorless polymers could be obtained after freeze drying from solution. 
 
Figure 4.16. Representative FT-IR-spectra of a CuAAC reaction 
between a polymeric azide and a low molecular weight alkyne.  
Linking efficiency was determined according to 1H-NMR 
spectra of the resulting compound by integration of the peak at 7.8 ppm 
corresponding to the proton of the triazole ring newly formed. In Table 
4.5, optimization of reaction conditions is summarized looking for an 
acceptable % of coupling and yield in aqueous conditions and in 
organic solvents. Reaction conditions have been optimized to nearly 
quantitative linking efficiencies by screening different solvents, 
temperatures, catalysts and concentrations (see Table 4.5). Besides 
monitoring the conversion of azides by IR, linking efficiency of the 
CuAAC reaction was also monitored by 1H-NMR by correlating the 
integration of triazole proton signal, which is formed during the 
CuAAC, with the α-proton of PGA (see Figure 4.17).  
 
Figure 4.17. 1H-NMR spectrum (D2O) of CuAAC reaction product 
between PGA-prop (20a) and NH2-EG(2)N3. The peak surrounded by a 
circle associates to the proton of triazole ring. 
8.5     8.0    7.5      7.0       6.5     6.0      5.5     5.0      4.5     4.0      3.5     3.0      2.5    2.0     1.5
δ(ppm)
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Table 4.5. Reaction conditions used during CuAAC.  
Experiment Solv. 
T 
°C 
CuSO4/ 
NaA. 
eq.a LEb 
% 
1 
PGA- 
prop 
(20a) 
+N3- 
EG(2) 
NH2 
H2O 25 0.3/0.5 3(20%) 0 
2 H2O 40 0.3/0.5 3(20%) 88 
3 H2O 40 1/5 6(40%) 97 
4 
DMF/ 
H2O 
40 0.3/0.5 6(40%) 48 
5 
DMF/ 
H2O 
40 1/5 2(9%) 67 
6 
+N3-EG(6) 
NH2 
H2O 40 1/5 6(40%) 96 
7 
PGA- 
EG(2) 
N3 
(20b) 
Propar 
gylamine 
H2O 25 0.3/0.5 3(14%) 0 
8 H2O 40 0.3/0.5 3(14%) 0 
9 
DMF/ 
H2O 
60 1/5 4(18%) 33 
10 
DMF/ 
H2O 
60 1/10 2(9%) 55 
11 
PGA- 
EG(6) 
N3 
 (20c) 
Propar 
gylamine 
H2O 25 0.3/0.5 3(14%) 0 
12 H2O 40 0.3/0.5 3(14%) 0 
13 
DMF/ 
H2O 
40 1/5 2(9%) 67 
14 
Propar 
gyl 
acrylate 
DMF/ 
H2O 
40 1/5 
2.4 
(11%) 
99 
a. eq. Equivalents of clickable molecule per polymer. The % 
corresponds with the % calculated of modified GAU (bearing N3 or 
alkyne depending on the polymer used) that will react theoretically. b. 
L.E: Linking efficiency calculated taking into account the previous 
percentage, and the % achieved. 
Summarizing, CuAAC reaction on PGA derivatives was 
achieved in aqueous as well as organic solutions. The use of 
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CuSO4/Sodium ascorbate (1/5) as catalyst at 40 °C was the optimal 
condition for CuAAC in aqueous media yielding to quantitative 
conversions. The use of DMF/H2O mixtures (4:1) with CuSO4/Sodium 
ascorbate (1/5) also allowed conjugation of hydrophobic but DMF 
soluble peptides/drugs. The linking efficiency was always lower when 
DMF/H2O mixtures were used (55-67 %), but acceptable, reproducible 
and predictable. This effect was attributed to intra-chain aggregation 
during conjugation of hydrophobic compounds making it increasingly 
difficult to reach the conjugation site due to steric hindrance. 
4.2.5. In vitro biological characterization. 
As for star-shaped polymers described in previous chapters, 
degradation of the modified polymers under presence of lysosomal 
enzyme cathepsin B was studied. In all cases, polymers were incubated 
in presence of cathepsin B, at pH 6 in acetate buffer and EDTA, under 
reductive conditions by using DTT in order to favor enzyme activity. 
Aliquots were collected over time and analyzed by GPC under aqueous 
conditions. 
On one hand, the influence of % of modification of one 
concrete moiety was tested by using PGA-prop (20a). Figure 4.18 
shows the plots of some examples of degradation profiles from 5, 10 
and 20 % of propargylamine modifications of linear PGAs. According 
to the GPC traces of the degraded samples over time, differences 
among the polymers where found. Concretely, degradation rate was 
greater upon polymer modification grade (at least in the case of PGA-
prop). This finding is in good agreement with literature where Kopecek 
and collegues demonstrated that both, the incorporation of hydrophobic 
co-monomers and modification of the carboxylic groups of glutamic 
acid side-chains with hydrophobic groups increased the lysosomal 
degradability of the co-polymers.15 
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a) PGA-prop(5)                           b) PGA-prop(10) 
 
c) PGA-prop(20) 
 
Figure 4.18. GPC traces showing kinetics of PGA-prop (20a) 
degradation upon Cathepsin B incubation 
The same experiment was performed using star-shaped 
polymers, bearing 10 and 20 % of propargylamine moieties showing 
similar results as those found for the linear counterparts. 
On the other hand, the influence of the introduced moiety size 
(length) for a fixed percentage of polymer modification (~ 30%) was 
studied by using PGA-EG(n)N3 with different EG number of units 
(20b-d).  
a) PGA-EG(2)N3                        b) PGA-EG(6)N3 
 
  
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
R
ef
ra
ct
iv
e 
In
de
x 
(m
V
)
Retention Volume (mL)
12.00 12.67 13.33 14.00 14.67 15.33 16.00
0.5 h
4 h
8 h
24 h
48 h
72 h
96 h
120 h
144 h
168 h
90
80
70
60
50
40%
30%
20%
10%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
R
ef
ra
ct
iv
e 
In
de
x 
(m
V
)
Retention Volume (mL)
12.00 12.67 13.33 14.00 14.67 15.33 16.00
0.5 h
4 h
8 h
24 h
48 h
72 h
96 h
120 h
144 h
168 h
90
80
70
60
50
40%
30%
20%
10%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
R
ef
ra
ct
iv
e 
In
de
x 
(m
V
)
Retention Volume (mL)
12.00 12.70 13.40 14.10 14.80 15.50 16.20
0.5 h
4 h
8 h
24 h
48 h
72 h
96 h
120 h
144 h
0%
0%
0%
0%
0%
0%
0%
20%
10%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
R
ef
ra
ct
iv
e 
In
de
x 
(m
V
)
Retention Volume (mL)
12.00 12.67 13.33 14.00 14.67 15.33 16.00
0.5 h
4 h
8 h
24 h
48 h
72 h
96 h
120 h
144 h
168 h
90%
80%
70%
60%
50%
40%
30%
20%
10%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
R
ef
ra
ct
iv
e 
In
de
x 
(m
V
)
Retention Volume (mL)
12.00 12.67 13.33 14.00 14.67 15.33 16.00
0.5 h
4 h
8 h
24 h
48 h
72 h
96 h
120 h
144 h
168 h
90%
80%
70%
60%
50%
40%
30%
20%
10%
[Chapter 4] 
226 
c) PGA-EG(9)N3 
 
Figure 4.19. GPC traces showing kinetics of PGA-EG(n)N3 (20b-d) 
degradation upon Cathepsin B incubation. 
As it can be observed in Figure 4.19, polymer degradation 
profile changed depending on EG length. In all cases, percentage of 
modification was around 30 %, however, for EG(9), no degradation 
was observed upon incubation with cathepsin B. This result could be 
attributed to the fact that EG(9) pendant groups might be shielding 
cathepsin B activity due to steric hinderance and consequently 
diminished enzyme accessibility. When EG(2) and EG(6), are 
compared, it can be observed that polymers modified with EG(6) 
moieties were degraded faster than EG(2) modified polymers. This 
could be again attributed to steric hindrance issues caused by the use of 
a shorter spacer which could limit the accessibility of the enzyme to the 
polymer backbone. More importantly, these findings could be directly 
correlated with a different biological performance of the modified 
polymers when used as Near InfraRed (NIR) fluorescence smart 
probes. As it will be explained in further detail in Chapter 8, the 
polymeric probe based on the EG(6) spacer showed the best 
performance in vitro. 
Finally, cell viability of a set of polyglutamic acid polymers 
(star-shaped and linear PGAs) modified by post-polymerization 
modification techniques with propargylamine residues was tested 
against SHSY5Y cell line. This time, in order to compare with 
propargylamine moiety related cytotoxicity, concentrations tested were 
according to % weight of propargylamine introduced in the polymer 
chains. As it can be observed in Figure 4.20, no toxicity was found at 
the concentrations tested 72 hours of treatments. 
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a) 
 
b) 
 
Figure 4.20. Cell viability assay of a) 4 star-shaped PGA-prop (St-
prop) against SHSY5Y cell line, 72 hours of treatments. b) 3 linear 
PGA-propargyl and propargylamine moiety against SHSY5Y cell line, 
72 hours of treatments. n> 3, mean ± SEM. 
4.3. CONCLUSIONS. 
In this chapter, a versatile methodology for the synthesis of 
polyglutamic acid (PGA) derivatives bearing orthogonal reactive sites, 
e.g. azides, alkynes, reactive disulfides, protected amines, etc. in 
combination with the carboxyl functionalities of PGA has been 
reported. Additionally, the linkage of water as well as DMF soluble 
compounds to PGA has been also efficiently carried out. This could be 
used for site-specific conjugation of a variety of bioactive agents of 
different nature (i.e. peptides, proteins, drugs). Therefore, the described 
protocols enable a versatile and controlled approach towards the 
development of next generation PGA-based polymer therapeutics. 
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  From in vitro results, several conclusions can be drawn. As it 
could be expected, degree of functionalization as well as nature of the 
motifs added within the polymer backbone do affect the degradation 
rate of the final construct. Those parameters should be then taken into 
account when talking about biodegradability and biocompatibility of 
polymeric systems, since the nature of the final structure will drive the 
final polymer properties. Upon modification, cell viability (72 h MTS 
assays) of the derivatized polyglutamates was not compromised up to a 
concentration of 10 M propargyl eq. against SHSY5Y cells. 
4.4. MATERIALS AND METHODS. 
4.4.1. Materials. 
All chemicals were synthesis grade, obtained from Aldrich and 
used without further purification, unless otherwise indicated. All EG 
amines were obtained from Iris Biotech GMB. All solvents were of 
analytical grade. Preparative SEC was performed using Sephadex G-25 
superfine from GE as well as PD MiniTrap G-10 ™ columns 
containing 2.1 mL of Sephadex™ G-10. 
4.4.2. Characterization techniques. 
NMR spectroscopy, GPC, CD, DLS, and IR were performed 
using the equipment and techniques according to Sections 2.4.2 and 
3.4.2. 
4.4.2.1. Small Angle Neutron Scattering (SANS). 
Small-angle neutron scattering (SANS) experiments were 
performed on the D11 difractometer at the Institute Laue-Langevin in 
Grenoble (France) by our collaborators from the School of Chemistry 
in Cardiff University (Cardiff, UK). Scattering data are expressed in 
terms of the scattering vector, Q, which is given by Q= 4π/λ·sin(ϴ/2) 
where λ is wavelength and ϴ the angle at which neutrons are scattered. 
The incident neutron wavelengths were variable between 4.5 and 40 Å, 
giving accessible Q-ranges of 0.0003 to 1 Å-1 using four different 
sample-detector distances. The detector may be placed at any distance 
between 1.2 and 39 metres from the sample position. Sample solutions 
were prepared at 10 mg∙mL-1 on a 1 g scale in D2O (pH 5.5, 0.1 M 
phosphate buffer) and placed in 2mm path length quartz cells, mounted 
in a sample changer thermostated at 37 °C (± 0.2). Data were corrected 
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for transmission intensity, electronic background and normalized 
against a flat scatter according to standard procedures for the 
instrument. The obtained scattering profiles I(Q) vs. Q were analysed 
according to I(Q) α Φ Vp P(Q) S(Q) + Binc where Φ is the volume 
fraction and Vp the particle volume. Binc is the incoherent scattering, 
generally dominated by the protons present in the sample, which 
usually depends on the concentration of polymer. The FISH modelling 
suite was used for the analysis16. FISH incorporates parameterized form 
factors, P(Q) and structure factors, S(Q), to describe the dimensions of 
the scattering particle and inter-particle interaction. 
4.4.3. Protocols.  
Degradations under the presence of cathepsin B as well as MTS 
assays for cell viability were performed according to protocols 
described in Chapter 3. 
4.4.3.1. End capping of PBLG with trimethylacetylchloride. 
In a two-neck round bottom flask of 50 mL fitted with a stir bar, an 
outlet and inlet of N2 and two septums, 2.74 g PBLG (0.151 mmol 
18177 g∙mol-1, 1.14 Ð, 1 eq.) was dissolved in 5 mL of anh. DMF. 
After that 132 µL of DIEA, (0.756 mmol, 129.24 g∙mol-1, 0.742 g∙mL-1, 
5 eq.) were added to the flask, followed by 93 µL of end capping agent, 
trimethylacetylchloride (0.756 mmol, 120.58 g∙mol-1, 0.979 g∙mL-1, 5 
eq.). Reaction was left to proceed for 4 hours. After that time, the 
solution was precipitated in an excess of cold diethyl ether and filtered 
off. The resultant polymer was washed with ddH2O. Finally, the 
polymer was obtained as a dried white solid after lyophillization. 
Yield: 85 %. 1H-NMR δH (300 MHz, CDCL3) 7.28 (5H, m) 5.06 (2H, 
m), 3.96 (1H, m), 2.54 (2H, m), 2.29 (2H, m), 1.19 (s, 9/83H, s). 
4.4.3.2. General procedure for the post-polymerization 
modification of PBLG by aminolysis.  
4.4.3.2.1. Synthesis of poly(γ-benzyl L-glutamate-co-N-
Boc-DOOA glutamate). 
In a two-neck round bottom flask of 25 mL fitted with a stir 
bar, an outlet and inlet of N2 and two septums, 200 mg of end capped 
polymer (0.913 mmol GAU, 1 eq.) were dissolved in 6 mL of anh. 
DMF. Then 20 eq. of the desired modification of N-Boc-DOOA were 
added in 2 mL of DMF under nitrogen atmosphere (i.e. 226.8 mg, 0.913 
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mmol for an amine modification of 5 %). After that, 21.7 mg of 2-
hydroxypyridine (0.228 mmol, 5 eq. from the desired percentage of 
modification) where added in two more mL of anh. DMF. Reaction was 
then left to proceed under N2 flow at 50 °C for 48 hours. After that 
time, 5 mL of THF were added to the flask in order to help with 
precipitation process. The solution was then precipitated in a large 
excess of cold diethyl ether, filtered off and washed with ddH2O. 
Finally, the polymer was obtained as a white solid after lyophillization.  
Yields: 60-90 % 1H-NMR δH (300 MHz, CDCl3) 7.29 (5H, m), 4.99 
(2H, m), 3.78 (1H, m), 3.61-3.44 (8xH, m), 3.39-3.31 (2xH, m), 3.25 
(2xH, s), 2.54 (2H, m), 2.16 (2H, m), 1.38 (9H, s), 1.19 (9/83H, s). x: 
percentage of modification 
4.4.3.2.2. Synthesis of poly(γ-benzyl L-glutamate-co-N-
Boc-ethylendiamine glutamate). 
In a two-neck round bottom flask of 25 mL fitted with a stir 
bar, an outlet and inlet of N2 and two septums, 200 mg of end capped 
polymer (0.913 mmol GAU, 1 eq.) were dissolved in 6 mL of anh. 
DMF. Then 40 eq. of the desired modification of N-Boc-
ethylendiamine were added in 2 mL of DMF under nitrogen 
atmosphere (i.e. 292.6 mg, 1.826 mmol for an amine modification of 5 
%). After that, 21.7 mg of 2-hydroxypyridine (0.228 mmol, 5 eq. from 
the desired percentage of modification) where added in two more mL of 
anh. DMF. Reaction was then left to proceed under N2 flow at 50 °C for 
48 hours. After that time, 5 mL of THF were added to the flask in order 
to help with the precipitation process. The solution was then 
precipitated in a large excess of cold diethyl ether, filtered off and 
washed with ddH2O. Finally, the polymer was obtained as a white solid 
after freeze-drying. 
Yield: 70-90 % 1H-NMR δH (300 MHz, CDCl3) 7.29 (5H, m), 4.97 
(2H, m), 3.86 (1H, m), 3.42 (2xH, m), 3.15 (2xH, m), 2.50 (2H, m), 
2.17 (2H, m), 1.34 (9H, s), 1.19 (9/83H, s). x: percentage of 
modification. 
4.4.3.3. Boc removal from modified PBLGs.  
To a round one neck bottom flask, fitted with a stir bar, 30 mg 
of N-Boc modified polymer was dissolved in 2 mL of chloroform. 
After that 10 eq. of HBF4∙Et2O (0.0625 mmol, 1.18 g∙mL-1), per Boc 
group of polymer, were added dissolved in 1 mL of chloroform. The 
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reaction was left to proceed for 3 hours. After that time, the polymer 
was precipitated in a large excess of cold diethyl ether, washed with 
diethyl ether (3x) and filtered off. A white solid was obtained after 
freeze-drying. 
Yields: 80-90 % 1H-NMR δH (300 MHz, CDCl3): 
a) Poly(γ-benzyl L-glutamate-co-N-Boc-ethylendiamine glutamate) 
7.29 (5H, m), 4.97 (2H, m), 3.86 (1H, m), 3.43 (2xH, m), 3.29 (2xH, 
m), 2.62 (2H, m), 2.24 (2H, m), 1.19 (9/83H, s).  
b) Poly(γ-benzyl L-glutamate-co-N-Boc-DOOA glutamate) 7.29 (5H, 
m), 4.99 (2H, m), 3.78 (1H, m), 3.61-3.44 (8xH, m), 3.39-3.31 (2xH, 
m), 3.25 (2xH, s), 2.54 (2H, m), 2.16 (2H, m), 1.19 (9/83H, s). x: 
percentage of modification.  
4.4.3.4. Method for post-polymerization modification of 
PGA using DMTMM. 
4.4.3.4.1. DMTMM∙Cl for aqueous solutions. 
In a one neck round bottom flask fitted with a stir bar and a 
stopper, 200 mg of PGA (1.55 mol GAU, 1 eq.) were suspended in 10 
mL of ddH2O. Afterwards the eq. for the desired modification of 
DMTMM∙Cl were added dissolved in 5 mL of ddH2O (i.e. 128.7 mg, 
0.465 mmol, 0.3 eq. for 30 % modification). After 10 minutes (0.93 
mmol 0.6 eq. for 30 % modification) of the corresponding amine were 
added and the pH was adjusted to 8 by adding some drops of 1 M 
NaHCO3 solution. Reaction was allowed to proceed overnight stirring 
at r.t. After this, as all by products are soluble in acid aqueous solution, 
either acid/base precipitation, dialysis (Vivaspin® MWCO 3000 Da), 
or size exclusion chromatography with Sephadex G25 columns, was 
done in order to purify the copolymer. A colorless amorphous solid was 
obtained after freeze-drying.  
Yields: 80-90 %. 1H-NMR δH (300 MHz, D2O): 
a) Poly(glutamic acid-co-propargyl glutamate): 4.30-4.02 (1H, m), 3.81 
(2xH, s), 2.48 (1xH, s), 2.35-2.02 (2H, m), 2.01-1.65 (2H, m). x: 
percentage of modification. 
b) Poly(glutamic acid-co-EG(6)OMe glutamate): 4.33-4.19 (1H, m), 
3.95-3.78 (20xH, m), 3.77-3.49 (2xH, m), 3.34 (3xH, s), 2.41-1.76 (4H, 
m). x: percentage of modification.  
c) Poly(glutamic acid-co-EG(n)N3 glutamate): 4.28-4.07 (1H, m), 3.65-
3.51 (RxH, m), 3.48 (2xH, t), 3.40-3.30 (2xH, m), 3.25 (2xH, d), 2.29 -
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2.00(2H, m), 1.98 -1.65 (2H, m). *R: 8 for EG2, 20 for EG6, 32 for 
EG9. x: percentage of modification.  
d) Poly(glutamic acid-co-cysteamine2TP glutamate): 8.4 (xH, m), 7.84 
(2xH, m), 7.28 (xH, m), 4.33 (1H, m), 3.48 (2xH, m), 2.95 (2xH, m), 
1.9-2.3 (4H, m). x: percentage of modification.  
4.4.3.4.2. DMTMM∙BF4 for organic solutions. 
In a two-neck round bottom flask fitted with a stir bar and two 
septums, 200 mg of PGA (acid form) (1.55 mol GAU, 1 eq.) were 
suspended in 10 mL of anh. DMF under N2 atmosphere. Afterwards the 
eq. for the desired modification of DMTMM∙BF4 were added dissolved 
in 5 mL of anh. DMF (i.e. 152.5 mg, 0.465 mmol, 0.3 eq. for 30 % 
modification). After 10 minutes (0.93 mmol 0.6 eq., for 30 % 
modification) of the corresponding amine were added and the pH was 
adjusted to 8 by adding DIEA. Reaction was allowed to proceed for 16 
hours, stirring at r.t. under N2 atmosphere. After this, the solvent was 
completely removed. The modified polymer was then suspended in 
ddH2O and converted into the sodium salt form by addition of NaHCO3 
1 M. As all by products are soluble in acid aqueous solution, either 
acid/base precipitation, dialysis (Vivaspin® MWCO 3000 Da), or size 
exclusion chromatography with Sephadex G25 columns, was done in 
order to purify the copolymer. A colorless amorphous solid was 
obtained after freeze-drying.  
Yields: 80-90 % 1H-NMR δH (300 MHz, D2O): 
a) Poly(glutamic acid-co-N-Boc-DOOA glutamate): 4.23 (1H, m), 3.52 
(8xH, m), 3.32 (2xH, m), 3.20 (2xH, m), 2.35-2.13 (2H, m), 1.99 (2H, 
m), 1.36 (9xH, s). x: percentage of modification. 
b) Poly(glutamic acid-co-N-Boc-ethylendiamine glutamate): 4.26 (1H, 
m), 3.21 (2xH, m), 3.11 (2xH, m), 2.21 (2H, m), 1.91 (2H, m), 1.35 
(9xH, s). x: percentage of modification. 
4.4.3.5. Boc removal from N-Boc-ethylendiamine and N-
Boc-DOOA modified PGAs. 
To a one neck round bottom flask fitted with a stir, 70 mg of 
modified PGA were dissolved in 10 mL of a 50/50 v/v CHCl3/TFA. 
Reaction was allowed to proceed for 5 hours. After that time, solvents 
were evaporated under vacuum. For purification, polymers were re-
dissolved in ddH2O with addition of NaHCO3. Then sodium salts forms 
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of the polymers were purified using dyalisis (Vivaspin® MWCO 3000 
Da) or size exclusion chromatography with Sephadex G25. 
Yield: 80-90 % 1H-NMR δH (300 MHz, D2O) 4.27 (1H, m), 3.44 (2xH, 
m), 3.09 (2xH, m), 2.66 (2H, m), 2.39-2.13 (2H, m). (i.e. for 
poly(glutamic acid-co-ethylendiamine glutamate)) 
4.4.3.6. Methodology for copper catalyzed alkyne-azide 
coupling (CuAAC) of PGA derivatives. 
a) CuAAC conditions for the coupling of hydrophobic peptides/drugs.  
In a two-neck round bottom flask fitted with a stirrer bar and a 
stopper, 1 eq. of copolymer (PGA-EG(2)N3, PGA-EG(6)N3 or PGA-
prop in each case) sodium salt was dissolved in ddH2O. After that, the 
corresponding amount for the desired % of substitution of clickable 
agent was added in dry DMF solution. Then, 5 eq. of sodium ascorbate 
in ddH2O solution were added. Then, the mixture was degassed by 
performing two freeze-pump-thaw cycles. One eq. of CuSO4 was 
weighted under N2 flow and added in ddH2O solution to the reaction 
mixture. The final complete mixture, containing a proportion 
DMF/H2O of 4:1, was degassed by performing another freeze-pump-
thaw cycle and left to react at 40 °C in an oil bath protected from light.  
b) CuAAC conditions for the coupling of water-soluble molecules. The 
synthesis was done according to a) but previously degassing ddH2O. 
1H-NMR δH (300 MHz, D2O): 7.8 (s)*, 4.30-4.02 (1H, m), 3.79 (s)*, 
3.63-3.46 (m)* 2.46 (s)*, 2.35-2.02 (2H, m), 2.01-1.65 (2H, m) when 
NH2PEG(n)N3 was coupled to PGA-prop polymers 
*Integration of peaks corresponds with the amount of functionalization 
(PEG, alkyne or azide). When PGA-EG(2/6)N3 polymers were used, 
propargyl singlet at 2.46 ppm disappeared. Peak at 7.8 ppm corresponds 
with the proton of the triazole ring formed in the CuAAC, and was used 
to determine coupling efficiencies. 
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5.1. INTRODUCTION AND BACKGROUND.  
One of the most appealing properties of some polymeric systems, 
apart from their rheological characteristics and thermoplastic character, is 
their self-assembly behavior that can be promoted in solution by the 
presence of functional moieties along the chain arms or by using selective 
solvents. Micellar structural parameters such as critical micellar 
concentration (CMC), aggregation number, core and shell dimensions, 
overall micelle concentration as well as thermodynamics and kinetics of 
micellization of complex structures, such as star-block copolymers and 
miktoarm stars, have been poorly investigated if compared to linear 
analogues. In general basis, star structures have higher CMC values and 
consequently, lower aggregation numbers than their linear block 
copolymers counterparts.  
The work of He et al. (He et al., 2009) can serve as an example of 
this micellar behavior. They synthesized a family of 4-arm star-block 
copolymers based on polyethylene oxide (PEO) (as inner block) and 
poly(methyl methacrylate) (PMMA). They found that micellar behavior of 
the polymers was affected by the pH of aqueous solutions: whereas at high 
pH values the star-blocks were dissolved adopting an extended 
conformation, at low pH and low degrees of neutralization large spherical 
micelles were formed presenting lower Rh (hydrodynamic radius) as 
degree of neutralization also decreased. In this concrete case, micellization 
behavior depended basically on the balance between the existing 
interactions, including electrostatic (due to carboxylic groups), 
hydrophobic and hydrogen bonding. A second and more clarifying 
example of the fact that the number of arms can influence micellization 
character has been reported by Strandman et al.1-3 They synthesized two 
different amphiphilic 4 and 8-arms PMMA-PAA (poly(acrylic acid)) star-
block copolymers with PMMA as inner blocks. They found for the 4-arm a 
morphological transition from spherical multimolecular micelles at pH 5 in 
salt-free aqueous solutions, to cylindrical micelles upon the addition of 
salts that were again transformed into spherical micelles with a pH increase 
up to 12 (swelling of the corona). In contrast, this effect was not occurring 
for 8-arm stars due to the fact that the higher number of arms resulted in 
higher repulsion and stretching of the PMMA core, leading only to 
spherical structures. 
Overall, it is well-known that macromolecular architecture is a key 
parameter for the tuning of micellar behavior and properties, and thus, it 
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must be well-considered for the design of new materials and their potential 
biological applications, in particular as drug delivery systems. 
Besides, the design of polymer self-assembled DDS has been 
mainly focused on amphiphilic and ionic systems which take advantage 
of hydrophobic effect and electrostatic interactions respectively.4 5, 6 In 
the case of amphiphiles, it is relevant to mention that although 
intermolecular hydrophobic interactions are predominant forces to drive 
self-assembly processes in water, they lack of the directionality 
achievable through other non-covalent interactions such as hydrogen 
bonding or π-π stacking. This leads to amphiphile shape dependent 
assemblies morphologies, where the balance and length of hydrophobic 
and hydrophilic domains rules the formation of spherical (micelles, 
vesicles…), elongated (fibers, worm-like micelles) or planar structures 
(bilayers).7 Overwhelming examples of amphiphilic block polymers 
can be found in literature in which the above described design rules are 
exploited to design structural but also versatile drug carriers. In fact, 
polymeric micelles have been extensively studied during the last 
decades as long circulating vehicles for i.v. administration of drugs.8-13  
It has been pointed out the myriad of possibilities that might 
arise from the combination of polymer and supramolecular chemistry 
combining robustness, multivalency and adaptability.14-18 In this 
context, the combination of polymer backbones incorporating self-
assembling motifs is gaining interest as a novel strategy towards the 
development of functional materials.18, 19 
In the context of the present work, introduction of functional 
motifs along polypeptide backbone can be achieved following different 
strategies: i) using functional NCA monomers;20-23 ii) grafting on the 
polymer backbone side chains through post-polymerization 
modifications as described in Chapter 4;24-28 iii) end-capping or 
chemical modification of terminal reactive ω-nitrogen atom29, 30 and iv) 
use of functional amine initiators in the ROP of NCAs.31-34  
Some ot those functional initiators have been explored in 
different fields over the last decades due to their structural simplicity, 
chemical accessibility, multivalency and deep understanding of their 
supramolecular self-assembly.35  
[Chapter 5] 
241 
 
Figure 5.1. Schematic representation of a special motif self-assembly 
into helical one-dimensional aggregates, which are stabilized by 
threefold intermolecular H-bonding. (Adapted from Cantekin et al. 35) 
For instance, Meijer and coworkers have studied extensively 
some of those self-assembly triggering motifs to build architectural 
diverse compounds with interesting self-assembling properties. 
Particularly relevant are the applications to build collagen like triple 
helix assemblies,36 one dimensional elongated fibers,37 thermoplastic 
elastomers based on nanorods,38 among others. Enhancing water 
solubility of those motifs through peripheral groups might, in some 
cases, result in the formation of stimuli responsive hydrogels.39-42 
Previous antecedents combining such motifs with polymers include the 
design of folding polymers based on polymethacrylates.43  
Regarding its biological applications, plentiful of those motifs 
been employed as scaffold to connect bioactive units such as cyclic 
RGD ligands,44 glycans as bacterial lectin inhibitors45 or as anti-
inflammatory compounds.46 Self-assembling properties can be 
modulated in aqueous systems through pH or ionic strength to build 
tailor made nanorods47-49 and peptide functionalized nanofibers50, 51 
with applications in biomedicine.52  
Overall, within this chapter, we will describe the synthesis of 
novel constructs bearing self-assembly triggering motifs as building 
blocks to promote the design of self-assembled materials to be used as 
PT. 
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5.2. RESULTS DISCUSSION. 
5.2.1. Use of self-assembly triggering motifs. 
Novel PGA-based systems bearing self-assembly triggering 
motifs were synthesized. When such systems were characterized by 
SANS, interesting data was found regarding compounds size. SANS 
experiments have been performed as routine technique in the lab in 
order to elucidate size and solution conformation of new constructs. 
When these architectures were analyzed by SANS and after adequate 
data treatment and fittings (Figure 5.2), gyration radius were found in 
the range of 70-160 nm, much higher than the ones expected for the 
“unimeric form” of these systems (between 5-10 nm) (Table 5.1). 
These experiments were carried out at relatively high concentration (10 
mg∙mL-1) and therefore, self-assembly could be triggered. SANS fitting 
analysis correlated these structures with “hard spheres with branches 
pointing outside”.  
 
Figure 5.2. SANS data plotting of various PGA-based constructs with 
self-assembling properties at 10 mg∙mL-1 (X). 
Moreover, when DLS measurements in PBS buffer pH 7.4 were 
performed, it was found out that those systems undergo a concentration 
dependent self-assembly process. At low concentrations “unimers” of 
5-10 nm diameter size were identified, whereas bigger structures of 
around 100-200 nm diameter size were formed at high concentrations. 
scattering vector, Q / A-1
0.001 0.01 0.1 1
sc
at
te
rin
g 
in
te
ns
ity
, I
(Q
) /
 c
m
0.01
0.1
1
10
12912.Q vs A4 
12964.Q vs A5 
12965.Q vs A6 
12966.Q vs A7 
12967.Q vs A8 
SE1           
SE3
SD2
SD4
SH3
Scattering vector (Q/A)
S
ca
tte
rin
g
in
te
ns
ity
Q
/ c
m
-1
X_1
X_2
X_3
X_4
X_5
[Chapter 5] 
243 
This phenomenon occurred in all systems bearing self-assembly 
triggering motifs, independently on the spacer used (ethyl, hexyl or 
DOOA). Nevertheless it did not occur in linear PGA (Figure 5.3). With 
increasing concentrations, it could be clearly observed the 
disappearance of the small structures and progressive appearance of the 
bigger ones, up to a point where only big structures of 100-200 nm size 
(diameter) were observed (2 mg∙mL-1). By plotting the scattered 
intensity, Mean Count Rate (MCR) in Kcps obtained against 
concentration, a value of critical aggregation concentration (CAC) can 
be obtained with the intersection of the two lineal curves31, 53-55 (Figure 
5.3). This CAC value not only represents the concentration above 
which aggregation processes are taking place, but also represents the 
maximum concentration of free non-aggregated polymer species 
present in the sample under that specific conditions (temperature, ionic 
strength, pH).  
a) b) 
 
c)     d) 
 
Figure 5.3. Size-concentration dependence analysis by DLS in PBS 
buffer at pH 7.4. a) Mean Count Rate (MCR) vs. concentration of PGA-
based constructs bearing self-assembly triggering motifs, DP 180 as 
example. b) Mean Count Rate vs. concentration of linear PGA polymer 
DP 150 as example. c) Example of correlation coefficient curves 
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obtained for PGA-based constructs bearing self-assembly triggering 
motifs. d) DLS size by intensity plot at different concentrations from 
PGA-based constructs bearing self-assembly triggering motifs, showing 
the increase in the population with high hydrodynamic radius when 
increasing the concentration. 
Table 5.1 summarizes CAC values, hydrodynamic radius (Rh) 
and gyration radius (Rg) obtained by DLS54, 56 and SANS respectively, 
for several PGA-based constructs bearing self-assembly triggering 
motifs, with different chain lengths. Similar Rh values were obtained 
for all of the measured polymers, and in general, higher CAC values 
were observed with greater chain lengths. 
Table 5.1. Summary of CAC values, hydrodynamic radius (Rh) and 
gyration radius (Rg) obtained by DLS and SANS for different PGA-
based constructs bearing self-assembly triggering motifs. 
Compound GAUa C.A.C.b Rhc (nm) Rgd (nm) 
X_1 99 0.20 60.1 160.7 
X_2 231 0.40 62.7 80.8 
X_3 102 0.30 53.0 69.1 
X_4 186 0.30 47.7 91.1 
X_5 234 0.55 123.7 84.5 
a. GPC in DMF/LiBr at 8 mg∙mL-1. b. Critical Aggregation 
Concentration (CAC) measured by DLS (mean count rate vs. 
concentration) in PBS at 20 °C. c. DLS data at 2 mg∙mL-1 in PBS buffer 
pH 7.4 at 20 °C expressed by intensity mean. dSANS data (ILL, 
Grenoble, measured at 10 mg∙mL-1 in PBS buffer pH 7.4 at 20 °C. 
Accordingly, a self-assembly process is proposed for these 
systems to lead bigger structures with hard sphere shapes bearing 
branching points outside directed (Figure 5.4). It must be noticed, that 
self-assembly process of these systems represents a reversible and 
dynamic equilibrium between free non-aggregated species and large 
assemblies with broad size distributions. Therefore, as it is a dynamic 
process, several considerations must be taken into account: First of all, 
kinetic effects might be playing an important role and the observed 
[Chapter 5] 
245 
metastable nanoconstructs might evolve with time. It has to be 
considered that the present study has been carried out after stabilization 
of all samples during 24 hours. Future work on these systems must 
address such kinetic consideration. Secondly, this process might be 
sensitive to different stimuli (physical or chemical) that might affect not 
only equilibrium in terms of CAC but also morphology and molecular 
arrangement of the assemblies. Lastly, although control and study of all 
parameters affecting the equilibrium seems a complicated task, it also 
opens the opportunity to prepare tailor-made DDS with a high potential 
to cover a wide range of different biological applications. 
 
Figure 5.4. Schematic representation of the self-assembly process 
followed by PGA-based constructs bearing self-assembly triggering 
motifs, studied according to DLS and SANS data interpretation. 
5.2.2. Elucidating the structure underlying self-assembly 
processes. 
In order to further elucidate the structures underlying this self-
assembly process, further advanced characterization was carried out. 
We used conventional techniques employed in supramolecular 
chemistry to unravel the role of the different non-covalent interactions 
responsible for self-assembly, the molecular packing within assemblies 
and the morphology of the nanoconstructs. Unfortunately, presence of a 
large polypeptide backbone hinders a suitable characterization through 
CD and NMR that might have been useful to study the non-covalent 
interactions responsible for the self-assembly process.57, 58 
On one hand, these architectures were tested following pyrene 
assay in order to investigate, not only the presence or absence of 
hydrophobic environments, but also to corroborate CACs determined 
via DLS analysis. Pyrene fluorescence has been generally used to 
measure CMC in micellar systems primarily due to the fact that its 
spectroscopic properties are highly sensitive to changes in the 
environmental polarity, and secondly, due to its poor water solubility 
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being prone to accommodate into hydrophobic cavities present 
specially in micellar aqueous solutions. The five emission bands of 
pyrene undergo significant changes to their vibrational fine structure 
intensities when fluorescence measurements are made in polar versus 
non-polar environment.59-62 The first and third bands show the greatest 
relative variation to one another when the microenvironment changes. 
Therefore, these two bands are used to determine the fluorescence ratio 
in the so-called I3:I1 method.59 This ratio is dependent on solvent 
polarity and hydrophobicity of the surrounding environment, making it 
useful to study aggregation properties.63 An alternative to this method is 
the study of the (0,0) bands in pyrene excitation spectra and the 
comparison of the intensity ratio I338/I333.64, 65 At low amphiphile 
concentrations this ratio corresponds to value characteristic of pyrene in 
water. At high concentrations this value corresponds to the value of 
pyrene entirely in the hydrophobic environment following an inverse 
sigmoidal curve to that obtained using the emission bands in I3:I1 
method. For this assay, several polymeric aqueous solutions at different 
concentrations ranging from 0.004 to 2 mg∙mL-1 were mixed with 3 μL 
of a pyrene stock solution (0.02 mg∙mL-1) in acetone. Samples were 
then heated at 37 °C for 2 hours and fluorescence measurements were 
performed 24 hours after. Each excitation spectra is recorded from 300 
to 360 nm with an emission wavelength of 390 nm at r.t. Finally, 
intensity ratio I338/I333 is plotted against polymer concentration in order 
to determine CAC values. As shown in Figure 5.5, the intensity ratio 
remains constant along the whole range of concentrations. This result 
suggests that hydrophobic environments within the assemblies, if 
present, are not capable of accommodating pyrene molecules within 
their cavities. According to previous reports, these motifs are prone to 
stack into one dimensional columnar assemblies in water37 when 
hydrophilic peripheral PEG groups are attached to the central core. 
Such assemblies might be consistent with this observation since such 
stacked column represents a hydrophobic domain but with a small 
width to allow pyrene molecules to intercalate.  
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Figure 5.5. Pyrene fluorescence assay with PGA-based constructs 
bearing self-assembly triggering motifs of 150 GAU.  
In order to unravel the molecular organization of the self-
assembly triggering motifs within the assemblies, SANS contrast 
experiments were performed with polymers bearing a D-labeled version 
of those motifs in LOQ SANS instrument at ISIS (UK) very recently, 
and data is still under treatment. Due to the large scales accessible with 
this technique (1-1000 Å) it is not only possible to obtain overall 
information on solution conformation but also exhaustive minor local 
details. In addition, selective deuterium labeling of different domains 
within polymers allows the differential “visualization” of the multiple 
domains in different solvents.66-69  
For that purpose, a deuterium (D) labeled motifs were 
synthesized in two steps using fully deuterated reagents. In the first 
step, Boc protected motifs were synthesized using DMTMM∙BF4 (19b) 
as carboxylic acid activator. Reaction proceeded for 48 hours in THF 
under N2. After purification, identity of this molecule was confirmed by 
1H-NMR and 2H-NMR. Then, Boc was easily removed with 
HBF4∙Et2O. Again, 1H-NMR and 2H-NMR confirmed the product 
identity (Figure 5.6). 
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a) 
 
b) 
 
Figure 5.6. 2H NMR spectra of the D-labeled motifs. a) N-Boc-
protected motifs (22) in H2O + 3 μL Acetone-d6 at 300 MHz. b) Amine 
free protected motifs (23) in H2O + 3 μL Acetone at 500 MHz. 
The D-labeled motif was used to yield PGA-based polymers 
bearing D-labeled self-assembly triggering motifs (Đ ~1.2, 26.3 kDa, 
40 GAU per arm), and this system was studied through SANS contrast 
experiments both in H2O and D2O solvents. 
Qualitatively, the contrast experiment in H2O shows a 
prominent bump compared to the sample in D2O. Aggregation of the 
self-assembling motif will result in differences on the scattering length 
density between the hydrophobic domain and the polymer backbone 
expressed in our system as a “bump” in I(Q) versus Q plot at high Q 
values. This feature provides a direct indication of a characteristic 
‘short’ dimension in the structure, suggesting the presence of self-
assembled domains. This points out the presence of organized domains 
in contrast to a random distribution of self-assembling moieties along 
10.0         9.0         8.0            7.0           6.0           5.0          4.0           3.0           2.0           1.0  
δ(ppm)
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the nanostructure, in agreement with previous reports in literature.35-37, 
50 This fact confirms that such moieties are the driving motif for the 
assembly of these architectures. Further data analysis and mathematical 
fitting strategies might help to elucidate molecular packing of such 
motifs within assemblies and help to draw a more realistic picture of 
the molecular organization of self-assembled PGA-based constructs 
(Figure 5.7).  
 
Figure 5.7. SANS contrast experiments with D-labeled core in D2O 
(outer H molecular organization determination) and H2O (D-labeled 
core molecular organization determination), at 10 mg∙mL-1 and 20 °C. 
When observed under the microscope using Transmission 
Electron Microscopy (TEM), PGA-based structures bearing self-
assembly triggering motifs, exhibited homogenous globular shaped 
nanoparticles of about 80-100 nm diameter with relatively low 
dispersities, further confirming the findings obtained in the first SANS 
experiment and DLS analysis (Figure 5.8). 
 
Figure 5.8. TEM micrographs from PGA-based structures bearing self-
assembly triggering motifs of a sample prepared in ddH2O at 1 mg∙mL-
1. 
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5.2.3. Towards more complex structures through bottom-up 
strategies. 
These interesting findings together with the need of new and 
more defined architectures with higher MW (to enhance passive 
targeting by the EPR effect), predictable structure and conformation, 
lower heterogeneity, higher drug loading capacity and greater 
possibility for multivalency, in nanomedicine in general, and in this 
project in particular, encouraged the following strategy. Based on the 
self-assembling motifs we proposed a strategy for the preparation of 
new DDS with higher MW in order to get longer circulation times in 
vivo, a requisite to potentially achieve brain accumulation. 
Functionalization of such PGA-based constructs via post-
polymerization methodologies (See Chapter 4) allowed to introduce 
cross-linkers. Reversible self-assembly of the amphiphilic block 
copolymers under specific physical stimuli (concentration, temperature, 
ionic strength) will be followed by covalent capture (cross-linking) to 
yield nanoconstructs stable to physical stimuli but prone to disassembly 
into the parent building-blocks under specific chemical/physiological 
triggers (depending on the linking chemistry used). The particularly 
relevant fact in this strategy is the synthetic economy through the use of 
bottom-up approach and the possibility of introducing several relevant 
biological molecules such as drugs (or combinations thereof) or 
imaging agents in a relative easy and orthogonal synthetic manner50 
(See Chapters 6, 7).  
More interestingly, after covalent entrapment of the structures, 
surface modifications can be performed (See Chapter 6) again with 
drugs, imaging agents or targeting residues in order to guarantee their 
adequate exposure to the receptors when needed, or even 
stealth/antifouling motifs.70, 71 That will lead to carriers with greater 
circulation times yielding to an enhanced tumor accumulation by EPR 
effect. The bioresponsive chemistry also implemented will allow 
nanostructure disassembly under selected triggers (i.e. pH, reductive 
environment) allowing better tumor penetration and subsequent drug 
release. These novel constructs will offer the following advantages: (i) 
Modulable size. (ii) Lower dependence on solution conformation 
regarding the cargo.72 (iii) Fully biodegradable, long circulating 
carriers. (iv) Multivalency suitable for combination therapy, even with 
chemically incompatible groups due to the possibility of co-assembling 
different components and, (v) Easy modulation of polymer surface for 
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stealth/antifouling properties, Z-potential and hydrophobicity, as 
diffusion across biological barriers is strongly dependent on these 
parameters.73 
5.2.3.1. Polymers modification and co-assembly studies. 
As stated before, the purposed strategy will be based on the 
entrapment of these bigger structures, obtained when the solution 
concentration used is above CAC values, by introduction of covalent 
bounds among polymer chains from different “unimers”. For that 
purpose, orthogonal functional moieties must be firstly introduced 
within the polymer chains, either in the same polymer (in order to 
achieve self-assembly), or in different polymer chains (pursuing co-
assembly processes). As mentioned before, the idea underlying this 
strategy is the use of these functional moieties for covalent entrapment 
of the large structures in order to obtain size concentration 
independence, precluding the dynamic and reversible equilibrium and 
therefore obtaining more stable assemblies against changes in the 
physico-chemical environment such as ionic strength or concentration. 
This fact is particularly relevant when i.v. administration of the 
designed DDS are pursued due to the dilution factor that those 
structures will face after administration, ensuring, in this way, the 
stability in size of those structures during circulation time and therefore 
enhancing their blood half-life.13 
As a first approach, in order to simplify the study and achieve 
the required proof of concept, irreversible click chemistry was proposed 
for covalent entrapment due to the easier characterization (when 
compared to reversible chemistry) (Figure 5.9). Nonetheless, the long 
term goal of this strategy is the use of biodegradable linkers in order to 
have nanostructures with adequate 3D features to promote passive 
targeting by EPR effect after i.v. administration and once accumulated 
in the target, capable to disassemble under specific physiological 
triggers, in order to enhance tissue penetration and subsequent drug 
release. 
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Figure 5.9. Schematic representation of covalent capture of co-
assembled polymers bearing orthogonal functionalities (alkynes and 
azides) through CuAAC click chemistry. 
For that purpose, several PGA-based structures bearing self-
assembly triggering motifs were modified with alkynes and azides 
using the optimized post-polymerization techniques either both in the 
same polymer chain or in different polymers. Those moieties will be 
used to promote covalent capture by the already optimized CuAAC 
chemistry but firstly, the co- and self-assembly properties of the new 
constructs must be studied.  
From 5 to 50 % of GAUs of the polymers were modified with 
propargylamine (24a) and NH2EG(2)N3 (24b) respectively. One 
polymer was also dually modified with 10 % alkyne and 20 % azide 
mol GAUs. Those polymers where analyzed by DLS and CAC was 
calculated. As negative control for the study, linear alkyne modified 
PGAs (5 and 10 mol% GAUs) were also measured leading to absence 
of aggregation processes in the concentration range studied. 
Surprisingly, compounds bearing both moieties (to be used in the 
covalent capture of self-assembled architectures) did not show 
aggregation and CAC could not be calculated in the concentration 
range studied (Figure 5.10). This could be attributed to the relatively 
high degree of structures modification that could interfere in the 
assembly process. Although, in the case of the structures bearing above 
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20 mol% of EG(2)N3 a CAC could not be determined by this method, a 
closer inspection to size distribution graphs looks controversial: 
whereas size distribution by number evidences the presence of star 
unimers (~2.5 nm radius), size distribution by intensity reveals the 
presence of large aggregates (> 40 nm radius). These findings point out 
that size measurements were carried out just in the equilibrium region 
were both species coexist, although in this particular case probably 
unimers are the major component.  
From these results, a general conclusion can be drawn. As 
expected, degree of modification, as well as nature of those 
modifications do have an influence in the aggregation processes. From 
Figure 5.10, it can be observed that, when hydrophilic moieties are 
included within star polymer backbone, CAC value of the assemblies 
increased by increasing the degree of modification and unimers seem to 
be the major component in those systems. Nevertheless, if hydrophobic 
moieties are included, CAC values are decreased with degree of 
modification and in this case, no unimers could be detected under the 
size measurement conditions used (See Table 5.2). Consequently, a 
general picture of the self-assembling process on these systems could 
be drawn. Firstly, the self-assembly equilibrium does take place, 
however, as its concentration range (CAC) is located close to that used 
in the measurement conditions, both species involved in the equilibrium 
can be observed. Secondly, increasing system hydrophobicity shifts the 
equilibrium towards the aggregated components leading to reduced 
CAC values and the absence of unimers. Aiming to reach a set of 
complex and bigger architectures with different inherent properties, 
such equilibrium was studied in more detail. These studies could be 
found later in this chapter (looking at ionic strength, [C] and 
temperature influence). 
a)                                                    b) 
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c)                                                     d) 
 
Figure 5.10. Mean count rate (MCR) vs. increasing concentrations 
plotting of a) alkyne modified polymers with different degrees of 
functionalization (24a); b) azide modified polymers with different 
degrees of functionalization (24b); c) linear PGA alkyne modified as 
negative control and (20a) d) alkyne + azide modified polymers with a 
total degree of functionalization of 30 mol% GAUs. 
Data obtained by DLS is summarized in Table 5.2. Modified 
polymers were also analyzed by SANS in order to gain insights into the 
real behavior of these constructs (data under mathematical treatment). 
Table 5.2. Summary of CAC values and hydrodynamic radius (Rh) 
obtained by DLS.  
Compound GAUa 
Mod. 
GAUb 
CACc 
Rhd 
(nm) 
Rhe 
(nm) 
X-prop(5) 24a_1 150 5 0.60 44.0 67.2 
X-prop(10) 24a_2 150 10 0.50 38.5 77.3 
X-prop(20) 24a_3 150 20 0.40 37.4 68.6 
X-prop(30) 24a_4 150 30 0.35 49.2 95.5 
X-prop(50) 24a_5 150 50 0.35 45.1 90.6 
X-EG(2)N3(5) 24b_1 150 5 0.50 2.3 69.0 
X-EG(2)N3(10) 24b_2 150 10 0.55 2.7 58.2 
X-EG(2)N3(20) 24b_3 150 20 --* 2.6 75.2 
X-EG(2)N3(30) 24b_4 150 30 --* 2.5 65.8 
X-EG(2)N3(50) 24b_5 150 50 --* 2.6 71.1 
* C.A.C. could not be calculated in the concentrations range employed. 
Aggregation (if occurs) might be found over 2 mg∙mL-1. a. GPC in 
DMF/LiBr at 8 mg∙mL-1. b. Data obtained by 1H-NMR in mol%. c. 
CAC measured by DLS in PBS at 20 °C and size measured by DLS at 2 
mg∙mL-1 in PBS at 20 °C by d. Number mean, and e. Intensity mean. 
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Assemblies’ morphology was also investigated through TEM. 
As shown in Figure 5.11, this morphology does not vary significantly 
from the parent compound with the different chemical modifications 
introduced. In all cases globular aggregates in the range of 100 nm were 
found. It must be noticed that TEM requires a full drying of samples, 
which is achieved by solvent evaporation at r.t. Such samples 
processing is not ideal for soft materials since the change of 
concentration upon solvent evaporation might result in further 
aggregation or distortion of the nanostructures present in the native 
solvated state. Nevertheless, in general these results are in good 
agreement with those found for the parent compound and also with 
DLS and SANS data obtained for these series of compounds.  
 
Figure 5.11. TEM micrographs of modified PGA-based structures 
bearing self-assembly triggering motifs at 1 mg∙mL-1 in ddH2O; a) X-
EG(2)N3(5); b) X-prop(10). 
Once self-assembly process of the modified polymers was 
confirmed, studies to assess co-assembly where done using DLS, by 
observation of CAC value shift of one of the compounds upon addition 
of constant amount (always below its CAC) of the second component.74 
Thus four series of solutions were prepared for the CAC determination 
experiments: X-EG(2)N3(5) (24b_1), X-prop(10) (24a_2), and the same 
series but with addition of the second component in a concentration 
below their CAC. Figure 5.12 shows the plots of scattered intensity 
against variable concentration of one of the components keeping 
constant the concentration of the counterpart (always bellow their 
CAC). Although the MCR values are lower for series containing both 
components, which can be attributed to a smaller size of the aggregates, 
qualitatively, it can be seen a decrease in CAC value in both cases 
when the second compound was added to the solution. These findings 
somehow suggest a synergy in the formation of mixed assemblies 
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through co-assembly processes (Figure 5.12) what is in good agreement 
with previous reports on PEG modified BTA species but also block-
copolymer systems.37 Nonetheless, these results are not yet conclusive, 
what motivated a deeper study of the co-assembly process through 
NMR techniques. 
a) b) 
 
Figure 5.12. Co-assembly study by DLS. Graphs showing CAC 
determination for X-EG(2)N3(5) (24b_1), in the presence of constant 
concentration of X-prop(10) (24a_2), (a) and vice versa (b).  
Further evidences on co-assembly of these architectures were 
studied through NMR techniques. Pulsed-gradient spin-echo NMR 
spectroscopy, known as diffusion NMR spectroscopy (or DOSY 
NMR), allows determining the self-diffusion coefficient of the species 
present in solution. The diffusion coefficient is related not only to 
intrinsic properties of the molecules (size, shape, MW, charge, etc.) but 
also to the surrounding environment such as concentration, solvent, 
temperature or ionic strength among others. In brief, application of 
NMR field gradients allows to “label” the spins along the direction of 
the applied gradient. Upon the use of certain pulse sequences (based on 
spin-echo) the spectra of the components in a mixture (chemical shifts) 
can be separated according to their diffusion coefficient, in a similar 
way to a size-exclusion chromatography.75, 76 This technique has been 
applied in different contexts such as MW prediction,77 effect of shape in 
polymers,78 bioconjugation studies,79 polypeptides80 and the study of 
supramolecular self-assembling systems81, 82 among other examples.  
In order to perform the present study, diffusion coefficients of 
X-EG(2)N3(5) (24b_1) above (2 mg∙mL-1) and below (0.1 mg∙mL-1) its 
CAC was investigated in a first step. Firstly, diffusion coefficients 
obtained from fitting the intensities to Stejskal-Tanner equation (see 
M&M) for the chemical shifts associated to both PGA (4.3 ppm) and 
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ethylene glycol (3.6 ppm) in the concentrated sample were identical, 
confirming the covalent attachment of the EG-azide residue to the 
polymer, as expected. Diffusion coefficient values obtained for the 
diluted (unimer) and concentrated (nano assembly) samples were 
3.12∙10-11 m2∙s-1 and 4.54∙10-12 m2∙s-1 respectively. As expected, 
diffusion coefficient is reduced in one order of magnitude upon self-
assembly of the small unimers into the large nanostructures due to the 
inverse relationship between size or hydrodynamic radius and diffusion 
coefficient in the Stokes-Einstein equation: 
ܴ௛ =
ܭ஻ . ܶ
6ߨ. ƞ. ܦ
 
Equation 5.1. Stokes-Einstein equation, where KB is Boltzman constant 
(1.3806488∙10-23 m2∙Kg∙s-2∙K-1), T is temperature (K), ƞ is dynamic 
viscosity (1.095∙10-3 Kg∙m-1∙s-1 for D2O at 298.15 K and 0.1 MPa),83 ܴ௛ 
is hydrodynamic radius and D is the diffusion coefficient. 
Size values obtained from this first analysis reveals that below 
CAC, these compounds are characterized by a Rh of 6.4 nm whereas the 
large nanostructures formed upon self-assembly above their CAC have 
a size of 44 nm (Rh). Similar results were obtained for X-prop(10) at 2 
mg∙mL-1 with a hydrodynamic radius of 46 nm. These findings are in 
good agreement with DLS data even though both techniques measure 
size in a different manner.  
Then, co-assembly process was tested in a similar way to that 
described in literature.81, 82 A sample containing X-prop(10) above its 
CAC (2 mg∙mL-1) in the presence of X-EG(2)N3(5) below its CAC (0.1 
mg∙mL-1) was prepared. X-EG(2)N3 was used at the lower 
concentration for this study, due to the fact that EG signals are more 
intense (3.2 ppm, 8H) in comparison with signals from propargyl group 
in compound X-prop with lower intensity (3.8 ppm, 2H). Besides, 
DOSY arrayed experiments are difficult to process in diluted samples 
yielding low quality fittings due to low intensities of the spectra 
recorded at high gradient strength values. As it can be seen in Figure 
5.13, 1H NMR spectra shows the signals corresponding to each of the 
components employed in DOSY NMR analysis. After data treatment, it 
can be seen that compound X-prop(10) shows the characteristic 
diffusion coefficient of self-assembled species (5.03∙10-12 m2∙s-1) 
expected for the concentration studied. However, compound X-
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EG(2)N3, that, at 0.1 mg∙mL-1 should present a larger diffusion 
coefficient when compared to the self-assembled constructs, reduced its 
diffusion coefficient in one order of magnitude from (3.12∙10-11 m2∙s-1) 
to (5.24∙10-12 m2∙s-1), being virtually equivalent to that found for X-
prop(10) component. These results suggest that although X-EG(2)N3 is 
below the CAC, it moves along with the self-assembled constructs from 
the counterpart X-prop(10), and thus, indirectly confirms that these 
architectures are able to co-assemble.  
a) Co-assembly  b) 1H NMR in D2O 
 
c) 
 
Figure 5.13. Co-assembly studies through DOSY NMR: a) Schematic 
representation of the conditions for co-assembly study; b) 1H NMR in 
D2O of a mixture containing 2 mg∙mL-1 of compound X-prop(10) 
(24a_2) and X-EG(2)N3(5) (24b_1); c) Graphs obtained by fitting the 
intensities of the arrayed DOSY spectra into Stejskal-Tanner equation 
and the calculated diffusion coefficients (D). 
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Moreover, confirmation of co-assembly process was assessed 
with the help of NOESY experiments (see M&M for further details). 
As observed in Figure 5.14, a clear NOE correlation was found for 
propargyl and ethylene glycol signals, a result that confirms the spatial 
proximity between both groups.  
 
Figure 5.14. 2D NOESY spectra showing NOE correlation of 
propargyl and EG protons of a mixture containing 2 mg∙mL-1 of each 
compound: X-prop(10) (24a_2) and X-EG(2)N3(5) (24b_1). 
5.2.3.2. Assembly size modulation and stimuli-
responsiveness to different parameters.  
With size-concentration dependence verified, the effect of 
different stimuli such as temperature and ionic strength were further 
investigated using a PGA-based construct bearing self-assembly 
triggering motifs without any modification as a model system. Size 
dependence on ionic strength of media was investigated after the first 
evidences found (Table 5.3) when measuring the same sample in 
ddH2O or PBS buffer 0.1 M pH 7.4. 
Table 5.3. Size determination of PGA-based construct bearing self-
assembly triggering motifs by DLS (PBS and ddH2O) and DOSY. 
Compound Rha (nm) Rhb (nm) Rhc (nm) Rhd (nm) Rhe (nm) 
X-PGA 36.4 69.1 123.7 2.7 124.4 
*Data obtained of a 2 mg∙mL-1 sample from a. DOSY NMR in D2O. b. 
DLS number mean in ddH2O. c. DLS intensity mean in ddH2O. d. DLS 
number mean in PBS 7.4. e. DLS intensity mean in PBS 7.4. 
4.4            4.0           3.6            3.2           2.8           2.4           2.0
δ(ppm)
2.0
2.5
3.0
3.5
4.0
4.5
δ(
pp
m
)
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From results obtained in Table 5.3, it can be concluded that 
presence of salt, and therefore, modulation of the ionic strength, highly 
affects the self-assembly equilibrium by shifting it towards unimer 
region. In the absence of salts, no unimers could be observed by DLS. 
This finding must be taken into account when performing covalent 
capture strategies since presence of unimers should be avoided in order 
to efficiently entrap the big assemblies. Thereafter, ionic strength was 
further studied as we decided to investigate the influence of different 
salts on aggregate size (Figure 5.15). Sodium chloride (NaCl), 
guanidinium hydrochloride (GuHCl), and sodium Sulphate (Na2SO4) 
were chosen due to their different nature. As can be observed in Figure 
5.15, the scattered intensity is progressively reduced with increasing 
salt content, being Na2SO4 the most disruptive. Furthermore, Rh (mean 
number) dependence on salt content reveals disassembly of aggregates 
just by addition of 50 mM of any salt.84, 85 
 
Figure 5.15. Ionic strength effect on size of PGA-based construct 
bearing self-assembly triggering motifs at 2 mg∙mL-1 and at 37 °C 
represented by the changes suffered in scattered intensity (MCR) (left) 
and in Rh by number (right) upon addition of increasing amount of 
different salts. 
Size dependence on concentration was studied at 37 °C in the 
concentration range of 1 to 10 mg∙mL-1. As it can be observed in Figure 
5.16, a sudden increase in size was observed above 5 mg∙mL-1 from 
~70 nm to ~100 nm. Size dependence on temperature was also found 
when the system was studied by DLS measurements at 10 mg∙mL-1 in 
the temperature range between 10 and 60 °C. As it can be observed in 
Figure 5.16, the highest construct was found at 60 °C. 
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          a) Tª effect at 10 mg∙mL-1            b) [C] effect at 37 °C 
 
Figure 5.16. a) Temperature effect on size of PGA-based construct 
bearing self-assembly triggering motifs at 10 mg∙mL-1. b) Size-
concentration dependence of PGA-based construct bearing self-
assembly triggering motifs at 37 °C. 
All these findings point out the fact that size modulation of the 
constructs is possible through fine tuning parameters such as 
concentration, temperature and ionic strength during covalent capture 
reaction conditions. This might open a door towards the preparation of 
a toolbox of tailor-made nanostructures with diverse sizes based on the 
same polymeric building block and modulated through physico-
chemical parameters. Following this line of reasoning, future work 
should be carried out to test the feasibility of covalently capture the 
dynamic and reversible metastable nanostructures under different 
environmental conditions.  
In the present chapter, we focused our strategy in single 
selected physico-chemical conditions in order to further achieve proof 
of concept for this hypothesis. 
5.2.3.3. Covalent entrapment of co-assembled structures by 
CuAAC. 
With clear evidences highlighting co-assembly of these 
structures, covalent capture was carried out through CuAAC click 
chemistry, using the optimized conditions in Chapter 4, and the 
polymers X-prop(10) and X-EG(2)N3(5). Those polymers were chosen 
in order to have an excess of propargyl units to ensure complete 
conversion, as the reaction will be performed in equimolar ratio of both 
functionalities. The reaction was carried out in ddH2O (constructs were 
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present in aggregated state as seen before), using a concentration to 
ensure the only presence of big structures within the polymeric mixture 
(ratio 1:1, 2 mg∙mL-1). The mixture was firstly sonicated for 5 minutes 
in order to promote homogenization. Then, CuAAC was performed 
according to M&M. Complete conversion was achieved after 3 days, 
according to 1H-NMR (triazole signal at 7.8 integrates for 5 mol%) 
(Figure 5.17). 
 
Figure 5.17. 1H-NMR in D2O showing the comparison of the two 
different polymers and the clicked system (25a). The red box highlights 
the signal corresponding to triazole peak at 7.8 ppm. 
The clicked system was studied by DLS measurements in 
comparison with a physical mixture 1:1 of both components separately 
after sonication. Dilution experiments were performed by diluting both 
samples up to 32 fold 1 mg∙mL-1 stock solution. In the case of the 
physical mixture, two different structures were already found at the first 
dilution (1:2 ratio). Nevertheless, for the clicked construct (25a), only 
big structures of about ~ 80-100 nm diameter were encountered, even at 
1/32 of the initial concentration (~0.03 mg∙mL-1) (Figure 5.18). The 
small decrease in the assemblies found for the clicked system (from 45 
to 30 nm in radius) might be due to the low eq. of effective cross-
linking groups (in this case azide, 5 mol%) resulting in an incomplete 
cross-linking of the self-assembled nanostructures. Future work will be 
carried out working with higher eq. of effective cross-linking groups in 
order to improve the stability upon dilution. 
  
X-EG(2)N3 (5) 24b_1
X-prop(10) 24a_2
X-Click 25a
9.0              8.0                7.0                6.0               5.0                 4.0                3.0          2.0
δ(ppm)
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   a)    b) 
 
c) 
 
Figure 5.18. DLS data showing the a) Concentration dependence of the 
physical mixture of X-prop(10) and X-EG(2)N3(5) and b) 
Concentration independence of the clicked structure (25a). c) 
Comparison of both measured systems in terms of size against 
concentration. All values correspond to measurements in PBS 7.4 and 
are represented in number. 
Cryo-TEM pictures of the clicked system confirmed the 
formation of spherical structures with a diameter size ~ 100 nm (Figure 
5.19). In contrast to conventional TEM technique, cryo-TEM allows to 
visualize samples under conditions similar to those found in the native 
hydrated state.86, 87 Further analysis of the nanoscopic morphologies in 
these systems should be performed under cryogenic conditions to avoid 
artifacts arising from the drying process. 
 
Figure 5.19. Cryo-TEM pictures of 25a at 2 mg∙mL-1. Dark spots 
represent spherical structures of 25a. 
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As expected for the proposed spherical structure, where 
carboxylic groups would be presumably exposed, Z-potential measured 
was rather negative (Figure 5.20). Although we cannot discard the 
possibility of partial protonation of inner carboxylic acids within the 
assemblies due to pK shift through cooperative intermolecular 
interactions upon self-assembly,88-91 CD data seems to discard the 
presence of α-helix conformation within the assemblies (attributed to 
protonation of carboxylates). As shown in Figure 5.20b, CD spectra of 
PGA-based construct bearing self-assembly triggering motifs (150 
GAU) looks controversial. Whereas PGA shows a clear random coil 
conformation pattern independently of concentration, the PGA-based 
construct bearing self-assembly triggering motifs shows a transition 
from random coil below CAC to a different secondary structure (Figure 
5.20). Such structure cannot be attributed to random coil nor α-helix 
pattern, evidencing the presence of a more complex conformation.92 
Further studies need to be performed in order to unravel this 
phenomenon.  
a)                                               b) 
 
Figure 5.20. a) Z-Potential Distribution of PGA-based X-Click 
structures (25a). b) CD spectra of PGA-based construct bearing self-
assembly triggering motifs of 150 GAU and linear PGA of 150 GAU 
both at 0.1 and 1 mg∙mL-1, in PB pH 7.4 at 37 °C. 
5.2.3.4. Alternative covalent capture strategies. 
In order to validate the versatility of this approach, other 
covalent capture strategies were implemented. The also non-reversible 
thiol-ene click chemistry, and the reductive-reversible disulfide 
chemistry were optimized in our systems. Thiol-based conjugation 
reactions are often performed using thiol-ene and thiol-yne click 
reactions. Thiol-maleimide chemistry represents indeed an interesting 
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alternative that has been demonstrated to proceed in an efficient manner 
under reagent free, mild conditions.93-96 On the other hand, di-thiol 
chemistry have been widely used for instance in cross-linked micelles97-
99 and hydrogels100-104 cross-linking by means of disulfide bonding due 
to its reversibility under reductive conditions. The use of disulfide 
bonding in our designed strategy will allow us to yield nanoconstructs 
stable to physical stimuli but prone to dissasembly into the building-
blocks under reductive media. 
First of all, the modification of such structures with activated 
di-thiol units (24c) (using cysteamine-2TP) and with maleimide groups 
(24d) (using NH2-CH2CH2-maleimide) was performed. Compound 
identity was determined by 1H-NMR, according to corresponding 
signals of pyridyl group (in the case of SS-2TP), and those from 
maleimide group (6.78 ppms) as depicted in Figure 5.21. 
a) 
 
b) 
  
Figure 5.21. 1H-NMR spectra (D2O) with corresponding assignments 
of a) X-SS2TP (24c_4); b) X-malei (24d_3). 
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Their aggregation behavior was also studied by DLS as for the 
previous compounds, leading to aggregated structures of around 100 
nm upon increasing the concentration as shown in Figure 5.22 and 
Table 5.4. 
Table 5.4. Summary of CAC values and Rh obtained by DLS for 
different modified polymers with SS-2TP and maleimide groups. 
Compound 
Mod 
GAUa 
CACb 
Rhc 
(nm) 
Rhd 
(nm) 
Rhe 
(nm) 
Rhf 
(nm) 
Rhg 
(nm) 
X-SS-2TP(5) 24c_1 5 0.40 2.3 78.5 50.2 145.4 30.2 
X-SS-2TP(10) 24c_2 10 0.30 2.6 94.5 56.5 79.9 29.9 
X-SS-2TP(15) 24c_3 15 0.20 4.1 111.2 - - - 
X-SS-2TP(30) 24c_4 30 0.30 2.5 51.0 - - - 
X-malei(5) 24d_1 5 0.40 2.7 133.9 82.3 118.9 38.5 
X-malei(10) 24d_2 10 0.35 2.7 101.3 74.6 135.1 31.9 
X-malei(35) 24d_3 35 0.30 4.2 100.5 - - - 
a. Data obtained by 1H-NMR in mol% GAU. b. CAC measured by DLS 
in PBS at 20 °C. c&d. Size measured by DLS at 2 mg∙mL-1 in PBS pH 
7.4 at 20 °C by c. Number mean, and d. Intensity mean. e&f. Size 
measured by DLS at 2 mg∙mL-1 in ddH2O at 20 °C by e. Number mean, 
and f. Intensity mean. g. DOSY data in D2O. 
 
Figure 5.22. Mean count rate vs. concentrations plotting of a) SS-2TP 
modified polymers (24c) with different % functionalization, b) 
maleimide modified polymers (24d) with different % functionalization. 
As it can be observed from Table 5.4, differences in size values 
obtained by number mean depending on the salt content (PBS or 
ddH2O) are remarkable once again, highlighting the previous argument 
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of a system under equilibrium processes. In addition, TEM microscopy 
confirmed the presence of big aggregates (Figure 5.23). 
 
Figure 5.23. TEM micrographs of modified polymers at 1 mg∙mL-1 in 
ddH2O; a) X-malei(35) (24d_3); b) X-SS-2TP(30) (24c_4). 
Once aggregation process was confirmed, the resulting 
structures where covalently captured by using both chemical strategies 
(Scheme 5.1). For this, polymers bearing 30 mol% SS2TP, and 35 
mol% maleimide groups were chosen, in order to have an excess of 
maleimide groups to ensure complete conversion (in the case of thiol-
ene chemistry). For di-thiol chemistry, two different attempts were 
performed using 5 and 30 % modified polymers. All reactions were 
performed at concentrations of 4 mg mL-1 for each compound in ddH2O 
for di-thiol chemistry and PBS buffer at pH 7.4 for thiol-ene, due to the 
need of controlling the pH over reaction time in order to guarantee 
maleimide group stability. After purification by dialysis, the success of 
the entrapment was ratified by 1H-NMR. In the case of di-thiol 
chemistry confirmation was achieved by disappearance of the aromatic 
signals corresponding to pyridyl groups while CH2 signals of 
cysteamine were kept, in the case of di-thiol chemistry. For thiol-ene 
reactions, the absence of the characteristic maleimide peak around 6.7 
as well as the pyridyl signals were indicatives of effective couplings. 
One example of such characterization is depicted in Figure 5.24. 
  
[Chapter 5] 
268 
a)      b) 
 
Scheme 5.1. Schematic representation of two strategies for covalent 
capture of self-assembled structures by click chemistry. a) Disulfide 
chemistry, b) Thiol-ene chemistry.  
 
Figure 5.24. 1H-NMR spectra (D2O) comparison of X-SS-2TP(5) and 
the clicked compound. 
Interestingly, depending on the degree of cross-linking, 
different structures can be built. While 5 mol% of SS cross-link lead to 
nanosystems perfectly soluble in aqueous solutions, higher degrees of 
cross-linking (30 mol%) trigger gelation processes. This finding 
highlights the versatility of those structures and the possibility to tune 
the final construct properties depending on desired application. Those 
gels could be easily used for other therapeutic applications that require 
Reversible Covalent Capture
(Di-thiol)
Non-reversible Covalent Capture
(thiol-ene)
25b 25c
X-Click di-thiol
X-SS-2TP (5)
9.0   8.5    8.0   7.5    7.0   6.5   6.0    5.5   5.0   4.5   4.0    3.5   3.0    2.5   2.0   1.5   1.0 
δ(ppm)
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a local administration such as wound healing or spinal cord injury 
among others. 
DLS measurements confirmed the covalent capture leading to 
stable structures of around 100 nm diameter. TEM microscopy of these 
two clicked systems showed the presence of better defined spherical 
structures when compared with non-covalently entrapped analogous as 
shown in Figure 5.25. Further studies regarding stability upon dilution 
and stimuli triggered disassembly are been carried out to explore the 
suitability of this approach. 
 
Figure 5.25. Examples of TEM micrographs of covalently captured 
structures at 1 mg∙mL-1 in ddH2O; a) X-Click through thiol-ene; b) X- 
Click through di-thiol using 30 % SS groups. 
5.2.3.5. Preliminary biological evaluation of the clicked 
architectures. 
As indicated in Chapter 3, and after exhaustive physico-
chemical characterization presented in the above paragraphs, some of 
the key features for the validation of the newly synthesized 
architectures as potential carriers for drug delivery or imaging probes 
are their toxicity in cell cultures and cellular trafficking. 
First of all, cell viability against SHSY5Y cell line of the three 
chemically different clicked architectures was studied. All of them 
resulted non-toxic up to 3 mg∙mL-1 when tested at 72 hours of 
incubation following an MTS protocol for cell viability determination. 
(Figure 5.26). 
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Figure 5.26. Cell viability assay of 3 different X-Click architectures 
against SHSY5Y cell line up to 3 mg∙mL-1, 72 hours of treatments (n> 
3, mean ± SEM). 
In parallel, cellular trafficking of CuAAC-clicked polymers 
(23a) was evaluated in SHSY5Y cells by flow cytometry at 37 °C (total 
uptake) and 4 °C (binding) in order to identify the role of energy-
dependent mechanisms (i.e. endocytosis). For that, the polymer was 
labeled with Oregon Green (= 488, 1 mol% GAU) following the 
protocol described in Chapter 4 (DIC/HOBt in DMF under inert 
conditions). As it could be expected, this globular shaped structure was 
fast internalized, showing around 95 % of positive already at 15 
minutes (Figure 5.27a). Furthermore, when this construct was 
compared with the linear PGA and star PGA, a significant increase in 
cell-associated fluorescence (CAF) was observed (Figure 5.27b). Not 
only 23a goes through a faster uptake (according to both CAF and % 
positive cells) but also, the amount of construct internalized is 
significantly greater when compared with the other 2 systems (Figure 
5.27).  
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a)  
 
b) 
 
Figure 5.27. a) Uptake kinetics against SHSY5Y cell line of X-Click-
OG-labeled polymer at different time points and different temperatures 
(4 °C for binding, 37 °C for total uptake). b) CAF representing the 
energy-dependent fraction of uptake, comparing the three architectures 
over time. n> 3, mean ± SEM. 
Confocal pictures were also obtained in order to confirm the 
results and to better identify subcellular localization (Figure 5.28). A 
clear co-localization with the lysosomal marker Lysotracker red was 
observed indicating that 23a would be an ideal carrier for drugs 
requiring a lysosomotropic delivery. 
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Figure 5.28. Confocal image of the uptake at 2 hours post-treatment of 
OG-labeled X-Click in SHSY5Y cell line following a pulse-chase 
experiment. Co-localization with Lysotracker Red was observed 
(yellow). 
5.3. CONCLUSIONS. 
Herein and based on the use of self-assembling motif, we have 
developed a strategy for the preparation of DDS incorporating 
polypeptidic (polyglutamates) chains. One of the most relevant features 
in this work is the combination of a discotic self-assembling core 
overwhelmingly exploited in supramolecular chemistry and materials 
science for the design of liquid crystals, 1D fibers or organo/hydrogels 
with a polymeric carrier such as poly-L-glutamic acid widely used in 
PT field. According to DLS, TEM and SANS, the resulting polymer 
undergoes spontaneous self-assembly in water yielding spherical 
objects. At first glance these results were surprising considering that the 
relative contribution of the hydrophobic self-assembling unit (352.26 
Da) in the polymers represents only 0.7-1.7 wt% of the whole polymer 
mass. However, evidences drawn from the present study reveals that 
such units are able to trigger the organization of anionic polyglutamate 
backbones into spherical objects and partially neglecting the 
electrostatic repulsions between anionic side chains. It might be argued 
that the discrete spherical morphology of the present nanostructures 
results from the combination of hydrophobic interactions and H-
bonding among motifs promoting 1D aggregation (as reported in 
literature, but hard to demonstrate in our system), and compensated by 
the electrostatic repulsions between PGA units.  
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Interestingly, chemical modifications within the polypeptidic 
backbone by post-polymerization modifications can prevent or 
significantly modify this aggregation behavior depending on the degree 
of modification as well as the nature of the groups included. 
Furthermore, fine tuning of the physico-chemical environment 
can lead to a wide variety of nanometric architectures of different size 
and shape which can be covalently entrapped to retain their solution 
conformation in the biological settings.  
Moreover, co-assembly of different building blocks has been 
effectively demonstrated. This behavior can be employed to construct 
relatively complex architectures combining drugs, imaging agents and 
active targeting moieties through bottom-up approaches in order to 
yield drug delivery systems or imaging probes for different therapeutic 
needs. Indeed, this possibility will be implemented in the next two 
chapters by means of surface modifications of covalently entrapped 
structures where the in vivo biodistribution as well as their potential use 
in the design of Alzheimer’s disease therapeutics will be addressed. 
In addition, current ongoing studies point out that molecular 
design and surface modification of those entrapped structures have been 
shown to play a crucial role in the morphologies of the aggregates from 
spherical particles to 1D self-assembled fibers or organo/hydrogels 
(data not shown). Undoubtedly, these findings open up the door for 
multiple libraries of structures. The reported data is only the “tip of the 
iceberg” for a family of compounds with promising potential to be used 
in nanomedicine. 
5.4. MATERIALS AND METHODS. 
5.4.1. Materials. 
All chemicals were reagent grade, obtained from Aldrich and 
used without further purification, unless otherwise indicated. All 
solvents were of analytical grade and were dried and freshly distilled. 
Deuterated chloroform-d1, DMSO-d6 and D2O were purchased from 
Deutero GmbH. Preparative SEC was performed using Sephadex G-25 
superfine from GE as well as PD MiniTrap G-10 ™ columns 
containing 2.1 mL of Sephadex™ G-10. Dialysis was performed in a 
Millipore ultrafiltration device fitted with a 1, 3, or 10 kDa MWCO 
regenerated cellulose membrane (Vivaspin®). 
[Chapter 5] 
274 
5.4.2. Characterization techniques. 
GPC, DLS, and SANS equipment used were those described in 
previous chapters (Chapters 2, 3 and 4).  
5.4.2.1. CRYO-TEM.  
Samples were vitrified in an FEI's vitrobot: A 60 μL drop of an 
aqueous suspension of the material was placed on a TEM holey carbon 
copper grid, excess of water was blotted away at the vitrobot with filter 
paper and the grid were freeze-plunged in liquid ethane. Samples were 
then transferred under liquid nitrogen atmosphere to a Gatan TEM 
cryo-holder equipped with a liquid nitrogen reservoir. After that, 
samples were transferred to a Tecnai T20 (FEI company) operated at 
200 KV. All observations were done at low temperature (100 K). 
5.4.2.2. TEM. 
Pictures were obtained from a transmission electron microscope 
FEI Tecnai G2 Spirit (FEI Europe, Eindhoven, Netherlands) using the 
digital camera Morada (Olympus Soft Image Solutions GmbH, 
Münster, Germany). Samples were prepared as detailed: a Mesh grid 
was placed over one sample solution drop for 3 minutes; then the grid 
was transferred to a drop of uranile acetate (2 % in ddH2O for one 
minute. Excess of uranile acetate was dried and the grid was placed in 
the grid holder and observed under the microscope. 
5.4.2.3. NMR Studies. 
NMR Spectroscopy. NMR spectra were recorded at 27 °C (300 
K) on a Bruker Avance III 500 MHz Bruker spectrometer equipped 
with a 5 mm TBI broadband probe. Data were processed with the 
software Mestrenova (Bruker GmbH, Karlsruhe, Germany). Samples 
were prepared at the desired concentration in D2O.  
Diffusion Experiments. Pulsed field gradient NMR 
spectroscopy was used to measure translational diffusion by fitting the 
integrals or intensities of the NMR signals to Stejskal−Tanner105, 106 
equation: I= I0 exp[-Dγ2g2δ2(Δ-δ ⁄ 3)], where I is the observed intensity, 
I0, the reference intensity (unattenuated signal intensity), D, diffusion 
coefficient, γ, the gyromagnetic ratio of the observed nucleus, g, the 
gradient strength, δ, the length of the gradient, and Δ, the diffusion 
time. Two-dimensional diffusion-ordered NMR spectroscopy (DOSY) 
was performed with a stimulated echo sequence using bipolar gradient 
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pulses. The lengths of delays were held constant at Δ= 100 ms, and 32 
spectra of 64 scans each were acquired with the strength of the 
diffusion gradient varying between 5 % and 95 %. The lengths of the 
diffusion gradient and the stimulated echo were optimized for each 
sample. Typical values were δ= 1.5 ms for the analysis of non-
aggregated species and 5 ms to study the nano assemblies.  
NOE experiments. Two-dimensional NOE experiments 
(NOESY) where recorded with a mixing time of 100 ms with 128 
scans.    
5.4.3. Protocols. 
5.4.3.1. Synthetic procedures. 
PGA synthesis, post-polymerization modifications and CuAAC 
chemistry used were done according to protocols described in previous 
chapters. Concretely: Chapter 2 (PGA synthesis) and Chapter 4 (Post-
polymerization modification, and CuAAC chemistry). 
5.4.3.1.1. Synthesis of D-labeled Boc-protected self-
assembly triggering motif (22). 
 In a two-necked round bottom flask, fitted with a stir bar and 
two septums, the deuterated precursor of the motif (19.7 mg, 0.093 
mmol, 1 eq.) was suspended in 5 mL THF anh. To the resulting 
suspension, DMTMM∙BF4 (106.84 mg, 0.326 mmol, 3.5 eq.) was added 
drop wise and stirred at r.t. for 15 minutes. After that, ethylene-d4-
diamine-N-tBoc diamine (50 mg, 0.6048 mmol, 6.5 eq.) was added and 
the reaction mixture was stirred for 48 h. The solvent was removed 
under reduced pressure, and the product was re-suspended in CHCl3 and 
extracted with aqueous HCl (0.5 M) (x3), aqueous NaHCO3 (1 M) (x3) 
and brine (x3). The organic residues were dried over Na2SO4 (anh.) and 
concentrated in vacuo. The product was purified through flash 
chromatography (TLC analysis (Rf= 0.3, CH2Cl2/MeOH (95:5)). A 
white solid was obtained after solvent removal under vacuo.  
Yield: 67 %. 1H-NMR δH (300 MHz, Acetone-d6) 8.64 (3H, 
m), 6.88 (3H, m) 1.37 (27H, s). 2H-NMR δH (300 MHz, Acetone (+3uL 
Acetone-d6) 9.45 (3H, m), 4.47 (6H, m) 4.28 (6H, m). 
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5.4.3.1.2. Synthesis of D-labeled self-assembly triggering 
motif (23). 
In a one-neck round bottom flask fitted with a stir bar and a 
stopper, the product 22 (40 mg, 0.062 mmol, 1 eq.) was dissolved in 
THF 10 mL, and HBF4∙Et2O (0.08 mL, 0.62 mmol, 10 eq.) was added 
to the solution. After stirring for 3 days TLC revealed the complete 
deprotection of Boc-amines (Rf= 0.5 CH2Cl2/MeOH (95:5), UV+ 
ninhydrine). Purification was performed through sequential and 
repetitive precipitation in MeOH/Et2O and MeOH/Hexane.  
 Yield: 80 %. 2H-NMR δH (500 MHz, H2O (+3uL Acetone-d6) 
9.23 (3H, m), 4.52 (6H, m) 4.06 (6H, m). 
5.4.3.1.3. Thiol-ene click chemistry for covalent 
entrapment. 
In a one neck round bottom flask fitted with a stir bar and a 
stopper, 50 mg of each of the functionalized sodium salt form of the 
polymers were dissolved in PBS buffer 7.4 both at a concentration of 4 
mg mL-1 for co-assembly. Sample was sonicated for 5 minutes. 
Afterwards, 11.9 mg (0.041 mmol, 0.15 eq.) of TCEP (tris(2-
carboxyethyl)phosphine) was added to the reaction mixture. The pH 
was checked to be around 7.4 and the reaction mixture was left to 
proceed under vigorous stirring, at r.t., over 16 hours. After that time, 
the resulting product was dialyzed using a MWCO 3000 Da. 1H NMR 
was used to check reaction success by taking into account the 
maleimide peak disappearance at 6.77 ppms. 
5.4.3.1.4. Di-sulfide chemistry for covalent entrapment. 
In a one neck round bottom flask fitted with a stir bar and a 
stopper, 100 mg of the -SS- functionalized sodium salt form of the 
polymer was dissolved in ddH2O at a concentration of 4 mg∙mL-1 for 
self-assembly. The sample was sonicated for 5 minutes. Afterwards, 
11.9 mg (0.041 mmol, 0.15 eq.) of TCEP (tris(2-
carboxyethyl)phosphine) was added to the reaction mixture. Reaction 
mixture was left to proceed under vigorous stirring, at r.t., over 2 hours 
to promote the removal of the 2TP groups. After that time, the resulting 
product was dialyzed using a MWCO 3000 Da. 1H NMR and DLS 
measurements were used to check reaction success. 
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5.4.3.2. CAC determinations by DLS. 
The compounds tested were dissolved in PBS 7.4 at different 
concentrations ranging from 0.004 to 2 mg∙mL-1. Linear PGAs were 
also used as negative controls. Each solution was freshly prepared for 
the measurements, sonicated for 5 minutes and left 24 hours to 
stabilize. DLS measurements were done per triplicate with fixed 
parameters for all samples. Data was expressed as the mean count rate 
(Kcps) against the concentration. CAC values were obtained from the 
curves intersections. 
5.4.3.3. Pyrene Assay. 
For these measurements, dilution series of the conjugates under 
study were prepared. A stock of 4 mg∙mL-1 of each compound was 
prepared in PBS 7.4 as well as a stock of pyrene of 0.02 mg∙mL-1 in 
acetone. Several dilutions are prepared to cover a wide range of 
polymer concentrations (from 2-0.004 mg∙mL-1) to which 3 µL of the 
pyrene stock solution in acetone were added. Then, all solutions are 
placed in vials and are incubated in an oven at 37 °C for 2 hours in 
order to evaporate the acetone. After storing the samples for 24 hours, 
measurements were carried out into a 1 cm path length PMMA 
fluorescence cell reaching a final volume: 1 mL). Each excitation 
spectra is recorded from 300 to 360 nm with an emission wavelength of 
390 nm at r.t. in a Jasco FP-8300 Spectrofluorimeter. The excitation 
and emission band slits are 5 and 2.5 nm respectively. Finally, data was 
expressed by plotting the intensity ratio I338/I333 against the polymer 
concentration in order to determine the CMC value.  
5.4.3.4. Co-assembly studies by DLS. 
X-EG(2)N3(5) and X-prop(10) solutions prepared from CAC 
determination studies ranging from 0.004 to 2 mg∙mL-1 were modified 
with 1 µL of X-prop(10) and X-EG(2)N3(5) respectively from stock 
solutions in order to have a final concentration of the added compound 
below its CAC. That means 0.1 mg∙mL-1 of X-prop(10) in X-EG(2)N3 
(5) series, and 0.2 mg∙mL-1 of X-EG(2)N3(5) in X-prop(10) series.  
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5.4.3.5. Cell viability against in SHSY5Y cell line. 
Cell assays to assess cell viability were carried out according to 
the protocol described in Chapter 4. 
5.4.3.6. Uptake studies against SHSY5Y cell line by flow 
cytometry and Live-cell Confocal Imaging. 
Cell assays and procedures for cellular uptake were carried out 
according to the protocol described in Chapter 4. 
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6.1. INTRODUCTION AND BACKGROUND. 
6.1.1. Neurodegenerative disorders. Incidence and costs. 
Brain disorders, including developmental, psychiatric and 
neurodegenerative diseases, represent an enormous disease burden, in 
terms of human suffering and economic cost. More than 600 disorders 
afflict the nervous system.1 Neurodegenerative diseases are defined as 
hereditary and sporadic conditions characterized by progressive 
nervous system dysfunction. These disorders are often associated with 
atrophy of the affected central or peripheral structures of the nervous 
system. They include diseases such as Alzheimer's disease and other 
dementias, brain cancer, degenerative nerve diseases, encephalitis, 
epilepsy, genetic brain disorders, head and brain malformations, 
hydrocephalus, stroke, Parkinson's disease, multiple sclerosis, 
amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), 
Huntington's disease, Prion diseases, and others. With progressive 
human ageing and the overall deterioration of our ecological 
environment, an increasing number of people is year by year affected 
by neurological disorders that encompass, in many cases, chronic and 
incurable states. Only in Europe it has been estimated that 35 % of all 
disease burden is attributable to brain-related disorders.2  
Thus, economic costs of brain disorders are correspondingly 
large, including not only cost of treatments, but also the lost 
productivity of patients and their caregivers, for whom it can represent 
an enormous emotional, practical, and financial burden. Hence, the 
overall disease burden from these disorders is much greater than would 
be suggested by mortality number.3 Just in Europe, the cost of brain 
diseases increased from 386 € billion per year (twice the estimated cost 
of cancer) in 20044 (including direct costs of treatment and indirect 
costs) to 798 € billion in 2010.5 That value includes direct health care 
cost (37 %), direct non-medical cost (23 %), and indirect cost (40 %). 
See Figure 6.1 for disaggregated data. The average cost per inhabitant 
was 5.550 €.  
Overall, the growing incidence and increasing costs caused by 
this family of diseases together with the lack of effective treatments, 
points out the need for novel approaches in order to address their 
enormous burden. 
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Figure 6.1. Absolute cost and type of cost of 19 brain disorders in 
Europe (billion €PPP 2010).5 Dementia includes AD. 
6.1.2. The nervous system.  
The nervous system is the part of an animal's body that 
coordinates its voluntary and involuntary actions and transmits signals 
between different parts of its body. In most animal species, it 
encompasses two main components, the central nervous system (CNS) 
and the peripheral nervous system (PNS). The CNS is formed by the 
brain and spinal cord, while the PNS consists mainly of nerves, whose 
axons connect the CNS to every other part of the body. The PNS 
consist of motor neurons (mediating voluntary movement), the 
autonomic nervous system (including the sympathetic nervous system), 
the parasympathetic nervous system (which regulate involuntary 
functions) and the enteric nervous system, that controls the 
gastrointestinal system. 
Nervous tissue is the main component of the brain and spinal 
cord in the CNS, and the branching peripheral nerves in the PNS. It is 
composed of neurons, or nerve cells, which receive and transmit 
impulses, and neuroglia (glial cells or glia) (see Figure 6.2). 
Neurons are nerve impulse-conducting cells considered the 
functional unit of the nervous system, which form the nerves, brain and 
spinal column. A typical neuron has a nucleated soma or cell body and 
the processes (axon and dendrites). They are classically classified 
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according to polarity in: bipolar neurons (in which the processes extend 
from opposite ends of the soma), (pseudo)unipolar neurons (in which 
the process extends from one end of the soma) and multipolar neurons 
(a neuron in which an axon and several dendrites extend from the 
soma). Furthermore, there is another classification according to the 
direction of nerve impulses in: sensory neurons or afferents (that 
transmit sensory information in the form of an action potential from the 
PNS to the CNS), motor neurons or efferents (that send nerve impulses 
away from the CNS to muscles or glands) and interneurons (that send 
impulses to another neuron). 
 
Figure 6.2. Cells from neuronal tissue redrawn from ref6.  
Glial cells are considered as supporting cells that assist the 
propagation of the nerve impulse as well as provide nutrients to the 
neuron. They are smaller than neurons, and vary in structure according 
to their function encountering astrocytes, microglial cells and 
oligodendrocytes NG2 glia in CNS; Schwann cells, satellite glial cells 
and enteric glia in PNS. 
The brain is the control center of the body. It controls thoughts, 
memory, speech, movement and regulates the function of many organs. 
The normal neuronal-vascular relationship is crucial for a good brain 
functioning. Indeed, neurons need a constant supply of oxygen and 
nutrients, thus, are located among 8-20 µm distance from capillaries.7 
Adult brain contains approximately 650 km of capillaries, and it has 
been estimated that almost every neuron in human brain has its own 
capillary.8 
[Chapter 6] 
292 
On the contrary, it is also critical to maintain brain homeostasis 
to keep normal brain function, and neurons are sensitive to many 
compounds and are subjected to many concentrations balances between 
outside and inside. Due to the high relevance of CNS functions, the 
brain is one of the most (if not the most) protected organs in the human 
body, being guarded by various barriers. Such barriers regulate nervous 
tissue homeostasis, and control the highly selective and specific 
uptake/efflux mechanisms, as well as the metabolism of endogenous 
and exogenous molecules. For that reason, accessibility of blood 
circulating compounds to the brain is one of the lowest compared to 
other organs, despite its dense capillary network. Most drug candidates 
have little effect in serious CNS disorders and many CNS drug 
development programs are discontinued mainly due to poor BBB 
permeation as the majority of candidates are either polar, with a MW > 
500 Da, are bound to plasma proteins or are pumped out of the brain by 
means of efflux pumps.9 Indeed, according to Pardridge10, only 2 % of 
small-molecule drugs and almost 0 % of biologic drugs do reach the 
brain, thus limiting the development of efficient treatments for brain 
diseases, especially in the case of antisense pharmaceuticals, gene 
medicines, and recombinant proteins.11-13 
Current drugs developed by pharmaceutical companies, capable 
to cross cell membranes and physiological barriers are both, smaller 
than 500 Da and lipophilic.10-12 In spite of all the limitations mentioned 
above, up to date, the main efforts to design strategies for the treatment 
of CNS disorders have been focused on drug discovery, rather than on 
the design of new approaches for brain targeting and active delivery.  
6.1.3. Barriers at the CNS. 
Concretely, three barriers regulate the transport of bioactives to 
brain parenchyma: (i) the blood brain barrier (BBB), localized in brain 
capillaries, between blood and interstitial fluid (ISF), representing the 
barrier between the lumen of cerebral blood vessels and brain 
parenchyma; (ii) arachnoid epithelial membrane (or meningeal barrier), 
an epithelial cell layer that covers brain tissue in the ventricles, limiting 
transfer from cerebrospinal fluid (CSF) to brain tissue. This barrier is 
the less studied and structurally the most complex of all brain barriers; 
and (iii) the blood-cerebrospinal fluid barrier (BCSFB), that involves 
the choroid plexus epithelium in the ventricles, representing the barrier 
among choroid plexus blood vessels and the CSF (See Figure 6.3). 
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Figure 6.3. Schematic representation of CNS barriers. a) Neurovascular 
unit from BBB, As: astrocyte, Peri: pericytes, Endo: endothelial cell 
and B.M.: basement membrane. b) The meningeal barrier. Blood 
vessels of dura are fenestrated and provide little barrier function; 
however, outer cells of arachnoid membrane (Arach) have tight 
junctions (arrowheads) forming the physical barrier between the CSF-
filled subarachnoid space (SAS) and overlaying structures. Blood 
vessels in arachnoid and on pial surface (PIA) have tight junctions with 
similar barrier characteristics as BBB. c) Blood-CSF barrier. Choroid 
plexus blood vessels are fenestrated and form a non-restrictive barrier 
(small arrows); however, the epithelial cells (Ep) have apical tight 
junctions (arrowheads) that restrict intercellular passage of molecules. 
d) Adult ventricular ependymal does not restrict the exchange of 
molecules at least as large as proteins between CSF and brain. Fetal 
CSF-brain barrier, a barrier between the CSF and brain parenchyma, 
has only been shown to be a functional barrier in the early developing. 
Redrawn from Saunders et al.14  
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6.1.3.1. Blood-brain barrier (BBB). 
6.1.3.1.1. Structure. 
In order to preserve brain homeostasis, brain vessels are 
modified to form the BBB. Since its discovery by Paul Ehrlich in 
1885,15 BBB has been considered the most critic and nearly 
undefeatable cellular barrier in the human beings that protects both 
brain and spinal cord. The BBB is a highly specialized and selective 
physical and physiological barrier that maintains such mentioned brain 
homeostasis by controlling the entry of compounds from blood to brain, 
and their efflux, as well as protects nervous tissue against potentially 
harmful xenobiotics and endogenous molecules that could be present in 
the bloodstream. It acts also as a metabolic barrier due to the high 
turnover of the intra and extracellular enzymes, what it must be taken 
into account in drug development.16, 17 The BBB is mainly formed by 
brain capillary endothelial cells (BCECs),18 although other cell types, 
such as pericytes, neuronal terminations, and perivascular astrocytes 
play an important role in BBB structure and function,19-21 forming the 
neurovascular unit (Figures 6.3 and 6.4). Moreover, the BCECs are 
closely connected by the presence of intercellular tight junctions (TJs). 
Due to their specific functions, BCECs possess specific features 
when compared to peripheral ECs:22-25 (i) they present remarkably 
lower number of endocytic vesicles, limiting the transcellular transport; 
(ii) absence of fenestrations; (iii) high electrical resistance due to the 
presence of the TJs that restrict the paracellular flux; (iv) higher 
mitochondrial volume, what reflects a higher metabolism; (v) 
specialized transport systems and (vi) lack of lymphatic drainage.  
The main components responsible for the structural integrity of 
the BBB are TJs and the adherent junctions (AJs).26 Such structures are 
closely located forming the junction complex between adjacent BCECs. 
While AJs are more involved in the initiation and maintenance of 
BCECs contact, TJs seal them to form a continuous tubular structure.27 
TJs are located in the upper part of the apical region of plasma 
membrane from BCECs and represents the most important seal to 
prevent paracellular diffusion, also taking part in the regulation of 
lateral diffusion between apical and basolateral plasma membrane 
domains, thus, keeping constant plasma membrane lipid and protein 
polarity.28 Such structures are composed by a complex network of 
parallel, interconnected, transmembrane and cytoplasmatic families of 
proteins (junctional adhesion molecules (JAMs),29, 30 occluding,31 
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claudins32, 33 and cytoplasmic accessory proteins). The high 
transendothelial electrical resistance (TEER) in brain endothelium 
(2000 ohm.cm2 compared to 2-20 ohm.cm2 in peripheral capillaries)34 is 
mainly due to the presence of the TJ complex.35 In respect to AJs, they 
have been reported to be essential in the maintenance of TJ and the 
junctional complex.36 Their main components are transmembrane 
glycoproteins from the cadherin superfamily linked to the 
cytoskeleton.37, 38 
Apart from the already described BCECs, pericytes, astrocytes, 
neurons, microglia and extracellular base membrane significantly 
contribute to BBB function and maintenance, although their full role 
remains still unknown.  
Astrocytes, a type of microglia cells, play a key role in BBB 
creation and maintenance since their end-feet contact directly with 
BCECs forming a net that acts as a very restrictive barrier.39, 40 They 
have been described to significantly influence neurovascular structure, 
maintenance and integrity; participating in the nutrition and metabolic 
support of neurons.41 The effect of astrocytes in BCECs relies on the 
secretion of numerous signaling molecules, such as cytokines, 
neutrophins and many factors.42, 43 Astrocytes are also related with the 
regulation of expression and polarized location of transporters such as 
P-glycoprotein (P-gp)44 and GLUT1.39 They have been suggested to 
play an important role in TJs formation and integrity.27, 45 Indeed, in 
vitro co-cultures of astrocytes and BCECs achieve high electrical 
resistances, a strong evidence of their implication.46, 47 
Pericytes are a type of mesenchymal cell that occupy the 
vascular space, between the capillary wall and astrocytes end-feet. 
Pericytes have been historically considered as mere scaffolds, but they 
have important roles in the communication with BCECs by direct 
physical contact and paracrine signaling pathways.48 They are known to 
play a regulatory role in vascular tone, stability, repair and angiogenesis 
both in CNS and non CNS.41, 49-51 Moreover, they have been related to 
the efflux transporters expression (i.e. ATP- binding cassette (ABC) 
transporters) as well as to the growth and function of the endothelium.51 
Furthermore, it has been demonstrated that pericytes deficiency 
increases BBB permeability to water and to a range of low and high 
molecular mass tracers injected i.v.50 In addition, it has been recently 
reported that the lack of pericytes in mice models lead to neuronal 
degenerative changes, learning and memory impairment and 
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neuroinflammatory responses.49, 52 All that together highlights the 
relevance of pericytes in the neurovascular unit. 
Microglia are the resident immune cells in the CNS derived 
from monocytes and macrophages, and perform an essential role in the 
immune response.53 Whereas in normal conditions, neurons and glial 
cells interact together to promote brain homeostasis, microglia become 
activated under brain injury or immunological stimuli and undergo 
alterations from the so-called resting state to an activated one.54 This 
activation starts a coordinated neuroinflammatory response which has 
been demonstrated to be involved in BBB impairments and 
consequently neurodegeneration.54-56 Nonetheless, the mechanisms by 
which this occurs are not fully understood yet.  
The basement membrane at BBB plays important roles 
including maintenance of capillary vessel morphology, cell adhesion, 
and prevention of plasma protein leakage from capillary vessels.57 It is 
constructed from extracellular matrix (ECM) such as collagen type IV, 
laminin, and bronectin, and regulated by matrix metalloproteinases 
(MMPs) and plasmin.58, 59  
Finally, neurons are also actively participating in this structure 
since neuronal terminations arrive to all cells forming the BBB.60-62  
 
Figure 6.4. Blood Brain Barrier structure. Redrawn from ref63. 
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6.1.3.1.2. Transport mechanisms across BBB. 
In general, nutrients, ions and other molecules cross the BBB 
following a paracellular diffusion between BCECs cells through the 
junctional complex or by the transcellular pathway across the cells. 
Paracellular pathway. The paracellular diffusion is a passive 
mechanism coordinated by TJs. Small water-soluble molecules as well 
as lipophilic solutes cross the BBB depending on electrochemical, 
hydrostatic and osmotic gradients. However, this pathway only plays a 
minor role in brain targeted drugs and is significantly reduced in BBB, 
when compared with other organs.64  
Transcellular pathway. This pathway can be energy or non-
energy dependent and includes all types of transport mechanisms across 
cells. Among them, it can be classified as passive or active, depending 
on energy requirement (adenosine triphosphate, ATP). 
 Passive transcellular mechanisms: are based on the 
transport of molecules by simple diffusion (transcellular diffusion) or 
facilitated diffusion (carrier-mediated transport) always following the 
concentration gradient. 
Transcellular diffusion. Using this pathway, lipid-soluble 
substances, such as oxygen, CO2, alcohol or steroid hormones are able 
to diffuse across both the luminal and the abluminal membrane of the 
capillary endothelium.65 This route is the most favored among passive 
mechanisms. Indeed the vast majority of CNS drugs follow this 
mechanism.66  
Carrier-mediated transport (CMT), is a saturable transport 
process.67 There are two forms of CMT, active transport (which could 
should be included in active transcellular mechanisms) and facilitated 
diffusion. For instance, entry of glucose by glucose transporter 1 
(GLUT1) is by facilitated diffusion, in the concentration gradient 
direction. In case of amino acids, there are different and selective 
energy dependent carrier proteins (active).68 These carriers are normally 
polarized and localized on both the luminal and abluminal membrane of 
the BCECs, operating in both directions.69 Overall, there are many 
selective carrier systems expressed in brain ECs.  
 Active transcellular mechanisms: Based on the use of 
ATP as energy, these transport mechanisms allow the interchange of 
molecules against gradient concentration, relying mostly on vesicle 
formation. 
[Chapter 6] 
298 
Receptor-mediated transcytosis (RMT). RMT represents the 
principal mechanism used by brain ECs to uptake essential molecules 
such as hormones, or high molecular mass proteins such as insulin, 
leptin, low density lipoproteins, transferrin or insulin-like growth 
factors (IGF) across BBB.70-73 This transport process is based on the 
receptor-ligand recognition at the luminal membrane of BCECs 
inducing the formation of coated pits that engulf the ligand leading to 
an endocytic vesicle. Then, such vesicle suffers the endosomal fusion 
when dissociation of the receptor from the ligand occurs74, 75 releasing 
the content by exocytosis. Finally, free receptor is recycled to cell 
surface or degraded through lysosomes. Nevertheless, complete 
crossing is never achieved since some vesicles fuse with lysosomes and 
their content is degraded. 
Currently, efforts done to achieve BBB crossing in CNS drug 
delivery are mainly directed to the use of this pathway since it is neither 
size limited nor lipophilicity-dependent. Basically, the strategies are 
based on association or conjugation to ligands capable to promote 
transcytosis upon receptor binding, forming the so-called molecular 
“Trojan horses”.10 Among such receptors, there are three widely 
investigated for drug delivery approaches: (i) insulin receptor (IR), (ii) 
transferrin receptor (TfR) and (iii) low-density lipoprotein receptor 
related proteins 1 and 2 (LDP-1 and 2). 
Adsorptive endocytosis (AE or adsorptive-mediated 
transcytosis AMT). This mechanism takes place through ionic 
interactions. Positively charge molecules such as cationized albumin, 
protamine or histone,75 interact with the negatively charged components 
of the EC membrane. This approach has been used for the delivery of 
drugs by means of albumin conjugation for instance,76, 77 and it has been 
also explored with antibodies for applications in diagnostics, 
neuroimaging and brain treatment.78  
Efflux transport system. The efflux transport is an active 
process for substance removal from the CNS to the circulation in order 
to prevent brain accumulation. Present in the BBB and in the BCSFB as 
well, this mechanism is the reason by which most of drugs that cross 
BBB, do not reach the necessary concentration for being therapeutically 
active.79, 80 One of the best known efflux transporter is P-glycoprotein 
(P-gp), a member of the ATP-binding cassette (ABC) transporters, 
localized in the luminal membrane of BCECs. P-gp forms part from the 
multidrug resistance receptors (MDRs), and actively transport many 
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anticancer drugs, antibiotics, immune system suppressors or ionic 
channel modulators out of the brain,81, 82 avoiding the accumulation of 
toxins or drugs in the brain.  
On the contrary to P-gp, there are also energy independent 
efflux transporters such as the organic anion transporter (OAT) and 
organic anion transporter polypeptide (OATP), that have dual function 
as efflux and influx transporters depending on compounds 
concentration on both sides of the BBB.83  
 
Figure 6.5. Schematic representation of transport mechanisms across 
BBB including diffusion, paracellular transport, carrier-mediated 
transport, receptor-mediated transport, adsorptive-mediated transport 
and efflux systems.  
6.1.4. BBB models. 
In addition to a better understanding of physiological and 
pathophysiological conditions of the brain and its diseases, methods 
able to select drug candidates more efficiently in the early preclinical 
stages are needed. Currently, selection of potential candidates for CNS 
diseases strongly relies on either in vitro or in silico estimation of BBB 
permeability, or/and on in vivo measurements of the total brain to total 
plasma drug concentration ratio.84 In silico, in vitro and in vivo 
methodologies have been the subject of much research and 
development in recent years.46, 47, 52, 85, 86 Several in silico and in vivo 
methods are well-established in the development of new drugs. In vitro 
methods are, however, more controversial. It is well-known that no 
simple in vitro model can mimic all BBB functionalities due to its 
inherent complexity.85 Nonetheless, it is nowadays consensual that the 
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model used must at least hold the most relevant features of BBB needed 
for the aim of the investigations, that are commonly directed either to 
CNS drug permeability,87, 88 elucidation of drug interactions at the 
BBB89, or to perform physiopathological,90 toxicological91 and 
immunological studies.92 For the first line of research mentioned, an in 
vitro model suitable for compounds screening in terms of BBB 
permeability, it should possess features such as low paracellular 
permeability and express key enzymes and carrier transport systems.39, 
93 The main advantages of in vitro models, in comparison to the in vivo 
models rely on their simplicity, lower cost and lower amounts of 
compounds required, their high throughput screening capacity, the 
possibility to quantify compounds in physiological buffers and the 
identification of early signs of cell toxicity, apart from the need of 
lower number of animals, better from an ethical as well as an 
economical point of view. Nevertheless, in vitro methods cannot 
substitute in vivo tests. At general basis, in vitro models encompass. 
(i) Physico-chemical models. Represent simple methods 
used to select candidates for CNS diseases based on their 
physiochemical properties. Immobilized artificial membrane 
chromatography (IAM),94, 95 parallel artificial permeability assays 
(PAMPA)96-100 and lipophilicity measurements are the most commonly 
used, however, they are mainly used for compounds transported by 
passive diffusion. 
(ii) Cell-based models were developed in order to obtain 
more reliable prediction. . Isolated microvessels present already a 3D 
structure. They are useful to study morphological aspects, expression 
and activity of transporters and to carry out drug delivery assays. 
Primary or low passage of immortalized cell lines of cerebral origin 
provide the closest phenotypic resemblance to that of the in vivo BBB88 
because many of their characteristics are genetically programed. Their 
main limitations rely on the fact that are not able to retain BBB 
properties. To overcome such drawbacks co-culture and triple co-
culture systems have been implemented through combination of 
primary or immortalized cell lines of BCECs, with astrocytes, 
astrocytic cell lines, C6 glioma cell lines, pericytes, mixed glial cells 
and/or cell conditioned media.46 Such models represent a more realistic 
scenario since all elements of the neurovascular unit strongly contribute 
to the development and maintenance of the BBB phenotype. 
Nonetheless, they are time-consuming and still do not fully reproduce 
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in vivo conditions. Cells lines of non-cerebral origin are also used to 
mimic BBB. Among them, of the most characterized and used cell line 
is the Madin- Darby Canine Kidney (MDCK) cell line, which is easy to 
grow, achieves a reproducible TEER value and can be transfected in a 
stable manner with the MDR1 gene, resulting in the polarized 
expression of P-gp, for instance.94, 101 More recently, Lippmann and 
coworkers have developed a promising model based on human 
pluripotent stem cells (hPSCs), were neural progenitor cells 
differentiated to mature neurons and astrocytes that can be used in co-
culture, representing a robust BBB model.102 Traditional techniques for 
mimicking the BBB are based on static two chamber systems 
(TranswellTM) separated by a cell monolayer grown on a polycarbonate 
membrane that represents the barrier. These static models have the 
limitation of low reproducibility of the anatomical and physiological 
features of the BBB, and consequently, poor correlation with the in vivo 
results. To address that, microfluidic BBB models to simulate the real 
environment have been also tested in 2D systems by applying flow-
induced shear stress across the monolayer.103-108 One step further is the 
use of dynamic in vitro models with tridimensional architecture (3D 
models) developed to reproduce more accurately the physiological 
features of the brain vascular segments, taking into account cellular 
movements, cell-cell interactions and the blood flow in the prediction 
of brain permeation.109 However these systems are not routinely used 
due to their technical demand and high cost. Extensive information 
about in vitro models can be found in literature.46, 47, 52, 85, 86  
Pathological in vitro models of BBB have been also developed 
to address drug permeability in disease-altered BBB.110 Among other 
alternatives involve the use of cells derived from invertebrates such as 
Drosophila melanogaster and Zebrafish.111 
Nevertheless, predicting CNS drug efficacy on the basis of an 
estimated BBB permeability is far from reality since there are many 
parameter that are not taken into account related with their 
pharmacokinetics (PK) and pharmacodynamics (PD) once 
administered. Such parameters include the ratio between drug 
concentration in brain parenchyma and blood levels as well as the 
further distribution within the brain compartments with special 
features.84 Thus, all those factors need to be addressed directly by in 
vivo studies. To date the most predictive PK/PD parameter for a desired 
effect in brain is now recognized to be the free drug concentration in 
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ISF.112 To this respect, tissue microdialysis is the only technique 
currently available that allows not only direct in vivo measurement of 
brain ISF concentration of unbound drug in vivo, but also the 
establishment of highly valuable PK/PD relationships.84, 112, 113 
6.1.5. Delivery strategies to the brain.  
As stated before, many drugs with potential therapeutic effects 
in the treatment of CNS pathologies fail due to poor pharmacokinetics 
and the limitations to cross BBB. Up to date, the challenge of brain 
drug delivery has been partly accomplished through several strategies, 
including invasive or non-invasive approaches. The majority of such 
techniques rely on the combination of several skills such as biology, 
biophysics as well as the use of nanotechnology to achieve this specific 
task. Invasive techniques encloses surgery-needed approaches and BBB 
disruption whilst non-invasive ones encompass drug modification by 
medicinal chemistry approaches and the use of nanotechnology (Figure 
6.6). 
Among non-invasive approaches, medicinal chemistry is a 
widely used approach to enhance passive diffusion across BBB by 
increasing the lipid solubility of polar small drug candidates with poor 
BBB permeability.9, 25, 123 Methylations, halogenations and in general 
polar groups blockage has been traditionally used together with the 
introduction of lipid moieties.67 Nevertheless, this approach encounters 
several difficulties: (i) when increasing the lipid solubility of the drug, 
non-specific bindings to plasma proteins and lipids contained in fat 
tissues are prone to increase too, as well as penetration in all body 
organs; (ii) structural modifications to the original drug can diminish 
the original affinity/activity for the target receptor;131-135 (iii) chemical 
modifications usually lead to increase on MW, thus affecting brain 
penetration.11 For that reasons is really difficult to design small drugs 
able to cross BBB since a well-optimized balance from 
physicochemical properties and pharmacokinetic profiles must be first 
accomplished, ending on effective CNS activity, acceptable absorption, 
distribution, metabolism and excretion/elimination (ADME) properties 
and favorable PK/PD profiles.  
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Figure 6.6. Schematic representation of current strategies to deliver 
drugs to the brain. Invasive techniques encloses surgery-needed 
approaches and BBB disruption whilst non-invasive techniques 
encompasses drug modification by medicinal chemistry and alternative 
approaches. Redrawn from ref25 
The use of fusion proteins and cell-penetrating peptides (CPP) 
to achieve BBB crossing included in medicinal chemistry approaches is 
becoming a popular strategy.75, 136-138 CPPs are short amphipathic 
cationic peptides (less than 30 amino acids) that facilitate rapid 
internalization of exogenous cargo including drugs, proteins, nucleic 
acids, liposomes or nanoparticles after chemical conjugation.139, 140 
Although the mechanism is not fully understood, their first contacts 
with cell surface are mediated by electrostatic interactions with 
proteoglycans, and there are some hints that point out to non-specific 
AMT. Several natural and synthetic peptides are under use for this 
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purpose encompassing the well-known TAT (transactivator of 
transcription), Penetratin, the Syn B vectors (derived from the 
antimicrobial peptide protegrin 1), or Mastoparan/transportan.140 In 
spite of their potential in promoting drug delivery, CPPs suffer from 
some limitations such as: (i) toxic effects on cell membranes and 
organelles; (ii) poor pharmacokinetics and short half-lives in biological 
media due to degradation by proteolytic enzymes; (iii) immunogenicity 
and complement activation. 
Microspheres and biodegradable wafers technologies have 
been also implemented to increase drug retention in the brain by using 
lipid-based polymeric devices in the first case, and biodegradable 
polymers in the second to form drug complexes.141-144 However, such 
technology is locally applied to the brain by stereotaxic surgery, what is 
safer than the previous invasive methods described, but still harmful.123  
Alternative methods include intranasal administration, the use 
of molecular Trojan horses (TH), genetic engineering, the use of 
nanotechnology-based systems, their combinations and combination 
with medicinal chemistry strategies (Figure 6.6).  
Intranasal route of administration have been successfully 
applied in the delivery of some small lipid molecules, nano-sized 
micelles and liposomes.145 Nevertheless, there are many physiological 
variables that influence the administration such as pH, high enzymatic 
activity of the epithelium, mucosal irritation or even nasal 
pathologies.123 Moreover, it is limited by drug’s lipophilicity. Genetic 
engineering strategies are based on the implantation of living tissue 
inside brain with the ability to secrete therapeutic molecules. For 
instance neural stem cells (NCS) have been implanted into 
hippocampus of AD and Down syndrome mice model in order to 
modify levels of tau/reelin-positive granules.146. Recent studies confirm 
the potential of such approaches,146, 147 however, they are still limited by 
the short survival rate of the inserted tissues.  
Among the strategies based on nanosystems two main 
approaches can be followed: the use of CNS delivery systems relying 
on BCECs uptake and notably adsorptive-mediated endocytosis or the 
use of targeted delivery systems via targeting BBB receptors (carrier-
mediated or receptor-mediated). The first strategy is followed by 
liposomal formulations (neutral or cationic), colloidal nanoparticles 
(neutral or cationic) and solid lipid nanoparticles, relying only in their 
intrinsic characteristics to cross biological barriers. Since this thesis 
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deals with the use of targeted drug delivery systems, the first approach 
will not be further commented and examples of those systems are 
reviewed in the excellent literature.9, 25 
Special mention will be done to the approach based on the use 
of TH and some examples in their use in targeted drug delivery will be 
addressed. TH are vectors able to bind specific receptors while carrying 
cargo molecules that can be transported across BBB.148-150 The general 
strategy to deliver biologics to the brain by the use of TH follows RMT, 
and involves the conjugation of a receptor-targeting moiety with the 
therapeutic of interest.151-153 that can be mABs, recombinant proteins, 
RNA, DNA, or nanomedicines. The most well studied BBB RMT 
targets include transferrin receptor (TfR), insulin receptor and the LDL 
receptors. 
TfR mediates iron delivery to the brain by binding the iron-
binding protein transferrin (Tf)154 and is expressed at high level at the 
BBB.155, 156 It has been widely used for BBB delivery.151, 152, 157 For 
instance, PEGylated liposomes decorated with Tf and CPP polyarginine 
demonstrated significant brain accumulation at 24 hours (4 % of 
injected dose, ID) after i.v. administration in rat. Nonetheless, despite 
its use, Tf is not the ideal ligand as endogenous Tf is present at high 
concentrations in the bloodstream and will always compete with the 
injected one.158 
Thus, antibodies targeting epitopes distal to Tf-binding site 
have been developed in order to overcome the competition limitation, 
and there are plenty of reported examples about them.157 For instance, a 
fusion protein of cTfRMAb, a chimeric mAb that binds to the mouse 
TfR, was used to deliver TNFߙ achieving 1.4 % ID in mouse brain159 
and showed significant neuroprotection in a mouse model of Parkinson 
Disease (PD).160 Erythropoietin and glial-derived neurotrophic factor 
(GDNF) have been also delivered by this strategy for PD treatment with 
promising results.161, 162 One of the most utilized anti-TfR mAb is 
OX26, with plenty of examples in literature.163-166 For example, 
PEGylated liposomes decorated with OX26 were used to deliver GDNF 
expression plasmids to treat PD in rat models achieving significant 
neuroprotection after 3 weeks of once-weekly injections.167 Apart from 
PD, a wide range of other neurological disorders are been targeted with 
anti-TfR antibodies.137, 168-170 
Recent approaches employ the iron-mimicking cyclic peptide, 
CRTIGPSVC, as the RMT-targeting ligand.171 Although it binds to the 
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Tf-binding site, this peptide is showing promising results in the 
treatment of CNS disorders.171, 172 For that reason, it has been one of the 
vectors selected within this thesis for BBB targeting. 
However, the use of TfR as a target for RMT may be limited 
due to: (i) TfR expression in vascular beds and parenchyma of other 
organs, what will lead to widespread distributions; (ii) Full transcytosis 
of TfR to the brain may be limited and depends on the affinity of the 
ligand for the receptor.173, 174 
The insulin receptor, IR, (also expressed at the BBB)156 
responsible for the transport of insulin71, 175, 176 to the brain has been 
also explored. As insulin itself cannot be used as vector (due to its short 
half-life in serum and the possibility to cause hypoglucemia upon 
administration of exogenous insulin),177 strategies are centered on the 
use of human IR mAbs (HIRMAb, and HIRMAb fusion proteins) for 
brain delivery.178 Indeed, the termed AGT-181 (ArmaGen 
Technologies), a HIRMAb fused with α-L-iduronidase (IDUA), and 
enzyme missing in Hurler’s syndrome is currently in clinical trials, 
representing the first effort to bring RMT-targeted antibodies to the 
clinic for the treatment of genetic lysosomal storage diseases.178-182 This 
system achieved approximately 2 % of ID in rhesus monkey brain 2 
hours after i.v. injection. Apart from AGT-181, HIRMAb has been 
fused to numerous other therapeutic proteins such as anti Aβ scFv,183, 
184 GDNF,185, 186 TNFR,187, 188 erythropoietin189 or paraoxonase.190 191 
Moreover, Pardridge et al. have successfully constructed a radiolabeled 
Aβ peptide conjugated to HIRMAb, as a diagnostic probe for AD.192-196 
Nevertheless, despite its efficiency, this approach is considered risky 
due to its involvement in glucose homeostasis. 
Other receptors exploited are the low-density lipoprotein 
receptor (LDLR) and low-density lipoprotein receptor-related proteins 
1 (LRP1) and 2 (LRP2), that are expressed in BCECs,155, 156 and 
mediate the transport of lipoproteins and a diverse array of other 
ligands (such as ApoE, HIV-1, TAT protein, lactoferrin, 
melanotransferrin, receptor associated protein…) across the BBB via 
RMT.197-199Although antireceptor Abs have not been reported for this 
family, overwhelming studies have explored de use of LDLR and LRP 
ligands and peptide ligand mimics as vectors for brain delivery. For 
instance NPs decorated with ApoE have been shown to cross the BBB 
in vivo.200, 201 Angiopep-2 (ANG-2) a 19 amino acid peptide, was 
reported as a ligand targeting LRP receptor,202-204 and has shown 
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promising results as a delivery vector in the treatment of glioma205-207 
mainly due to its elevated reported rate of transcytosis.202 Furthermore, 
a peptide-paclitaxel conjugate with 3 molecules of paclitaxel linked to 
ANG-2, termed ANG1005 has been shown to have activity against 
glioblastoma, and to extend the survival of mice with intracerebral 
tumors.205 These systems enters the brain through LRP1202 and is not a 
substrate for the P-gp efflux transporter. ANG1005 is being developed 
by Angiochem for glioma treatment and is the most advance system for 
BBB targeting with numerous Phase I clinical trials completed.208, 209 
and Phase II trials under way.210 Besides, DOX and etopoxide 
conjugated to ANG-2 lead to ANG1007 and ANG1009, respectively 
with increased brain penetration.211 Moreover, ANG-2 has been also 
investigated in the delivery of genes, peptides, proteins, antibodies and 
enzymes.212-217 Furthermore, ANG-2 is becoming popular in targeted 
nanomedicines to cross BBB with a growing number of examples in 
literature.218 For instance, ANG-2 conjugated with PEG-co-poly(3-
caprolactone) NPs was developed as a dual targeting drug delivery 
system for glioma treatment.219ANG-PEG-DOX-AuNPs, loaded with 
DOX through hydrazone, and functionalized with ANG-2 was able to 
deliver and release DOX in glioma and to increase survival time of 
glioma-bearing mice.220 Dual peptide-modified liposomes with ANG-2 
and neuropilin-1 receptor (tLyP-1) for brain tumor targeting and 
penetration were designed and loaded with siRNAVEGF and DTX 
showing good results after systemic administration against mice with 
U87MG tumors.221 ANG-2-pluronic F127-conjugated 
superparamagnetic iron oxide nanoparticles have been recently 
proposed as nanotheranostic agents for BBB targeting.222 The examples 
listed are just a few from the increasing body of literature about ANG-2 
uses in nanoconstructs.223-233 Due to all this background information, in 
this thesis, ANG-2 has been also selected as vector for brain delivery. 
Apart from those, other less studied receptors are becoming 
popular as targets for BBB crossing such as diphtheria toxin receptor,234 
or acetylcholine receptors.235, 236 Glutathione (GSH) is recently been 
investigated as targeting vector since BBB express transporters for this 
molecule. For instance, glutathione pegylated liposomal doxorubicin 
(2B3-101) is being developed as a new treatment for patients with brain 
cancer and is currently in Phase I/II clinical trials.237 
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6.1.6. In vivo Imaging. 
Improving the characterization of compounds and their effects 
in early, and not yet so costly phases is key to shorten drug discovery 
development process. Moreover, and linked with that, knowledge about 
a given disease or disease model, and their early diagnosis and 
characterization is a required step to develop biomarkers and to 
discover molecular targets for effective treatments. In this context, in 
vivo imaging emerge as a highly necessary battery of techniques to 
address several crucial questions concerning drug discovery and 
development. Although, no single imaging modality can answer all 
possible questions in this complicated domain, to find out the potential 
of such techniques in a certain disease area is important. For instance, a 
combination of neuroimaging tests are needed to provide diagnostic 
support and to elucidate underlying mechanism of pathologies. Hence, 
encompassing CNS bioimaging to achieve a whole picture includes the 
use of nuclear medicine techniques such as Positron Emission 
Tomography (PET) and Single Photon Emission Computed 
Tomography (SPECT); and morphological information obtained by 
Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). 
A complete review of imaging strategies within pharmaceutical 
research is beyond the scope of this thesis, however Table 6.1 gives an 
overview of current imaging modalities considered of interest.  
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6.2. RESULTS AND DISCUSSION. 
Within this dissertation, in vivo PET and ex-vivo gamma 
counter were used to follow biodistribution of radionuclide labeled 
polymers. For fluorescently labeled systems, ex-vivo fluorescence 
imaging was applied. PET was used as imaging technique since it 
allows monitoring via positron emitter-labeled compounds and it has 
been demonstrated to be more sensitive than MRI or CT.239 However, 
high costs and the need for a cyclotron limit its use. Very briefly, the 
system detects pairs of gamma rays emitted indirectly by a positron-
emitting radionuclide (tracer), which is introduced into the body. As the 
radionuclide decays, positrons are annihilated by electrons, giving rise 
to gamma rays that are detected simultaneously. One of the most 
advantageous characteristic of PET is its capability to detect organ 
accumulation in a high accurate rate, regardless of tissue depth.240  
In this thesis, positron emitters 68Ga, 111In were incorporated 
into linear, hybrid di-block and star-shaped PGAs through 
complexation chemistry. In order to accomplish stable complexation of 
the metal radioisotope, the incorporation of chelating agents into the 
polymer backbone represented a prerequisite. The most commonly used 
chelating agents for 68Ga and 111In are based on polyamine carboxylic 
acids such as diethylene triamine pentaacetic acid (DTPA), 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), or 1,4,7-
triazacyclododecane-1,4,7-tetraacetic acid (NOTA). For the 
biodistribution of radiolabeled PGA-based architectures, DOTA 
derivative chelating agent with a free amine group suitable for 
conjugation (DO3A-NH2) was selected as forms stable complexes with 
several M2+ and M3+ ions such as 68Ga, 111In, and others. 
6.2.1. Technique validation. Linear non-targeted PGA labeling 
and in vivo evaluation using PET.  
In a first approach, in collaboration with Dr Inmaculada 
Conejos Sanchez, (shared research and also presented in her PhD 
thesis), in vivo biodistribution studies of linear homopolymer PGA (100 
GAU) was studied using PET as well as ex-vivo radioactivity 
measurement using a gamma counter. For that purpose, PGA-DO3A-
68Ga was first synthesized and in vivo evaluated. DO3AtBu-NH2 
derivative was used instead of DOTA for several reasons: a free amino 
group was desired for a straightforward conjugation to the PGA 
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backbone; the free COOH groups of DO3A-NH2 could interfere with 
further conjugations to the PGA chains; DO3A-NH2 forms stable 
complexes with the chosen radionuclides as well as DOTA; tBu 
protecting groups provide solubility in most organic solvents and the 
tert-butyl ester removal procedures do not need harsh conditions that 
could damage the polypeptide chain as well as further molecules 
included afterwards. Therefore, 9.8 mol% GAU of DO3A-tBu-NH2 was 
effectively conjugated via amide bond to a linear homopolymers 
PGA100 following the strategy depicted in the Scheme 6.1. Quantitative 
conjugation efficiency was achieved (since 10 mol% GAU was 
pursued) with a reasonable mass yield of 80 %. P Percentage of 
modification was calculated according to 1H-NMR analysis by 
comparing the corresponding integral of the α-protons of PGA (4.24 
ppm) with the 27 protons of tBu groups at 1.40 ppm (Figure 6.7).  
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Scheme 6.1. Synthetic route to PGA-DO3A (27a). 
 
Figure 6.7. 1H-NMR spectrum (D2O) of PGA-DO3A-tBu (26a). 
Removal of tBu groups was optimized in order to limit the 
exposure time in the acidic solutions of the synthesized architectures to 
avoid damage to the polymeric carriers as well as to the peptidic 
sequences for BBB targeting planned to be introduced afterwards. 
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Finally, 3 hours in a mixture TFA/H2O (95:5) lead to successful 
deprotections without compromising the integrity of the carriers. Figure 
6.8 shows the comparison between PGA-DO3A-tBu (26a) and PGA-
DO3A (27a) where the signal at 1.40 ppm corresponds to tBu groups. 
 
Figure 6.8. 1H-NMR spectra (D2O) of PGA-DO3A-tBu (26a) and 
PGA-DO3A (27a). 
68Ga labeling was performed at CIEMAT by our collaborators 
(Madrid) reaching radiochemical yields of 86.3 % ± 3.4 (n= 5), and 
radionuclide purity (RNP) was < 3.4∙10-4 ± 0.4∙10-4 in all cases. 
Animal experiments to test biodistribution and 
pharmacokinetics (PK) profile of PGA-DO3A-68Ga (28a) were carried 
out at the Unit of Biomedical Applications of Radioisotopes and 
Pharmacokinetics at CIEMAT (Madrid). PGA-DO3A-68Ga, (28a) was 
injected i.v. to FVB/NJ mice. Animals were monitored by PET only up 
to 3 hours due to 68Ga decay (Figure 6.9). Five mice per time point 
were sacrificed (corresponding to 0.25, 0.5, 1, 2 and 3 h) and different 
organs were extracted for radioactivity measurement ex vivo (Figure 
6.10). According to the results from biodistribution, a renal excretion 
profile (bladder and kidney signals) with no specific accumulation in 
any organ was obtained. This was further confirmed in the ex vivo 
analysis where the higher percentage of the injected dose (ID) 
corresponded to the kidneys.  
δ(ppm)
PGA-DO3A (27a)
PGA-DO3AtBu (26a)
7.5      7.0      6.5      6.0       5.5      5.0      4.5      4.0      3.5      3.0       2.5     2.0       1.5     1.0  
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Figure 6.9. PGA-DO3A-68Ga (28a) (50.1 µCi) PET images (Sagittal, 
coronal and transverse images) obtained 18 min after administration 
during 60 min acquisition (top) and 160 min after administration during 
40 min acquisition (bottom).  
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Representation of the % ID∙mL-1 in plasma was used to assess 
PK parameters (Figure 6.11). The best fit was obtained with a two-
compartmental model. From the parameters obtained, the half-life 
estimation of the conjugate was 0.59 hours.  
 
Figure 6.11. % ID∙mL-1 in serum against time of Linear PGA-DO3A-
68Ga (28a). 
6.2.2. First Generation. Linear PGA and DB PEG-PGA 
labeled and targeted polymers synthesis and in vivo evaluation by 
PET. 
6.2.2.1. Synthetic strategies to reach BBB-targeted linear 
PGA and DB PEG-PGA with peptidic residues. 
Within this first attempt to reach the BBB, two peptidic 
sequences widely recognized as potential candidates to achieve BBB 
active targeting have been chosen. These peptide sequences are the 
already mentioned ANG-2 and the iron-mimicking cPEP. As initial 
approach, both peptides were conjugated to linear PGA100 and hybrid 
di-block copolymer (DB) PEG42-PGA100 through a small linker 
previously introduced in the polymer side-chains (Scheme 6.2).  
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By post-polymerization modification techniques using 
DMTMM∙Cl as previously described in Chapter 4, reactive disulfides 
were easily introduced to allow conjugation of ANG-2 via disulfide 
bond. Cysteamine-2TP was used for that purpose achieving 7 and 10 
mol% of sulfhydryl pendant groups for PGA and DB respectively as 
calculated by 1H-NMR after purification by dialysis using Vivaspin® 
MWCO 3000 Da (Figure 6.12).  
Then, tBu groups were easily deprotected by using the already 
optimized conditions. In order to avoid disulfide bond breakages, TIPS 
(triisopropylsilane) was used at the ratio TFA:H2O:TIPS (95:2.5:2.5) 
during 3 hours reaching quantitative yields. It has to be mentioned, that 
basic conditions were also tried in order to avoid the exposure of the 
disulfide bridges to acids, however, these conditions did not lead to any 
successful results due to solubility issues.  
 
Figure 6.12. 1H-NMR (D2O) of PGA-DO3A-SS2TP (30a) as example 
after tBu deprotection, showing the peaks used for modification 
estimations (pyridine ring 8.4 ppm (CHaromat), 7.84 ppm (CHaromat), and 
7.28 ppm (CHaromat). 
After removal of the tBu protecting groups, ANG-2-SH was 
effectively conjugated via disulfide bonds. The final conjugate was 
purified by SEC using Sephadex commercial PD10 columns and 
functionalization was quantified by NanodropTM (λ= 280 nm) using the 
absorbance from the tryptophans encountered in the targeted conjugates 
(Figure 6.13).  
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a)                                                  b) 
 
Figure 6.13. Absorbance elugrams by NanodropTM of the fractions 
obtained by SEC (PD10 columns) of a) PGA-DO3A-ANG (31a) and b) 
DB-ANG (31b).  
Peptide loading was calculated according to 1H-NMR and 
further confirmed by amino acid (AA) analysis (Table 6.2), achieving 
95 and 90 % conjugation efficiency of ANG to PGA and DB 
respectively. It has to be mentioned that quantification by 1H-NMR was 
never easy due to complexity of the samples. In this case, the 
estimation was done according to the aromatic signals corresponding to 
the tyrosine (1) and phenylalanine (3) (Figure 6.14). For that reason, 
peptide content was always confirmed by AA analysis. 
 
Figure 6.14. 1H-NMR spectrum (D2O) of the polymer conjugate DB-
DO3A-ANG (31b) as example. The complex spectrum allow to 
estimate peptide content by using the 19 aromatic protons (3 
phenylalanines and 1 tyrosine). 
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Table 6.2. ANG conjugate characterization summary. 
Conjugate 
MW 
kDa 
mol% GAU 
wt% DO3A 
mol% 
GAU 
linker 
mol% GAU  
wt% ANG 
1H-NMR 
AA 
analysis 
PGA-DO3A-
ANG (31a) 
32.0 
10 mol% 
15 wt% 
7 
4.7 mol% 
36 wt% 
3.9 mol% 
32 wt% 
DB-DO3A-
ANG (31b) 
30.4 
11 mol% 
15 wt% 
10 
4.5 mol% 
32 wt.% 
3.5 mol% 
27 wt% 
Following the same strategy by using DMTMM∙Cl, N-Boc-
ethylendiamine was conjugated to the polymer backbone in order to 
introduce free amines for the conjugation of cPEP via amide bonding. 
After purification by dialysis, percentage of modification was 
calculated according to the 1H-NMR spectra signal at 1.37 ppm 
corresponding to the Boc group. 9 and 11 mol% GAU were obtained 
for PGA and DB respectively (conjugation efficiency of 90 % and 110 
%). Both, Boc and tBu groups were then easily deprotected in 
CH2Cl2/TFA (3:2). The purified polymers were then reacted with 
previously N-Hydroxysuccinimide (NHS) activated cPEP, in order to 
form a stable amide bond between the introduced amines and the C-
terminus activated acid of cPEP. NHS activation of cPEP was carried 
out with DCC and posterior addition of NHS as described in M&M. 
Percentage of NHS activation was determined as 100 %, estimated 
according to CH2 signal belonging to NHS ring at 2.6 ppm (Figure 
6.15). 
 
Figure 6.15. 1H-NMR spectrum (DMSO-d6) of NHS-cPEP (34). 
Once conjugated, cPEP content was estimated by 1H-NMR by 
integrating the broad signal at 0.88 corresponding to the isopropyl 
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group of valine and the two CH3 of the isoleucine present in the peptide 
sequence (Figure 6.16).  
 
Figure 6.16. 1H-NMR spectrum (D2O) of DB-DO3A-cPEP (35b) as 
example showing peptide content estimation.  
Table 6.3 summarizes the results obtained in the performed 
cPEP conjugations. 
Table 6.3. cPEP-derivatized conjugate characterization summary. 
Conjugate 
MW 
kDa 
mol% GAU 
wt% DO3A 
mol% 
GAU 
linker  
mol% GAU 
wt% cPEP 
1H-NMR 
AA 
analysis 
PGA-DO3A-
cPEP (35a) 
22.0 
2 mol% 
5 wt% 
9 
2.75 mol% 
12 wt% 
n.d. 
 
DB-DO3A-
cPEP (35b) 
24.6 
9 mol% 
19 wt% 
11 
3.4 mol% 
13 wt% 
2.8 mol% 
11 wt% 
6.2.2.2. In vivo evaluation of BBB targeted linear PGA and 
DB PEG-PGA conjugates. 
These four DO3A-bearing targeted systems based on PGA and 
PEG-PGA carriers were labeled with radionuclides (68Ga) and 
evaluated in preliminary in vivo experiments performed at CIEMAT by 
our collaborators. Two main purposes were pursued with this first 
attempt: on one hand, comparison between two different architectures 
(linear homopolymers PGA and hybrid di-block copolymer PEG-PGA); 
on the other hand the experiment was used to screen the best vector 
(targeting unit) to reach BBB among ANG-2 and iron mimicking cPEP, 
both conjugated within the polymers backbones. Thus, PGA- and DB-
DO3A-68Ga-ANG, and PGA and DB- DO3A-68Ga-cPEP were 
evaluated in FVB/NJ mice. A dose between 0.2-1.4 MBq of the DO3A-
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68Ga-labeled systems (21 ± 4 µg compound/g body weight was injected 
intravenously. Animals were monitored up to 3 hours by PET (again no 
longer times were used due to Ga decay), and one mouse was sacrificed 
per time point (0.5, 1, 2, 3 h) (Figures 6.17 to 6.20). As for PGA-
DO3A-68Ga, organs were extracted and radioactivity was measured 
(Figure 6.21). 
 
Figure 6.17. PGA-DO3A-68Ga-ANG (36a) (31.8 µCi). PET images 
(Sagittal, coronal and transverse images) obtained immediately after 
administration during 30 min acquisition time. 
 
Figure 6.18. PGA-DO3A68Ga-cPEP (37a) (25.5 µCi). PET images 
(Sagittal, coronal and transverse images) obtained immediately after 
administration during 30 min acquisition time. 
 
Figure 6.19. DB- DO3A68Ga-ANG (36b) (35.6 µCi). PET images 
(Sagittal, coronal and transverse images) obtained immediately after 
administration during 30 min acquisition time. 
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Figure 6.20. DB-DO3A68Ga-cPEP (37b) (36.2 µCi). PET images 
(Sagittal, coronal and transverse images) obtained immediately after 
administration during 30 min acquisition time. 
Although only one animal per time point was used as a first 
attempt in order to evaluate the targeting units, as expected, 
biodistribution studies confirmed renal excretion profiles for all the 
compounds as it can be observed from the intense signals in bladder 
and kidneys. Also, the graphs represented in Figure 6.21 corroborated 
this fact. Figure 21 shows the % ID normalized per gram of tissue of 
the 4 targeted systems in comparison with non-targeted PGA, after 
organ extraction and radioactivity measurements. Again, it has to be 
mentioned that only up to 3 hours after injection was evaluated due to 
the short half-life of 68Ga radioisotope (68 min). No major differences 
where observed if compared PGA and DB as nanocarriers. As a general 
trend, both ANG bearing systems show a greater % ID∙g-1 tissue in 
most of organs, including brain (the target organ of this study). The 
greatest accumulation in brain for ANG bearing systems was found at 
0.5 hours post injection. On the contrary, for cPEP labeled compounds 
the highest brain signal was found at 1 hour. Unfortunately, only a 
maximum of 0.02 % of the injected dose reached the brain, and the 
signals were not sustained on time as clearance was rapidly observed. 
This signal decrease could be explained by a possible pump-out of the 
conjugates from the brain by the strong efflux systems. Moreover, as no 
perfusion was carried out prior to organ extractions, the obtained brain 
signal could also correspond to the accumulation in the blood vessels 
surrounding the brain. The amount that reached the brain was under the 
expectations as in literature BBB crossing efficiency ranges from 1 %, 
to a maximum of 4 % ID. This fact could be attributed to system 
conformation in solution which could mask the peptide ligands 
avoiding their recognition by the specific receptors. As wt. % loading 
of cPEP was lower in both structures compared to ANG loading, from 
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this study, it was not easy to select one of the targeted moieties and 
both were used in further conjugate generation.  
 
Figure 6.21. Normalized data (injected dose (ID) per gram of tissue) 
for each organ extracted from biodistribution study comparing cPEP 
and ANG-2 targeted system. Non-targeted linear PGA was used as 
control. Time course experiment.  
[Chapter 6] 
325 
Summarizing, these first preliminary results let some hints in 
order to further move in BBB targeting goal: 
-Better exposure of the peptide sequences to their target 
receptors is a requisite to achieve greater brain accumulation. 
-Longer body residence time is needed in order to increase the 
chances of the polymeric systems to accumulate in the target organ.  
6.2.3. Second Generation Constructs. Development and in vivo 
evaluation. 
To overcome these previous limitations detected with the first 
pilot study, different synthetic strategies where proposed. First, the use 
of star-shaped polymers. Their presumably global structures let us to 
hypothesize that higher loading and greater exposure of the peptidic 
sequences would be achieved with these systems. Second, the use of a 
different synthetic pathway for the development of di-block copolymers 
by introducing the targeting units in a semi-telechelic approach. 
Although this latter approach would lead to a decrease in peptide 
loading (only one per polymer chain as maximum), a better could be 
achieved. 
Moreover, a different radionuclide was used in order to be able 
to explore longer time points post-administration. In this case, 111In was 
chosen due to the compatibility with the already designed synthetic 
strategies using DO3A as complexating agent (it also forms stable 
complexes). The higher half-life of 111In (2.08 days) allowed to better 
identify compounds half-life. Nevertheless, in vivo images could not be 
taken as SPECT instruments were not available for 111In. 
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6.2.3.1. Synthetic strategies towards targeted St-PGA and 
DB2 PGA-PEG radioactive probes. 
For the synthesis of star-shaped labeled polymers, exactly the 
same strategy as for their linear counterparts was followed as depicted 
in Scheme 6.2. We used a 3-arm star-shaped PGA initiated with 
ethylendiamine based initiator (see Chapter 3) with MW 16610 Da (110 
GAU), and Ð 1.23. One St-DO3A-68Ga labeled carrier as control (28c) 
and two different targeted carriers St-DO3A-68Ga-ANG (36c), St-
DO3A-68Ga-cPEP (37c), were synthesized and evaluated. The physico-
chemical characteristics of those polymers are summarized in Table 
6.4. 
The new hybrid di-blocks, PGA-PEG (DB2) were synthesized 
by introducing a PEG block through the N-terminus of the PBLG 
homopolymers after the polymerization process, as shown in Scheme 
6.3. 
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Reactions were carried out using a PBLG block of 92 GAU (Ð 
1.12), in HFIP at 40 °C during 72 hours. HFIP was chosen as solvent 
due to its well-known ability to open secondary structures in order to 
facilitate the accessibility of the free amine of the N-terminus of the 
benzyl protected polymer to the activated carboxylic acid on the PEG 
block. Three different di-blocks were synthesized: a DB2 as control 
(38a) using methoxyPEGNHS MW 3023 Da; a DB-Fmoc (38b), with 
protected amine moiety in order to conjugate cPEP in further steps 
using Fmoc-PEGNHS MW 4847 Da; and a DB-SS4TP (38c) with 
activated disulfide in order to conjugate ANG by steps using 4TPSS-
PEGNHS MW 3219 Da. PEG signal at 3.62 ppm in 1H-NMR in CDCl3 
was used in all cases to confirm DB2 synthesis. After di-block synthesis 
and purification, benzyl groups of PGA block were easily deprotected 
following the optimized basic conditions using NaOH/ THF mixtures 
(39). 
DO3A groups were introduced later on by post-polymerization 
modification techniques using DMTMM∙Cl (Scheme 6.4). DO3A 
content of the polymers was determined as 16 mol% GAU in all cases 
according to NMR (conjugation efficiency of 80 %). In the case of 
DB2-DO3A and DB2-DO3A-ANG synthesis, the tBu groups where 
deprotected in the following step using the mixture TFA:TIPS:H2O 
(95:2.5:2.5). For DB2-DO3A-cPEP, the peptide conjugation was prior 
to tBu groups deprotection. Similar peptide conjugation and 
characterization approaches as those previously described were 
followed. Conjugate details are summarized in Table 6.4.  
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At the moment, DB2 conjugates are under evaluation at 
CIEMAT. The following results correspond to the evaluation of star-
shaped family. 
As for 68Ga, radioisotope labeling was carried out in CIEMAT 
using a similar procedure (see M&M). The radio-labeled solution was 
purified by size exclusion chromatography (SEC) (Figure 6.22). 
 
Figure 6.22. % Activity measured after 111In labeling and purification 
by SEC of St-DO3A as example. 
6.2.3.2. In vivo evaluation of non-targeted St-PGA. 
Biodistribution and pharmacokinetics (PK) comparison with linear 
PGA. 
For biodistribution and PK studies, 88 FVJ/B mice (4-5 per 
time point) were anesthetized with isofluorane and doses between 37 
KBq and 2.5 MBq 111In-eq of the three star constructs were injected i.v. 
(1-20 µg∙g-1 body weight). Then, 4-5 mice were sacrificed per time 
point (0.5, 1, 2, 4, 8 and 24 h). As for 68Ga labeled polymers, blood and 
organs were extracted and radioactivity was measured using a gamma 
counter.  
Biodistribution of linear PGA was previously performed using 
68Ga radioisotope, therefore, only short times (up to 3 hours) could be 
recorded due to radionuclide decay (about 68 min for 68Ga). If short 
time points (0.5, 1 and 2 hours) of the % ID∙g-1 tissue of PGA-DO3A-
68Ga (28a) and St-DO3A-111In (28c) are studied, a general greater 
accumulation in all organs with the star shaped polymer was observed, 
when compared with the linear counterpart. (Figure 6.24). 
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Figure 6.24. Radioactivity normalized data for each organ in respect to 
the % injected dose (% ID) per gram of tissue, of St-PGA compared 
with its linear counterpart. Time course experiment. n> 4, mean ± SEM. 
Representation of the % of ID∙mL-1 in plasma was also used to 
assess PK parameters. The best fit was obtained with a two-
compartmental model. The two-compartment model is more complex 
and takes into account the existence of a gap in the body distribution 
after i.v. administration of a single dose (Figure 6.25). This model 
considers the body as two interconnected compartments, one known as 
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central compartment (where the compound rapidly access), and the 
peripheral compartment, with greater accessibility constrains, precisely 
comes through the first one. Since clearance occurs mainly from the 
central compartment, the drug distributed in the peripheral 
compartment must return to the center for this phenomenon to occur. 
Most drugs are adapted to a two compartment model, since the one 
compartment model is too simple considering only one compartment, 
and assuming that the drug administered is rapidly and uniformly 
distribute through the whole organism (Figure 6.25). 
a)                                               b) 
 
Figure 6.25. Schematic representation of the two models for 
pharmacokinetics estimations. a) One compartment, where Ka: 
absorption constant and Kc clearance constant, t b) Two-compartments, 
where PC: peripheral compartment, CC: central compartment, K1,2: 
distribution constant to the PC K2,1: return constant from the PC. 
After a proper adjustment using the mathematical expression of 
the two-compartments model (Equation 6.1), pharmacokinetic 
parameters of both compounds were extracted, and compared as shown 
in Table 6.5. In general basis α mainly depends on the compound 
distribution (from central to peripheral compartments) and β mainly 
depends on compounds clearance where α+β = K1,2 +Kc + K2,1. 
ܥ(ݐ) = ܣ. ݁ିఈ௧ + ܤ. ݁ିఉ௧ 
Equation 6.1. Mathematical expression of the fit to two compartments 
model. α and β are two constants that depend solely on the constants of 
transference among both compartment (K1,2 and K2,1).  
Although the plasmatic profiles were similar for both 
compounds, differences could be drawn PK parameters obtained for 
PGA-DO3A-68Ga (28a) with St-DO3A-111In (28c) were compared. 
Their biological or terminal half-life estimated as Ln2/β, resulted to be 
13 times greater for the star polymer, this fact could be in part 
attributed to the use of different radionuclides for the study. The use of 
111Indium allowed to study and estimate PK parameters of the stars 
A B
Dose Dose
Ka Kc
PC
CC
K1,2
KcKa
K2,1
a b
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providing more reliable results due to the higher semidesintegration 
period for 111In (2.1 days) compared to 68Ga (68 min). 
Table 6.5. Pharmacokinetic parameters of PGA and Star-shaped PGA. 
 
St-DO3A-111In (28c) PGA-DO3A-68Ga (28a) 
Parameter Value Std E 
CV 
(%) 
Value Std E 
CV 
(%) 
α (h-1) 4.74 0.42 8.93 7.28 2.57 35.37 
β (h-1) 0.06 0.04 66.11 1.18 0.59 50.08 
AUC (%ID∙h∙mL-1) 5.45 0.76 13.90 8.50 0.67 7.90 
t1/2β (h) 12.05 7.96 66.04 0.59 0.29 50.03 
Ke (h-1) 4.11 0.53 12.82 4.63 1.50 32.40 
K12 (h-1) 0.62 0.27 43.35 1.98 0.71 35.89 
K21 (h-1) 0.07 0.04 60.26 1.85 0.98 52.78 
Cmax (%ID∙mL-1) 22.37 5.14 22.96 39.35 15.5 39.52 
Cl (mL∙h-1) 18.35 2.55 13.88 11.77 0.92 7.86 
Vss (mL) 46.34 44.45 95.91 5.25 2.53 48.16 
*Value: Estimate, Std E: Standard Error. 
In any biologic system, the loss of a radiolabeled compound is 
due to both physical decay of the radionuclide, and the biological 
elimination of the radiolabeled compound. The net or effective half-life, 
time required for the radioactivity in an organism to be reduced to half 
through the combined effects of the physical decay of the isotope and 
the biological elimination of the isotope could be calculated by 
Equation 6.2: 
1
൫ݐଵ/ଶ൯௘௙௙௘௖௧௜௩௘
=
1
൫ݐଵ/ଶ൯௣௛௬௦௜௖௔௟
+  
1
൫ݐଵ/ଶ൯௕௜௢௟௢௚௜௖௔௟
 
Equation 6.2. Effective half-life estimation. 
As the effective terminal half-life was 12.05±7.96 hours and 
0.59±0.29 hours for star and linear PGA, respectively, the biological 
terminal half-life was then 15.87±9.47 hours and 1.23±0.40 hours for 
both compounds, respectively.  
 In the case of the two compartment model a number of volume 
terms can be also defined. Vss, the appropriate volume of distribution 
when plasma concentrations are measured in steady state conditions, is 
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the most useful Vd. This Vss value was about 9 times higher for the star 
polymer compared to the linear one, meaning a greater distribution of 
the carrier.  
The Clearance value (Cl) from the central compartment, 
estimated as the ratio of dose/AUC (area under the plasma 
concentration-time curve), was also slightly higher for the star-shaped 
polymer (18.35 vs. 11.77 mL∙h-1 for linear PGA). The renal clearance 
value of inulin (a model compound that is excreted only by glomerular 
filtration) has been established to be around 20 mL∙h-1 in FVB mice.241 
This value is really close to the value obtained for the star polymer. 
Thus it could be claimed that the polymer was cleared out only by 
glomerular filtration. In the case of linear PGA, the value was slightly 
smaller. This could be explained by a possible binding to plasma 
proteins, reducing the glomerular filtration, or by tubular reabsorption.  
6.2.3.3. In vivo evaluation of BBB targeted St-PGA. 
Biodistribution and pharmacokinetics. 
Targeted star polymers bearing ANG (36c) and cPEP (37c) 
were also evaluated. The % ID per gram of tissue at different time 
points, of the two targeted polymers in comparison with the non-
targeted star-shaped carrier is represented in Figure 6.26. According to 
the graphs, it can be observed that the majority of the ID for all 
compounds was found in the kidneys (around 40-60 % in peptide 
bearing compounds, and 20-40 % for the star control), confirming a 
renal excretion profile. This was in good agreement with the MW of the 
compounds, below 60000 Da (cut-off of the renal glomeruli). Liver 
showed around 1-2 % ID for the targeted compounds, and 3-4 % for the 
non-targeted star. The % ID in the rest of the organs was very low 
including the brain, where does not reach 0.05 %. 
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Figure 6.26. Radioactivity normalized data for each organ in respect to 
the % injected dose (% ID) per gram of tissue for St-PGA compared 
with its targeted counterparts. Time course experiment. Error bars are 
not included for clarity reasons. n> 5, mean ± SEM. 
PK parameters were calculated as described before for linear 
PGAs by using the representation of the % ID∙mL-1 in serum over time. 
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As for the previous compounds, PK corresponds to a two-compartment 
model for the three star systems (Figure 6.27). 
        a) Non-targeted (28c) 
 
         b) With ANG (36c)                              c) With cPEP (37c) 
 
Figure 6.27. Two-compartment model fittings (PK) of % ID∙mL-1 in 
serum with time of star-shaped PGAs targeted (b and c) and non-
targeted (a). n> 5, mean ± SEM. 
Selected PK parameters are summarized in Table 6.6. As it can 
be observed, half-life in plasma was found to be between 12-16 hours 
in all the cases. Always higher than that obtained with linear PGA. Vss 
of the targeted stars (171.4 mL for cPEP and 177.8 mL for ANG) is 
much higher than the one of the non-targeted star (46.34 mL). This is 
indicative of a significantly higher distribution of the targeted stars in 
the body. 
As explained before, from the clearance value of the inulin we 
could state that the non-targeted star carrier (Cl: 18.35 mL∙h-1) was 
excreted by glomerular filtration. In the case of the peptide bearing 
stars, this clearance values are slightly higher (31.65 and 33.39 mL∙h-1 
for cPEP and ANG respectively). Therefore, other mechanisms of renal 
excretion (i.e. tubular secretion) could be present in the kidneys in this 
case.  
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Table 6.6. Pharmacokinetic parameters of St-DO3A-111In-cPEP (37c) 
and St-DO3A-111In-ANG (36c). 
 
St-DO3A-111In-cPEP St-DO3A-111In-ANG 
Parameter Value Std E 
CV 
(%) 
Value Std E 
CV 
(%) 
α (h-1) 2.30 0.25 11.1 1.73 0.12 6.65 
β (h-1) 0.04 0.05 123.75 0.06 0.03 47.74 
AUC (%ID∙h∙mL-1) 3.16 0.63 19.93 3.00 0.27 9.03 
t1/2β (h) 15.79 19.52 123.63 12.08 5.76 47.7 
Ke (h-1) 1.79 0.42 23.63 1.26 0.14 11.17 
K12 (h-1) 0.49 0.34 69.51 0.45 0.11 24.59 
K21 (h-1) 0.06 0.06 107.1 0.08 0.03 41.42 
Cmax (%ID∙mL-1) 5.67 0.96 16.87 3.77 0.31 8.18 
Cl (mL∙h-1) 31.65 6.31 19.93 33.39 3.01 9.03 
Vss (mL) 171.30 265.10 154.69 177.84 93.01 52.3 
6.2.4. Third Generation Constructs. Development and in vivo 
evaluation by optical imaging. 
6.2.4.1. Synthetic route to reach dually labeled and targeted 
systems through bottom-up approach of self-assembled polymers. 
The constructs synthesized through bottom-up approach via 
covalent capture of self-assembled polypeptides obtained by controlled 
NCA polymerization and adequate post-polymerization modifications 
were in vivo evaluated in terms of biodistribution and pharmacokinetics 
of targeted and non-targeted constructs. From the results obtained in the 
biodistribution study with star shaped polymers, only ANG-2 
derivatives will be evaluated for BBB crossing, as a first approach. For 
that, cross-linked polymers through CuAAC were dually labeled with 
DO3A-Gd3+ and Cy5.5 for MRI and optical imaging techniques, 
respectively in order to have a dual probe with a view to future 
biomedical applications. Moreover, ANG was easily introduced 
following the same strategy described in Section 6.2.2.1. 
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Briefly, PGA-based systems with self-assembly triggering 
motifs of 150 GAU were modified by post-polymerization techniques 
with propargylamine units (11 mol%), and NH2EG(2)N3 units (7 
mol%), respectively. Those polymers were mixed to allow self-
assembly at 2 mg∙mL-1 in ddH2O and covalent capture through CuAAC 
as described in Chapter 5. After an adequate characterization to achieve 
compound identity by 1H-NMR (triazole peak at 7.8 ppm) and DLS 
measurements, the clicked polymer was used in further labeling 
strategies. DMTMM∙Cl was employed in order to activate the 
carboxylic acids to allow the introduction of DO3AtBu-NH2 in the first 
place, followed by Cy5.5 in the synthesis of the non-targeted system. 
DO3A modified units were quantified as described for the synthesis of 
radiolabeled polymers by 1H-NMR. On the other hand, Cy5.5 content 
estimation was carried out by fluorescence (prior calibration curve of 
Cy5.5 dye in PBS buffer was obtained (Figure 6.29)).  
 
Figure 6.29. Cy5.5 calibration curve in PBS at pH 7.4. 
For the non-targeted construct, tBu proctecting groups from 
DO3A were easily removed at this point, using the mixture 
TFA:TIPS:H2O (95:2.5:2.5). In the case of the targeted polymer, 
cysteamine-2TP units were introduced again by post-polymerization 
modification in aqueous media prior to the introduction of Cy5.5. 
Quantification was determined as 10 mol% of GAU by 1H-NMR. Then, 
the tBu protecting groups from DO3A were removed, and ANG was 
conjugated following previous strategies by means of disulfide 
bonding. Finally, Gd3+ was complexed to DO3A bearing constructs 
using 1:1 eq. (DO3A:GdCl3) ratio. The reaction took place in PBS 0.1 
M at pH 8 (GdCl3 precipitation was observed at lower pHs) and 
monitored by titration using 4-(2-pyridylazo)resorcinol. This titrating 
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agent turns from yellow to orange in the presence of free Gd3+. After 5 
hours reaction time, no free Gd3+ was detected. The reaction was 
purified by dialysis and absence of free Gd3+ was again tested. 
Conjugates physico-chemical characteristics are summarized in Table 
6.7. 
Table 6.7. Conjugate physico-chemical characteristics for in vivo 
biodistribution by fluorescence. 
Compound 
mol% GAU 
wt% DO3A 
wt% 
Gd 
mol% 
GAU/ wt% 
Cy5.5 
mol% GAU/ 
wt% ANG 
X-Click-DO3A-Gd-
Cy5.5 (45) 
10.0 mol%  
20.3 wt% 
12.0 
0.5 mol%  
3.1 wt% 
- 
X-Click-DO3A-Gd-
Cy5.5-ANG (50) 
10 mol%  
17.6 wt% 
10.4 
0.5 mol% 
2.7 wt% 
1.5 mol% 
13.8 wt% 
The Z-potential of the clicked architectures before, and after 
surface modifications was recorded in ddH2O at 20 °C and the results 
are depicted in Figure 6.30. As it can be observed, surface 
modifications with DO3A-tBu (26e) and cysteamine-2TP (46), 
significantly decrease de negative Z-potential obtained for the clicked 
structure with all the carboxylic groups unmodified and presumably 
exposed at the surface (25a).  
 
Figure 6.30. Z-potential obtained at 20 °C from clicked structures at 1 
mg∙mL-1 in ddH2O, before and after the subsequent surface 
modifications. 
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The introduction of the negatively charged Cy5.5 within the 
structure resulted in an increase on Z-potential obtained (47). Finally, 
when ANG-2 peptidic sequences where conjugated (49), Z-potential 
dramatically decrease to almost neutral, probably due to a shielding 
effect provided by the 19 aa sequences. 
Furthermore, size of the systems was estimated by TEM to be 
in the range of 70-100 nm diameter (Figure 6.31). 
 
Figure 6.31. TEM micrographs of a) X-Click-DO3A-Gd-Cy5.5 (45), 
and b) X-Click-DO3A-Gd-Cy5.5-ANG (50). 
In order to compare the results obtained from fluorescence 
techniques with PET, a new construct based on X-Click systems was 
also synthesized following the procedures already described through 
this chapter. In this case, X-Click PGA was successively modified with 
DO3A, cysteamine-2TP, and ANG peptide. Conjugate characteristics 
are shown in Table 6.8. This construct is still under evaluation in 
CIEMAT, however a good correlation with the results already obtained 
is expected. 
Table 6.8. X-Click-DO3A-ANG (31d) conjugate physico-chemical 
details. 
Conjugate 
mol% GAU 
wt% DO3A 
mol% GAU 
linker 
mol% GAU 
wt% pepa 
X-Click-DO3A-
ANG (31d) 
30 mol%  
35.3 wt% 
20 
2.75 mol% 
1 6.5 wt% 
a: Data obtained by 1H-NMR 
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6.2.4.2. In vivo evaluation of BBB targeted clicked systems 
by optical imaging. 
Once synthesized and characterized, these complex 
architectures were evaluated in vivo. Biodistribution experiments were 
carried out using C57Bl/6 mice and fluorescence techniques taking 
profit from Cy5.5 dye on the polymeric carriers. Targeted and non-
targeted architectures were administered i.v. through the tail vein to 
isofluorane anesthetized mice, at a dose of 4.15 mg∙Kg-1 Cy5.5 eq. Two 
animals were then sacrificed at different time points (1, 3, 7, 14 and 24 
hours). Prior to sacrificed, mice were first anesthetized with a lethal 
anesthesia cocktail, blood was extracted from the cava vein, and 
perfusion with saline was carried out in order to accurately determine 
the amount of compound in the brain. Then, organs were extracted and 
their fluorescence was measured using the red filter in MAESTRO™. 
For fluorescence quantification, normalized data was obtained by 
taking always the same pixel area for all organs expressed as average 
signal (counts∙s-1). A calibration curve of the compounds in the same 
MAESTRO™ was carried out in order to estimate the fluorescence 
corresponding to the injected dose. Biodistribution data obtained from 
non-targeted and targeted polymer is depicted in Figures 6.32 - 6.34. 
When both compounds were compared, no major differences in 
biodistribution were encountered as it can be observed in Figure 6.33. 
Renal excretion profiles could be observed in both cases. However, the 
targeted compound was found to accumulate in a higher extend in 
organs such as liver and kidney. Notably, when the biodistribution data 
from these bigger architectures was compared with that from the non-
clicked stars (Figure 6.26), a greater accumulation in the lungs at early 
time points was observed. This fact was in good agreement with the 
nature of the architectures used, since sizes above 100 nm tend to 
accumulate in lungs. Hence, this family of architectures could have a 
potential use in order to target lung diseases such as lung cancer. 
Nevertheless, these carriers also demonstrated to be safe as not weight 
loss in the animals was observed (see further details in Chapter 7). 
Besides, lung accumulation was significantly diminished over time, 
validating them as possible carriers. 
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Important to note, the ANG bearing compound offered greater 
brain accumulation at early time points when compared to the non-
targeted counterpart. Nonetheless, similar accumulation was found for 
both compounds at late time points such as 24 hours. Remarkably, the 
amount found in the brain in both cases was between 1-1.5 % ID, which 
is 20-30 times greater than the one obtained for non-clicked stars (0.05 
% ID). As mentioned before and according to literature, the normal % 
ID for those systems who are able to reach the brain is usually between 
1-2 % ID, with the maximum obtained with 4 %.242 
 
Figure 6.33. Biodistribution by optical imaging at different time points 
of targeted and non-targeted clicked architectures. Time course 
experiment. Error bars are not included for clarity reasons. 
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a) 
 
b) 
 
Figure 6.34. Organ fluorescence images obtained at MAESTRO™ 
from a) non-targeted, b) targeted clicked compounds. 
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6.3. CONCLUSIONS. 
The BBB represents a huge challenge for the transport of 
bioactive compounds to the brain. Herein, we aimed to overcome such 
limitation for the treatment of the vast majority of neurodegenerative 
diseases. To achieve that, and after being evaluated in vitro, different 
polymeric carriers with increasing complexity (linear, di-block 
copolymer, stars and PGA-based clicked systems) were purposed as 
candidates for BBB crossing. Firstly, their in vivo biocompatibility, 
safety, non-specific accumulation in any organ, and adequate excretion 
profile were evaluated, confirming their suitability as nanovectors after 
targeting moieties conjugation. Secondly, the biodistribution of targeted 
polymeric derivatives (with peptidic targeting ligands Angiopep2205, 211 
and the iron mimicking cyclic peptide171) were studied paying particular 
attention to brain accumulation in order to validate them as possible 
carriers through BBB.  
Different imaging techniques were used (PET and fluorescence 
optical imaging), being PET the most adequate for brain detection due 
to its sensitivity as the % ID able to cross BBB is usually very low (< 
4% ID). 
Non-targeted polymeric constructs from linear homopolymers, 
DBs PEG-PGA or simple stars did not crossed the BBB. When targeted 
systems were explored, preliminary data with ANG bearing carriers 
showed greater % ID in the brain than cPEP. Star derivatives seemed to 
perform better than the linear counterparts although brain concentration 
was not maintain in any case. DB systems gave in all cases lower 
percentages probably due to conformational issues, where PEG blocks 
could presumably form an outer shell hiding the peptide molecules 
attached in the polypeptide block.  
These preliminary results pointed out the need for new 
architectures with higher MW (to increase blood residence time in 
order to promote higher brain accumulation), and capable to better 
expose the peptide ligands to the corresponding receptors. Therefore, a 
more complex 3er generation systems by means of ANG-clicked 
structures was selected. Such constructs, after adequate labeling and 
ANG conjugation, were evaluated using fluorescence imaging 
techniques and presented a much greater accumulation in brain (up to 
1.5 % ID). Those results encourage us in the use of the clicked 
nanovectors for neurodegenerative applications. Moreover, taking into 
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account that data was obtained with fluorescence imaging, which 
usually provides underestimated values, further studies using PET are 
currently being conducted to elucidate brain accumulation of those 
structures in a more realistic way. 
6.4. MATERIALS AND METHODS. 
6.4.1. Materials. 
All chemicals were reagent grade, obtained from Aldrich and 
used without further purification, unless otherwise indicated. All 
solvents were of analytical grade and were dried and freshly distilled. 
Deuterated chloroform-d1, DMSO-d6, and D2O were purchased from 
Deutero GmbH. PGA-based architectures: PGA, St-PGA, DB PEG-
PGA X-Click, were synthesized according to protocols described in 
Chapters 2, 3, 4 and 5. DO3AtBu was purchased from Chematec. Cy5.5 
(6S-IDCC) was obtained from Mivenion. Angiopep2-cystein Ac-
FFYGGSRGKRNNFKTEEYC and the iron mimicking cPEP Ac-
CRTIGPSVC (disulfide bridge) sequences were obtained from Selleck 
Chemicals LLC. Preparative SEC was performed using Sephadex G-25 
superfine from GE as well as PD MiniTrap G-10 ™ columns 
contenting 2.1 mL of Sephadex™ G-10. Dialysis was performed in a 
Millipore ultrafiltration device fitted with a 3, or 5 kDa MWCO 
regenerated cellulose membrane (Vivaspin®). 
Animals. FVB/NJ albino mice (CIEMAT Laboratory Animals 
Facility, Madrid) were housed on a 12-hour light and 12-hour dark 
cycle with free access to food and water. All animal protocols were 
approved by the Institutional Animal Care and Use Committee at 
CIEMAT (Madrid). 
C57Bl/6 mice (Animal Imaging Center, Zurich, Switzerland) 
were kept at standard housing conditions: light/dark cycle of 12 hours, 
temperature of 20-24 °C, relative humidity minimum 40 %, with free 
access to food and water. All experiments were performed in 
accordance with the Swiss Federal Act on Animal Protection. 
6.4.2. Characterization techniques. 
6.4.2.1. NanodropTM. 
The collected fractions from ANG purifications through 
Sephadex G25 pre-packed commercial columns (PD10), were analyzed 
by UV-VIS recording the absorbance at 280 nm from each eluted 
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sample. For that, 2 µL of each fraction were placed in NanodropTM ND-
1000 UV-Vis Spectrophotometer and the absorbance at 280 nm was 
measured. Data was plotted in order to be able to identify those desired 
fractions containing only the polymeric conjugate. 
6.4.2.2. MaestroTM 
Ex vivo Near-infrared imaging; 2D-in vivo imaging was 
performed using Maestro 500 imaging system (Cambridge Research 
Inc, Woburn, USA). For Cy5.5 measurements, a band pass filter from 
615 nm-665 nm and a highpass filter over 690 nm were used for 
excitation and emission light, respectively. The fluorescence was 
detected by a CCD camera. A series of images was acquired at different 
wavelengths and then subjected to spectral un-mixing as described by 
Gao et al.243 This enabled the un-mixing of the Alexa680 fluorescence 
pattern from tissue autofluorescence. 
6.4.3. Protocols. 
6.4.3.1. Radionuclide labeling. 
In order to introduce radionuclides within the polymer 
backbone of the different architectures, modification of those with 
groups serving as complexating agents for radionuclides is a 
prerequisite. Within this thesis dissertation, DO3A-NH2 was chosen. 
The synthetic strategy for the DO3A is depicted in Scheme 6.1. 
6.4.3.1.1. Conjugation of DO3AtBu-NH2 for radionuclide 
complexation. 
Due to the good solubility either in aqueous or organic solvents 
of DO3AtBu-NH2, conjugations were possible in both media. For linear 
and star PGA in carboxylic acid forms, conjugations were carried out in 
organic solvents (DMF) by using the standard DIC/HOBt protocol. In 
the case of DBs PEG-PGA or PGA-PEG and clicked structures as 
sodium salt forms (either due to the purification steps done before or to 
incompatibility of acid precipitation methods to obtain the acidic 
forms), the conjugations were done in aqueous media using the 
previously described DMTMM∙Cl protocol of post-polymerization 
modification (Chapter 4). 
Briefly, for acid forms of PGAs: 
In a two-neck round bottom flask fitted with a stir bar and two 
septums, 300 mg (of PGA, 2.32 mmol GAU, 1 eq.) was dissolved in 20 
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mL of anh. DMF under nitrogen flow. Then, 53 μL of DIC (44 mg, 
0.35 mmol, 0.15 eq.) were added and reaction was left to proceed for 5 
minutes at r.t. Afterwards, HOBt (47 mg, 0.35 mmol, 0.15 eq.) was 
added directly. Reaction was then left to proceed for 10 minutes before 
DO3AtBu-NH2 (141 mg, 0.23 mmol, 0.1 eq.) was added for 10 % 
modification. *Note: amounts of carboxylic acid activators and 
DOTAtBu-NH2 vary depending on the desired percentage of 
modification. The pH was adjusted to 8 by adding ~100 μL of DIEA. 
The mixture was left stirring for 48 hours at r.t. and protected from 
light. Finally, solvent was partially removed under vacuo, precipitated 
into a large excess of cold acetone, filtered off and washed three times 
with cold acetone. A pale yellow solid was obtained after drying. The 
percentage of modified GAU was calculated according to the tBu 
groups’ signal at 1.4 ppm in comparison with the alpha proton of PGA 
backbones in 1H-NMR spectra  
For sodium salt forms: 
In a one-neck round bottom flask, 0.72 mmol GAU of PGA-
based structure (PEG-PGA, PGA-PEG or X-Click) was dissolved in 5 
mL ddH2O. DMTMM∙Cl (i.e. 0.144 mmol for 20 % modification) was 
then added, in another 2 mL of ddH2O, to the reaction mixture and left 
stirring for 10 minutes. After that, DO3AtBu-NH2 (i.e. 0.144 mmol for 
20 % modification) was added in 3 mL more of ddH2O. pH of the 
reaction mixture was adjusted to 8 by adding sodium bicarbonate 1 M. 
The contents were left stirring for 24 hours at r.t. After that time, the 
products were purified via dialysis using Vivaspin® MWCO 3000. Pale 
yellow solids were obtained after freeze drying. Percentage of 
DO3AtBu-NH2 introduced was estimated by 1H-NMR according to the 
signal at 1.41 ppm corresponding to tBu groups. Yields: 70-90 %. 
Conjugation efficiency: 70-80 %. 
6.4.3.1.2. Deprotection of DO3A tBu-NH2. 
For radionuclide complexation, the protecting tBu groups from 
carbonyl moieties must be previously removed. Two different protocols 
were used depending on the compound nature. For constructs without 
any sensitive group to TFA conditions, the first protocol was applied. 
The use of TIPS in the second protocol was introduced in order to 
prevent disulfide bonds breakage during deprotection conditions. Thus, 
Protocol 1. The construct was dissolved in CH2Cl2/TFA (3/2, 
v/v) mixture and left under vigorous stirring for 16 hours at r.t. After 
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that time, the solution was precipitated by pouring into a large excess of 
cold diethyl ether. Pale yellow solid was obtained after filtering, 
washing with diethyl ether and drying under vacuum. Complete 
deprotection was achieved as confirmed by 1H-NMR. Yields: 80-90 %.  
Protocol 2. The construct was dissolved in TFA/H2O/TIPS 
(95/2.5/2.5, v/v) mixture and left stirring at r.t. during 3 hours. After 
that, the contents were precipitated into a large excess of cold diethyl 
ether. A pale yellow solid was collected, washed with diethyl ether and 
dried over vacuum. Complete deprotection was confirmed by 1H-NMR 
analysis. Yields: 80-90 % 
6.4.3.1.3. 68Ga and 111In complexation. 
As a first step, 68Ga and 111In radionuclides on each case from 
commercial solutions, were eluted, purified and concentrated. 
Afterwards, the obtained radionuclide was transferred into a microwave 
tube and the pH was adjusted to 3.5-4 by adding HEPES buffer and 
HCl 2 M (to avoid 68Ga hydroxylation during complexation). 
Immediately after, the DO3A labeled system was added in 500 μL of 
aqueous solution 10 mg∙mL-1. The reaction mixture was heated at 90 °C 
for 5 minutes by using a laboratory microwave with monomodal 
radiation (Discover Benchmate, CEM). The reaction was stopped after 
5 min at r.t. by the addition of 50 μL of 50 mM EDTA. Then, 
purification was performed with molecular exclusion chromatography 
cardtrige (Bio Gel P-6 Biorad) using PBS pH 7 as eluent. The elution 
profile was determined by fractionating, 0.77 mL per fraction, and 
measuring each with a dose calibrator (VDC 405, Veenstra). 
Radiochemical yield (RY) was calculated as percentage of the activity 
in each fraction eluted from the molecular exclusion cartridge of the 
total activity purified and corrected for the decay.  
6.4.3.2. Fluorescence labeling with Cy5.5. 
For Cy5.5 labeling, the protocol described in Chapter 4 based 
on the post-polymerization modification using DMTMM∙Cl in aqueous 
solutions was applied. Briefly, in a one-neck round bottom flask, PGA-
based polymer was dissolved in ddH2O (1 eq. GAU). Then, the 
carboxylic groups were activated using DMTMM∙Cl (i.e. 0.02 eq. for 2 
% modification). Reaction was allowed to proceed for 10 minutes. 
After that time, Cy5.5 (i.e. 0.02 eq. for 2 % modification) was added in 
ddH2O. The pH was adjusted to 8 by adding sodium bicarbonate 1 M. 
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Reaction was left to proceed for 24 hours, protected from light. For 
purification, the products were submitted to both Sephadex G25 and 
dialysis using Vivaspin® MWCO 5000. 
Cy5.5 content estimation was carried out by fluorescence (λem: 
595 nm, λex: 680 nm) after the building of an appropriate calibration 
curve of Cy5.5 dye in PBS buffer.  
Yields: 60-70 %. Conjugation efficiency 70-90 %. 
6.4.3.3. DO3A-Gd3+ labeling for MRI. 
In a one-neck round bottom flask, the corresponding DO3A 
bearing polymer as sodium salt form (1 eq. of modified DO3A GAU 
units) was dissolved in PBS 0.1 M pH 7.4. Then, GdCl3 (1 eq.) 
dissolved in ddH2O was dropped into the main solution. During this 
process, pH was monitored and remained constant to 8. The degree of 
Gd (III) complexation was determined by titrating aliquots during 
reaction process using 4-(2-pyridylazo) resorcinol which turns from 
yellow to orange in the presence of free Gd). No free Gd was detected 
after 5 hours reaction time. The reaction was then stopped and purified 
by dialysis using Vivaspin® MWCO 5000. Absence of free Gd was 
again confirmed by using the titrating method described before with the 
dialyzed contents. 
6.4.3.4. Second Generation DB PGA-PEG synthesis. 
The synthetic route to reach DB PGA-PEG (DB2) is depicted 
in Scheme 6.3.  
6.4.3.4.1. PBLG-PEG di-block synthesis. 
The new hybrid di-blocks, PGA-PEG (DB2) where synthesized 
by introducing a PEG block through N-terminus of PBLG 
homopolymers after the polymerization process. Briefly, PBLG block 
(100 mg, 0.005 mmol, 1 eq., 20200 g∙mol-1 Ð 1.12), was dissolved in 
10 mL of HFIP. The contents were heated up to 40 °C. Then, 1.3 eq. of 
corresponding PEG block (19.5 mg methoxyPEGNHS MW 3023 for 
DB2 control; 31.2 mg of FMOCPEGNHS MW 4847 for NH2 
functionalized DB2; or 20.7 mg of 4TPSS-PEGNHS MW 3219, for SS 
functionalized DB2), were added dissolved in 2 mL more of HFIP. 
Reaction mixture was allowed to proceed for 72 hours at 40 °C. Then, 
the products were purified by concentration and precipitation into a 
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large excess of diethyl ether. After drying, PEG signal at 3.62 ppm in 
1H-NMR in CDCl3 was used in all cases to confirm DB2 synthesis.  
6.4.3.4.2. Benzyl removal from PBLG-PEG. 
Benzyl groups of PBLG block were easily deprotected 
following the optimized basic conditions with NaOH/ THF mixtures in 
M&M from Chapter 2. Products were obtained as white powders after 
lyophillization. Complete deprotection and PEG integrity was 
confirmed by 1H-NMR in D2O. 
6.4.3.5. Peptide sequences conjugation. 
Two different strategies for peptide sequences conjugation were 
performed: on one hand, conjugation of the targeting groups into the 
polymer backbone, through a previously introduced linker for 
orthogonal bioconjugations (for linear, star, X-Click and DB PGAs); on 
the other hand, in the case of DB2, a semitelechelic conjugation at the 
end of the end-functionalized PEG block. Both strategies will be 
described for ANG and iron mimicking cPEP conjugations. 
6.4.3.5.1. Angiopep2-SH conjugation. 
a. Conjugation to the polymer backbone.  
a1. Linker/spacer conjugation: 2TP activated cysteamine 
coupling. The spacer was introduced following the protocol described 
for post-polymerization modification with cysteamine-2TP using 
DMTMM∙Cl previously described in Chapter 4. Briefly for 10 % GAU 
modification: in a one-neck round bottom flask fitted with a stirrer bar 
and a stopper, 0.4 mmol GAU of PGA construct (linear, star, DB or X-
Click) was dissolved in 10 mL of ddH2O. Then, DMTMM∙Cl (0.04 
mmol, 0.1 eq., for 10 % modification) was added in 2 more mL of 
ddH2O. Reaction was left to proceed for 10 minutes. After that time, 
cysteamine-2TP (0.08 mmol, 0.2 eq., for 10 % modification) was added 
to the reaction mixture and the pH was adjusted to 8 by the use of 
NaHCO3 1 M solution. Reaction was allowed to proceed for 16 hours, 
and purified by dialysis using Vivaspin® MWCO 3000. The 
cysteamine-2TP content was determined according to 1H-NMR as 
explained in Chapter 4. 
Yields: 80-95 %. Cysteamine-2TP loading: 7 mol% GAU for 
linear PGA; 10 % for DB PEG-PGA; 9 % for St-PGA; 10 % for X-
Click. 
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a2. DO3AtBu deprotection. After linker introduction, the tBu 
groups from DO3A were removed since no side reactions will occur 
anymore within the carboxylic groups from DO3A. This step was 
carried out according to the conditions described previously within this 
chapter, using TFA/H2O/TIPS. Yields: Quantitative 
a3. ANG conjugation within the polymeric platform by disulfide 
bonding. ANG was conjugated following the same protocol for all 
constructs and using always the same eq. of peptide than the 
modifications obtained with reactive disulfides. Hence, briefly, in the 
case of 10 % SS-2TP modified St-PGA: in a one-neck round bottom 
flask fitted with a stir bar and a stopper, 45 mg of St-PGA-DO3A-
Cys2TP (0.18 mmol GAU, 1 eq.) were dissolved in 4 mL of ammonium 
acetate 150 mM pH 5. In parallel, ANG was dissolved in 3 mL of 
HEPES buffer 10 nM pH 7.4. The two solutions were mixed up and the 
pH was checked to be 6. Reaction was allowed to proceed under 
stirring for 16 hours. Then, the product was concentrated and purified 
through a PD-10 column. Fractions from the SEC purification were 
analyzed by absorbance measurements in NanodropTM to determine the 
conjugate fractions. ANG content was firstly estimated by 1H-NMR 
and amino acid analysis performed at the University of Barcelona 
(Unitat de Tècniques Separatives I Síntesi de Pèptids Centres Cientifics 
I Tecnològics). Yields: 60-70 %. Peptide contents:  
Table 6.9. ANG loadings summary. 
Conjugate 
mol% GAU/ wt% peptide 
1H-NMR AA analysis 
PGA-DO3A-ANG 4.7mol%/ 36 wt% 3.9 mol%/ 32 wt% 
DB-DO3A-ANG 4.5 mol%/ 32 wt% 3.5 mol%/ 27 wt% 
St-DO3A-ANG 4.0 mol/% 27 wt% 5.1 mol%/ 33 wt% 
X-Click-DO3A-ANG 2.75 mol%/ 16 wt% n.d. 
X-Click-DO3A-Gd-Cy5.5-
ANG 
1.5 mol%/ 13.8 wt% n.d. 
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b. Telechelic Conjugation to DB2-SS4TP 
After DO3AtBu-NH2 conjugation and tBu groups’ removal by 
protocols described before, ANG was conjugated to PEG-SS4TP block 
chain end. The procedure followed was analogous to the one described 
in the previous paragraph but using different eq. (1 eq. of PGA-PEG-
SS4TP chains to 2 eq. of ANG). Yield: 75 %. Conjugation efficiency: 
80 % according to 1H-NMR (0.8 eq. per polymer chain); 30 % 
according to AA analysis (0.3 eq. per polymer chain). 
6.4.3.5.2. Cyclic peptide conjugation.  
a. Conjugation to the polymeric backbone. 
a1. Linker/spacer conjugation. N-Boc-ethylendiamine coupling. 
The protocol used for the N-Boc-ethylendiamine coupling was post-
polymerization modification using DMTMM∙Cl previously described in 
Chapter 4. Briefly, for 10 % modification, 0.403 mmol GAU of 
polymer (1 eq.) was dissolved in 10 mL of ddH2O. Then, 0.04 mmol of 
DMTMM∙Cl (11.14 mg, 0.1 eq.) was added and the reaction was left to 
proceed for 10 minutes. After that time, N-Boc-ethylendiamine (12.8 
mg, 0.08 mmol, 0.2 eq.) and the mixture was left reacting for 16 hours. 
For purification, dialysis was performed using Vivaspin® MWCO 
3000. Percentage of modification was calculated according to the 1H-
NMR spectra. Yields: 80-90 %. N-Boc-ethylendiamine loading: 9 
mol% GAU for linear PGA; 10 % for DB PEG-PGA; 8 % for star-
PGA. 
a2. Boc and tBu groups simultaneous deprotection. Both, Boc 
and tBu groups were then easily deprotected in CH2Cl2:TFA (3:2) for 
16 hours following the protocol described previously in this chapter for 
tBu from DO3A deprotection. Yield: Quantitative. 
a3. COOH activation of Iron mimicking cPEP C-terminus. In a 
two-necked round bottom flask fitted with a stir bar and two septums, 
30 mg of cPEP (0.032 mmol, 1 eq.) were dissolved under inert 
atmosphere in anh. DMSO (0.5 mL). Then, 8.7 mg DCC (0.042 mmol, 
1.3 eq.) were added to the reaction mixture. After 5 minutes, 4.8 mg of 
N-Hydroxysuccinimide (NHS) (0.042 mmol, 1.3 eq.) were added and 
the reaction was left to proceed for 16 hours at r.t. and under nitrogen 
flow. After that time, the contents were precipitated into a large excess 
of cold diethyl ether, filtered off, and dried. Yield: 95 %. Percentage of 
NHS activation was determined as 100 %, estimated according to the 
CH2 signal belonging to the NHS ring at 2.6 ppm.  
[Chapter 6] 
358 
a4. cPEP conjugation through amide bond. As for ANG 
conjugation, the eq. of peptide used for the conjugation were the same 
as the percentage of linker incorporation achieved for each case. Thus, 
briefly, in the case of linear PGA-DO3A-ethylendiamine (9 % linker): 
in a one-neck round bottom flask fitted with a stir bar and a stopper, 
22.5 mg of polymer (0.14 mmol, 1 eq.) were dissolved in 4 mL of PBS 
0.1 M pH 7.4. After that, 13 mg of activated cPEP (0.0126 mmol, 0.09 
eq.) were added to the reaction mixture. Reaction was left to proceed 
under vigorous stirring for 5 hours. Then, the product was purified by 
SEC using a commercial PD-10 column. Peptide content was estimated 
by 1H-NMR in D2O and quantified by amino acid analysis at the 
University of Barcelona (Unitat de Tècniques Separatives i Síntesi de 
Pèptids Centres Cientifics i Tecnològics). 
Yields: 75-80 %. Peptide Loading: 
Table 6.10. Iron mimicking cPEP loadings summary. 
Conjugate 
mol% GAU/ wt% peptide 
1H-NMR AA analysis 
PGA-DO3A-cPEP 2.75 mol%/ 12 wt% n.d. 
DB-DO3A-cPEP 3.4 mol%/ 13 wt% 2.8 mol%/ 11 wt% 
St-DO3A-cPEP 6.0 mol%/ 20 wt% 7.4 mol%/ 23 wt% 
b. Telechelic conjugation. 
After DO3AtBu-NH2 conjugation by the protocol previously 
described in this chapter, cPEP was conjugated to the PEG-NHFMOC 
block chain end. Firstly, the Fmoc group was removed. In a round 
bottom flask fitted with a stir bar and a stopper, PGA-DO3AtBu-PEG-
NHFMOC was dissolved in a mixture of piperidine 20 % in DMF for 3 
hours. The product was then precipitated into a large excess of cold 
diethyl ether, filtered off, and dried over vacuum. Yield: Quantitative. 
Complete deprotection was achieved according to 1H-NMR in D2O. 
After that, the procedure for the conjugation of NHS activated 
cPEP followed was analogous to the one described for the backbone 
conjugations but using different eq. (1 eq. of PGA-PEG-SS4TP chains 
to 2 eq. of cPEP). Yield: 70 %. Conjugation efficiency: 80 % according 
to 1H-NMR (0.8 eq. per polymer chain); 50 % according to AA analysis 
(0.5 eq. per polymer chain). 
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6.4.3.6. Z-Potential measurements. 
Z-potential measurements were performed at 20 °C using a 
Malvern ZetasizerNanoZS instrument, equipped with a 532 nm laser 
using Disposable folded capillary cells, provided by Malvern 
Instruments Ltd. (Worcerstershire, UK). Polymer solutions (0.1 mg∙mL-
1) were prepared in ddH2O. The solutions were filtered through a 0.45 
μm cellulose membrane filter. Z-potential was measured for each 
sample per triplicate with n> 3 measurements. 
6.4.3.7. Biodistribution by PET imaging and ex-vivo 
radioactivity measurement. 
*PET imaging was only possible with 68Ga-labeled polymers 
since SPECT equipment was not available for 111In-labeled systems. 
PET imaging of 68Ga-labeled polymers was complemented with ex-vivo 
radioactivity measurements in a gamma counter, which was the only 
option for 111In-labeled systems. 
68Ga-labeled polymers. Animals’ weight was 25 ± 4 g. For 
pharmacokinetics and biodistribution study, 50 mice were used. Mice 
were anesthetized with 1.5 % isofluorane, and a dose between 0.2 and 
1.4 MBq per mouse (21 ± 4 µg compound/g body weight) was injected 
i.v. through the tail vein. Blood samples were obtained at different time 
points (0.25, 0.5, 1, 2 and 3 hours) post injection by terminal bleeding 
via cardiac puncture following isofluorane anesthesia. Organs (lungs, 
heart, spleen, kidneys, liver and brain) and some tissues (muscle, fat) 
were isolated, rinsed with normal saline, weighted, and radioactivity of 
each sample was measured using Cobra II auto-gamma counter per 
triplicate. Blood samples were centrifuged (3000 rpm, 10 min, 25 °C) 
and plasma supernatant was collected. % ID and % ID∙g-1 were 
calculated by comparison with standards taken from the injected 
solution for each animal. Data was expressed as the mean ± SD. 
111In-labeled polymers. Animals’ weight was 22 ± 4 g. For 
pharmacokinetics and biodistribution study, 88 mice were used (4-5 for 
each time point). Mice were anesthetized with 2 % isofluorane, and a 
dose between 37 KBq and 2.5 MBq of compound per mouse (1-20 µg 
compound/g body weight) was injected i.v. through the tail vein. Blood 
samples were obtained at different time points (0.5, 1, 2, 4, 8 and 24 
hours) post injection by terminal bleeding via cardiac puncture 
following isofluorane anesthesia. Organs (lungs, heart, spleen, kidneys, 
liver and brain) and some tissues (muscle, fat) were isolated, rinsed 
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with normal saline, weighted, and radioactivity of each sample was 
measured using Cobra II auto-gamma counter per triplicate. Blood 
samples were centrifuged (3000 rpm, 10 min, 25 °C) and plasma 
supernatant was collected. % ID and % ID∙g-1 were calculated by 
comparison with standards taken from the injected solution for each 
animal. Data was expressed as the mean ± SD. 
6.4.3.8. Pharmacokinetics of radiolabeled systems. 
Plasma concentration versus time data of radioactivity were 
analysed by a two-compartment model with bolus input and first-order 
elimination rate. The model is described by the following equation: 
ܥ(ݐ) = ܣ. ݁ିఈ௧ + ܤ. ݁ିఉ௧ 
Apparent terminal half-life (t1/2) is calculated as Ln2/β and the 
plasma clearance (Cl) for each compound is estimated as the ratio of 
dose/AUC (area under the plasma concentration-time curve). Initial 
estimates of PK parameters were computed by WinNonLin (ver. 5.2, 
Pharsight Corporation, Mountain View, CA) using curve stripping. PK 
parameters were A, B, α and β. From these parameters, several derived 
PK parameters were computed: AUC (A/α + B/β), Cl (D/AUC), Vss, 
Cmax (A+B) and apparent terminal half-life. As plasma concentrations 
often span a wide range, it is useful to employ a weighting procedure 
for the raw data that allows one to fit low concentrations and high 
concentrations simultaneously. We used weighting by the deviation 
standard of the concentration. The Nelder-Mead simplex algorithm, 
which is implemented in WinNonlin, was used as fitting algorithm. 
6.4.3.9. Biodistribution by Optical Imaging. 
Biodistribution experiments were carried out using C57Bl/6 
mice. Animals weight was 23 ± 4 g. Mice were anesthetized with 1.5 % 
isofluorane. Targeted and non-targeted architectures were administered 
i.v. through vein tail via cannula, at a dose of 4.15 mg∙Kg-1 Cy5.5 eq. 
Blood samples were extracted from cava vein at different time points 
(1, 3, 7, 14 and 24 hours) from anesthetized mice with a lethal 
anesthesia cocktail (i.e. for 20 g mice 200 µL from the solution 
containing ketamine 100 mg∙Kg-1, xylasin 100 mg∙Kg-1, acepromacide 
2 mg∙Kg-1). Perfusion with 10 mL of saline was then performed. Organs 
were extracted (brain, liver, kidney, heart, stomach, spleen, lung) 
immediately after and their fluorescence was measured using the red 
filter in MAESTRO™. For fluorescence quantification, normalized 
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data was obtained by taking always the same pixel area for all organs 
expressed as average signal (counts.s-1). See section 6.4.2.2. A 
calibration curve of the compounds in the same MAESTRO™ was 
carried out in order to estimate the fluorescence corresponding to the 
injected dose.  
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7.1. INTRODUCTION AND BACKGROUND. 
7.1.1. Alzheimer’s Disease. 
7.1.1.1. Statistics. Incidence and Prevalence. 
Alzheimer's disease (AD) is a neurodegenerative process of the 
central nervous system, characterized by loss of short term memory and 
attention, subsequently affecting other cognitive skills such as 
language, abstract thinking, critical judgment and recognition of places 
or people. This progressive loss of cognitive abilities is associated with 
a decline in a person’s capability to be independent and care for one’s 
own needs. Such devastating disease represents the most unmet medical 
need in neurological disorders.1 
 
Figure 7.1. Human brain under normal conditions compared to advance 
Alzheimer’s.1 
Globally and in developed countries in particular, dementias are 
a growing burden, since main types of dementia are associated with 
aging and the average population age is increasing worldwide. Indeed, 
when AD was identified by the German physician Alois Alzheimer in 
1906, this disorder was considered a rare disease. Unfortunately 
nowadays, AD is the most common cause of dementia in elderly 
people, accounting for about 70 % of all cases in Europe and North 
America. On the contrary, in Russia and Japan vascular dementia is 
more frequent than AD and in Africa AD has a low incidence. 
However, when considered globally, it represents 50-70 % of all forms 
of dementia worldwide. 
AD is one of the largest global public health challenges to be 
faced. Currently, over 35 million people worldwide is living with the 
disease and this number is expected to double by 2030 reaching up to 
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115 million in 2050, more than triple.2 Besides the cost of medication 
and therapy, patients with AD require special medical care. The global 
economic cost is around US$ 604 billion. It is expected that due to life 
expectancy and the new lifestyles, the costs of dementia will grow 
exponentially by 2050 (when the baby boom generation will reach 65 
years old). Approximately 10 % of the population in developed 
countries, with over 65 years of age, and 50 % above 85 years old are 
diagnosed with AD, representing the 7th leading cause of death in 
countries such as the United States. 
 
Figure 7.2. AD global forecast from 2013-2015 represented in millions 
of people suffering from AD worldwide.2 
Only in Spain, this dementia is currently suffered by more than 
1.5 million people and the cost of the disease is over 37,000 million 
euros. Besides, with an aging population, deaths in Spain derived from 
AD have doubled from 2000 to 2011, year in which 11,907 deaths were 
registered, according to National Statistics Institute (INE). Diseases of 
the nervous system are the 4th most common cause of death in Spain 
(20,254, 5.2 %), behind vascular diseases (30.5 %) cancer (28.2 %) and 
respiratory pathologies (10.9 %).3 
 
Figure 7.3. Main causes of Death in Spain. Vascular diseases occupy 
the top position (30.5 %) followed by tumors (28.2 %), respiratory 
0
100
200
2013 2030 2050
35.5
71.2
115
AD global forecast 2013-2050
Millions of people suffering from AD
5.2 %
30.5 %
28.2 % 
10.9 %
30.4 %
Main causes of Death in Spain
Nervous system
Vascular Diseases
Tumors
Respiratory Diseases
Other
[Chapter 7] 
381 
diseases (28.2 %) and nervous system affections including dementias 
(5.2 %).3 
The therapeutic armory for AD has increased over the last 
years, and new disease-modifying drugs are coming out. However, 
current available drugs only induce moderate symptomatic benefits but 
do not target neuronal impairment.  
7.1.1.2. Disease hallmarks and progression. 
In general, AD is a multiple and entangled process, caused by 
complex interactions among multiple genetic, epigenetic and 
environmental factors. Regarding genetics, mutations in three genes 
(amyloid protein precursor (APP), presenilin (PS)-1 and PS-2) cause 
early-onset autosomal dominant AD (< 60 years old), which represents 
less than 1 % of AD cases.4 On the other hand, apolipoprotein (apo) E4 
has been genetically linked to a late-onset familial and sporadic AD (> 
60 years old) which accounts for most AD cases.4  
Although there are several clear disease hallmarks, the specific 
cause of Alzheimer's remains unknown. Based on clinical observation 
and autopsy, the disease has been characterized by three cardinal 
changes in the brain: 
(i) The appearance of extracellular deposits, named senile 
cerebral plaques laden with β-amyloid peptide (Aβ) and dystrophic 
neurites in neocortical terminal fields. 
 
Figure 7.4. Representation of disease neurons with extracellular Aβ 
deposits in Alzheimer’s disease vs. healthy neurons from healthy 
patients. Adapted from ref5 
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(ii) The formation of abnormal intracellular filaments 
(neurofibrillary tangles) made up of a highly phosphorylated form of 
microtubule-associated protein tau in the perikaryia of certain neurons 
in medial temporal-lobe structures, accompanied by neurophil threads 
in axons and nerve terminals. 
 
Figure 7.5. Representation of healthy neurons where microtubule-
associated protein tau is placed as structural scaffold for microtubule 
stabilization, vs. disease neurons where hyperphosphorilated state of tau 
protein leads to microtubule disintegration and the formation of 
neurofibrillary tangles within the misfolded protein. Adapted from ref.6 
(iii) The loss of vulnerable neurons, mainly pyramidal, 
cholinergic, noradrenergic and serotonergic neurons. The death of 
cholinergic neurons leads to a deficit in acetylcholine (Ach), a major 
transmitter involved in memory. 
Loss of white matter, congophilic (amyloid) angiopathy, 
inflammation, and oxidative damage are also present hallmarks of the 
disease. 
Generally, neurodegeneration begins in the entorhinal cortex 
with pyramidal cell loss (the most abundant neurons in the cortex), 
neurofibrillary tangles and neurophil threads, and then spreads in an 
anatomically defined pattern to other brain regions: particularly the 
hippocampus and parietal and temporal regions of neocortex. Senile 
plaques first appear in the frontal cortex, and then spread over the entire 
cortical region, whereas hyperphosphorylated tau and insoluble tangles 
initially appear in the limbic system (entorhinal cortex, hippocampus, 
dentate gyrus) and then progress to the neocortex. 
Symptoms can vary in severity and chronology but in any case 
they reflect the gradual expansion of degenerative damages within the 
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brain. Furthermore, the rate of progression is also highly variable. 
People with Alzheimer's live an average of eight years, but some people 
may survive up to 20 years. According to recent studies, changes in 
brain may start even 20 years or more before symptoms appear. At 
early stages, before symptoms can be detected with current tests, 
plaques and tangles begin to form in brain areas involved in: learning 
and memory, thinking and planning. Hence, when people is usually 
diagnosed with dementia, they are at least in mild-to moderate 
Alzheimer’s stages. 
In mild to moderate stages, brain regions important in memory, 
thinking and planning develop more plaques and tangles leading to 
serious problems with memory or thinking that already interfere with 
work or social life. In moderate stages, areas involved in speaking and 
understanding speech are also damaged. Furthermore, as AD 
progresses, individuals may experience changes in personality and 
behavior and they find problems in recognizing friends or family. 
In advanced AD, most of the cortex is seriously damaged. The 
brain shrinks dramatically due to widespread cell death. Individuals 
lose their ability to communicate, to recognize family and loved ones 
and to care for themselves. Figure 7.6 shows disease progression from 
healthy to advanced AD brains. 
 
Figure 7.6. AD progression in brain cross sections from healthy brain 
without any physiological damage to mild-to-moderate AD brain where 
typical cortical and hippocampus shrinkage and ventricles enlargement 
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starts to occur, ending in advanced AD, with severe damages. Adapted 
from ref.6 
Many hypothesis have been postulated to explain AD 
pathogenesis, encompassing Aβ cascade, tau, cholinergic, oxidative 
stress and metal hypothesis as the main ones.7-9 Nevertheless, no single 
hypothesis can completely explain the causes of AD. Moreover, 
whether these changes are causes or consequences of AD is still not 
fully elucidated. 
In amyloid cascade hypothesis, the accumulation of soluble Aβ 
into toxic oligomers and amyloid plaques is thought to promote the 
pathogenic cascade leading to tau hyperphosphorylation, intracellular 
neurofibrillary tangles, synaptic dysfunction, neuronal death and, 
ultimately, loss of cognitive functions.9, 10 Aβ are the hydrolytic 
products from APP cleavage by β-secretase (BACE1) and posterior 
cleavage by γ-secretase. Under non-amyloidogenic conditions, such 
cleavage is performed first by α-secretase followed by γ-secretase 
leading to non-amyloidogenic substrates (see Figure 7.7).10 The main 
species generated in the amyloidogenic cleavage are Aβ40 and Aβ42. 
Whereas Aβ40 is the most abundant, Aβ42 is more prone to aggregation. 
The imbalance among Aβ production and clearance plays a central role 
in AD pathogenesis. Apart from senile plaques Aβ also deposits in the 
cerebral vascular wall leading to cerebral amyloid angiopathy (CAA).11, 
12 Thus, according to this cascade, bioactive agents with the ability to 
reduce Aβ production, inhibit Aβ aggregation or enhance Aβ clearance 
are good candidates for AD therapies.  
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Figure 7.7. APP cleavage pathways. Non-amyloidogenic pathway 
involves APP extracellular cleavage by α-secretase in a first stage 
generating sAPPα and the fragment C83, which is subsequently cleaved 
by γ-secretase enzyme leading to non-amyloidogenic peptide p3 that is 
also released to the extracellular space. On the contrary, the 
amyloidogenic pathway is initiated by β-secretase cleavage of APP 
leading to sAPPβ and C99 peptide this time. C99 is then cleaved by γ-
secretase leading to Aβ peptides prone to aggregate forming first 
dimers and small oligomers and later on fibrils and plaques. Redrawn 
from ref.13 
Tau hypothesis is the second most accepted hypothesis, 
according to which tau hyperphosphorylation triggers the formation of 
neurofibrillary tangles inside neurons, main cause in AD onset.14 Once 
tau is aggregated, such agglomerates can be transported from one nerve 
cell to another along the neural network of axons that connect them. In 
consort with this hypothesis, tau protein has become a target for AD 
strategies by inhibition of its phosphorylation or aggregation, reduction 
of its levels, tau immunization or microtubule stabilization.15 
Cholinergic neurons are affected even in very early stages of 
AD, pointing out (in the cholinergic hypothesis) that this condition 
contributes to the severity of the cognitive and behavioral deficits.16 
Indeed, most of the current drugs for AD symptomatic treatment 
(donepezil, galantamine, rivastigmine) were born with this hypothesis.17 
According to the oxidative hypothesis, oxidative stress 
generated during aging causes serious damage to cell function and 
viability18 and is intimately related to AD onset. Consequently, 
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antioxidants such as flavonoids and polyphenols are under study for 
AD treatments.19 
Linked to the oxidative hypothesis, metal hypothesis includes 
the role of metal ions in AD development, by postulating that metals 
such as Cu2+, Zn2+, Fe3+ bind to Aβ causing the production of reactive 
oxygen species.20 Hence, metal chelators have been suggested as 
therapeutic strategy in AD.21, 22 
Activated microglia and reactive astrocytes have been found to 
be located on the surroundings of senile plaques. Furthermore, their 
biochemical markers are overexpressed in AD brains.23 Recent studies 
suggest that microglia may have contradictory roles along AD onset 
and progression. Firstly, phagocytic microglia engulf and remove Aβ. 
Nevertheless, when activated chronically (as in AD), microglia releases 
chemokines and a cascade of damaging cytokines (interleukines (IL) 
IL-1, IL-6, and TNFα).24 Furthermore, reactive astroglia also release 
acute-phase reactants such as α1-antichymotrypsin, α2-macroglobulin, 
and C-reactive protein that can aggravate as well as ameliorate AD. A 
crosstalk between systemic and central innate immune system by the 
release of inflammatory mediators leading to the migration of T cells 
and immune cells into the brain has also been observed in AD.25 Thus, 
microglia activation leads (indirectly) to BBB disruption.26, 27 Overall, 
the contradictory roles of microglia makes more difficult the 
identification of effective treatments. Non-steroidal anti-inflammatory 
drugs (NSAIDs) have been reported to decrease the risk of suffering 
from AD, and slow disease progression.28 
Finally, mitochondrial dysfunction is also found in AD brains.29 
Indeed, the exposure to Aβ triggers the inhibition of key mitochondrial 
enzymes in the brain.30, 31 Cytochrome c oxidase is specifically 
impaired32 and subsequently, electron transport, ATP production, 
oxygen consumption, and mitochondrial membrane potential can be 
damaged. Furthermore, the increase of radical formation cause 
oxidative stress, release of cytochrome c and consequently apoptosis.33 
7.1.1.3. Current treatments and approaches. 
Drug development for AD has been a slow and difficult 
process. Only five drugs are approved for the treatment of AD 
including four Acetylcholinesterase (AChE) inhibitors (tacrine, 
donepezil, rivastigmine, galantamine) and an N-methyl-D-aspartate 
(NMDA) receptor AD antagonist (memantine).34, 35 Tacrine was 
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approved by the FDA in 1993, donepezil in 1996, rivastigmine in 1998, 
galantamine in 2001, and memantine in 2003. Since 2003, no new 
treatments have been approved mainly due to many failures in AD drug 
development with both small molecules and immunotherapies due to 
poor effectiveness or unacceptable toxicities.36-40 Indeed, 72 % of the 
agents failed in phase I, 92 % in phase II and 98 % in phase III, 
highlighting the high attrition rate for AD treatment. Importantly, from 
2002 to 2012, 244 compounds were tested in the 413 AD trials 
performed, from which, the largest number are focused in addressing 
symptomatic effect (improve cognition), followed by disease-
modifying small molecules and disease-modifying immunotherapies as 
reviewed recently by Cummings et al.37  
Drug strategies under clinical development are in consonance 
with the different hypothesis described before, as can be seen in Table 
7.1. An extensive summary of clinical trials and late-stage drug 
development for AD up to 2014 can be found in literature.41 
Table 7.1. Mechanism of action of current AD drugs under clinical 
development (as of February 2004, from ref.37) 
 Phase 1 Phase 2 Phase 3 Total 
Symptomatic for cognition 5 10 10 25 
Symptomatic for behavior 2 3 4 9 
Disease-modifying small 
molecule (amyloid-related) 
4 5 1 10 
Disease-modifying small 
molecule (tau-related) 
3 0 1 4 
Disease-modifying small 
molecule (neuroprotector) 
2 19 4 25 
Disease-modifying 
immunotherapy 
4 8 3 15 
Therapeutic device 2 4 0 6 
Stem cells 0 1 0 1 
Total 22 50 23 95 
Overall, there is still a long way to go in order to achieve 
effective and safe treatments for such chronic neurodegenerative 
disease. Past failures and the dichotomies of symptomatic versus 
disease-modifying, early stages versus late stages treatment, and 
amyloid versus non-amyloid hypothesis, suggest that there is still much 
to be understood. Moreover, the fact that disease mechanisms are not 
fully elucidated, the multiple present hallmarks with unclear origin 
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(what is cause and what is consequence?), BBB handicap, limitations in 
diagnosis to identify early and treatable stages, the many difficulties 
found in clinical trials that require long-term treatments (especially for 
preventive approaches), and the need for multi-target and personalized 
therapy are hindering the appearance of novel promising candidates for 
AD treatment. To this respect, nanomedicine is envisaged as possible 
solution for efficient diagnosis and treatment approaches.  
7.1.1.4. Nanomedicine as treatment for AD. 
As mentioned before, some of the main challenges of AD 
treatment rely on the fact that (i) BBB impedes drug delivery into the 
CNS, and (ii) the lack of understanding on the exact pathogenesis of 
AD. Among the already described strategies for CNS delivery in 
Chapter 6, non-invasive approaches are preferred in AD therapy to 
allow better patient compliance and to avoid any safety concerns, as 
well as the relatively high costs of the invasive techniques. Among non-
invasive approaches, nanomedicine is gaining increasing interest. 
Current nanopharmaceuticals for AD encompass Aβ targeting, metal 
ions binding, cholinesterase inhibition, neuroprotection and estrogen 
replacement therapy.  
Aβ targeted nanotherapeutic strategies include the modulation 
of Aβ production, inhibition of Aβ aggregation, and enhancement of Aβ 
clearance. Modulation of Aβ production can be achieved by targeting 
the enzymes responsible for the APP cleavage (β-secretase BACE1 and 
γ-secretase). However, only BACE1 represents a good target for 
clinical applications provided that γ-secretase is related to many other 
processes and its inhibition has demonstrated to lead to unwanted side 
effects.42-44 To this respect, Alvarez-Erviti et al. developed modified 
exosomes as carriers for brain-targeting delivery of BACE1 siRNA 
with promising results (Table 7.1).45 Regarding the inhibition of Aβ 
aggregation, Li et al. synthesized polyoxometalate (POM)-peptide 
particles from POM and Aβ15-20 inhibitor of aggregation together with 
Congo Red to monitor the inhibition process.46 On the other hand, the 
polyphenolic curcumin (further analyzed later on in this chapter) has 
been also used against Aβ aggregation47, 48 in several nanosystems 
including PEG-PLA nanoparticles from Cheng et al.49 and PLGA 
nanoparticles from Mathew et al (See Table 7.1).50 Song et al. have 
recently developed a nanostructure based on apolipoproteinE3-
reconstituted HDL. Such system demonstrated to accelerate Aβ 
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degradation, decreased Aβ deposition, while attenuating microgliosis, 
thus, ameliorating neurologic changes and rescue memory deficits in 
AD mice model.51 Immunotherapy has been also effectively applied to 
inhibit Aβ deposition. For instance, Canovi et al. built a nanoliposome 
loaded with Aβ-MAb (anti Aβ monoclonal antibody) with high affinity 
for Aβ42 monomers and fibrils.52 
Normal metal ion distribution in the CNS, (i.e. cooper, iron or 
zinc) is altered by several fold concentration in AD conditions.53-55 
Furthermore, senile plaques are enriched with these metals what 
indicates their involvement in Aβ aggregation and Aβ-induced 
oxidative stress.56, 57 Hence, metal chelators are postulated as candidates 
to disrupt and prevent Aβ plaques. For instance, Liu et al, conjugated 
the iron chelator 2-methyl-N-(2’-aminoethyl)-3-hydroxyl-4-pyridinone 
(MAEHP) to functionalized polystyrene nanoparticles leading to Nano-
N2YP a potential inhibitor of Aβ aggregation and neurotoxicity, 
demonstrated in vitro.58 
The AChE inhibitor rivastigmine has been delivered using 
liposomal formulations in order to increase its limited plasma half-life 
(< 1.5 hours).59, 60 
Regarding neuroprotection, PEG-PEI-Rho associated kinase 
(ROCK-II) siRNA polyplex has demonstrated to decrease Aβ 
production, protect from neurodegeneration and promote axonal 
growth.61-63  
Finally, Mittal et al. constructed estradiol-loaded tween 80 (T-
80)-coated PLGA nanoparticles capable to achieve significantly 
increased levels of estradiol in brain after oral administration, showing 
also good results in the prevention of the expression of Aβ1-42 
immunoreactivity.64 
Nonetheless, most of the studies are still at very early stages of 
development (even in vitro for some of them, see Table 7.2), thus, 
further research must be done to evaluate their real potential. 
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7.2. RESULTS AND DISCUSSION. 
7.2.1. Towards neuroprotective therapies for AD. 
As stated in Chapter 1, PT possess all the necessary 
requirements for diagnosis and treatment of CNS disorders and brain 
tumors. As also mentioned, moderate current treatments to AD offer 
only symptomatic benefit, but do not aim to delay or stop disease 
progression. Therefore, scientific efforts have been focused on the 
understanding of key molecules and pathways in physiological 
processes, as well as drug discovery for AD treatment. Within our 
group, to achieve polymeric nanomedicines of controlled architecture 
bearing drugs with neuroprotective or neuronal rescuer action is one of 
our main lines of research for the treatment of AD. This PhD thesis is 
part of such strategy. 
One example of neuroprotective agents are the propargylamine-
bearing drugs Selegiline®, Rasagiline®, Ladostigil® and M30®, which 
are described as MAO-B (monoamine oxidase-B) inhibitors.70-72 In 
brain, MAO-B is localized in glial cells, and MAO-B levels increase 
with neuronal cell death. MAO is an important enzyme to metabolize in 
vivo endogenous and diet-derived biogenic amines via oxidative 
deamination. Major substrates are noradrenaline, adrenaline, dopamine, 
β-phenylethylamine (PEA) and serotonin. It has been recently 
established that their protective effect does not only result from MAO-
B inhibition, as it is found in other propargylamine-containing 
molecules that do not inhibit this enzyme, such as the s-optical isomer 
of Rasagiline®. It seems that this effect is directly related to the 
propargylamine moiety. Indeed, propargylamine moiety itself has been 
also evaluated confirming its neuroprotective-neurorescuer character.73  
CH3
N
CH3
HN
SELEGILINE RASAGILINE
HN
O
O
N
LADOSTIGIL
N
OH
N
M30
MAO-B INHIBITORS  
Figure 7.8. Chemical structure of propargyl-derivatives compounds. 
The anti-Parkinsonian drugs, Selegiline® and Rasagiline®, and the 
multifunctional propargylamine-derivatives, Ladostigil® and M30®. 
The propargylamine moiety is circled. 
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On the other hand, as already stated, neuroinflammation is 
implicated in the pathogenesis of many neurodegenerative disorder, 
including AD. Hence, for AD therapeutics, there is a rational to develop 
drugs that attenuate inflammatory cascades that contribute to 
neurodegeneration and amyloid production or accumulation. To this 
respect, curcumin and curcuminoids are compounds known to inhibit 
inflammation while reducing plaque deposition in AD models.74-77  
Curcumin (diferuloylmethane) is a polyphenolic compound 
derived from turmeric spice from curcuma longa.78 Naturally occurring 
curcuminoids are a mixture of curcumin (77 %), demethoxycurcumin 
(DMC) (17 %), and bisdemethoxycurcumin (BDMC) (3 %).79 (See 
Figure 7.9). 
 
Figure 7.9. Structure of the different curcuminoids present in curcuma 
turmeric spice from curcuma longa. 
Indeed, the lower prevalence of AD incidence in India, is 
generally attributed to the turmeric spice consumption as part of curry, 
and it is assumed that people who eat curcuma regularly, have lower 
incidence of AD.80, 81 
Curcumin antagonizes many steps in the inflammatory cascade, 
including activator protein-1 transcription, activation of nuclear factor-
kB, iNOS, and JNK.82-84 It also exerts a potent antioxidant activity for 
NO-related radical generation.85 In contrast to non-steroidal anti-
inflammatory drugs (NSAIDs) who have adverse side effects including 
gastrointestinal ulceration and liver or kidney toxicity, curcumin seems 
to be relatively safe, even in clinical trials for prevention of relapse of 
ulcerative colitis.86, 87 Many therapeutic applications have been already 
attributed to curcuminoids such as the suppression of mutagenesis, 
chemoprevention for a wide variety of cancers, inhibition of 
atherosclerosis or of viral and bacterial growth.88-93 Furthermore, 
Curcumin Demethoxycurcumin
Bisdemethoxycurcumin
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curcumin has been shown to mediate anti-proliferative effects through 
suppression of cyclin D1 and anti-apoptotic gene products,94-96 induce 
cytochrome C release, activate caspases97, 98 and p5399 and have anti-
angiogenic effects through the down-regulation of vascular endothelial 
growth factor (VEGF).94, 100 On the basis of the results from these 
studies, curcumin is currently in clinical trials for the treatment of 
various cancers and for AD among many other pathologies.101 Some of 
the biological properties of curcuminoids are summarized in Figure 
7.10.  
 
Figure 7.10. Established immuno-protective effects of curcumin, 
highlighting the great potential and ability to act as antioxidant, anti-
inflammatory, and anticancer drug. Redrawn from ref.102 
Curcuminoids are described to selectively bind to Aβ plaques 
being able to prevent fibril formation and to disrupt already formed 
fibrils, thus, acting in the aggregation process.103, 104 They also reduced 
phosphorylated tau protein burden.105 Moreover, the curcuminoid 
family has been recently identified as AChE inhibitors as well as β-
secretase inhibitors,106, 107 overall, covering most of the pathogenic 
hypothesis postulated for AD onset and development. Furthermore, 
curcumin-releasing mechanically adaptive intracortical implants have 
recently demonstrated that curcumin improve the proximal neuronal 
density and blood-brain barrier stability.108 
Hence, although it has been reported that curcumin/ 
curcuminoid administration attenuates cognitive deficits, 
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neuroinflammation and plaque pathology in AD models,48, 103, 109, 110 its 
poor solubility in water, poor oral absorption in both humans and 
animals, and the low systemic bioavailability have limited its clinical 
benefits.111 
As a maximum goal for this part of the project we aim to obtain 
combination conjugates for systemic administration with synergistic 
effect using the neuroprotective-neurorescuer propargyl moieties and 
the neuro-antiinflamatory curcuminoids, looking for a new therapeutic 
strategy in AD.  
To this aim, the already explored complex PGA structures were 
chosen as carriers due to their good in vivo performance, in terms of 
biodistribution and brain accumulation. Hence, the synthetic strategy 
was based on a bottom-up approach by taking profit of the self and co-
assembly properties of the previously described star-shaped 
polyglutamates. One possibility could be the conjugation of 
curcuminoids to the 3-arm star shaped polymeric aggregates obtained 
from the bottom-up approach after covalent entrapment in order to 
build combination therapy constructs with curcuminoids presumably 
exposed at the surface (Figure 7.11). An alternative approach would be 
the conjugation of propargyl residues to a 3-arm star shaped 
architecture and the linkage of curcuminoids + azide moieties to 
another 3-arm star polymer. Those structures will presumably co-
assemble when mixed at fixed concentrations above their CAC value, 
and covalent entrapping will follow to obtain a final construct with 
defined structure independent from the concentration. This later 
strategy is only valid if the drug is stable under click reaction conditions 
and do not contain functional groups that might interfere (which is the 
case). However, a whole study of the new system including the drug 
had be done before in order to optimize the conditions for the covalent 
capture of the new architectures. For targeting moieties and/or imaging 
agents the second approach would not be suitable as these residues 
should be included at the end of the strategy in order to secure binding 
and receptor recognition (in the case of targeting moieties) or to avoid 
quenching effects (in the case of imaging agents). 
According to the reported data from propargylamine residues, it 
seems that release from the drugs depicted in Figure 7.8, is not a 
request for activity, since the methylated residue itself is able to exhibit 
neuroprotective-neurorescuer properties. Thus, herein we propose the 
direct conjugation of these propargylamine residues within the 
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polymeric architectures selected by post-polymerization modification 
techniques by using non-biodegradable covalent linkages. On the other 
hand, conjugation of the curcuminoid will be carried out through a 
biodegradable ester linkage so that the selected curcuminoid could be 
released to trigger its biological activity. Among curcuminoids, BDMC 
was chosen due to its higher stability in physiological conditions (pH 
7.4) when compared to curcumin. Similar biological outputs have been 
described for all curcuminoids.112  
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7.2.2. Design of combination therapy through bottom-up 
approaches. 
First of all, in order to optimize the conjugation chemistry of 
BDMC into PGAs, as well as to study their self-assembly behavior, 
several PGA-based systems bearing self-assembly triggering motifs, 
were modified with BDMC. After many attempts using different 
carboxylic acid activators, DMTMM∙BF4 was chosen with the aid of 
DMAP as catalyst yielding conjugation efficiencies between 30-40 %. 
It has to be mentioned that the activation of BDMC alcohols by 
tosylation did not improve conjugation efficiency.  
Table 7.3. BDMC-conjugates details. 
Conjugate 
TDC wt% 
(Abs 415 nm ) 
FDC wt% of TDC 
(Abs 415 nm, HPLC) 
X-BDMC (0.5 wt%) (51a) 0.5 >1 
X-BDMC (1 wt%) (51b) 1.0 >1 
X-BDMC (2.5 wt%) (51c) 2.5 >1 
*TDC: total drug content; FDC: free drug content. 
Self-assembly of the BDMC-conjugates necessary to follow the 
bottom-up approach was confirmed by DLS measurements as shown in 
Figure 7.12. 
 
Figure 7.12. Mean Count Rate (Kcps) at increasing concentrations 
obtained by DLS for X-BDMC conjugates showing self-assembly. 
CAC= 0.6 for 51b and CAC=0.7 for 51c. 
As stated before, two strategies towards the design of polymer-
based combination constructs bearing propargyl amine moieties + 
curcuminoids were followed. For that aim, a bottom-up approach based 
on the synthesis and covalent capture of PGA-based systems was used. 
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Taking into account that propargyl amine will be used as one of the 
drugs for these nanostructures, covalent capture through CuAAC was 
chosen. In order to always have free propargyl groups, double eq. were 
used when compared to the number of azides introduced. The first 
strategy consisted on the synthesis of two different modified polymers 
with propargyl amine moieties (10 mol% GAU) and NH2EG(2)N3 (5 
mol% GAU), their covalent capture, and posterior conjugation of 
BDMC to the already entrapped structure. In the second strategy, 
BDMC was conjugated into one of the two modified unimers, 
(concretely into the azide modified one due to its less hydrophobicity), 
prior to covalent capture by CuAAC. Nonetheless, this latter strategy 
did not succeed due to poor stability of BDMC upon the CuAAC 
conditions. Results obtained in some of the experimental attempts are 
summarized in Table 7.4, where X-BDMC-Click refers to BDMC 
conjugation prior click chemistry and X-Click-BDMC, stands for 
BDMC conjugation after the covalent capture step. 
Table 7.4. Physico-chemical characteristics of BDMC-conjugates 
through bottom-up approach. 
Conjugate 
TDC wt% 
(Abs 415 nm ) 
FDC wt% of TDC 
(Abs 415 nm, HPLC) 
X-EG(2)N3-BDMC (52) 1.25 >1 
X-BDMC-Click (53) 0.11 >1 
X-Click-BDMC (54a) 2.00 >1 
X-Click-BDMC (54b) 4.00 >1 
7.2.3. In vitro evaluation. 
7.2.3.1. Cell Viability. 
Firstly, cytotoxicity of BDMC bearing polymers was explored 
up to 15 μM drug-eq. According to previous studies found in literature, 
a curcuminoid concentration range of 0.1-1 μM should be enough to 
induce a therapeutic benefit by diminishing oxidative stress.113 
Moreover, the IC50 value for Aβ aggregation and lipid peroxidation of 
curcuminoids is also found in that concentration rage, indicating that 
such a dose should be enough in order to produce antioxidant and anti-
inflammatory effects.114 As it can be observed from Figure 7.13, non-
significant toxicities up to 10 μM drug-eq. were found. The compound 
X-Click-BDMC (54b) with 4 wt% of BDMC was selected for further 
investigations (100 % cell viability at 10 μM). 
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Figure 7.13. Cell viability of BDMC derivatives against SHSY5Y cell 
line. 72 hours MTS assay. n> 3, mean ± SEM. 
7.2.3.2. Drug release profiles. 
Since a pH degradable linker (ester) was used for the 
conjugation of BDMC, the kinetics of drug release under hydrolytic 
conditions was consequently studied. Samples of X-Click-BDMC 4 
wt%, (selected from cell viability experiments) were incubated at 37 ºC 
at different pHs including 5.0 (lysosome), 6.5 (endosome) and 7.4 
(blood) up to 96 hours. A sustained and controlled drug release profile 
was obtained after HPLC analysis. About 20 % of the conjugated drug 
was released within 2 days at pH 5.0 whereas pH 6.5 and 7.4 showed a 
much slower release profile. 
 
Figure 7.14. Drug release profiles at different pH (5.0, 6.5 and 7.4) of 
X-Click-BDMC (4 wt%). Time course experiments were done per 
triplicate. n> 3, mean ± SEM. 
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7.2.3.3. Prevention of fibril formation in vitro. 
In order to achieve proof of concept, activity of the compounds 
was checked in a first attempt using an accepted model based on the use 
of Hen Egg White Lysozyme (HEWL) for protein amyloid formation. 
HEWL is a monomeric protein composed of 129 amino acids with helix 
rich conformation, and it represents one of the best known model 
proteins to study protein aggregation.115, 116 It has been demonstrated 
that under acidic pH this protein undergo amyloid aggregation (Figure 
7.15b). Hence, activity of several BDMC bearing conjugates, as 
inhibitors of fibril formation was checked by Thioflavin T (ThT) 
fluorescence measuring, which is in correlation with fibril formation. 
ThT is a benzothiazole salt used as a dye to visualize and quantify the 
presence or fibrillization of misfolded protein aggregates, or amyloid, 
both in vitro and in vivo (i.e. plaques composed of amyloid beta found 
in the brains of Alzheimer's disease patients). ThT Assay measures 
changes of fluorescence intensity of ThT upon binding to amyloid 
fibrils (Figure 7.15a). The enhanced fluorescence can be observed by 
fluorescence microscopy or by fluorescent spectroscopy. The 
spectroscopic assay is normally used to monitor fibrillization over time. 
a)                                                         b) 
 
Figure 7.15. a) Schematic representation of ThT fluorescence changes 
upon protein fibrillization. b) Pictures of HEWL unimers and HEWL 
fibrils upon heating at 60 °C and vigorous stirring during 24 h, pH 2.0. 
Then, several BDMC bearing compounds and free BDMC, for 
comparison, at two different concentrations (10 and 50 μM BDMC-eq.) 
were incubated for 24 hours with HEWL (2 mg∙mL-1 solution) at 60 °C 
under vigorous magnetic stirring, and at low pH in order to favor 
amyloid aggregation. PBS solutions and the polymeric carrier were 
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used as positive controls. It is worth mentioning that, no fibrillation was 
found neither when HEWL was incubated at r.t. nor when no magnetic 
stirring was used. Aliquots of the fibril samples were taken at different 
time points and mixed with ThT aliquots for 5 minutes. Finally, 
fluorescence was measured in a VictorTM Wallace (λexc 450 nm and λem 
510 nm) and background fluorescence from curcuminoid subtracted. 
(Figure 7.16). By this assay, it could be concluded that the polymer 
conjugates exhibits a fibril inhibitor behavior slightly better (although 
no significantly different) than free BDMC. It was also clear that, 
activity of the conjugates was mainly due to the presence of 
curcuminoid and not to the PGA chains. The use of higher 
concentrations (50 μM drug-eq.) did not improved the results obtained 
when compared with lower concentrations (10 μM drug-eq.). 10 μM 
BDMC-eq was selected then, as the concentration to move forward. 
a) 
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b) 
 
Figure 7.16. ThT fluorescence intensity changes upon time in HEWL 
samples incubated with different BDMC conjugates at a) 10 µM 
BDMC-eq. and b) 50 µM BDMC-eq. n> 3, mean ± SEM. 
These results were further confirmed by TEM, as it can be 
observed in Figure 7.17. 
 
Figure 7.17. TEM pictures obtained from HEWL incubated samples 
within the different BDMC polyglutamate derivatives at 10 μM 
BDMC-eq. (c-e) in comparison with a) Control PBS and b) Free 
BDMC 10 μM. 
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7.2.3.4. Effects of X-Click-BDMC on Aβ induced 
neurotoxicity in hippocampal organotypic cultures. 
These studies were performed in collaboration with the 
company Neuropharmatest S.L. who developed the organotypic 
cultures. The neuroprotective effect of the curcuminoid bearing 
polymeric structure was evaluated in organotypic cultures from 
entorhinal cortex-hyppocampus.117 In order to study neuroprotection, 
the experimental design involved pretreatments with the conjugate prior 
to an Amyloid-β peptide (Aβ1-42) triggered injury. This ex vivo model 
has been previously validated to determine neurotoxicity and 
constitutes an effective manner to identify the neuroprotective effect of 
molecules with real therapeutic potential against AD.118 The 
organotypic cultures of slices containing both entorhinal cortex and 
hippocampus are an excellent ex vivo model to monitor the structure 
and physiology of these regions of the limbic system. They preserve the 
principal circuits of hippocampus, including its main excitatory input 
coming from the entorhinal cortex. Besides, they can be maintained for 
long periods of time, optimal to evaluate pharmacological activity on 
neurons or glial cells of the different treatments upon time.117 
Hippocampus and entorhinal cortex are among the most affected 
regions in AD, accumulating a high density of extracellular deposits of 
Aβ peptide, and are partially responsible of the progressive memory 
loss and cognitive impairment observed in this neurological 
disorders.119  
Previous work has provided strong evidence that the synthetic 
peptide Aβ1-42 is able to induce neural injury in this type of organotypic 
culture.118 Hence, the aim was to analyze this cell damage and its 
putative prevention by a pretreatment with the X-Click-BDMC 4 wt% 
using propidium iodide (PI) staining. PI is a polar compound 
impermeable to intact cell membranes, but capable to penetrate 
damaged cells and to bind to nuclear DNA, providing a bright red 
fluorescence.120 This labeling, allow us the quantification of the density 
of degenerated cells in a given region. In our case, the region of interest 
(ROI) was the CA1 region of hippocampus (cornus ammonis 1), where 
several studies have found neurodegenerative effects induced by Aβ 
peptides. 
Viability of the organotypic cultures in the presence of X-Click-
BDMC and absence of Aβ peptides was firstly investigated (48 hours 
incubation). Slices were stained with PI, fixed and finally analyzed by 
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confocal microscopy according to M&M. Our polymer conjugate, up to 
0.2 µM BDMC-eq, did not induce significant changes in IP positive 
nuclei density when compared to control cultures (0.005 µM F(4,18)= 
11.096, ρ= 1; 0.05 µM F(4,18)= 11.096, ρ= 1; 0.2 µM F(4,18)= 11.096, ρ= 
0.41). At 0.5 µM drug-eq. concentration an increase in cell death was 
observed (F(4,18)= 11.096, ρ < 0.0001) (See Figure 7.18).  
 
Figure 7.18. Changes in density (nuclei/1000 µm2) of PI stained nuclei 
in pyramidal layer of CA1 region of hippocampal organotypic cultures 
comparing control cultures treated with vehicle and cultures treated 
with different concentrations of X-Click-BDMC (0.005, 0.05, 0.2 and 
0.5 µM drug-eq.). Asterisk indicate statistically significant differences 
after ANOVA analyses followed Bonferroni’s post hoc tests. n> 3, 
mean ± SEM. 
The concentrations of 0.05 and 0.2 µM drug-eq. were then 
selected in order to have the maximum tolerated concentration to 
provide neuroprotective effects in Aβ1-42 treated cultures. In this case, 
organotypic slices were pretreated with the polymer conjugate 48 hours 
before Aβ cell death induction. Thereafter, cultured slices were treated 
with a second dose of conjugate and Aβ1-42 (1 µM final concentration). 
48 hours later, cell death was quantified after staining with PI, fixation 
according to M&M and analysis by confocal microscopy. In this case, 
pretreatment with 0.2 µM BDMC-eq. induced a significant increase in 
cell death (F(5,19)= 9.574, ρ= 0.006) but not in the case of 0.05 µM 
BDMC-eq. Cultures treated with Aβ1-42 increased cell death when 
compared to controls (vehicle (F(5,19)= 9.574, ρ= 0.0001), and 0.05 µM 
drug-eq. of polymer conjugate (F(5,19)= 9.574, ρ= 0.006)) as shown in 
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Figure 7.19. Pretreatment of cultures with 0.05 µM polymer conjugate 
(F(5,19)= 9.574, ρ= 0.005) or 0.2 µM (F(5,19)= 9.574, ρ= 0.026) before 
Aβ1-42 addition induced a significant decrease in the density of PI 
labeled nuclei when compared with cultures treated only with Aβ1-42 
peptide. (Figure 7.19 and 7.20). 
 
Figure 7.19. Changes in density (nuclei/1000 µm2) of PI stained nuclei 
in pyramidal layer of CA1 region of hippocampal organotypic cultures 
comparing control cultures treated with vehicle (No polymer/No Aβ), 
cultures pretreated with different concentrations of polymer conjugate 
(0.05 µM drug-eq. (Polymer 0.05/No Aβ ) and 0.2 µM drug-eq. 
(Polymer 0.2/No Aβ), exposed only to Aβ1-42 peptide (No polymer/Aβ) 
or exposed to Aβ1-42 and pretreated with different concentrations of 
polymer conjugate (0.05 µM drug-eq. (Polymer 0.05/Aβ ) and 0.2 µM 
drug eq. (Polymer 0.2/Aβ). Blue asterisk in bars indicate statistically 
significant differences from control group and red asterisk indicate 
statistically significant differences from cultures exposed only to Aβ1-42 
peptide (No polymer/Aβ), after ANOVA analyses followed by 
Bonferroni’s post hoc tests. n> 3, mean ± SEM. 
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Figure 7.20. Confocal microscopic analysis of PI staining in the 
pyramidal layer of the CA1 region of hippocampal organotypic 
cultures. A: Control cultures treated with vehicle (No polymer/ No Aβ) 
showing the presence of some scarce nuclei faintly labeled with PI. B: 
Cultures exposed only to Aβ1-42 (No polymer/Aβ) showing abundant PI 
stained nuclei. C & D: Cultures exposed to Aβ1-42 peptide and pretreated 
with 0.05 µM drug-eq. (Polymer 0.05/Aβ) and 0.2 µM drug-eq. 
(Polymer 0.2/Aβ). Density of PI is sensibly decreased in these 
conditions. All the microphotographs in this figure are single confocal 
planes. Scale bar: 25 μm. 
Overall, the construct bearing BDMC tested in organotypic 
cultures shows no toxicity after 48 hours of treatment at the different 
concentrations tested, except for 0.5 µM concentration. When repeated 
doses were applied (in the case of the pretreatment experiment), the 0.2 
µM concentration resulted toxic for the non Aβ1-42 peptide treated 
cultures, however, this concentration was effective for Aβ1-42  toxicity 
prevention. Pretreatment with polymer conjugate at either 0.05 or 0.2 
µM of drug-eq. significantly reduced cell death in Aβ1-42 peptide treated 
cultures. As 0.05 µM concentration resulted enough to produce 
significant neuroprotective effects against Aβ1-42 neurotoxicity without 
being toxic, this concentration was selected to move forwards. Further 
experiments are ongoing in order to identify the possible mechanisms 
of neuroprotection followed by our constructs.  
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7.2.4. X-Click-DO3A-Gd-Cy5.5-BDMC-ANG as the selected 
theranostic agent. From synthesis to in vivo biodistribution studies. 
Taking into account the results obtained in the biodistribution 
experiments with the clicked architectures as well as the potential of the 
BDMC conjugates to treat AD pathology, the design of a final construct 
combining all those features was planned as the next step. Thus, 
synthesis of a new architecture including targeting units (ANG), 
labeling agents (Cy5.5 and DO3A-Gd) and therapeutic agents 
(propargyl moieties and BDMC), based on a bottom-up approach 
through covalent capture of self-assembled structures was carried out. 
In this way, a targeted architecture with potential theranostic 
applications was built up. 
Synthetic wise, first of all, the X-Click-BDMC conjugate was 
obtained as previously described by achieving 2.1 mol% of BDMC 
loading according to UV-Vis quantification at 415 nm with a free drug 
content < 1 wt% of the total drug. DO3A-NH2 cysteamine-2TP and 
Cy5.5 were subsequently introduced following previously described 
protocols for synthesis and purifications (see Chapter 6). Finally ANG-
2-SH was effectively conjugated via disulfide bonds. The final 
conjugate was purified by SEC using Sephadex commercial PD10 
columns. The fractions eluted where monitored by absorbance at 280 
nm in Nanodrop® in order to identify those corresponding to the 
targeted conjugates. Peptide loading was calculated according to 1H-
NMR and UV-Vis via calibration curve at 280 nm achieving 75 % 
conjugation efficiency. Gd3+ was complexed in the last step yielding to 
compound 59 (Figure 7.21, Table 7.5.). 
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Conjugate size was investigated by TEM microscopy as shown 
in Figure 7.22. Bigger sizes than for the previous clicked structures 
were found (100-200 nm) as it could be expected from the high degree 
of surface modification. 
 
Figure 7.22. TEM micrographs of X-Click-DO3A-Gd-Cy5.5-BDMC-
ANG (59). 
As for the other clicked structures evaluated, biodistribution 
experiments were carried out using C57Bl/6 mice and optical imaging 
techniques taking profit from the presence of Cy5.5 dye. The conjugate 
was administered i.v. through tail vein to isofluorane anesthetized mice, 
at a dose of 4∙15 mg∙Kg-1 Cy5.5 eq. Two animals were then sacrificed 
at different time points (1, 3, 7, 14 and 24 h). Again, before sacrificed, 
mice were first anesthetized with a lethal anesthesia cocktail, blood was 
extracted from the cava vein, and perfusion with 10 mL of saline was 
carried out in order to accurately determine the amount of compound in 
brain. Organs were then extracted and their fluorescence was measured 
using the red filter in MAESTRO™. For fluorescence quantification, 
normalized data was obtained by taking always the same pixel area for 
all organs and it was expressed as average signal (counts∙s-1). % ID was 
calculated by using a prior calibration curve of the compound. Data 
obtained has been summarized in Figures 7.23 and 7.24.  
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The biodistribution profile was comparable to those obtained 
for the other clicked architectures (45 and 50, both without BDMC). 
Renal excretion profiles were again observed, and lung accumulation at 
the early time points highlights the bigger size of the structures. 
Although no signs of toxicity were observed, further nanotoxicological 
evaluation is being carried out in order to fully demonstrate the safety 
of these constructs (biochemical analysis, pathological analysis, etc.). 
 
Figure 7.24. Biodistribution at different time points of X-Click-DO3A-
Gd-Cy5.5-BDMC-Ang. 
In the brain, ANG bearing compound offered higher 
accumulation at the early time points, and slow clearance at longer time 
points. Once more, the amount found in brain for these clicked 
architectures is 20-25 times greater than the one obtained for the un-
clicked stars (0.05 % of the ID), being around 1.2 % ID in this case. 
[Chapter 7] 
413 
Figure 7.25 shows the organ fluorescence obtained at the different time 
points in the evaluation of compound 59. 
 
Figure 7.25. C57B1/6 mouse organ fluorescence images obtained at 
MAESTRO™ upon treatment with X-Click-DO3A-Gd-Cy5.5-BDMC-
Ang. 
7.2.5. In vivo activity. 
7.2.5.1. Initial Aβ plaque burden establishment. 
After biodistribution results, a preliminary study to achieve 
proof of concept of pharmacological activity in vivo was designed. For 
that purpose, the mouse strain ArcAbeta was used as Alzheimer’s 
mouse in vivo model. As our idea is to tackle the disease from a 
neuroprotective point of view, young animals (from 8-11 months) were 
chosen. Since this mouse model starts to accumulate plaque burden at 
around 6-9 months of age, excessive and irreversible amounts of Aβ 
plaques will not be present. All experiments carried out with the 
ArcAbeta model were performed at Prof. Rudin’s group (ETH-Zurich) 
through a MINECO-funded research stay. 
As AD mouse models usually present a significant variability 
among the number and stage of plaques, a first experiment was 
designed in order to assess plaque burden on each specific animal. For 
that purpose, the well-known Aβ plaques binding tracer AOI987 was 
used.121 Hintersteiner et al. established that the difference of the 
normalized signal intensities Irel between transgenic and non-transgenic 
mice was highest for a dosage of 0.1 mg∙Kg-1 at 3-4 hours after 
injection, and dye was completely washed out 24 hours after i.v. 
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administration.121 Thus, animals were first head saved and fluorescence 
before and 3 hours after the injection of 0.1 mg∙Kg-1 of AOI987 was 
measured at MaestroTM. Differences among both measurements provide 
an idea about plaque burden before starting the treatments. Figure 7.26 
shows the results. 
 
Figure 7.26. Graphic representation of the difference of fluorescence 
intensities (average signal in scale counts) registered before and after 
AOI987 injection for each ArcAbeta animal related to plaque burden. 
Measurements were register in the spectral section between 660-800 
nm. Yellow bars belong to the animals that were treated afterwards 
with saline, and green bars show the animal group that was treated with 
compound (59). 
In theory, this previous gained data could be used as internal 
standards for each mouse in order to reduce the high variability inherent 
from the animal model. This could be done by measuring plaque 
burden using the same method at the end of the experiment. 
7.2.5.2. Animal treatments. 
Firstly, in vivo safety is a go/no go step for any tested 
compound in order to proceed with its validation. Therefore, a pilot 
study with 59 was designed with a dose schedule selected based on PK 
studies. In this first experiment, animal weight was monitored and 
animal brains were analyzed looking for signs of pharmacological 
activity. Three different groups of animals were chosen: wild type 
animals as control (x2), ArcAbeta animals used as non-treated controls 
injected with saline (x7) and ArcAbeta animals treated with compound 
59 at a comparable dose as that used in the biodistribution studies (2 
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mg∙Kg-1 BDMC eq.) (x7). Although the selected dose could be 
considered low by comparing with different curcuminoid treatments 
found in literature,48, 122 taking into account that 1 % reaches the brain 
(Figure 7.24), it would be enough to trigger therapeutic effects.114  
Animals were injected six times within two weeks without 
showing signs of toxicity as it is depicted in Figure 7.27 where no 
weight loss of the treated animals was observed.  
 
Figure 7.27. Experimental design from the treatments performed in 
ArcAbeta model together with the animal weight registration as a proof 
of treatment safety. 
7.2.5.3. Final plaque burden establishment. 
As previously done for initial plaque burden, the AOI987 was 
planned to be injected i.v. through vein tail in order to determine final 
plaque burden after treatments. Nonetheless, the experiment could not 
be completed. Animals treated showed a huge signal in the head in the 
spectral range of AOI987 fluorescence due to Cy5.5 signal coming 
from compound 59, even before AOI987 injection. To check if this 
signal was due to compound circulation and not by brain accumulation, 
blood was collected and also measured at MaestroTM just before animal 
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killing. Levels in blood were comparable those observed at 24 hours in 
the biodistribution study (same dose used in both experiments). Thus, 
confirming a real accumulation of the compound in the brain region. 
 
Figure 7.28. Blood levels from compound (59) measured by 
fluorescence registered in the spectral range of 660-800 nm 
wavelengths, of ArcAbeta treated animals, 24 hours after experimental 
design (day 15). “Biod” refers to the equivalent amount found at 24 
hours post-administration in the biodistribution study. The different 
numbers refer to the individual treated mouse.  
Animals were killed 24 hours after the last injection and brains 
were cryo-preserved for histological analysis in order to alternatively 
analyze performance. 
Further evidence of brain accumulation was obtained when 
fixed cryo-sections of 10 μm were scanned using the Slide Scanner 
Pannoramic 250 (3D Histech) (Figure 7.29). Nevertheless, although 
there is a clear evidence of compound 59 presence in brain after 
reperfusion, further studies must be done in order to confirm whether 
these spots are located inside the brain or just attached to brain 
vasculature. In the worst scenario, as curcuminoids are described to 
cross the BBB, accumulation in brain vasculature will allow to increase 
compound 59 concentration in brain areas where BDMC can be 
released and enter the brain to perform its biological output. 
[Chapter 7] 
417 
 
Figure 7.29. Zooms from 10 μM brain slides scanned at Slide Scanner 
Pannoramic 250 (3D Histech), after paraformaldehyde fixing, 
corresponding to non-treated and treated animals in the corresponding 
channel of Cy5.5. 
As AOI987 tracer could not provide the expected output from 
the in vivo activity due the masking problem arose by the significant 
accumulation of 59 in mice heads, histological analysis was carried out. 
To that aim, brain slices from samples of treated and untreated 
ArcAbeta mice, as well as control wild types were processed. 10 µm 
thickness slices were fixed using paraformaldehyde 4 % and 
subsequently incubated with the monoclonal antibodies mouse anti-Aβ, 
as well as rat anti-mouse F4/80 antibody for microglia activation 
detection. Staining with the secondary antibodies mouse Alexa 488 and 
Rat Alexa 594 allowed the identification of small and few amyloid 
plaques and microglia activation mainly in the surroundings of such 
deposits. An example of amyloid plaque detection and microglia 
activation after staining optimizations can be found in Figure 7.30.  
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Figure 7.30. Example of staining of half-brain cross-sections from 
untreated ArcAbeta mice. In green, Aβ deposits detected using 1:1000 
dilution of primary mouse monoclonal antibody Beta Amyloid, 1-16 
(6E10) stained with secondary mouse Alexa 488. In red, microglia 
activation detected using 1:500 dilution of rat anti mouse monoclonal 
antibody F4/80, stained with secondary rat anti-mouse Alexa 594. In 
yellow, merge. 
Although the analysis of these brains is still ongoing including 
histological analysis as well as TEM micrographs, unfortunately up to 
now, no determinant proof of pharmacological activity can be drawn.  
On one hand, ArcAbeta model itself encompasses a high 
variation in plaque development including variation in the number of 
plaques as well as variation in the age where process starts. 
Furthermore, variations according to the gender were also found. In our 
specific case, most of the male mice did not present any detectable 
plaque by immunohistochemistry (regardless treatment) whereas 
females presented a highly variable number of plaques. At the 
experiment design, we aimed to overcome such variations by using 
each animal as its own control with the aid of the AOI987 tracer. 
However, that was not possible due to the high signal found in mice 
heads after treatments. With toxicity issues already addressed, next 
steps will include the design of a proper in vivo activity study. Such 
experiment will be based on the long-term treatment of a reasonable 
number of young Alzheimer’s bearing mice for neuroprotection with all 
of them having exactly the same age and same gender (females) in 
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order to diminish variations. Long-term experiments will provide a 
more realistic scenario of the disease and more valuable conclusions 
regarding the potential of polymer therapeutics could be drawn from 
there.  
7.3. CONCLUSIONS. 
In this work, PT, concretely, polymer-drug conjugates for the 
treatment of AD have been synthesized and properly characterized. 
According to previous results obtained in Chapter 6 in terms of 
biodistribution profiles, the bigger covalently captured structures were 
preferred in order to promote brain accumulation, necessary to achieve 
effective treatments for CNS disorders. Curcuminoids, concretely 
BDMC was chosen as a model drug due to its already demonstrated 
activity and potential for the treatment of AD. In combination with 
propargylamine moieties (in clinical studies in AD patients), BDMC 
was conjugated to the clicked structures via ester bonding. In vitro 
performance of the developed constructs was evaluated in terms of cell 
viability, drug release profiles, and in vitro activity as inhibitors of fibril 
formation. Furthermore, when tested in organotypic cultures, 
pretreatment with either 1 or 5 µM BDMC-eq. significantly reduced 
cell death in Aβ1-42 peptide treated cultures. In vitro results, together 
with the biodistribution of BDMC-bearing clicked structure by optical 
imaging highlighted the potential of these nanomedicines for AD 
treatments. Furthermore, compound in vivo safety was demonstrated, 
and a great accumulation in brain surroundings was encountered upon 
treatment. Considering the preliminary results obtained, further ex vivo 
investigation considering other pathological hallmarks of the disease 
where BDMC could be effective are being explored and a proper in 
vivo activity experiment is planned in order to unravel the full potential 
of these systems as nanotherapeutics for neurological disorders. 
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7.4. MATERIALS AND METHODS. 
7.4.1. Materials. 
All chemicals were reagent grade, obtained from Aldrich and 
used without further purification, unless otherwise indicated. All 
solvents were of analytical grade and were dried and freshly distilled. 
Deuterated chloroform-d1, DMSO-d6, and D2O were purchased from 
Deutero GmbH. X-Click architectures were synthesized according to 
conditions described in Chapter 5. DO3AtBu was purchased from 
Chematec. Cy5.5 (6S-IDCC) was obtained from Mivenion. Angiopep2-
cystein Ac-FFYGGSRGKRNNFKTEEYC was obtained from Selleck 
Chemicals LLC. Bisdemethoxycurcumin was obtained from TCI 
chemicals. Glucose was obtained from MERCK, L-glutamin in GBSS 
was purchased from Sigma-Aldrich, Optimem-1 was obtained from 
GIBCO, Aβ1-42 was purchased from TOCRIS. CellMaskOrange® was 
obtained from Molecular-Probes Life Technologies. Beta amyloid 1-16 
(6E10) Monoclonal Antibody was purchased from Covance. Rat anti 
mouse F4/80 was purchased from AbD Serotec. Anti-Fluorescein/ 
Oregon Green Goat polyclonal IgG Alexa Fluor 488 were purchased 
from Invitrogen. Preparative SEC was performed using Sephadex G-25 
superfine from GE as well as PD MiniTrap G-10 ™ columns 
containing 2.1 mL of Sephadex™ G-10. Dialysis was performed in a 
Millipore ultrafiltration device fitted with a 3, or 5 kDa MWCO 
regenerated cellulose membrane (Vivaspin®). 
 Animals: Transgenic ArcAbeta mice and wild type littermates 
(C57Bl/6 mice) of either gender (Division of Psychiatry Research, 
University of Zurich) were used. Animals were kept at standard 
housing conditions: light/dark cycle of 12 hours, temperature of 20-24 
°C, relative humidity minimum 40 %, with free access to food and 
water. All experiments were performed in accordance with the Swiss 
Federal Act on Animal Protection. 
7.4.2. Characterization techniques. 
The equipment used for characterization within this chapter is 
already described in previous ones. See Chapter 2 for NMR and GPC; 
Chapter 3 for VictorTM Wallace; Chapter 5 for TEM microscopy; 
Chapter 6 for Nanodrop ® and MaestroTM. 
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7.4.3. Protocols. 
7.4.3.1. Bisdemethoxycurcumin (BDMC) conjugation to 
PGA-based polymers. 
 Conjugation of BDMC was carried out using DMTMM∙BF4 
protocol described in Chapter 4 with slight modifications. Briefly, in a 
two-necked round bottom flask, fitted with a stirrer bar and two 
septums, the corresponding polymer was dissolved in 10 mL of anh. 
DMF under nitrogen atmosphere. After that, 1.5 eq. of DMTMM∙BF4 
of the desired percentage of GAU modification was added in 5 mL 
more of anh. DMF. Reaction was left to proceed for 10 minutes. Then, 
1.5 eq. of the desired percentage of GAU modification were added to 
the reaction mixture, followed by a catalytic amount of DMAP. The pH 
was checked to be around 7. Reaction was then left to proceed for 72 
hours. For purification, the mixture was poured into a large excess of 
diethyl ether. After isolation, the yellowish solid was converted into 
sodium salt form by careful addition of NaHCO3 1 M. Then, the 
aqueous solution was washed with diethyl ether till no yellowish 
coloration was found in the organic phase. Finally, the product in 
aqueous phase was purified by dialysis using Vivaspin® MWCO 5000, 
and freeze-dried. BDMC contain was determined by UV-VIS at 415 
using a calibration curve with free BDMC. FDC was estimated by 
HPLC following the method: eluent A was ddH2O and eluent B was 
acetonitrile. Samples were analyzed using the following gradient: from 
40 % B to 80 % B over 20 min using Lichrospher 100 RP 18, 5.0 µm 
(dimension: length x ID)= 125 x 4.0 mm). BDMC retention time (tr) 
5.98 minutes. Experiments were done per triplicate. % of free drug was 
established by performing a calibration curve with BDMC dissolved in 
the mixture ddH2O/Acetonitrile (50/50) and injected under the same 
HPLC conditions 
7.4.3.2. Synthesis of X-Click-DO3A-Gd-Cy5.5-BDMC-ANG 
(59). 
Starting from X-Click-BDMC (2.1 mol% GAU loading of 
BDMC) sodium salt, all the methods developed for the synthesis of 59 
are described in M&M of Chapter 6. Firstly, DO3A-NH2 was 
conjugated following the already described DMTMM∙Cl protocol for 
reaction conditions. The product was purified by dialysis using 
Vivaspin® MWCO 5000 and DO3A-NH2 content was estimated as 10 
% GAU according to 1H-NMR and further confirmed after Gd 
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complexation. After that, the isolated product was then modified with 
cysteamine-2TP following the same procedure for conjugation and 
purification as for DO3A-NH2. Cysteamine-2TP content was estimated 
as 10 % GAU by 1H-NMR in D2O according to the corresponding 
aromatic signals of 2TP group. Next, Cy5.5-NH2 was then conjugated 
to the already synthesized construct using the same DMTMM∙Cl 
protocol for reaction conditions. Purification was also performed by 
dialysis using Vivaspin® MWCO 5000, and the Cy5.5 content was 
determined by fluorescence at λexc: 595 nm, λemi: 680 nm as 0.95 mol% 
of GAU. ANG-2-SH was effectively conjugated via disulfide bonds in 
HEPES buffer at pH 7.4 over 16 hours. The final conjugate was 
purified by SEC using Sephadex commercial PD10 columns. The 
fractions eluted where monitored by absorbance at 280 nm in 
Nanodrop® in order to identify those corresponding to the targeted 
conjugates. Peptide loading was calculated according to 1H-NMR and 
UV-VIS via calibration curve at 280 nm achieving 1.5 mol% of GAU 
(75 % conjugation efficiency). Finally, Gd3+ was complexed in the last 
step by following the protocol of Chapter 6, in PBS 0.1 M yielding to 
compound 59. 
7.4.3.3. Cytotoxicity assessment of BDMC-conjugates. 
SHSY5Y cell line was seeded in sterile 96-well microtitre 
plates at a cell density of 35000 cell∙cm-2. Plates were incubated for 24 
hours and BDMC bearing compounds (0.2 μm filter sterilized) were 
then added to give a final concentration range of 0-15 µM eq. BDMC. 
After 72 hours of incubation, MTS/PMS (20:1) (10 μL of manufacturer 
solution) was added to each well, and the cells were incubated for a 
further 2 hours. Optical density of each well was measured at 490 nm. 
Plates were read spectrophotometrically using a VictorTM Wallac plate 
reader. The absorbance values were represented as percentage of cell 
viability taken as 100 % cell viability of untreated control cells.  
7.4.3.4. Drug Release Kinetics. 
 Drug release kinetics of X-Click-BDMC 4 % were performed at 
three different pHs (5.0, 6.5 and 7.4). In all cases, as BDMC might 
precipitate in the aqueous solution upon degradation, a stock solution 
was prepared, and from that one, aliquots of 100 µL containing the 
same mg of polymers were prepared at the beginning of the experiment. 
Hence, the whole aliquot will be taken for HPLC analysis, avoiding the 
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loss of precipitated product. Briefly, X-Click-BDMC 4 wt% was 
dissolved at 4 mg∙mL-1 in PBS buffers at different pH and subsequently 
aliquoted. Samples were incubated at 37 °C and freeze-dried at 
different time points, re-suspended in 100 µL of the mixture 
ddH2O/Acetonitrile (50/50) and injected in HPLC following the 
method: eluent A was ddH2O and eluent B was acetonitrile. Samples 
were analyzed using the following gradient: from 40 % B to 80 % B 
over 20 min using Lichrospher 100 RP 18, 5.0 µm (dimension: length x 
ID= 125 x 4.0 mm). BDMC retention time (tr) 5.98 minutes. 
Experiments were done per triplicate. % of drug released was 
established by performing a calibration curve with BDMC dissolved in 
the mixture ddH2O/Acetonitrile (50/50) and injected under the same 
conditions as for the degradation samples. 
7.4.3.5. Prevention of HEWL Lysozyme fibril formation. 
Thioflavin T fluorescence assay. 
 HEWL fibrils were formed using 2 mg∙mL-1 Hen Egg White 
Lysozyme in acidic buffer 12 Mm HCl containing 140 nM NaCl and 
2.7 mM KCl (pH 2). Samples were magnetically stirred at 60 °C up to 
24 hours for fibril formation. Kinetics of fibril formation was followed 
from time cero by ThT-based titration method. Typically, a 100 μM 
solution of ThT was prepared by dissolving ThT powder in PBS pH 
7.4. Aliquots of 20 μL of HEWL solution were collected at time 
intervals and mixed with 100 μL of ThT solution in a dark 96-well 
plate. Samples were left to stabilize for 5 minutes and fluorescence was 
measured at 590 nm in the plate reader VictorTM Wallace. For 
compounds evaluation in terms of prevention of fibril formation, those 
fibrils were incubated with 10 or 50 μM BDMC eq. of the compounds 
dissolved in a minimum volume of PBS buffer 7.4. In control samples, 
the same amount of PBS buffer without compound was added. Free 
BDMC was added dissolved in a minimum amount of ethanol 
(maximum ethanol percentage 1 % in the final volume).  
7.4.3.6. Prevention of neurotoxicity induced by Aβ1-42 in 
organotypic cultures. 
7.4.3.6.1. Organotypic hippocampal slice cultures. 
Mice pups (B6.Cg-Tg(Thy1-YFP)HJrs/J) were used to obtain 
transverse hippocampal organotypic slice cultures with a McIIwainTM 
Tissue Chopper (350 µM thick).117 Briefly, brains were placed into 
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Petri dishes filled with cold (4 °C) sterile dissecting medium (1 % 
glucose (0.5 g∙mL-1), 0.2 % penicillin/streptomycin, 0.5 % L-glutamin 
in GBSS. The overlying pia was gently removed and coronal cuts were 
made to remove portions of the rostral and caudal poles, leaving the 
frontoparietal region intact. The right and left cortices were cut 
simultaneously in the coronal plane at a thickness of 350 µM using 
McIIwainTM Tissue Chopper. Slices obtained were transferred into 
dissecting medium and separated gently by agitation. Slices containing 
hippocampus and entorhinal cortex were placed on moistened 
translucent membranes of tissue culture inserts (0.4 µM, Millicel-CM, 
Millipore, Bedford, MA. USA) and immersed in 1 mL of Serum-
OPTIMEM culture medium (25 % heat inactivated horse serum, 25 % 
HBSS, 50 % Optimem-1 supplemented with 10 µL∙mL-1 glucose. Three 
slices were cultured in the same insert and six inserts were placed 
together in 6-well plates. To ensure that slices from control and treated 
groups were cultured under identical conditions, three inserts from each 
place were designated as control group and the other three as treated 
groups. Cultures were stored in a humid atmosphere at 37 °C in 5 % 
CO2 for 16 days (HERAcell® 150i, Thermo Scientific) and medium 
was changed three times per week, always replacing half of it (0.5 mL 
out of 1). 
7.4.3.6.2. Organotypic culture viability assay upon X-
Click-BDMC treatments. 
The polymer conjugate was dissolved in ddH2O and added to 
the culture media at different concentrations at day 16th of organotypic 
culturing. Compounds were incubated within the cultures for 48 hours. 
After that, tissue cultures were stained with PI (10 µM) for 10 minutes, 
washed with PBS (x3) and fixed with paraformaldehyde (PFA) 4 %. 
Tissue samples were again washed with PBS (x3), let to dry, and 
mounted using DAKO-glycergel media containing DAPI. Cell damage 
was assessed by fluorescent image analysis of PI uptake. Cultures were 
observed with an upright confocal microscope (Leica TSE). Images 
were captured and analyzed using FIJI Image Software. After capture 
of images, the density of PI nuclei was analyzed in the pyramidal layer 
of CA1. For each experimental group, mean ± SEM was determined 
and the resulting values analyzed by one-way ANOVA with the 
number of slices as the “n”. Significant effects were further analyzed by 
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Bonferroni post-hoc test, using the IBM SPSS statistics software 
(version 22). 
7.4.3.6.3. Aβ1-42 neurotoxicity induction and prevention 
by using X-Click-BDMC. 
For the establishment of Aβ1-42 toxicity induction, 1 mg of Aβ1-
42 peptide was dissolved in ddH2O to prepare a stock solution of Aβ1-42 
(0.5 mM) that was stored at -20 °C. Prior to use, Aβ1-42 was aggregated 
at 37 °C for 72 hours. In order to establish neurotoxicity inducement, 
on the 16th day of the organotypic culture, Aβ1-42 peptide was added by 
replacing half of the media, obtaining a final concentration of 1 µM. In 
the case of pretreated cultures, (controls with and without Aβ1-42), the 
polymer conjugated dissolved in ddH2O was added at different 
concentrations (0.05 and 0.2 µM) at 14th (prevention) and 16th 
(maintenance) days After that, tissue cultures were stained with PI (10 
µM) for 10 minutes, washed with PBS (x3) and fixed with 
paraformaldehyde (PFA) 4 %. Tissue samples were again washed with 
PBS (x3), let to dry, and mounted using DAKO-glycergel media 
containing DAPI. Cell damage and statistical analysis were carried out 
as for the previous epigraph. 
7.4.3.7. In vivo Biodistribution. 
In vivo biodistribution studies were performed as for Chapter 6, 
section 6.4.3.7. 
7.4.3.8. Plaque burden determination using AOI987 tracer. 
 Transgenic ArcAbeta mice and wild type littermates (C57Bl/6 
mice) were shaved in the head for the study. Then, mice were 
anesthetized using 1.5 % of isofluorane and fluorescence was recorded 
as background prior to tracer injection at MaestroTM at the spectral 
range 660-800 nm. For this, mice were transferred to a pre-warmed (37 
°C) platform in the small animal imaging system (CriMaestro 500), 
with maintained anesthesia using an anesthesia mask. Then, AOI987 
tracer was injected i.v. (0.1 mg∙Kg-1).121 Three hours after injection, 
animals were again anesthetized using 1.5 % isofluorane and 
fluorescence was again recorded. For fluorescence quantification, 
normalized data was obtained by taking always the same pixel area for 
all of the organs expressed as average signal (counts∙s-1). (See section 
6.4.2.2) 
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7.4.3.9. In vivo preliminary activity study. 
Transgenic ArcAbeta mice and wild type littermates as controls 
(C57Bl/6 mice) were used. Animals weight was 27.5 ± 5.5 g. Mice 
were anesthetized with 1.5 % isofluorane. Compound 59 was 
administered i.v. through the vein tail via cannula, at a dose of 2 
mg∙Kg-1 BDMC eq. six times during two weeks (see Figure 7.27). 
ArcAbeta control animals were injected with equivalent volumes of 
saline. 24 hours after the last injection, animals were sacrificed. Blood 
samples were extracted from the cava vein of the anesthetized mice 
with a lethal anesthesia cocktail (i.e. for 20 g mice 200 µL from the 
solution containing ketamin 100 mg∙Kg-1, Xylasin 100 mg∙Kg-1, 
Acepromacide 2 mg∙Kg-1). Blood fluorescence was registered at 
MaestroTM following previous described protocols in Chapter 6. 
Perfusion with 10 mL of saline was then performed. Brains were 
extracted immediately after and frozen for histological analysis 
according to Section 7.4.3.10.1. 
7.4.3.10. Histology. 
7.4.3.10.1. Tissue freezing and conservation. 
Immediately after animal sacrifice, perfused brains were 
extracted and frozen embedded in OCT (Tissue-Teck®; Sakura Finetek 
USA) at -40 °C using 2-methylbutane and liquid nitrogen. Cryostat 
NX70 (Thermo Scientific) was employed for brain sectioning. Coronal 
frontal sections of 10 μM were cut from previously frozen in OCT 
brains. When cut, sections were transferred to a microscope slide by 
touching the slide to the tissue and preserved at -80 °C till used for 
histology processes. 
7.4.3.10.2. Brain sections fixing and 
immunohistochemistry protocols. 
a) Brain fixing and staining for Compound 59 accumulation 
determination. 
Brain sections were left drying for 16 hours prior fixation. A 
border surrounding brain slices was made using a lipid pen. Then, the 
microscope slide containing brain sections were placed into a wet 
chamber and fixed with paraformaldehyde 4 % over 10 minutes. After 
that, samples were washed three times with PBS 1X for 10 minutes 3 
times. Next, samples were stained with a dilution 1:50 in PBS 1X, from 
the commercial recommendation (1.5X) of CellMaskOrangeTM a 
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specific membrane marker, for 30 minutes protected from light. 
Afterwards, samples were again washed with PBS 1X for 10 minutes 3 
times. Finally, samples were mounted with DAKO glycergel mounting 
medium and covered with cover slips.  
b) Brain fixing and staining for plaque burden determination 
combined with macrophage activation markers. 
Brain sections were left drying for 16 hours prior fixation. A 
border surrounding brain slices was made using a lipid pen. Then, the 
microscope slide containing brain sections were placed into a wet 
chamber and fixed with paraformaldehyde 4 % over 10 minutes. After 
that, samples were washed three times with PBS 1X for 5 minutes. 
Next, samples were incubated with a mixture of two antibodies in PBS 
containing 1:1000 of primary mouse monoclonal antibody Beta 
Amyloid, 1-16 (6E10), 1:500 rat anti mouse monoclonal antibody 
F4/80, 1:100 Normal Goat Serum (NGS) and 1:100 Triton. Samples 
were left slowly shaking overnight at 4 °C. After that tissues were 
washed with PBS 1X 3 times for 10 minutes, and the stained with the 
secondary antibodies for each primary one at dilutions 1:1000 for each 
antibody (mouse 488 and rat 594) with 1:100 NGS and 1:100 triton. 
Samples were left at r.t. slowly stirring for 1 hour. Then, slides were 
washed with PBS 1X for 10 minutes three times. Finally, samples were 
let dry, mounted using DAKO glycergel mounting medium and covered 
with cover slips.  
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8.1. INTRODUCTION AND BACKGROUND. 
8.1.1. Exposing the need for early diagnosis. 
This additional chapter has been developed on the frame of a 
European Project based on the development of molecular diagnosis 
probes that could be redirected in the frame of this thesis towards 
neuroimaging, possibility currently being explored with some of the 
developed probes.  
LiVIMODE (Light-based Functional In Vivo Monitoring of 
Disease-related Enzymes) was a European research consortium within 
FP7 with scientists from universities, research organizations, and a 
global healthcare leader, Sanofi-Aventis. 
Structural tissue changes are commonly late indicators of a 
pathological cascade. Understanding the molecular processes in living 
cells during the formation and progression of diseases such as cancer, 
rheumatoid arthritis and osteoarthritis is crucial for the development of 
new diagnostic tools and treatments. Non-invasive visualization of 
unique molecular processes behind human pathology (or models) 
would provide highly specific and potentially early indicators of 
ongoing diseases. These molecular processes are, i.e., up regulation or 
activation of specific disease related factors, in particular enzymes such 
as proteases like metalloproteases (MMPs) or cathepsins.  
In this context, LIVIMODE main aim was the development of 
novel powerful imaging agents, which were intended for the direct 
visualization and investigation of disease-related molecular processes in 
living cells and in diagnostic imaging. The efforts were mainly focused 
on highly sensitive optical imaging methods, which allow such direct 
visualization of specific molecular events (disease-related enzymes 
activity) in the living cell. The overall objective of LIVIMODE was 
thus to develop an in vivo imaging platform based on protease-activated 
smart ligands that allow non-invasive quantitative assessment of target 
expression in diseased tissue (diagnosis) and monitoring of disease 
progression (staging). These tools are of high relevance for disease 
detection, monitoring of disease progression, developing animal models 
of human disease and evaluating novel therapies.  
Imaging of specific molecular events puts high demands on the 
sensitivity of the imaging technique, therefore the main methods of 
interest for this task are nuclear and optical imaging methods, in 
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particular those in the near-infrared spectral domain, capable of sensing 
nano- and femtomolar concentrations of analytes in vivo. Hence, optical 
imaging was proposed within this consortium, which is optimally suited 
for this task as it provides excellent sensitivity and allows visualizing of 
molecular events via fluorescence signal. Moreover, significant 
progress has been recently made in the area of optical imaging 
technology, enabling a three-dimensional quantitative mapping of 
fluorophore distribution within a turbid medium (tissue). Non-invasive 
quantitative imaging of disease-specific molecular markers has the 
potential to overcome the limitations of the currently available imaging 
technologies such as X-ray-CT, MRI. Conventional imaging methods, 
such as angiography, CT, MRI, and radionuclide imaging, rely on 
contrast agents (i.e. iodine, gadolinium, and radioisotopes) that are 
“always on”.1 Although these indicators have proven clinically useful, 
they lack of sensitivity due to inadequate target-to-background signal 
ratio. A unique aspect of optical imaging is that fluorescence probes 
can be designed to be activatable, that is, only “turned on” under certain 
conditions. This feature of “turning on” only at the target has been 
termed as activatable or “smart”. 
However, while optical imaging technology has rapidly 
evolved over the last years, the availability of smart imaging agents that 
change their fluorescence properties upon disease related events 
remains a challenge. To date, activatable protease agents for optical 
imaging have already been successfully applied2, 3 to visualize primary 
tumors and metastases,3-6 inflammatory processes in active 
atherosclerotic plaques,7, 8 degenerative joint diseases9-12 and pulmonary 
inflammation13-15 among other applications.16, 17 Nonetheless, the most 
critical gap in molecular imaging approaches is the availability of 
target-specific and tissue-specific imaging probes. Nevertheless this 
first generation of activatable imaging agents tend to suffer from 
insufficient selectivity for the targeted disease-related molecular event, 
and from suboptimal pharmacokinetic properties.18 Thus, the purpose of 
this project was to overcome this gap by providing target specificity as 
well as tissue specificity.  
Among disease-related factors, proteases are a class of enzymes 
usually highly up-regulated. The combination of their high disease-
specific expression levels with their ability to cleave substrates at high 
turnover rate make them attractive targets for imaging probes. On the 
frame of this project, targets for the smart probes were selected from 
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proteolytic enzymes with the aim of enabling the monitoring of critical 
processes occurring in tumor progression, inflammation and 
degenerative joint diseases. In all these cases, symptomatic complaints 
of patients are often made at a late-stage and effective treatments may 
no longer be available. For that reason, is crucial to be able to monitor 
disease progression (and treatment) at the early stages in order to decide 
suitable treatment options, dosage schedules or even drug 
combinations. Molecular mechanisms that underlay those diseases are 
different, however, it has been clearly shown that proteases play key 
roles in early and progressive stages of all of them.19-22 Proteases cleave 
biologically important molecules with a high turnover rate, in a specific 
manner and affect the disease progression by changing cellular 
environments. Moreover, many of them are elevated and localized in 
the lesions making them the perfect targets for this technology, where 
non-invasiveness is pursued. Hence, herein, selective chemical probes 
cleavable by locally activatable proteases (smart probes) leading to 
signal changes for diagnosis were purposed. 
As mentioned at the beginning of the chapter, although the 
target-diseases are those listed before, this approach could be used for 
the development of smart-activatable probes for the early diagnose of 
neurodegenerative diseases as well (particularly MMPs 2, 9, 12 and 13, 
as well as Cathepsin B for AD diagnosis).23-31  
8.1.2. Proteases of interest. 
8.1.2.1. Monitoring tumor microenvironment, angiogenesis 
and hypoxia. 
Recent approaches for cancer therapy target tumor 
microenvironment in contrast to classical chemotherapeutic agents that 
target cancer cells. That communication within the tumor 
microenvironment is mainly mediated by proteases. During cancer 
progression, some proteases have been found to be overexpressed 
disturbing the normal balance between proteases and their endogenous 
inhibitors and leading to the activation of downstream effector 
molecules. The following examples of proteases are well studied and it 
is well known that they are overexpressed in cells or interstitium of the 
tumor microenvironment, as well as their role in tumor development or 
treatment. Therefore, that makes them ideally suited for activation of 
smart probes. 
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Tumor-associated fibroblasts (TAFS) are involved in 
carcinoma cell invasion and increase the tumor interstitial fluid 
pressure, decreasing delivery of anti-cancer drugs.32-34 FAP fibroblast 
activation protein, is his inhibitor and is highly expressed in tumor-
associated fibroblasts.35, 36 Therefore, a probe detecting FAP protease 
activity could be used to detect the presence of tumor-associated 
fibroblasts.37 Some metalloproteases have a great potential as 
diagnostic biomarkers and are highly overexpressed in various 
tumors,21, 38-40 as well as cysteine cathepsins that contribute to tumor 
angiogenesis, inflammation, metastasis spread and tumor cell 
apoptosis.41-44 Cysteine proteases caspases play a major role in cancer 
cell apoptosis.45-48 Table 8.1 summarizes the opportunities to develop 
smart activatable probes based on the activity of the mentioned 
proteases. 
Table 8.1. Proteases of interest for cancer and joint diseases. 
Protease Protease Class Cancer OA 
ADAMTS-4 Metallo + + 
ADAMTS-5 Metallo + + 
Caspase 1 Cysteine - + 
Caspase 3 Cysteine + ? 
Caspase 7 Cysteine + ? 
Cathepsin B Cysteine + + 
Cathepsin K Cysteine - + 
Cathepsin L Cysteine + ? 
Cathepsin S Cysteine + + 
Legumain Cysteine + ? 
FAP Serine + ? 
MMP-13 Metallo + + 
MMP-2 Metallo + + 
MMP-9 Metallo + + 
MMP-14 Metallo + ? 
MMP-12 Metallo + ? 
CPA4 Metallo + - 
CPD/TAFI Metallo +/? -/+ 
*ADAMTS: A disintegrin and metalloproteinase with thrombospondin motifs, 
CPA: Carboxypeptidase A CDP: Carboxypeptidase D, FAP: fibroblast 
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activation protein, MMP: Matrix metalloproteinase OA: Osteoarthritis, TAFI: 
Thrombin-activatable fibrinolysis inhibitor 
8.1.2.2. Osteoarthritis: diagnosis, treatment and challenges. 
Osteoarthritis is the most prevalent age-related degenerative 
joint disease characterized mainly by a gradual loss of articular 
cartilage and deformation of the bone;49, 50 and currently there is no 
effective disease-modifying treatment except surgery. There are many 
causes of cartilage loss and many etiological factors to its 
progression.51-54 The primary cause is the elevated level of proteases,19, 
20, 55 therefore, it is attractive to consider selective protease inhibitors as 
potential therapeutics. The main gap in this field is the lack of early-
stage disease diagnostic tools, key for the success of any current 
therapy. Therefore, the development of non-invasive imaging methods 
capable to detect molecular changes is required. 
8.1.3. Smart Imaging Agents. 
Activity based imaging agents (smart probes) are commonly 
designed as FRET (fluorescence resonance energy transfer) pairs, 
photoactivatable fluorescent or bioluminescent probes generating a 
fluorescent or luminescent signal upon enzymatic hydrolysis of a 
chemical linker or a peptide bond.56 Near-infrared (NIR) fluorescence 
(650-900 nm) detection is the preferred range because it avoids the 
background fluorescence interference of natural biomolecules, 
providing a high contrast between target and background tissues. 
Modern NIR fluorescent in vivo imaging is usually performed with 
internally quenched FRET probes with an emission band in the near 
infrared. Indeed, protease probes have commonly been based on 
peptidic substrates coupled to FRET pairs.57 An alternative to this 
approach is the development of high densely loaded fluorophores into a 
polymer backbone in such a way that self-quenching phenomena does 
occur. In this case, polymer degradation under specific biological 
stimuli (including protease activities) will trigger the fluorescence 
signal.3 Figure 8.1 shows both strategies. Up to date, both strategies 
suffer from different limitations: FRET pair based small probes, exhibit 
limited cell permeability in vivo, poor tissue specificity and non-
specific cleavage by related proteases; High-densely loaded polymeric 
probes offer good tissue selectivity but poor and limited protease 
selectivity (limited to polymer degradation). 
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a) 
 
b) 
 
Figure 8.1. First generation activatable probes for proteases. a) 
Classical design using a peptidic sequence preferred by the desired 
protease combined with a FRET reporter pair (NIR Dye and Quencher). 
b) Poly(lysine) based activatable probe (polymeric probe) densely 
loaded with a fluorescent reporter (self-quenching). 
Thus, there is an exposed need for a second generation of smart 
activatable imaging agents. In order to design a successful activatable 
smart probe, several considerations must be taken into account. It has to 
be: (i) highly selective for the disease related enzyme, that (ii) 
accumulate at the target site, (iii) while being efficiently cleared from 
the remaining part of the body. Those considerations could be defined 
as tasks for this project, where: 
a) Target specificity was achieved by the use of modern 
medicinal chemistry based on reverse designs using chemically 
optimized selective protease inhibitors with high affinity for the desired 
protease that can be indeed transformed into not only selective but also 
catalytically efficient smart agents. This task was accomplished by our 
pharmaceutical collaborators from Sanofi-Aventis, EMBL and CEA-
Saclays. 
b) Tissue specificity. The second task was to provide a 
biocompatible polymeric scaffold for the low molecular weight smart 
activatable probes to enhance the tissue and molecular selectivity as 
well as the pharmacokinetic properties. The selective enrichment in the 
tissue of interest should either occur passively through enhanced 
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permeability and retention effect or by specific tissue-targeting 
residues. This second task was the one developed in our lab using 
polyglutamic acid based carriers. 
Therefore, our contribution and main aim within LIVIMODE 
was to enhance the tissue and molecular selectivity of the low 
molecular weight smart activatable probes synthesized by other 
partners. This was achieved by means of polymer therapeutics: (i) 
Seeking selective enrichment in the tumor/joint environment through 
EPR effect and by specific tissue-targeting residues (RGDs, for tumor 
targeting, Rothenfluh peptides for cartilage targeting, alendronates for 
bone targeting…). For specific proteases, this resulted in higher signal 
intensity in tumors/joints and improve specificity versus protease 
activity expressed in other locations. (ii) Improving pharmacokinetics 
of probes (optimized half-life, tissue distribution) and by, (iii) 
Optimizing signal intensity by targeting retention of cleaved probe.  
8.2. RESULTS AND DISCUSSION. 
In this study highly specific turnover-based reporters, were 
combined with polymeric carriers for an efficient tissue selective-
delivery of activatable smart probes. The potential of PGA as 
nanocarrier systems for optical imaging of disease related enzymes is 
presented here in terms of in vitro assays, in cell cultures and in some 
cases, in terms of in vivo proof of concept. In the frame of this 
additional chapter, only the most relevant results from the LIVIMODE 
project are discussed. 
8.2.1. Smart probes. 
In order to achieve the previously described goal, linear PGA 
was used as polymeric platform due to its intrinsic properties already 
described in the introductory chapter. On one hand, several 
functionalities (alkynes, azides, or maleimides) for orthogonal 
couplings were introduced within the developed smart probes in their 
synthetic strategies carried out by our partners. On the other hand, the 
corresponding complementary moieties were included within the PGA 
backbones in order to accomplish those named orthogonal reactions. 
These functionalities were easily introduced following the post-
polymerization modification methodology described in Chapter 4.  
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8.2.1.1. MMP-based probes. 
As introduced before, MMP family is involved in the 
breakdown of extracellular matrix in normal physiological processes, 
such as embryonic development, reproduction, and tissue remodeling, 
as well as in disease processes such as inflammatory disorders, 
regulation of tumor microenvironment and diseases such as atheroma, 
arthritis, cancer and tissue ulceration. MMP-12 also known as 
macrophage elastase (ME), is almost exclusively produced by 
macrophages58 and is essential for macrophage migration.59 MMP-12 is 
considered an important target due to its involvement in diseases such 
as cancer,60 asthma,61 allergy,62 pulmonary (emphysema)63 and skin 
inflammation,64 as well as in arthritic.65 Biological studies of Gelatinase 
B (or MMP-9) relate such proteolytic enzyme primarily with cancer 
and later on with vascular and inflammatory diseases. These facts have 
generated interest in targeting MMP-9 in acute lethal conditions, such 
as bacterial meningitis, sepsis and endotoxin shock, and in acute 
aggravations of chronic diseases.66 Finally, MMP-13 or collagenase 3 
was firstly encountered and described in human breast cancer.67 68 
Later, it was correlated with OA, after finding it in chondrocytes69 and 
as an mRNA in synovial membrane in OA and rheumatoid arthritis 
(RA).70, 71 
Due to their high relevance under pathophysiological 
conditions, efforts have been devoted in the development of selective 
probes for such enzymes. A detailed description of the probes 
developed for MMP detection so far can be found in the very recent 
review by Knapinska and Fields.72 The main handicaps in the 
development of MMP probes is that their recognition sequence is 
usually broad and shared among MMPs. For instance, the commercial 
probe MMPsense, with the sequence Gly-Gly-Pro-Arg-Gln~IleThr-
Ala-Gly, detects the activity of MMP-2, -7, and -9 in vivo by 
fluorescent molecular tomography.73, 74  
8.2.1.1.1. MMP-12 conjugates. 
As a first approach, and in order to optimize the chemistry and 
characterization of the final constructs, “in vitro” smart probes were 
developed. This family of activatable probes was based on the classical 
design using a peptidic sequence (substrate for MMP-12) combined 
with a FRET reporter pair (dye and quencher) and a chemical tag, for 
their conjugation within the polymer backbone (Scheme 8.1). The 
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FRET pair of these so-called “in vitro” probes consisted on the highly 
fluorescent 7-methoxycoumarin group that is efficiently quenched by 
energy transfer to the 2,4-dinitrophenyl group. 
 
Scheme 8.1. Generic chemical structure of MMP-12 in vitro probes.  
Within the optimization process for probe conjugation different 
parameters were taken into account in a first study: linker design 
(spacer) and peptide loading. For that purpose, three different spacer 
length were used: -CH2-, in the case of alkyne-functionalized polymers 
with propargyl amine; -EG(2)-, in the case of azide-functionalized 
polymers with NH2-EG(2)-N3, and -EG(6)- in the case of azide-
functionalized polymers with NH2-EG(6)-N3. In all cases, probe 
conjugation was carried out with the optimized conditions for CuAAC 
(Chapter 4), in DMF/ddH2O mixtures (4:1), under nitrogen atmosphere 
and at 60 °C during 72 hours (Scheme 8.2). 
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Scheme 8.2. Conjugation scheme of the activatable probe to 
functionalized PGAs. 
Purifications were done either by SEC using PD10 columns or 
via dialysis MWCO 3.000. Probe loading was estimated according to 
absorbance of the fractions at λ= 332 nm (extinction coefficient of the 
free probe ε= 21470 M-1∙cm-1) and confirmed by 1H-NMR. The absence 
of free probe within the polymeric construct that could lead to 
interferences and/or artefacts in the in vitro testing was confirmed by 
mass spectrometry using MALDI-TOF (absence of the corresponding 
peaks from the free probes); and by diffusion NMR (DOSY), where the 
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diffusion coefficient of only one specie was observed. The final 
conjugates were also characterized by CD, where the random coil 
conformation of linear PGA was conserved after conjugations. 
Examples of the characterization techniques used in general for the 
PGA-probe conjugates are depicted in Figure 8.2. 
a)                                             b) 
 
 c)                                                d) 
 
Figure 8.2. Physico-chemical characterization carried out for each 
PGA-probe conjugate. PGA-MMP-12 conjugate as example. a) UV-
VIS spectra; b) DOSY-NMR; c) 1H-NMR; d) CD. 
Table 8.2 summarizes the main characteristics of the PGA-
MMP-12 in vitro conjugated probes.  
Table 8.2. PGA-MMP-12 in vitro conjugate probes characterization. 
Conj. Linker mol% Spacer 
mol% 
probe 
wt% 
probe 
MW 
kDa 
GAU 
SP.1 11 % Alkyne CH2 1.5 13.0 24.3 138 
SP.2 16 % Azide EG(6) 1.5 10.0 30.7 138 
SP.3 30 % Azide EG(2) 3.2 22.5 28.9 138 
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Once the polymeric probes were synthesized and properly 
characterized, enzymatic assays against different MMPs were 
performed in order to establish their selectivity and specificity against 
MMP-12 probe after probe conjugation. For that purpose, kinetic 
studies during 2 hours were carried out in multi-well plates where the 
fluorescence release over time of each probe due to enzyme cleavage 
was recorded. The obtained degradation curve of the substrate was used 
to calculate the Kcat/Km ratio, as a representative measurement of the 
degradation rate of the substrate upon enzyme addition. Table 8.3 
summarizes the results obtained for the three different MMP-12 in vitro 
probes against the MMPhs 9, 12, 8, 13 and 2 (h stands for human 
origin). 
Table 8.3. Catalytic efficiency by means of Kcat/Km constants ratio. 
 Kcat/Km Values (M-1·s-1) with [Enzyme]= 10 nM 
 MMP9h MMP12h MMP8h MMP13h MMP2h 
Free probe 116345 185000 269 91474 14534 
SP.1 85246 190000 500 51365 43754 
SP.2 93664 550000 500 154740 71257 
SP.3 1352 67255 245 37680 1354 
Figure 8.3 shows the representation of the catalytic efficiency 
obtained for each polymeric probe in comparison with the free 
substrate. From the results obtained, several conclusions can be drawn. 
To begin with, enzyme selectivity for MMP-12 was kept in all cases, 
however, differences among the enzymatic profiles of the conjugates 
were observed. In the case of SP.1 conjugate, with the shorter spacer, 
the selectivity for MMP-12 was kept and slightly increased, whereas for 
SP.2 conjugate (the longer spacer) this selectivity was dramatically 
increased. On the other hand, regarding probe loading, SP.3 conjugate 
(with the highest loading, 3.2 mol%) shows a worse performance when 
compared with conjugate SP.2 (1.5 mol% probe loading). 
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Figure 8.3. Catalytic efficiency (Kcat/Km, M-1∙s-1) displayed by MMPs 
in cleaving various probes.  
These preliminary results clearly support the overall concept 
that smart activatable probes can be designed bearing linkers and 
conjugated to carrier scaffolds without losing catalytic turnover by the 
target enzyme. In particular, results obtained with SP.2 are very 
promising as not only selectivity for the specific enzyme was kept but 
also could be increased depending on the length of the polymer-probe 
spacer used, as well as the percentage of probe loading gained. All the 
above results lead to suspect that these probes may adopt a folded 
conformation in solution placing in close proximity the quencher and 
the fluorophore groups, a property that may influence the recognition 
and the efficacy of the corresponding MMP in cleaving these probes. 
These results were in good agreement with those obtained at CEA-
Saclays with free MMP-12 probes, where different spacers among 
fluorophore and quencher, the use of different fluorophore or 
quenchers, and the positions of those within the probe structure 
demonstrated to dramatically affect their selectivity and specificity 
against MMP-12. 
With these preliminary results using in vitro probes one step 
further in the development of MMP-12 selective probes was performed. 
For that purpose, in vivo NIR dyes and quencher were used. In the 
concrete case of MMP-12 developed probes from CEA, Cy5.5 (6S-
IDCC) was used as dye, and quenched by the use of QSY21. The 
chemical tag alkyne was selected in this case, in order to be able to take 
profit from the optimized chemistry in the previous study. 
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Scheme 8.3. Chemical structure of the MMP-12 selective probe used 
for conjugation to PGA. 
As a first approach, PGA-EG(6)N3 was selected for probe 
conjugation due to the antecedents observed on the spacer influence 
with in vitro MMP-12 probes. Conjugation and conjugate purification 
were performed following the same protocol as that used for the 
previous probes. Probe quantification (Table 8.4) was carried out this 
time by 1H-NMR as well as by fluorescence output of Cy5.5 λexc= 595 
nm, λem= 680 nm.  
Table 8.4. PGA-MMP-12 in vivo conjugate probe characterization. 
Conj. 
mol% 
linker 
Spacer 
mol% 
probe 
wt% 
probe 
MW 
kDa 
GAU 
SP.4 16  EG(6) 1.6 21.0 38.6 155 
After adequate characterization, the polymeric probe was tested 
in vitro on a panel of MMPs, in PBS buffer. The kinetic constants 
obtained are summarized in Table 8.5 as well as, the related enzymatic 
curves are plotted in Figure 8.4. 
Table 8.5. Catalytic efficiency by means of Kcat/Km constants ratio. In 
MMP12, “h” stands for human and “m” stands for mouse. Kcat/Km 
Values (M-1∙s-1) with [Enzyme]= 10 nM 
MMP 1h 2h 3h 7h 8h 9h 12h 13h 14h 12m 
Free  29696 62500 440 47593 2794 1043 504533 71893 300 650000 
SP.4 260 61383 660 41193 500 2300 561733 41083 6633 600000 
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a) 
 
b) 
 
Figure 8.4. a) Kinetic profiles of substrate cleavage upon MMPs 
addition in buffer at 2 nM MMP concentration. b) Kcat/Km values 
obtained from the enzymatic curves in buffer at 10 nM MMPs. 
As it can be clearly observed in Figure 8.4, selectivity and 
efficacy were conserved when the probe (MMP12 substrate) is coupled 
to PGA chains. Moreover, substrate processing ratio was even higher 
when conjugated to the polymer (Kcat/Km values from 5∙105 mol-1∙s-1 for 
the free substrate to 5.8∙105 mol-1∙s-1 when conjugated into PGA 
backbone). 
Furthermore, enzymatic degradation on other proteases 
(ADAMTS-4, ADAMTS-5, Tumor necrosis factor (TNF)-converting 
enzyme (TACE), Angiotensin-I converting Enzyme (ACE), and Neural 
endopeptidase (NEP)) have also been performed with this conjugate. 
The polymeric probe resulted to be highly selective for MMP12h, when 
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compared with the rest of proteases as summarized in Table 8.6 and 
Figure 8.5. 
Table 8.6. Catalytic efficiency of SP.4 towards other proteases in PBS 
buffer. 
Kcat/Km Values (M-1·s-1)  
ADAMTS-4 ADAMTS-5 TACE ACE NEP MMP12h 
500 500 500 500 13230 561733 
 
Figure 8.5. Representation of the catalytic efficiency of PGA conjugate 
SP.4 towards other proteases. 
No degradation was observed when the conjugate was exposed 
to diluted mouse plasma and PBS buffer over time as shown in Figure 
8.6. 
 
Figure 8.6. Diluted plasma and buffer stability of the SP.4 conjugate. 
Any probe degradation was observed. 
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After this first validation of the in vivo PGA-MMP12 conjugate 
probe SP.4, the influence of plasma proteins on the enzyme processing 
turnover was also studied. As the previous results strongly suggested 
that this series of probes adopt particular conformations in solution that 
may influence their ability to be cleaved by MMPs, one could expect 
that the presence of plasma proteins may also affect these 
conformations. Hence, the same experiments were performed in diluted 
mouse plasma (50 times). As it can be seen in Figure 8.7, there was no 
impact on MMP-12 mouse catalytic efficiency in cleaving the substrate 
under these conditions, but strikingly, MMP12 human was found to be 
much less active. These results illustrated how difficult could be to 
anticipate the effect on the substrate conjugation onto the polymer. 
a) 
 
b) 
 
Figure 8.7. a) Kinetic profiles of substrate cleavage upon MMPs 
addition in diluted mouse plasma at 2 nM MMP concentration. b) 
Kcat/Km values obtained from the enzymatic curves in diluted mouse 
plasma at 10 nM MMPs.  
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As it could be expected, the presence of plasma proteins makes 
a difference in enzymes turnover. Although the polymeric probe 
exhibits a slightly slower processing by MMP12m in mouse diluted 
plasma when compared with the same processing in buffer, the 
selectivity and efficacy of MMP-12m in the substrate cleavage was 
retained validating it for in vivo applications.  
Indeed, in vivo validation of the probe was performed in CEA-
Saclays with a breast cancer orthotopic model based on the tumor cell 
line 4T1. Briefly, 4T1 cell line was injected in the mammary fat pad of 
female Balb/C mice to induce a well-vascularized tumor of 100 to 200 
mm3 in 15 days. The polymeric probe SP.4 and the parent free probe 
were i.v. injected in mice and the in vivo tumor fluorescence was 
followed during 24 hours by IVIS®. Probe biodistribution was assessed 
by the ex vivo imaging of the different organs at 24 h post-injection 
showing renal filtration and a urinary excretion for both probes. 
In vivo fluorescence of tumor after injection of the polymeric 
probe SP.4 or the free probe exhibits different kinetic profiles. For the 
non-grafted probe, tumor fluorescence signal shows a maximum at 60 
min post-injection, followed by a rapid decrease. For SP.4 probe, the 
signal increases during the first hour post-injection and remains stable 
up to 24 h, demonstrating the high impact of the polymer conjugation 
significantly enhancing tumor accumulation and therefore specific 
signaling (data not shown, obtained at Vincent Dive Lab).  
Finally, regarding linker design, a family of conjugates with 
different spacer length, of the same MMP-12 in vivo probe were 
developed (Table 8.7) in order to get further understanding of the 
spacer influence on their performance. This study is still ongoing.  
Table 8.7. Physico-chemical characteristics of PGA-MMP-12 in vivo 
conjugate probes (with different spacers). 
Conj. 
mol% 
linker 
Spacer 
mol% 
probe 
wt% 
probe 
MW 
kDa 
GAU 
SP.5 32 EG(2) 1.9 22,6 43.4 155 
SP.6 27 EG(6) 1.9 20,8 47.1 155 
SP.7 28 EG(9) 1.7 17,6 50.1 155 
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8.2.1.1.2. MMP-9 conjugates. 
As for MMP-12 selective probes, an optimization process with 
the so-called in vitro probes was first carried out. For that purpose, two 
MMP-9 in vitro probes were provided from CEA-Saclays in order to 
perform the bioconjugations with the linear polymers (Scheme 8.4).  
 
Scheme 8.4. Schematic chemical structure of MMP-9 in vitro probes. 
On one hand, and in order to further confirm the need of a 
spacer and the influence of the probe loading in the final construct 
processing by the enzyme, a conjugate with direct attachment of the 
probe (NH2 functionalized), and high loading (5.8 mol%) was 
synthesized SP.8 (Table 8.8) and in vitro evaluated (Figure 8.8). The 
synthesized polymeric probe displayed a worse enzymatic processing 
when compared with the free substrate. The selectivity for MMP-9 was 
kept, whereas the efficacy in the turnover was dramatically decreased. 
These results confirmed the need of a longer spacer between probe and 
polymer (SP.9) and the fact that high probe loadings do not improve the 
probe performance in vitro. However, conjugation to the polymer, 
independently of the spacer length and probe loading, decreased probe 
selectivity. In both conjugates, probe selectivity was lost upon 
conjugation to PGA. For SP.8 conjugate (direct conjugation), catalytic 
efficiency decreased by only a factor of 2.5, but the conjugate was less 
selective than the free substrate. With SP.9 conjugate (EG(6) spacer), 
the catalytic efficiency showed a 20-fold decreased, compared to the 
parent free substrate. 
Table 8.8. Physico-chemical characterization of PGA-MMP-9 in vitro 
conjugate probes (with different spacers and loadings). 
Conj. 
mol% 
linker 
Spacer 
mol% 
probe 
wt% 
probe 
MW 
kDa 
GAU 
SP.8 - - 5.8 35.9 26.0 110 
SP.9 16 EG(6) 1.0 7.0 33.6 152 
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Figure 8.8. Catalytic efficiency (Kcat/Km, M-1∙s-1) displayed by MMPs 
in cleaving various MMP-9 selective probes at 200 nM probe 
concentration. 
The in vivo analogous of the probe (NIRF, Cy5.5. and QSY21 
as quencher, Scheme 8.5) was then developed and conjugated into the 
PGA backbone through, once again, CuAAC chemistry. Interestingly, 
the free in vivo probe (same sequence as the in vitro probe, but different 
dye/quencher pair), exhibited really poor specificity for MMP-9h when 
tested in buffer. Such specificity was slightly increased when the same 
probe was tested in diluted plasma. Hence, it was decided to draft it 
onto a polymeric backbone to check whether this specificity could be 
increased. 
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Scheme 8.5. Chemical structure of MMP-9 in vivo probes. 
Following previous guidelines with MMP-12 probes and MMP-
9 in vitro probes, a low probe loading (SP.10) was aimed (Table 8.9). 
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Table 8.9. Physico-chemical characteristics of PGA-MMP-9 in vivo 
conjugate probe. 
Conj. 
mol% 
linker 
Spacer 
mol% 
probe 
wt% 
probe 
MW 
kDa 
GAU 
SP.10 27 EG(6) 2.2 25.2 57.9 184 
The conjugated MMP-9 substrate was then tested in vitro in 
PBS solution in a first step, against a panel of MMPs, showing a 
decrease in the catalytic efficiency but an improvement on selectivity 
upon conjugation (Figure 8.9). 
a) 
 
b) 
 
Figure 8.9. a) Kinetic profiles of substrate cleavage upon MMPs (4 
nM) addition in PBS at 200 nM of probe concentration. b) Kcat/Km 
values obtained from the enzymatic curves in PBS. 
Besides, when the conjugated probe was tested in mouse 
diluted plasma, selectivity against MMP-9h was found considerably 
increased, when compared with the parent free substrate. 
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a) 
 
b) 
 
Figure 8.10. a) Kinetic profiles of substrate cleavage upon MMPs (4 
nM) addition in diluted mouse plasma at 200 nM of probe 
concentration. b) Kcat/Km values obtained from the enzymatic curves in 
diluted mouse plasma. 
Overall, the conjugate SP.10 was found to be highly selective 
for MMP-9h in diluted mouse plasma what validates it for in vivo use. 
Further studies with this conjugate are on the pipeline of this project, 
including in vivo biodistributions and as well as efficacy and selectivity 
determinations in vivo.  
Additionally, and in order to further study the probe loading 
effect without the influence of other parameters, the same polymeric 
backbone bearing azide groups with EG(6) spacer were used in order to 
graft different probe loadings and check its effect on protease 
selectivity. Table 8.10 summarizes the wt% achieved in all cases. 
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Table 8.10. Physico-chemical characterization of different PGA-MMP-
9 in vivo conjugate-probes. 
Conj. 
mol% 
linker 
Spacer 
mol% 
probe 
wt% 
probe 
MW 
kDa 
GAU 
SP.11 27 EG(6) 0.6 9.2 39.8 155 
SP.12 27 EG(6) 1.3 16.8  43.7 155 
SP.13 27 EG(6) 4.2 39.5  60.1 155 
As usual, probe cleavage and fluorescence release was 
monitored over time for all conjugated probes when exposed to 
MMP9h (Figure 8.11). 
 
Figure 8.11. Kinetic profiles of substrate cleavage upon MMP9h (6.6 
nM) addition in PBS at 200 nM of probe concentration. 
According to these results, it could be concluded that, with 
MMP-9, higher probe loading (SP.13) induces auto-quenching 
phenomenon, as the fluorescence signal does not increase in the 
expected factor (at least a factor 3 is expected between SP.12 and 
SP13). Lower probe loading (SP.11 and SP.12) resulted in greater 
catalytic efficiency. 
8.2.1.1.3. MMP-13 conjugates. 
After all the general studies carried out on MMP-9 probes as 
well as MMP-12 probes, MMP-13 probe was directly designed for in 
vivo applications using the FRET pair Cy5.5 and QSY21 and following 
the already optimized physico-chemical characteristics regarding spacer 
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as well as probe loading. The general chemical formula of this MMP-
13 selective probe was similar to the one of MMP-9 in vivo selective 
probes (Scheme 8.5), but changing the R substituent. The probe was 
clicked into PGA polymer backbone via CuAAC as described before 
and its characteristics are summarized in Table 8.11. 
Table 8.11. Physico-chemical characterization of PGA-MMP-13 in 
vivo conjugate probe. 
Conj. 
mol% 
linker 
Spacer 
%mol 
probe 
wt% 
probe 
MW 
kDa 
GAU 
SP.14 16 EG(6) 1.5 20.7 39.0 155 
Once purified and characterized, the polymeric MMP-13 
selective probe was tested against several MMPs in PBS buffer. Probe 
selectivity and catalytic efficiency was slightly increase upon 
conjugation (from kcat/Km 4.6∙105 M-1∙s-1 of free substrate to 6.5∙105 M-
1∙s-1 in conjugated probe) (Figure 8.12).  
 
Figure 8.12. Kcat/Km values obtained from the enzymatic curves in PBS 
buffer obtained at 400 nM of probe concentration. 
After that, the probe was also validated in mouse diluted 
plasma in order to be used for in vivo monitoring of disease related 
enzymes. Although catalytic efficiency was decreased, selectivity 
against MMP13 enzyme was proven to be guaranteed in plasma, 
allowing us to proceed for in vivo studies (Figure 8.13). 
  
[Chapter 8] 
460 
a) 
 
b) 
 
Figure 8.13. a) Kinetic profiles of substrate cleavage upon MMPs 
addition in diluted mouse plasma at 400 nM of MMP13h concentration. 
b) Kcat/Km values obtained from the enzymatic curves in diluted mouse 
plasma. 
The polymeric probe (SP.14) potential for in vivo monitoring of 
OA progression due to MMP-13 specificity was then tested in Oxford, 
at Hideaki Nagase laboratory. Briefly, an OA model was first 
developed for this project, based on the destabilization of the medial 
meniscus (DMM) (Figure 8.14).  
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Figure 8.14. OA model developed within Hideaki Nagase lab in 
Oxford University.75 
This model was well established and used to test two smart 
probes (free, and conjugated) against MMP13. The probes were tested 
both i.v. and six weeks after the surgery and fluorescence was recorded 
over time (48 h) in the DMM knee, the DMM contralateral (from the 
injured animal but without surgery), and sham knee (from control 
animals with surgery but without damage) (Figure 8.15). Whereas free 
substrate was hardly able to be distinguished between the different 
knees, the polymeric probe was able to discriminate among DMM and 
sham operated animals 6 weeks after surgery. Moreover, PGA-probe 
was able to distinguish between DMM operated and contralateral knees 
also six weeks after surgery.  
a) 
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b) 
 
c) 
 
Figure 8.15. Fluorescence intensity due to probe activation in vivo after 
i.v. injection of the probes over time. a) Free MMP-13, 6 weeks after 
surgery, n= 3. Paired t test: DMM vs. DMM contralateral, ρ < 0.001; 
DMM vs. Sham, ρ= 0.29 (n.s.). b) PGA-MMP-13, 6 weeks after 
surgery, n= 3. Paired t test: DMM vs. DMM contralateral, ρ= 0.0053; 
DMM vs. Sham, ρ= 0.0008. c) PGA-MMP-13 vs. free MMP-13 probe 
in DMM damaged knee. n= 3, ρ= 0.0086. 
Fluorescence images taken 48 hours after i.v. administration of 
SP.14 probe in operated animals (Figure 8.16) highlight the results 
obtained. 
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Figure 8.16. Fluorescence images raw data, taken 48 hours after PGA-
probe SP.14 i.v. injection. Probe was injected 6 weeks after surgery.  
When time course experiments over the progression of the 
DMM damaged knee were performed, differences among the 
conjugated and non-conjugated probes were also found. The 
unconjugated MMP-13 selective probe was able to distinguish among 
knees only when injected 8 weeks after surgery. On the contrary, the 
PGA-MMP-13 conjugate probe was able to discriminate already at six 
weeks post-surgery (Figure 8.17). This is crucial due to the main 
objective pursued within the development of these activatable smart 
probes was based on early detection. 
a) 
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b) 
 
Figure 8.17. Maximum fluorescence intensity (MFI) of probes 
activation over course of DMM. a) Free activatable probe. Data from 8 
h after i.v. delivery of the probe. n= 5 * ρ<0.05. b) PGA-probe SP.14. 
Data from 2 days after i.v. delivery of the probe. n= 5 * ρ<0.05. 
One critical gap to address within smart probes development is 
their specificity for the desired enzyme/protease. In order to answer that 
question, it is necessary to use specific enzyme inhibitors (MMP-13 in 
this case) and to look for specific signal attenuation upon inhibitor 
addition. For that purpose, in another study, an MMP-13i inhibitor76 
was administered (per os) p.o. 1 day before and 4 hours before imaging, 
always at 6 weeks post-surgery, and the fluorescence due to probe 
activation was measured (Figure 8.18). The PGA-probe signal was 
effectively attenuated to fluorescence levels below those obtained for 
DMM contralateral and Sham knees, confirming the presumed 
specificity of the polymeric probe.  
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Figure 8.18. Maximum fluorescence intensity (MFI) registered for 
PGA-probe over time at 6 weeks post-surgery and influence of the 
specific inhibitor for MMP-13. Inhibitor was administered p.o. 1 day 
before and 4 hours before imaging. n= 5. 
One step further in the development and validation of this smart 
probe, as well as one of the aims of this project was to check their 
ability to monitor the progress on the disease when talking about the 
evaluation of novel therapies. For this purpose, SP.14 probe was used 
in order to follow the treatments of injured animals with different doses 
of the mentioned MMP-13 inhibitor p.o., daily. Importantly, this 
inhibitor was never administrated simultaneously to probe injection. 
The polymeric probe was able to show a decrease on the MMP-13 
levels (and presumably, a decrease on the inflammation in the OA 
injured knee) in DMM knees after the treatments with 0.3 mg∙Kg-1 of 
inhibitor. When a dose of inhibitor 10 times higher was administered, 
the fluorescence levels found were close to those found in the DMM 
contralateral, already at six weeks post-surgery. Results suggested that 
30 mg∙Kg-1 inhibitor dose was required to restore OA damage in vivo.  
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Figure 8.19. PGA-probe used to follow OA treatment with MMP-13 
inhibitor p.o. daily. Inhibitor treatment was stopped when PGA-probe 
injection. n= 5. 
Thus, from these results, it could be concluded that this smart 
probe could be a potential tool in monitoring specific MMP-13 activity 
and disease progression in osteoarthritis, being the first of its class with 
such remarkable behavior. 
8.2.1.2. Cathepsin-B based probes. 
As mentioned in the introduction, Cathepsins are good 
candidates to be used as targets for activatable probes development. 
Among cathepsins, cathepsin B is of major relevance for cancer 
diagnosis and therapy as abnormal regulation of cathepsin B and its 
overexpression has a direct correlation with increased invasive and 
metastatic potential in many cancers.43, 77 Several cathepsins (B, S and 
L)-sensitive activity-based probes78 have been designed as suicide 
substrates, which label the enzyme covalently and inactivate it upon 
binding.79-81 Several fluorogenic peptide substrates,82 for optical 
imaging of cathepsin B activity in vitro and substrate-based NIRF 
polymeric probe83, 84 for non-invasive optical imaging of cathepsin B 
activity in vivo have already been synthesized. Nonetheless, such 
probes might be less suited for in vivo applications due to their peptidic 
character.3, 85, 86  
With the same purposes, Cathepsin B probes were developed, 
by collaborators from EMBL (Germany). Those activatable probes 
were synthesized through a strategy known as “reverse design”. The 
recently developed “reverse design” concept is based on transferring 
the selective profile of an optimized cathepsin inhibitor into a selective 
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probe by replacing the warhead of such an inhibitor by a cleavable 
peptide bond and subsequently attaching appropriate reporter groups 
for optical imaging (Scheme 8.6).15]  
 
Scheme 8.6. General chemical formula of Cathepsin B probes. For in 
vitro probes, FRET pair coumarin 343/TAMRA. For in vivo probes, 
FRET pair Cy5.5/BHQ-3. 
In a similar way as for MMP probes, in vitro probes were first 
designed in order to perform optimization processes as well as to 
confirm probe selectivity and efficacy after conjugation to PGA. The in 
vitro probe included the FRET pair coumarin 343/TAMRA 
(Tetramethyl-6-Carboxyrhodamine), and alkyne as the chemical tag for 
conjugation. Following CuAAC conditions, the probe was successfully 
conjugated to azide functionalized PGA polymers using the already 
optimized EG(6) spacer between probe and polymeric backbone. The 
synthesized conjugate details are summarized in Table 8.12. 
Table 8.12. Cathepsin B selective in vitro polymeric probes details. 
Conj. 
mol% 
linker 
Spacer 
mol% 
probe 
wt% 
probe 
MW 
kDa 
GAU 
SP.15 16 EG(6) 3.5  22.6 39.3 152 
After adequate characterization of the Cathepsin B selective in 
vitro polymeric probe (SP.15), its selectivity and efficacy was tested 
against different recombinant cathepsins. 
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Figure 8.20. Cleavage of cathepsin B reporter in vitro probe at 
[Probe]= 50 ng∙mL-1 and [Enzyme]= 25 nM, in vitro. Change in 
fluorescence emission intensity at em= 695 nm of probe after addition 
of cathepsins B, K, L, S and V (excitation at ex= 670 nm). 
Figure 8.20 noticeably shows how the selectivity of the 
polymeric probe to be processed by Cathepsin B was retained upon 
conjugation, thus, validating the strategy of conjugation also for the 
activatable probes synthesized through reverse design. 
Afterwards, selective Cathepsin B probes for in vivo 
applications were also developed. The in vivo probes were based on the 
NIRF Cy5.5/BHQ-3 (Black Hole Quencher®-3), containing also alkyne 
moieties for bioconjugations. CuAAC chemistry was once again used 
for probe grafting into the polymeric backbone and the synthesized 
conjugate details are given in Table 8.13. 
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Table 8.13. Cathepsin B in vivo polymeric probe (SP.16) details. 
Conj. 
mol% 
linker 
Spacer 
mol% 
probe 
wt% 
probe 
MW 
kDa 
GAU 
SP.16 16 EG(6) 1.2  14.4 35.0 152 
The selectivity and efficacy of cleavage of the fluorogenic 
substrate after coupling to the polymer was again verified against 
recombinant cathepsins in vitro and it confirmed that the selectivity was 
preserved after conjugation (Figure 8.21).  
 
Figure 8.21. Cleavage of cathepsin B in vivo probes at [Probes]= 10 
μM and [Enzyme]= 25 nM, in vitro. Change in fluorescence emission 
intensity at em= 695 nm of probes after addition of cathepsins B, K, L, 
S and V (excitation at ex= 670 nm). (a) Free Probe; (b) PGA-Probe 
(SP.16). 
Conjugation of the probe to polymers slightly decreased the 
turnover efficiency (2.6 fold, Figure 8.22) presumably owing to 
constrained substrate accessibility after conjugation. Nevertheless, 
when the kinetics of the PGA-probe was compared with an analogous 
dendrimeric87 polyglycerol-based conjugate of the same probe, the 
linear PGA construct exhibited a much better performing in terms of 
turnover processing.  
With the Kcat/Km values exceeding 10.000 M-1∙s-1 the conjugate 
seemed to be the ideal candidates for monitoring of cathepsin B activity 
in vivo.  
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Figure 8.22. Probe cleavage rate (V: velocity) against probe 
concentration (S: substrate) by cathepsin B. Free probe, PGA-probe and 
a dendrimeric version of the conjugate are compared. Solid lines were 
generated using nonlinear regression analysis. The table shows the 
kinetic parameters of cleavage by cathepsin B. 
Additionally, mass spectrometry analysis from the probes after 
being processed by Cathepsin B revealed the same cleavage site for 
both probes (free and PGA-conjugate) as shown in Figure 8.23. 
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Figure 8.23. MALDI-TOF mass spectra of PGA-Probe before (blue) 
and after (red), Free Probe before (green) and after (yellow) cleavage 
by cathepsin B. The quencher-bearing fragment with m/z 732.4 
generated by cathepsin B cleavage is encircled. 
Although Cathepsin B can be located extracelullarly, is mostly 
present intracellularly in the lysosomal compartments. This fact make 
the PGA conjugate even better system for Cathepsin B targeting due to 
its capacity to follow lysosomal pathways through endocytosis. With a 
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view to cancer applications, NIFR microscopy was also performed in 
cultured 4T1-breast cancer cells, confirming intracellular probes 
localization as shown in Figure 8.24. Moreover the polymer conjugated 
probe exhibited a substantially higher signal as compared to the non-
conjugated probe and the commercially available imaging agent for 
monitoring cathepsin activity Prosense 680. 
 
Figure 8.24. NIRF microscopy study of cellular uptake of probes by 
cultured 4T1 cells. 
It is well-known that both tumor and immune cells secrete large 
amounts of cathepsin B.88 Taking into account that fact, the evaluation 
of the probes in co-culture of breast carcinoma MDA-MB-231 cells 
with THP-1 cells differentiated into macrophages seemed to be the next 
step towards probe validation. The free probe, PGA-probe (SP.16) and 
the dendrimeric analogue dPG-probe conjugate were incubated in the 
co-cultures, and a fluorescence signal increase was observed, being the 
highest associated with our PGA-probe conjugate. These signals were 
effectively inhibited by the broad spectrum cathepsin inhibitor E-64 and 
a more cathepsin B selective CA-074 in all the cases, suggesting that 
the probes were specifically cleaved by cathepsin B also in cell culture 
(Figure 8.25).  
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Figure 8.25. Fluorescence intensity for cathepsin B probes in co-
cultures. Cathepsin inhibitors E-64 and CA-074 could successfully 
block the fluorescent signal, while all three probes could detect 
cathepsin B activity in co-culture supernatants. 
Overall, the in vivo probe SP.16 can be considered as a good 
candidate for in vivo monitoring of Cathepsin B, and further in vivo 
studies on 4T1 tumor models are currently ongoing to demonstrate that. 
On top of that, Cathepsin B has been also reported to be 
overexpressed in inflammation sites, and its activity is related to 
inflammation processes.89, 90 That fact, make it also good aspirant to be 
used in inflammatory diseases. As proof of concept, the probe was 
tested in a rapid model of inflammation developed at Hideaki Nagase’s 
group. The probes were directly injected into the site of inflammation 
(paw) at 10 μM probe eq., and fluorescence signal was quantified over 
time (Figure 8.26). 
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a) 
 
b) 
 
Figure 8.26. Fluorescence data acquired over time after local probe 
(blue, free probe, Red, PGA-Conjugate) injection. a) Raw data. b) 
Normalized data with baseline correction. 
When data wass normalized, similar signal was found for both 
probes at early time points, however, the polymeric probe exhibited a 
much great signal after 24 hours post-injection when compared with the 
free probe, meaning that the conjugated probe is longer retained in the 
inflamed paw (Figure 8.26). These encouranging results convinced us 
to further to proceed with the development of this class of polymeric 
probes. 
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Figure 8.27. Fluorescence raw images at 24 hours after local injection 
in the inflamed paw comparing free and conjugated probe. 
8.2.1.3. Other probe conjugates. 
Within the LIVIMODE project, other enzyme selective probes 
were also synthesized, conjugated into PGA polymeric carriers, and 
evaluated. This is the case of cathepsin S selective probes as well as 
FAP selective probes. As stated in the introduction, both enzymes 
represent good target candidates for the development of smart probes in 
order to monitor disease progression and several activatable probes 
have been already developed using them as target enzyme.37, 91  
In the case of Cathepsin S selective probes provided from 
EMBL, different conjugation strategies were explored. Even though 
CuAAC was a very efficient coupling method, it entailed exhaustive 
purifications in order to remove copper below the allowed limits for its 
use in biological applications. For that reason, acid/base chemistry and 
thiol-ene maleimide couplings were implemented for the conjugation of 
the cathepsin S probes whose chemical tag was based on primary 
amines or maleimide groups (Scheme 8.7). 
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Scheme 8.7. General chemical formula of Cathepsin S probes. For in 
vitro probes, FRET pair coumarin 343/7-methoxycoumarin. For in vivo 
probes, FRET pair Cy5.5/BHQ-3. 
Linear PGA polymer was used for the direct conjugation of the 
Cathepsin S probe bearing amine as chemical tag on one hand leading 
to the conjugate SP.17. As already seen for other probes, the 
introduction of a spacer improved the probe performance in vitro 
against different enzymes. For that reason, an EG(4) spacer was 
attached to the Cathepsin S in vitro probe using FMOC-NH-EG(4)-
COOH. Then, the derivatized probe was conjugated to PGA via 
acid/base chemistry to lead the conjugate SP.18. On the other hand, two 
probes bearing maleimide groups as chemical tags (in vitro and in vivo 
probes) were effectively conjugated to cysteamine-2TP modified PGAs 
(see Chapter 4) using thiol-ene chemistry, yielding the smart polymeric 
probes SP.19 and SP.20. 
Table 8.14. Physico-chemical characteristics of Cathepsin S polymeric 
probe conjugates. 
Conj. 
mol% 
linker 
Spacer mol% probe 
wt% 
probe 
MW 
kDa 
GAU 
SP.17 - - 1.0 (in vitro) 6.8 17.8 110 
SP.18 - EG(4) 1.5 (in vitro) 9.7 18.8 110 
SP.19 5  (CH2)2 1.1 (in vitro) 8.8 14.6 85 
SP.20 5  (CH2)2 0.8 (in vivo) 13.0 26.0 155 
The polymeric in vivo probe SP.20 deserves a special mention 
as it was found to be highly selective for Cathepsin S, when tested in 
vitro (data not shown).  
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The same studies as those explained for SP.16 (Cathepsin B 
selective probe) were performed with Cathepsin S probes, such as 
cellular uptake in 4T1 tumor cell line in comparison with free probe, 
mass spectrometry in order to determine the cleavage site, co-culture 
experiments for Cathepsin activations in presence and absence of 
specific inhibitors, etc. (data not shown). All of them showed similar 
results as those obtained for the Cathepsin B polymeric probe, 
validating again the use of PGA polymers as nanocarriers for in vivo 
monitoring of disease related enzymes.  
Finally, FAP probes from EMBL were also conjugated. In this 
case, the main objectives were a) to study the influence of probe 
lipidation by using lipidated (SP.22) and non-lipidated probes (SP.21) 
and b) to address the influence of polymer size on the final construct in 
vitro/in vivo performance (SP.23 and SP.24). FAP probes conjugates 
synthesized are summarized in Table 8.15. Their in vitro behavior in 
terms of protein specificity and catalytic efficiency are currently under 
study. 
 
Scheme 8.8. General chemical formula of FAP probes. For in vitro 
probes, FRET pair coumarin 343/7-methoxycoumarin. For in vivo 
probes, FRET pair Cy5.5/BHQ-3. *Note, for SP.22, the in vitro probe 
used contained an additional lipid moiety.  
Table 8.15. FAP activatable polymeric probes family details. 
Conj. 
mol% 
linker 
Spacer mol% probe 
wt% 
probe 
MW 
kDa 
GAU 
SP.21 16 azide EG(6) 1.4 (in vitro) 11.7 35.4 152 
SP.22 16 azide EG(6) 1.4 (in vitro) 14.3 36.3 152 
SP.23 16 azide EG(6) 4.1 (in vivo) 38.4 49.5 152 
SP.24 27 azide EG(6) 4.2 (in vivo) 35.2 66.7 184 
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8.2.2. Targeting strategies. 
As stated in the introductory part, targeting strategies were also 
included in the scope of the LIVIMODE project with the aim of 
enhancing tissue specificity of the synthesized probes. 
8.2.2.1. OA targeting. 
With the purpose of improving cartilage targeting in the 
selected polymeric probes such as the MMP-13 selective SP.14 several 
strategies for OA targeting were pursued. First of all, the use of the 
cartilage-binding sequence developed by Rothenfluh et al.92 was 
explored. Hence, in order to validate this peptide as cartilage vector, the 
conjugation of two peptidic sequences to PGA used as carrier was 
performed. One of them was the oligopeptide WYRGRL, specific to 
cartilage binding.92 The other ws the scrambled sequence YRLGRW 
(Tyr-Arg-Leu-Gly-Arg-Trp), to be used as negative control.  
The starting peptidic products were provided of a FMOC 
protecting group in the N-terminus and have the C terminus as free 
acids. Since PGA is a polyacid, the easiest and fastest way to conjugate 
these oligopeptides to its backbone, taking into account the peptidic 
sequences, was by direct attachment of the NH2 at the N-terminus (after 
removal of the protecting group) to the carboxylic groups of the 
polymer backbone. For that purpose, as the carboxylic group of the 
peptide is free, the synthesis was designed in order to avoid any 
undesired crosslinking. For that reason, the activation of the carboxylic 
groups of the backbone was done in a previous step by using 5‟N-
hydroxysuccinimide to yield PGA-NHS activated. The FMOC group 
was removed from the peptides with piperidine (20 %) in methanol; and 
on one hand, the direct conjugation between the free amine of the N-
terminus of the peptides and the activated carboxylic groups of the 
polymer backbone was performed. 
On the other hand, the introduction of an EG(4) spacer was also 
designed prior to the conjugation of PGA. Due to its cationic character, 
the presence of Arg in the peptide sequences, could lead to electrostatic 
interaction between the carboxylic groups of PGA, which could have an 
influence in the final conformation of the conjugate, and subsequently, 
in the targeting moieties exposure. In order to diminish the effect of this 
interaction, the introduction of the EG spacer was proposed. The 
peptide was PEGylated with FMOC-EG(4)COOH. Pursuing that aim, 
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and taking into account that the peptide sequence has the C-terminus as 
free carboxylic acid, the activation of the carboxylic group of the 
FMOC-EG(4)-COOH was done previously and separately with N-
Hydroxysuccinimide. The FMOC group of the PEGylated peptides was 
then removed by using piperidine (20 %) in methanol and the product 
was conjugated to PGA-NHS activated via peptidic bond. As those 
peptides contain both arginine amino acids in their sequences, in order 
to avoid secondary reactions with the less reactive secondary amine 
from arginine, the reaction was performed this time at 4 °C. 
The four conjugates (PGA-cartilage binding sequence, PGA-
random sequence, PGA-EG(4)-cartilage binding sequence, PGA-
EG(4)-random sequence) and a linear PGA were then label with Cy5.5 
taking profit from the NHS activation. Below the structures of the 5 
conjugates synthesized are shown, and their main characteristics are 
summarized in Table 8.16. 
 
Scheme 8.9. Chemical formula from cartilage targeted polymeric 
platform (CT). 
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Table 8.16. Cartilage targeted polymer platform (CT). 
Polymer MW 
kDa 
mol% 
dye 
wt% 
dye 
mol% 
pep 
PGA-Cy5.5 (CT.1) 23.6 0.70 3.2 0 
PGA-Cart-Cy5.5 (CT.2) 24.2 0.80 3.6 3.92 
PGA-Scram-Cy5.5 (CT.3) 24.2 0.70 3.2 5.00 
PGA-EG(4)-Cart-Cy5.5 (CT.4) 24.3 0.86 3.9 3.43 
PGA-EG(4)-Scram-Cy5.5 (CT.5) 24.5 0.83 3.7 4.80 
This family of conjugates bearing targeting and non-targeting 
units was then tested in vivo in order to determine targeting efficiency. 
Their half-life was first determined after intra-articular injection in the 
knees (Figure 8.28) showing no major differences among the different 
polymeric construct. Half-life in the range of 3.8-6.9 in all cases (Table 
8.17). 
 
Figure 8.28. Half-life determination of different PGA-targeted 
polymers. n= 4, 2 animals, 2 knees, no significant differences between 
knees were found. 
Table 8.17. Fitted half-life after intra-articular injection of cartilage 
targeted polymers polymer platform (CT). 
Polymer Fitted Half-life (h) 
CT_1 5.19 
CT_2 3.84 
CT_4 6.93 
CT_5 4.93 
Knees were extracted, frozen and sectioned and their 
fluorescence was analyzed at 640 nm. From the pictures of Figure 8.29 
[Chapter 8] 
481 
it could be concluded that all the polymers do reach the chondrocytes in 
the cartilage and seem to be either inside, or just around them. The 
results suggest that the use of these targeting moieties were not 
improving the passive targeting of the polymeric itself given by the 
EPR effect. 
 
Figure 8.29. Knee cryo-sections from the intra-articular injections at 24 
hours post-injection. Pictures taken at 20X magnification. The red 
channel is tuned to Cy5.5, whereas the green channel is using the 
autofluorescence of the tissue. 
After those preliminary results, the use of Rothenfluh peptides 
as cartilage binding sequences was discarded. Then further detailed in 
vivo characterization was performed with PGA-Cy5.5 (CT_1) in order 
to validate its use for OA in vivo monitoring. Biodistribution after i.v. 
administration of CT_1 was studied by fluorescence imaging 
techniques (Figure 8.30a and b). As expected for a PGA-based probe, it 
followed a renal excretion profile. However, surprisingly, a high 
accumulation in the knees was found after 24 hours post administration. 
This fact was further confirmed with histology. Knees were frozen and 
sectioned. Cryo-sections were then observed at the microscope (Figure 
8.30c) at 40X, showing CT_1 probe accumulation in the knee. These 
findings all together suggest that PGA-based probes can be considered 
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highly suitable for their use in OA disease progress monitoring. 
Moreover, PGA nanocarriers combined with the previously developed 
MMP-13 highly selective probes offers the perfect recipe for this aim. 
a) 
 
b) 
 
c) 
 
Figure 8.30. a) PGA-Cy5.5 (CT_1) biodistribution after i.v. 
administration at 24 hours post-injection obtained ex-vivo. b) Ex-vivo 
fluorescence example of the injected probe 24 hours post injection. c) 
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Knee cryo-section at 40X magnification. Red channel was used for 
Cy5.5 whereas the green channel for tissue autofluorescence. 
Apart from the use of Rothenfluh peptides for cartilage binding, 
other targeting strategies were also proposed and pursued. Alendronates 
(ALN) for bond targeting were also included in PGA-based 
nanocarriers as well as RGD cyclic peptides for cancer targeting. 
Nevertheless, those families of compounds are not yet tested, thus, their 
results will not be discussed herein. 
8.3. CONCLUSIONS. 
As enlightened in the introduction the most critical gap for the 
monitoring of early events related to early stages of disease lies in the 
lack of target-specific and tissue-specific imaging probes. Within this 
project, we pursued to overcome this gap with a novel approach aiming 
towards highly specific smart (activatable) imaging agents. This 
approach was exemplified on a selected set of disease-relevant protease 
targets, with consequences for improved monitoring of life-threatening 
or chronic diseases such as cancer or degenerative joint disease, 
respectively. This will impact disease management at multiple levels: 
early diagnosis and disease staging, development and characterization 
of novel disease-relevant animal models that are critical for therapy 
development, and finally the evaluation of novel therapeutic drug 
candidates. Once validated these imaging strategies will constitute 
valuable biomarkers for demonstrating proof-of-mechanism and 
eventually proof-of-efficacy for novel drug candidates.  
To this end, linear scaffolds of biocompatible polymers (PGA) 
were synthesized and derivatized with chemical tags complementary to 
those used for smart probes and several corresponding conjugates were 
generated. Overall the results of these studies show that a selective 
enrichment of dye-labeled polymers was possible and that such probes 
could be attached to these scaffolds via several conjugation methods 
while retaining and even increasing their ability to be cleaved by 
selected proteases. 
Preliminary in vivo studies of selected conjugates in those 
adequate in vivo models carried out by our partners clearly point out 
that these smart polymeric probes are highly suitable as early-detection 
molecular diagnostic tools with a high signal to noise ratio and a slow 
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clearance rate. In particular with MMP-13 probe, the data suggested 
that this macromolecular probe could be qualified as an excellent 
candidate for theranostic applications in combination with adequate 
drugs. Furthermore, at the preclinical level, our approach offers a 
significant potential for multimodal imaging due to easy conjugation to 
PET or MRI tracers and would further assist in conceptualizing clinical 
studies. 
8.4. MATERIALS AND METHODS. 
8.4.1. Materials. 
All chemicals were reagent grade and used without further 
purification, unless otherwise indicated. All EG amines were obtained 
from Iris Biotech GMB. All solvents were of analytical grade. 
Preparative SEC was performed using Sephadex G-25 superfine from 
GE as well as PD MiniTrap G-10 ™ columns containing 2.1 mL of 
Sephadex™ G-10. 
8.4.2. Characterization techniques. 
NMR spectroscopy, GPC, CD, DLS, DOSY-NMR and UV 
were performed using the equipment and techniques according to 
previous chapters. 
8.4.3. Protocols. 
8.4.3.1. General procedure for click conjugation of the 
probes through CuAAC. 
In a two-necked round bottom flask fitted with a stirrer bar and 
a stopper, 1 eq. of the respective copolymer PGA-EG(2/6)N3 or PGA-
prop sodium salt was dissolved in ddH2O. After that, the corresponding 
amount for the desired % of substitution of clickable agent (smart 
probe) was added in dry DMF solution. Then, 5 eq. of sodium ascorbate 
in ddH2O were added. After that, the mixture was degassed by 
performing two freeze-pump-thaw cycles. Afterwards, 1 eq. of CuSO4 
was added in aqueous solution to the reaction mixture. The final 
complete mixture, containing a proportion DMF/H2O of 4:1, was 
degassed by performing another freeze-pump-thaw cycle and left to 
react at 40 °C in an oil bath for 3 days protected from the light.  
For purification, the solvent was completely removed under 
vacuum. The colored solid was re-dissolved and purified by PD10 
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column collecting fractions of 0.5 mL. Two clear fractions were found 
corresponding with the conjugated and unconjugated probe. 
Additionally, dialysis using Vivaspin® MWCO 3000 was performed to 
those fractions belonging to the polymer-probe conjugate. The % of 
probe conjugated was determined using different methods depending 
on the probe conjugated. Basically, probe content was determined by 
1H-NMR. Besides, probe content was estimated by spectroscopic 
techniques. For those in vitro probes, a calibration curve using the 
maximum of absorbance of the probes (λ: 332 for MMPs in vitro 
probes, λ: 455 for Cathepsin and FAP in vitro probes) was used. In vivo 
probes content based on Cy5.5 was quantified according to the 
fluorescence either of the eluted fractions from SEC, or via calibration 
curve using Cy5.5. Each fraction was diluted in a 1/200 proportion in a 
96 dark well-plate. Fluorescence of each fraction was measured using 
the filters of Cy5.5. λexc= 595 nm, λemi= 680 nm.  
SP.1. Yield: 80 % Conjugation efficiency (CE) 50 %; mol probe to 
GAU 1.5 % (2.07 eq. per polymer chain), 13 wt%, MW conjugate: 24.3 
kDa. 
SP.2. Yield: 85 % CE 50 %; mol probe to GAU 1.5 % (2.07 eq. per 
polymer chain), 10 wt%, MW= 30.7 kDa. 
SP.3. Yield: 64 % CE 36 %; mol probe to GAU 3.2 % (3.52 eq. per 
polymer chain), 22.5 wt%, MW= 28.9 kDa. 
SP.4. Yield: 90 % CE 80 %; mol probe to GAU 1.6 % (2.43 eq. per 
polymer chain), 21 wt%, MW= 38.6 kDa. 
SP.5. Yield: 90 % CE 86 %; mol probe to GAU 1.9 % (2.9 eq. per 
polymer chain), 22.6 wt%, MW= 43.4 kDa. 
SP.6. Yield: 85 % CE 86 %; mol probe to GAU 1.9 % (2.9 eq. per 
polymer chain), 20.8 wt%, MW= 47.1 kDa. 
SP.7. Yield: 85 % CE 78 %; mol probe to GAU 1.7 % (2.6 eq. per 
polymer chain), 17.6 wt%, MW= 50.1 kDa. 
SP.9. Yield: 40 % CE 50 %; mol probe to GAU 1 % (1.5 eq. per 
polymer chain), 7 wt%, MW= 33.6 kDa.  
SP.10. Yield: 80 % CE 65 %; mol probe to GAU 2.2 % (4 eq. per 
polymer chain), 25.21 wt%, MW= 57.9 kDa. 
SP.11. Yield: 70 % CE 60 %; mol probe to GAU 0.6 % (1 eq. per 
polymer chain), 9.2 wt%, MW= 39.8 kDa. 
SP.12. Yield: 75 % CE 65 %; mol probe to GAU 1.3 % (2 eq. per 
polymer chain), 16.8 wt%, MW= 43.7 kDa. 
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SP.13. Yield: 80 % CE 84 %; mol probe to GAU 4.2 % (6.5 eq. per 
polymer chain), 39.5 wt%, MW= 60.1 kDa. 
SP.14. Yield: 60 % CE 75 %; mol probe to GAU 1.5 % (2.3 eq. per 
polymer chain), 20.74 wt%, MW= 39.0 kDa. 
SP.15. Yield: 70 % CE 70 %; mol probe to GAU 3.5 % (5.32 eq. per 
polymer chain), 22.6 wt%, MW= 39.4 kDa. 
SP.16. Yield: 75 % CE 60 %; mol probe to GAU 1.2 % (1.8 eq. per 
polymer chain) 14.4 wt%, MW= 35.0 kDa. 
SP.21. Yield: 90 % CE 62 %; mol probe to GAU 1.36 % (2.01 eq. per 
polymer chain), 11.75 wt%, MW= 35.4 kDa. 
SP.22. Yield: 62 % CE 64 %; mol probe to GAU 1.4 % (2.13 eq. per 
polymer chain), 14.29 wt%, MW= 36.3 kDa. 
SP.23. Yield: 86 % CE 83 %; mol probe to GAU 4.2 % (6.2 eq. per 
polymer chain) 38.4 wt%, MW= 49.5 kDa. 
SP24. Yield: 97 % CE 84 %; mol probe to GAU 4.2 % (7.7 eq. per 
polymer chain) 35.2 wt%, MW= 66.7 kDa. 
8.4.3.2. Direct attachment of the amino functionalized in 
vitro smart probe to PGA. 
 The standard DIC/HOBt procedure with slight modifications 
was applied in this case. Briefly, in a two-necked round bottom flask 
fitted with a stirrer bar and two septums, PGA was dissolved in anh. 
DMF under N2 flow. After that, DIC (1.5 eq. from the desired 
percentage of modification) was added to the mixture. After 10 
minutes, 1.5 eq. from the desired percentage of modification were 
added as solid form. Reaction was left to proceed for 10 minutes more. 
After that time, the corresponding amount of probe was added. The pH 
was adjusted to 8 and the reaction was allowed to proceed for 16 hours 
protected from light. Finally, the solvent was removed under vacuum 
and the product was dissolved in ddH2O (by adding 100 L of NaHCO3 
1M to convert it into the sodium salt form of PGA). The product was 
purified by SEC using PD10 commercial G25 columns followed by 
dialysis (Vivaspin®, MWCO 3000). Upper part of the tube was freeze-
dried and the obtained yellowish solid was analyzed by NMR (D2O). 
Probe content was quantified by UV-VIS at λ: 332 nm in the case of 
MMP probes, and λ: 455 nm for Cathepsin S probes. 
SP.8. Yield: 90 % CE 97 %; mol probe to GAU 5.8 % (6.4 eq. per 
polymer chain), 36.0 wt%, MW= 26 kDa. 
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SP.17. Yield: 90 % CE 33 %; mol probe to GAU 1 % (1.1 eq. per 
polymer chain) 6.85 wt%, MW= 17.8 kDa. 
8.4.3.3. EG spacer introduction prior to direct conjugation 
of the amino functionalized in vitro smart probe to PGA. 
In order to introduce an EG spacer between the polymer and the 
probe, FMOC-EG(4)-COOH was attached to the amine functionalized 
probe prior to do polymer conjugation. The carboxylic group of 
FMOC-EG(4)-COOH was activated with DIC/HOBt, in anh. DMF. 
Afterwards, the probe HHY-29 was added and the pH was adjusted to 8 
by adding DIEA. The reaction was left to proceed for 16 hours stirring 
under nitrogen atmosphere. After that time, the solvent was evaporated 
and the product was passed through a C18 column eluting with 
methanol. The yellowish fraction was collected. The product was 
directly deprotected with 2 mL Et2NH/DMF (1/4) during 45 minutes. 
The solvent was then evaporated and the product was directly used for 
the conjugation to PGA, by using the above protocol based on 
DIC/HOBt as activator of the carboxylic groups for probe conjugation 
and purification. 
SP18. Yield: 95 % CE 50 %; mol probe to GAU 1.5 % (1.65 eq. per 
polymer chain) 9.72 wt%, MW= 18.8 kDa 
8.4.3.4. General procedure for the conjugation to maleimide 
probes.  
In a round bottom flask fitted with a stirrer bar and a stopper, 1 
eq. of the PGAcoCysteamine2TP PGA sodium salt was dissolved in 
300 mM HEPES buffer pH 7.4. Next, the corresponding amount for the 
desired % of substitution of maleimide compound was dissolved in 
DMF and added to the polymer solution (buffer/DMF ratio 5.5/1). 
Finally, 10 eq. of TCEP dissolved in HEPES buffer were added, and the 
reaction mixture was left stirring for 16 hours at r.t. protected from 
light. Upon reaction, the mixture was purified using a PD10 column 
collecting fractions of 0.5 mL. One part of each fraction was diluted 
with ddH2O water and their fluorescence (for in vivo probe bearing 
Cy5.5, λexc= 595 nm, λemi= 680 nm) or absorbance (for in vitro probe at 
λ: 455 nm) was measured in order to identify the conjugate and 
quantify the linking efficiency. Finally, the conjugate containing 
fractions were combined and freeze dried.  
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SP.19. Yield: 70 % CE 40 %; mol probe to GAU 1.1 % (1 eq. per 
polymer chain) 8.8 wt%, MW= 14.6 kDa. 
SP20. Yield: 75 % CE 50 %; mol probe to GAU 0.8 % (7.7 eq. per 
polymer chain) 13.0 wt%, MW= 26.0 kDa. 
8.4.3.5. Synthesis of targeted polymers for cartilage binding. 
8.4.3.5.1. PGA activation with 5’-N-hidroxysuccinimide 
(NHS). 
In a two-necked round bottom flask fitted with a stirrer bar and 
two septums, 190 mg (1.4 mmol GAU, 1 eq.) of PGA as acid form was 
dissolved in 10 mL of anh. DMF. Afterwards, 88 mg (0.7 mmol, 126.2 
g∙mol-1, 0.5 eq.) of DIC were added. The reaction was left stirring at r.t. 
for 5 minutes. After that time, a catalytic amount of 4-
Dimethylaminopyridine (DMAP) was added and 81 mg (0.7 mmol, 0.5 
eq.). The pH was checked to be 8. The mixture was left stirring for 16 
hours under N2 atmosphere. The solvent was removed and the polymer 
was precipitated by adding 40 mL of a mixture CHCl3/ Acetone: (4/1) 
and centrifuged during 5 minutes at 8.000 r.p.m. After removal of the 
supernatant, the white solid was washed three times with 30 mL of 
methanol, and dried under vacuum. Yield: 90 %, 44 % NHS activation 
according to 1H-NMR (signal at 2.4 ppm in DMSO-d6). 
8.4.3.5.2. EG(4) spacer introduction. 
As the peptidic sequences (cartilage binding and scramble 
sequence) have both the C- terminus deprotected, it was necessary to 
previously activate the FMOC-EG(4)-COOH using NHS protocol for 
the introduction of an EG spacer. 
a. NHS activation of FMOC-EG(4)-COOH. 
In a two-necked round bottom flask, fitted with stirrer bar and 
two septums, Fmoc-EG(4)-COOH (100 mg, 0.205 mmol, 1 eq.) was 
dissolved in 5 mL of anh. CH2Cl2 under nitrogen atmosphere. Next, 
DCC (85 mg, 0.410 mmol, 2 eq.) dissolved in 5 mL more of anh. 
CH2Cl2, was added and the mixture was left reacting for 10 minutes. 
After that time, NHS (47.2 mg, 0.410 mmol, 2 eq.) was added as a 
solid. The reaction was left stirring for 16 hours. After that time, the 
crude was filtered off and the solvent was removed under vacuo. Yield: 
80 %. The degree of NHS activation was determined as 90 % according 
to 1H-NMR as well as using the indirect method TNBS assay93 for 
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estimation of free amino groups when the NHS activated sample is 
reacted with an equimolar amount of Glygly-NH2. 
b. Peptides derivatization with EG(4) spacer. 
Fmoc-EG(4)-NHS was reacted with the free amino groups of 
the cartilage binding and scramble peptidic sequences. For that purpose, 
1 eq. of Fmoc-EG(4)-NHS was dissolved 5 mL of in anh. CH2Cl2 under 
nitrogen atmosphere and 0.8 eq. of the corresponding peptide was 
added afterwards in 5 more mL of anh. CH2Cl2. The pH was adjusted to 
8 by adding 50 μL of DIEA. The reaction was left stirring under 
nitrogen flow for 16 hours. Then, the solvent was completely removed. 
In a direct step, the reaction crude was Fmoc deprotected by using 4 
mL of a mixture of piperidine/methanol (20/80, v/v). Reaction was left 
to proceed for 1 hour and the solvent was completely removed. The 
Fmoc deprotected product was then purified using a C18 column in 
methanol collecting fractions of 1.5 mL The corresponding fraction 
were put together, and solvent was evaporated yielding to a white solid. 
Yields: 60 % for cartilage binding derivatized sequence, and 65 % for 
scramble sequence. Reaction success was checked by 1H-NMR were 
EG(4) signals were present, and the corresponding aromatic Fmoc 
signals were not. Apart from that, UV-VIS was performed and peptide 
content was determined as 100 % according to the Absorbance of 
tryptophan amino acid from the peptides (ε: 5.579 M-1∙cm-1 at λ: 278 
nm). 
8.4.3.5.3. Peptides conjugation to activated PGA-NHS 
and Cy5.5 labeling.  
In a two-necked round bottom flask fitted with a stirred bar and 
two septums, 40 mg (0.233 mmol, 1 eq.) of NHS activated PGA was 
dissolved in 10 mL of anh. DMF under nitrogen atmosphere. The 
system was cooled down to 4 °C by using an ice bath. Then 0.012 
mmol of peptide (0.05 eq. for 5 % modification with derivatized or not 
derivatized, cartilage binding sequence, or scramble sequence) was 
added together with a catalytic amount of DMAP. The pH was adjusted 
to 8 with the addition of 50 μL of DIEA and the reaction was left to 
proceed for 24 hours. After that time, 0.0023 mmol of Cy5.5-NH2 (0.01 
eq.) was added and the mixture was left reacting for 24 hours more. 
After that time, the products were purified by SEC using commercial 
PD10 columns eluting with ddH2O. Peptide content was estimated by 
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UV-VIS using tryptophan absorbance at 278 nm. Cy5.5 percentage of 
modification was determined by fluorescence using λexc= 595 nm, λemi= 
680 nm. Yields: 50-70 % Peptide and Cy5.5 content is summarized in 
Table 8.16 
8.4.3.6. In vitro testing of MMP probes. 
In vitro testing of MMP probes was performed at CEA-Saclays, 
in Paris by Vicent Dive group with the assistance in some of them of 
this PhD aspirant. Briefly, enzymatic assays were carried out in 50 mM 
Tris-HCl buffer, pH 6.8, 10 mM CaCl2, at 25 °C. The assays were 
performed in black 96-well plates (non-binding surface plates; Corning 
Costar Catalog No. 3651). Progress curves were monitored by 
recording the increase in fluorescence resulting from substrate cleavage 
at the corresponding wavelengths depending on the probe tested. The 
conditions of a typical experiment were 100 mL of buffer and 1-10 nM 
of MMP (R & R Systems). The reaction was then initiated by addition 
of 0.1-0.5 µM of probe. Data were collected for 1 hour. The Kcat/Km 
values were determined from first-order full-time reaction curves (S < < 
Km; S= 0.5 µM) and fitted with the integrated Michaelis-Menten 
equation by nonlinear regression: P= S0(1-exp(-kt)), where P is product 
concentration; S0 is substrate concentration (probe) at t (time)= 0; exp is 
exponential; k is (Kcat/Km) + E; and E stands for enzyme concentration. 
The kinetic parameters Km and Kcat were estimated according to the 
direct linear plot method. 
8.4.3.7. In vitro testing of Cathepsin B probes. 
In vitro testing of Cathepsin B probes was performed at Josef 
Stefan Institute in Ljubljana, Slovenia by Boris Turk group. 
8.4.3.7.1. Cleavage Site Determination of Cathepsin B 
probes.  
Cleavage site in all three probes was determined using MALDI-
TOF/TOF UltraFlextreme III mass spectrometer (Bruker, Germany) 
controlled by the FlexControl 3.3 software package. All three probes 
were mixed with cathepsin B in 1:100 molar ratio in 50 mM MES 
buffer pH 6.0 with 1 mM DTT and incubated until no further increase 
of fluorescence was observed. Samples were then desalted and 
concentrated using C18 tip before 1 µL of the sample was applied to a 
MALDI target plate as a 1:1 (v/v) mixture of sample and matrix 
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(matrix: 20 mg∙mL-1 DHB, dissolved in 30 % acetonitrile and 0.1 % 
TFA). UV laser beam (nitrogen laser, λ= 337 nm) was used for 
ionization, ions were accelerated in positive ion mode to a kinetic 
energy of 25 kV. External calibration of mass spectra was performed 
using Peptide Calibration Standard II (Bruker, Germany). 
8.4.3.7.2. Kinetics of Cathepsins probe hydrolysis. 
Kinetics of cathepsin B probes (conjugated and unconjugated), 
hydrolysis by cathepsin B was measured in accordance with standard 
procedures.94 Accordingly, probe (1-30 µM final concentration) was 
prepared in 0.1 mM PBS buffer pH 6.0 with 1 mM DTT. Cathepsin B 
was then added and fluorescence increase was measured continuously 
using Tecan M1000 (Tecan) fluorescence plate reader. The KM and 
Kcat/Km values were determined by nonlinear regression analysis and 
GraphPad Prism software (GraphPad Software, Inc.) using the 
experimentally determined reaction velocities at given substrate 
concentrations.  
8.4.3.7.3. Cleavage of Cathepsin B selective probe and 
SP.16 (PGA-Probe) in co-cultures of MDA-MB-231 and THP-1 
cells. 
THP-1 cells were seeded (~106 cells∙mL-1) on a 150 mm plate 
and differentiated with 30 ng∙mL-1 PMA for 48 hours in RPMI media. 
Medium was then exchanged and cells were grown for additional 24 
hours. MDA-MB-231 cells were grown in DMEM. For the co-culture, 
both plates with cells were washed with sterile PBS twice, MDA-MB-
231 cells were detached using Hank's based enzyme free cell 
dissociation solution and suspended in 10 mL PBS pH 6.0 with 0.5 mM 
DTT. Cells were then added to THP-1 cells for 2 hours in a 2:1 ratio. 
Next, cells were removed by centrifugation and protein supernatants 
containing secreted extracellular proteins were concentrated on a 
MWCO 3.000 (Milipore) filter device to a final concentration of 1-2 
mg∙mL-1. Before the addition of probes, cathepsin B activity in the 
supernatant was verified with zRR-AMC (Bachem) substrate. For the 
test 100 μg of supernatant was pipeted into 96 well plate and probes 
were added to a final 5 μM concentration. In control experiment, E-64 
(Peptide Institute) or CA-074 (Peptanova) inhibitors were used at 10 
μM final concentration, which is sufficient to completely block any 
cathepsin activity in cellular experiments.94 In order to evaluate the 
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total fluorescence of the probes in the supernatant, complete hydrolysis 
was performed by addition of 100 nM recombinant cat B. Fluorescence 
was then measured in 2 minute intervals over 2 hours using TECAN 
M1000 at excitation and emission wavelengths of 670 nm, and 695 nm, 
respectively. All experiments were performed in triplicate.  
8.4.3.8. In vivo testing of the polymeric probes and targeting 
strategies. 
In vivo testing of Cathepsin B conjugate in inflamed paw 
mouse model, in vivo testing of MMP-13 probe conjugate in DMM OA 
mouse model and in vivo testing of targeted polymeric probes were 
performed at Imperial College London, UK by Hideaki Nagase’s group. 
Such results were presented with the only purpose of highlighting the 
potential of our polymeric probes provided the good performance in 
vivo, and the experimental part will not be further discussed herein. 
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The growing incidence and increasing costs caused by 
neurodegenerative disorders, together with the lack of effective 
treatments, point out the need for novel approaches in order to address 
their enormous burden. Most of the current therapies mainly rely on 
palliative healing without stopping disease progression. Moreover, 
Central Nervous System (CNS) drug discovery and development is a 
challenging task due to the presence of the most impenetrable 
biological barrier in the human body- the blood brain barrier (BBB).1-3 
Invasive and non-invasive strategies are under study in order to bypass 
the BBB and achieve effective drug concentrations at the brain 
parenchyma within the therapeutic window.4, 5 In this thesis, we 
combined non-invasive approaches based on the use of targeted 
nanosystems for effective brain accumulation, together with molecular 
Trojan horses in order to promote BBB entry.6-12  
Polymer therapeutics (PT) have been proposed as the ideal 
technological platform towards the design of valuable treatments as 
well as diagnostic tools for CNS related diseases. With several products 
in the market, and a growing number under clinical development,13-16 
PT hold key characteristics to surpass the main limitations suffered 
from low Mw tracers or drugs, and even biologicals (peptides, proteins, 
antibodies, oligonucleotides). Those features include: (i) improved 
pharmacokinetic profile and enhanced plasma half-life; (ii) the 
possibility to include targeting moieties for specific active targeting; 
(iii) carrier multivalency allowing tunable drug(s) loading capacity and 
combination approaches, including theranostics; (iv) controlled and 
sustained drug release of conjugated drugs upon bioresponsive linkers 
under specific environments; (v) PT provide stability and reduced 
immunogenicity to the bioactive compound and possess optimal size to 
allow better penetration.17  
It is currently accepted that future challenges and opportunities 
to move this platform technology forward are based on (i) new 
molecular targets, (ii) polymer-based combination therapy, (iii) control 
on polymeric platforms and their conformational behavior in solution, 
and (iv) exhaustive physico-chemical characterization, essential to 
transform a promising conjugate into a candidate for clinical 
evaluation, following regulatory indications as exposed in Chapter 
1.18,19 Additionally, limitations with existing polymeric systems such as 
their lack of biodegradability, biocompatibility and multifunctionality 
inevitably lead to side effects and poor patient compliance. New PT 
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based on amino acids are excellent candidates for drug delivery, as they 
do not suffer from these limitations. In particular, polyglutamates 
(PGA) constitute a versatile platform which has been effectively used 
as building blocks in polymer drug conjugates and polymeric micelles 
for various medical applications ranging from cancer to tissue 
regeneration.18, 19 Moreover, it is expected its FDA approval after 
approval of PGA-paclitaxel conjugate, OpaxioTM for the treatment of 
various cancers alone or in combination (in 2012 OpaxioTM was 
designated as orphan drug in combination with radiotherapy and 
temozolomide for the treatment of glioblastoma multiforme).20-24 
Besides, there is a growing interest in the development of smart 
polymeric systems, where new and more defined architectures with 
higher MW (to enhance passive targeting by the EPR effect), 
predictable structure and conformation, lower heterogeneity, higher 
drug loading capacity and greater possibility for multivalency are key 
desirable parameters. Furthermore, as mentioned above, the use of 
adequate physico-chemical techniques in order to exhaustively 
characterize new complex systems is a requisite. 
With all that in mind, this thesis dissertation aimed to achieve 
new well-defined and exhaustively characterized structures, based on 
polyglutamates, to be used as carriers for the treatment and/or diagnosis 
of neurodegenerative disorders (concretely Alzheimer’s Disease (AD)), 
by means of BBB bypassing using active targeting strategies with 
molecular Trojan horses. 
In order to accomplish the already exposed goals of this highly 
ambitious project and with the aim of “building the house from the 
foundation”, the initial efforts were devoted to the development of a 
new, easy and versatile methodology for the synthesis of polymeric 
platforms based on PGA. Among the techniques for the synthesis of 
polypeptides,25-31 the ring opening polymerization (ROP) of N-
carboxyanhydrides (NCA) represents the most commonly applied 
polymerization technique to produce polypeptides and polypeptide-
based block copolymers on a multigram scale.32-34 The possibility to use 
non-natural amino acids combined with the use of functional and 
macromolecular initiators makes it a powerful approach to yield 
functional polypeptide based homo- and multi-block copolymers, with 
different architectures that could ultimately lead to different and 
unexpected properties for the desired biological applications. 
Unfortunately, this polymerization method suffers from different 
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inherent mechanistic limitations34 making the synthesis of well-defined 
systems, a challenging task. Indeed, it requires the use of ultra-pure 
NCA monomers and initiators, ultra-dried solvents, and the avoidance 
of risk factors such as the presence of moisture, traces of CO2 or any 
impurity that could lead to undesired reactions, precise control over 
pressure and temperature…among other factors. Even then, secondary 
and undesired terminating processes can occur due to the coexistence of 
two main mechanisms within the polymerization process. Several 
attempts have been carried out by different research groups in order to 
minimize or even avoid these secondary reactions.35-40 Although great 
advances have been achieved, all these methods have their own 
limitations. For example, high vacuum techniques (HVT) require 
complex and expensive experimental setup, hexamethyldisilazane 
(HMDS) amines are sensitive to hydrolysis, while heavy metal catalysts 
must be carefully removed to avoid non-specific toxicity in biomedical 
applications.  
Overall those methods, the Schlaad methodology38 caught our 
attention (Scheme 2.4). This method is based on the use of primary 
amine hydrochloride salts as initiators in order to avoid the undesired 
activated monomer mechanism (AMM). The principle of this strategy 
is based on the so-called dormant species caused by the equilibrium 
among primary amine and the ammonium salt that minimize the 
monomer deprotonation. Nonetheless, undesired reactions still occur 
due to the presence of chloride anions, which are well-known to lead to 
initiations. Hence, in order to overcome those limitations, we proposed 
a novel approach using, for the first time, ammonium salts as initiators 
but with non-nucleophilic tetrafluoroborate counterions what will offer 
the advantages of the Schlaad method without its main drawback. This 
anion is less hydrophilic and thus, better soluble in a broad range of 
organic solvents and it has lower nucleophilicity than the related nitrate 
or halide salts.41-43 Indeed, the BF4- is considered to be inert during the 
polymerization due to equal charge distribution provided by its 
tetrahedral symmetry, and the presence of highly electronegative 
fluorine atoms, which diminishes the nucleophilicity of the anion 
avoiding, consequently, the undesired monomer deprotonation and 
guaranteeing the living character of the polymerization. This hypothesis 
was indeed experimentally demonstrated with the optimization of a new 
methodology leading to well-defined polypeptides and polypeptide-
based block copolymers with controlled and adjustable MW (up to 
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degree of polymerization 800), low polydispersity (Đ) (<1.2), 
quantitative yields, with preserved end group integrity and avoidance of 
racemization at the chiral centers (Table 2.4). Furthermore, the 
synthesis could be performed without the need of complex 
experimental setup, in large scale, with good batch to batch 
reproducibility and the lack of toxic impurities, what is crucial for 
further use in the field of nanomedicine. Indeed, this methodology has 
been the base of a spin-off company within the laboratory, what 
demonstrates its industrial feasibility.44 
Herein, the versatility of the reported method was firstly 
explored for the synthesis of homopolymers using n-butyl and 
neopentilamine tetrafluoroborate salts as initiators. Then, the method 
was extended to the design of end-functionalized polymers derived 
from the use of functionalized initiators, such as, alkyne and azide 
bearing initiators what opened the door for site-specific conjugation of 
bioactive molecules such as antibodies, proteins or imaging probes. The 
synthesis of hybrid di-block copolymers was also demonstrated by the 
use of polyethylene glycol (PEG) based initiators (Table 2.4).45  
Once the polymerization process was successfully achieved, the 
following step was the optimization of the benzyl protecting group 
removal. An ideal method should be able to reach complete PBLG 
deprotection in the absence of racemization, in order to avoid changes 
in the secondary structure of the synthesized polypeptides. These 
changes could induce dramatic modifications in the biological behavior 
of a designed nanomedicine, such as, altered immunological properties, 
degradation profiles, and ultimately, a modified and probably 
unpredictable pharmacokinetics and biodistribution. All that together, 
point out the relevance of the selected deprotection methodology. 
While the use of TFA/HBr or acetic acid/HBr was known to produce 
complete deprotection in the absence of racemization,46 these 
conditions were not suitable for sensitive functional end groups derived 
from functional initiators as well as PEG based block copolymers, both 
acid-sensitive. Thus, an alternative basic methodology based on the use 
of a NaOH suspension in THF was also optimized for homopolymers as 
well as PEG based di-block co-polymers in order to achieve benzyl 
group removal without stereochemical changes (Figure 2.17).45  
Regarding the stated need for the design of novel architectures 
to be used as carriers in certain drug delivery strategies, branched 
polymers represent outstanding aspirants due to their unique 
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rheological, mechanical and biomedical properties derived from their 
structures, inaccessible for linear polymers. Hence, we decided to 
explore the possibilities of the newly described BF4 methodology in the 
synthesis of star-shaped polyglutamates, taking profit from the living 
character and the control over the initiation step provided by our 
method. Thus, a simple yet powerful methodology for the synthesis of 
3-arm star-shaped polyglutamic acid with well-defined structures, 
precise MW and low Đ (<1.2) was applied, following a divergent 
method from novel multifunctional initiators. Four different 3-arm 
initiators were synthesized and characterized including one with 
reducible disulfide bonds within the arms. The relevance of this latter 
initiator relies on the possibility of star disassembling into the 
individual arms. This fact enables the characterization of the individual 
arms what demonstrated the homogeneity of our systems, as expected 
from a living polymerization and efficient initiation47 (Figure 3.7, Table 
3.1).  
As mentioned before, multivalency, inherent to PGA, is a 
desired characteristic in order to get high loading capacities. This can 
be further improved with the introduction of orthogonal functionalities 
within the polymer backbone to allow site-specific bioconjugations. 
Pursuing that aim, a versatile post-polymerization modification 
technique was implemented.48 This technology encompasses the use of 
4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methyl morpholinium 
(DMTMM) salts for carboxylic acid activations, necessary for acid/base 
chemistry with functionalized amines. In this way, various reactive 
functional groups were easily introduced under mild reaction conditions 
(needed to keep the polymer backbone integrity), such as, alkynes, 
azides, reactive disulfides or protected amines (Scheme 4.6). This 
methodology was very versatile as could be used in aqueous as well as 
in organic solvents by changing the salt counteranion from chloride to 
BF4, respectively. This versatility allowed us to introduce hydrophilic 
as well as hydrophobic molecules within the polymer backbone (Tables 
4.2 and 4.3). Hence, the described post-polymerization modification 
method represents a powerful and attractive approach for the synthesis 
of functional polymers, overcoming the limited functional group 
tolerance of many controlled polymerization techniques.48 
Importantly, these newly synthesized polyglutamates should be 
biologically evaluated, in vitro and, if promising (safety/benefit) in vivo 
by means of adequate cell and animal models in order to demonstrate 
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their potential therapeutic applications. First, their biocompatibility, 
biodegradability and cell trafficking were considered key aspects to be 
studied.  
Polymer degradation profiles in the presence of the lysosomal 
enzyme cathepsin B were first performed. The results obtained from 
several star-shaped polyglutamates as well as with the functionalized 
polymers yielded to the conclusion that, the architecture and the degree 
and type of functionalization do have an important influence on the 
degradation rate. For instance, the hexyl-based star-shaped PGA 
presented a slower degradation rate when compared with its analogous 
ethyl-based initiated polymer (Figure 3.10). Furthermore and looking at 
linear polymers, the degree of functionalization as well as the nature of 
the chains added within the polymer backbone do affect the degradation 
rate of the final construct as seen in the case of the different PEGylation 
grades (Figure 4.19).  
Their in vitro biocompatibility (MTS assays) against different 
cell models was apparently not compromised with the use of different 
architectures nor with the degree of modifications introduced at least up 
to the concentrations tested (3 mg∙mL-1) (Figures 3.13 and 4.20).  
In the cell uptake studies, different PGA architectures (linear, 
hybrid di-block PEG-PGA, and star) were prior labeled with the 
fluorescence tag Oregon Green (λ: 488 nm) to allow in vitro evaluation. 
Those studies revealed energy-dependent mechanisms, independently 
of the MW or the architecture, since absence of uptake at 4 °C was 
found for all the polymers tested. When linear PGAs of different MWs 
were tested, no changes in the internalization profile and cell associated 
fluorescence (CAF) intensity were found, meaning that, at least for 
linear polymers, their MW did not affect the degree of cell 
internalization. Interestingly, cell uptake was significantly increased (in 
about 3 fold) when star-shaped polymers where used, highlighting the 
importance of the architecture in the biological output (Figure 3.19). 
This fact could be ascribed to the inherent properties of star-shaped 
polymer, which has in general, more compact structure with globular 
shape and large surface areas among other interesting features, making 
them relevant candidates to be used in drug delivery and molecular 
imaging among other biological applications49, 50 
Then we went through the synthesis of PGA-based systems 
with self-assembly properties. When exhaustive physico-chemical 
characterization of such systems was carried out through a battery of 
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techniques including DLS, DOSY and NOESY-NMR, CD, 
transmission electron microscopy (TEM), fluorescence techniques and 
small angle neutron scattering (SANS), interesting data regarding 
solution conformation aspects were found. According to the findings, 
those systems undergo  self-assembly processes showing a clear 
structure/conformation-concentration dependency encountering 
“unimers” of 5-10 nm size at low concentrations, whereas 
supramolecular structures of around 100-180 nm were mainly seen at 
high concentrations. This phenomenon occur in all those systems, 
nevertheless it did not occur in linear PGA. Critical Aggregation 
Concentration (CAC) values could be obtained by DLS 
measurements.51-54 A self-assembly process leading to organized bigger 
structures with hard sphere shapes bearing branching points directed to 
the outside was suggested with the aid of TEM imaging and SANS 
fittings among other findings (Figures 5.2 and 5.8). Indeed, SANS 
contrast experiments confirmed the presence of organized domains 
along the nanostructure, fact in good agreement with previous reports in 
literature.55-58 These findings suggested that such motifs are the driving 
force for the assembly of these architectures. The stimuli-
responsiveness of such systems under different physico-chemical 
environments (temperature, ionic strength, or concentration), as well as 
the influence of the degree and nature of the polymer functionalization 
on the dynamics of the process were studied. Summarizing, it could be 
said that the carrier size was clearly dependent on the environmental 
conditions. Importantly, the aggregation process could be tuned and 
even prevented depending on the polymer functionalization. 
Apparently, hydrophilic residues above 30 mol% loading prevented 
system aggregation. This could be a useful tool in the design of highly 
controlled polymeric constructs.  
Considering all this, we proposed a strategy for the preparation 
of novel drug delivery systems (DDS) with higher MW that would 
allow longer circulation times in vivo, adequate functionalities to 
enhance BBB crossing and subsequently accumulate therapeutics as 
well as imaging probes in the brain in a concentration capable to 
diminish AD burden.  
The developed strategy was based on the covalent entrapment 
of the supramolecular architectures with the aid of click chemistry 
reactions, in order to yield nanoconstructs stable to physical stimuli 
(concentration. temperature, ionic strength). For that purpose, 
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functionalization of these PGA-based systems via post-polymerization 
methodologies was used to introduce cross-linkers. Co-assembly 
studies were carried out in order to verify that those construct do 
intercalate, necessary for cross-linking. After that, the covalent capture 
of the self-assembled constructs was carried out, firstly by using 
CuAAC click chemistry, but later extended to the copper free thiol-end 
and reversible disulfide chemistries. This latter strategy would allow to 
build architectures with sizes >100 nm suitable for long circulating 
times, but prone to disassemble under reductive media.59  
The preliminary biological evaluation of those structures 
against selected cells revealed their absence of toxicity and exhibited a 
significantly enhanced cell internalization rate when compared with the 
linear and star under the conditions tested, as shown by flow cytometry 
(Figures 5.26 and 5.27).  
Once the main architectures established, the selection of the 
transcytosis-trigger residues to be used towards BBB crossing had to be 
done. ANG-260-66 and CRTIGPCSVC (cPEP)67, 68 were chosen as 
vectors on a first approach. For that, polymer-conjugates from both 
peptides by means of different linking chemistries (amide bonds for 
cPEP whereas disulfide chemistry for ANG) using the first family of 
synthesized polymeric platforms (homopolymers, di-block PEG-PGA, 
and star polymers) were developed (Scheme 6.2). Such polymeric 
family was previously labeled to allow in vivo biodistribution studies 
through non-invasive imaging by PET, with DO3A-68Ga in the case of 
homo and di-block copolymers, and DO3A-111In for star-shaped 
polymers. In vivo studies were chosen to evaluate BBB crossing 
capability since they represent the most suitable and reliable manner in 
contrast to reported cell-based BBB models.  
Hence, biodistribution studies were carried out in FVB/NJ 
mice. After i.v. administration, animals were monitored and sacrificed 
at different time points and radioactivity quantified in each organ, as 
well as in blood and plasma. Plasma levels allowed the extraction of 
pharmacokinetic parameters, including polymer plasma half-life. A 
renal excretion profile and a non-specific organ accumulation were 
observed for all carriers, showing their suitability to be used in DDS 
(Figures 6.21 and 6.26). Regarding their pharmacokinetics, branched 
polymers in general (with and without targeting units) presented a 
greater plasma half-life (from 12 to 16 hours) when compared to their 
linear counterparts (0.6 hours) (Table 6.5). Consequently, an enhanced 
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brain accumulation was observed for the star-shaped polymers in 
comparison with the linear or di-block copolymers, although it was still 
considered not significant (< 1% injected dose (ID)). Several 
explanations could be drawn to this respect, being among them, the 
need for a better exposing of the targeting ligands allowing better 
receptor recognition and the need for greater circulation times to further 
promote brain accumulation. The covalently captured structures, 
resulted from the self-assembly process of the novel PGA-based 
systems previously described, offered a higher MW (to improve plasma 
half-life) and a greater and less hindered surface area (to enable a better 
exposition of the targeting vectors), therefore were considered potential 
candidates.  
Hence, by means of a bottom-up approach, the surface 
modification of such nanostructures was carried out. Cy5.5 probe was 
conjugated in order to allow biodistribution monitoring by fluorescence 
optical imaging (NIR) on one hand. On the other hand, based on the 
previous data obtained, ANG-2 was chosen as BBB vector and surface 
conjugated via disulfide bonds. The synthesized constructs (with and 
without targeting unit) were in vivo analyzed in terms of biodistribution 
in C57BI/6 mice (Animal Imaging Center, Zurich, Switzerland). After 
its i.v. administration through the tail vein, animals were sacrificed at 
different time points and fluorescence in blood and the extracted organs 
(after organ reperfusion) was recorded using MAESTROTM. In this 
case, the nanostructures tested also exhibited renal excretion profiles 
without unexpected toxicities from unspecific accumulations (Figure 
6.32). Remarkably, the % ID obtained in brain in all cases was 
significantly higher than with the previous carriers, with values up to 
1.5 % ID considered similar to those in literature for systems that 
“cross” the BBB.16  
Up to this point it could be said that, one of the major challenge 
in this thesis was already accomplished, as we were able to design 
biodegradable, multivalent and well-controlled drug delivery carriers 
capable to surpass the BBB. 
With the optimized covalently captured constructs capable to 
promote brain accumulation, therapeutics for AD treatment and/or 
diagnostics were pursued always taken into account the advantages to 
implement combination therapies. Curcuminoids, in particular 
bisdemethoxycurcumin (BDMC), was selected as a model drug with far 
demonstrated activities and a great potential for the treatment of AD. In 
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combination with propargylamine moieties, BDMC was conjugated to 
the clicked structures via ester bonding. Then, the BDMC-decorated 
structures were in vitro evaluated in terms of cell viability, drug release 
profiles at different pHs, and in vitro activity as inhibitors of fibril 
formation. In order to achieve proof of concept, the activity of the 
compounds was firstly checked using an accepted model based on the 
use of Hen Egg White Lysozyme (HEWL) for protein amyloid 
formation. Several BDMC bearing compounds and free BDMC for 
comparison at two different concentrations (10 and 50 μM drug-eq.) 
were incubated for 24 hours with HEWL and their inhibitory potential 
was measured by Thioflavin T (ThT) fluorescence at different time 
points (Figure 7.16). These results were further confirmed by TEM 
(Figure 7.17).  
In addition, the neuroprotective effect of the curcuminoid 
bearing polymeric structures was evaluated in organotypic cultures 
from entorhinal cortex-hyppocampus.69 In order to study 
neuroprotection, the experimental design included pretreatments with 
the polymer conjugate prior to Amyloid-β peptide (Aβ1-42)-induced 
neurotoxicity. In these conditions, pretreatment with either 1 or 5 µM 
BDMC-eq. significantly reduced cell death in Aβ1-42 peptide treated 
cultures (Figures 7.19 and 7.20). 1 µM BDMC-eq. was selected as the 
concentration to move forward and further experiments are ongoing in 
order to identify possible mechanisms of neuroprotection. 
As for the other clicked structures evaluated, biodistribution of 
BDMC bearing compounds dually labeled with DO3A-Gd3+ and Cy5.5 
was carried out using C57Bl/6 mice and optical imaging techniques. 
The biodistribution profile was comparable to those obtained for the 
other clicked architectures analyzed (targeted and non-targeted both 
without BDMC). Renal excretion profiles were again observed, 
significant brain accumulations (around 1.2 % ID), and lung 
accumulation at the early time points highlights the bigger size of the 
structures (Figure 7.23). Finally, looking for a definitive proof of 
pharmacological activity, a preliminary in vivo experiment in a young 
AD mouse model (ArcABeta 8-11 months) was performed. Multiple 
doses during a 2-week treatment were administered (Figure 7.27). This 
model resulted highly variable and up to now no conclusive data 
regarding activity could be drawn. A more controlled in vivo 
experiment is ongoing. Importantly, from this first in vivo experiment 
the safety of our carriers was fully demonstrated. 
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So far, the data obtained from the organotypic cultures together 
with the in vivo biodistribution data and safety profiles with BDMC-
bearing clicked architectures highlights the promising potential for the 
use of these novel nanomedicines in AD treatments. Those preliminary 
results encourage us for further in vitro investigation considering other 
pathological hallmarks of the disease where BDMC could be effective, 
as well as proper in vivo activity experiments are planned in order to 
unravel the full potential of these systems as nanotherapeutics for 
neurological disorders. 
Finally, in the frame of a FP7-European project, LIVIMODE, a 
PGA-based in vivo imaging platform based on protease-activatable 
smart ligands to allow non-invasive quantitative assessment of target 
expression in diseased tissue (diagnosis) and monitoring of disease 
progression (staging) was developed. Such probes were based on a 
NIRF pair and cleavable sequences by specific enzymes. Upon enzyme 
cleavage, quencher release led to fluorescence detection. By means of 
optimized conjugation to PGA-based carriers, tissue specificity was 
provided to the enzyme specific activatable smart probes synthesized 
by our collaborators. Several NIRF probes where conjugated applying 
different linking chemistries to PGA derivatives. To this respect, 
conjugates from MMP-9, 12 and 13, cathepsins B and S, as well as 
FAP selective probes were generated and evaluated. Overall, the results 
from the polymeric probes in terms of enzymatic studies showed that a 
selective enrichment of dye-labeled polymers was possible and that 
such probes retained and even enhanced their ability to be cleaved by 
the specific proteases in a selective manner. In vivo studies 
corroborated this fact. 
For instance, the MMP-12 as well as the cathepsin-B generated 
probes exhibited a really good performance in vitro, with great potential 
to be used in cancer detection. Remarkably, with MMP-13 selective 
polymeric probe, its potential use in the early detection of osteoarthritis 
was demonstrated with outstanding results in a mouse model of 
osteoarthritis based on the destabilization of the medial meniscus 
(DMM). Active targeting strategies were additionally investigated. 
Regarding OA targeting, the use of the well-known Rothenfluh 
peptides did not improve conjugate accumulation, which was found to 
accumulate “per se” in the damaged knees from the DMM OA model 
after i.v. injection. 
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As a conclusion it could be said that the results obtained so far, 
clearly point out that these smart polymeric probes are highly suitable 
as early-detection molecular diagnostic tools with a high signal to noise 
ratio and a slow clearance rate. In particular, with MMP-13 probe the 
data suggested that this macromolecular probe could be qualified as an 
excellent candidate for theranostic applications in combination with 
adequate drugs. Furthermore, at the preclinical level our approach 
offers a significant potential for multimodal imaging due to easy 
conjugation to PET or MRI tracers apart from OI and would further 
assist in conceptualizing clinical studies. Finally, it is important to note 
that, the therapeutic indication of these molecular diagnosis probes 
could be easily redirected towards neuroimaging with the developed 
constructs within this thesis, possibility currently being explored with 
some of the developed probes (MMP12, MMP9 or cathepsin B). 
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 A novel versatile methodology for N-Carboxyanhydride Ring 
opening polymerization (NCA ROP) was applied to enable easy, 
multigram scale synthesis of well-defined narrowly distributed 
polyglutamates (PGA). Ammonium salts with non-nucleophilic 
tetrafluoroborate counteranions have been used, for the first time, as 
initiators, allowing to reach, without the use of complex and expensive 
techniques, polymers with MW (up to 800 units), low Đ (< 1.2), 
controlled chain end functionality, adequate stereoselectivity and 
absence of traces of toxic impurities, a requisite for future biomedical 
applications. 
 The living character of this technology, and the fact that the 
initiator is always introduced within the C-terminus of the polymer 
backbone, allow the synthesis of different polyglutamate-based systems 
depending on the initiator used, ranging from homopolymers, to di-
block copolymers (peptidic or hybrid), as well as C-terminus 
functionalized polymers for further site-specific bioconjugations. 
 The deprotection protocol enabled acidic as well as basic 
deprotection of PBLG, allowing the synthesis of hybrid PEG based 
block copolymers and the incorporation of sensitive functional groups, 
always maintaining the correct stereochemistry.  
 The versatility of this technology has been far demonstrated 
with its use to reach polyglutamate-based star-shaped polymers with 
low Đ (< 1.2) in a relatively short time and in a variety of MW 
including high and adjustable molecular mass. Moreover, reducible 
initiators containing disulfide bonds gave convincing evidence of the 
living character of the methodology with comparable MW in all arms. 
 A useful methodology for the synthesis of PGA derivatives 
bearing orthogonal reactive sites, e.g. azides, alkynes, reactive 
disulfides, protected amines, etc. in combination of the carboxyl 
functionalities of PGA has been reported. The use of DMTMM and its 
wide range of possibilities allowed the linkage of water as well as DMF 
soluble compounds to PGA, which could be used for site-specific 
conjugation of a variety of bioactive agents of different nature (i.e. 
peptides, proteins, drugs). 
 Novel PGA-based structures have been designed, bearing self-
assembling motifs that has been demonstrated to induce the 
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organization of anionic polyglutamate backbones. According to DLS, 
TEM and SANS, the resulting polymers undergo spontaneous self-
assembly in water yielding spherical objects. Chemical modifications 
within the polypeptidic backbone as well as the tuning of physico-
chemical conditions can prevent or significantly modify this 
aggregation behavior leading to a vast range of nanometric 
architectures of different size and shape.  
 Moreover, co-assembly of different building blocks also takes 
place, allowing to open a wide field for the construction of relatively 
complex architectures. These structures can be covalently entrapped to 
retain their solution conformation in the biological settings using 
different reversible or irreversible linking chemistries.  
 In vitro biocompatibility (MTS assays) was not compromised 
with the use of the different polymeric architectures as well as degree 
of functionalization. The degree of functionalization as well as the 
nature of the chains added within the polymer backbone significantly 
influenced the degradation rate of the final construct.  
 Energy-dependent mechanisms of internalization were 
observed for all polymers (independently of the MW or the 
architecture), presumably through endocytic mechanism due to the 
absence of uptake at 4 °C and lysosomal co-localization with 
fluorescence markers. This degree of internalization was highly 
increased when star-shaped polymers where used as unimers and even 
more with the complex covalently entrapped architectures. All this 
together highlights the importance of the architecture in the biological 
output. 
 Different PGA-based architectures with and without targeting 
units for BBB crossing (c-PEP and ANG-2) were in vivo evaluated in 
terms of biodistribution and pharmacokinetic profiles by means of 
different imaging techniques, such as PET and fluorescence optical 
imaging. Linear, di-block copolymers and star-shaped unimers did not 
reach significant brain accumulation in comparison with already 
existing systems. Nonetheless, the newly described architectures 
resulting from self-assembled PGAs, decorated with imaging agents 
and targeting units (ANG-2), by surface modifications of covalently 
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entrapped structures, showed interesting in vivo biodistributions with 
relevant brain accumulations (up to ~1.5 % ID). 
 The established bottom-up synthetic approach has been 
effectively used to synthesize bisdemethoxycurcumin (BDMC) and 
propargyl bearing combination conjugates with potential application as 
a neurorescuer-neuroprotective therapy in Alzheimer’s disease. In vitro 
proof of activity has been achieved in terms of inhibition of fibril 
formation, and as neuroprotective agent against Aβ1-42 peptide induced 
neurotoxicity in organotypic cultures. Conjugate in vivo safety was 
demonstrated in an AD mouse model after a repeated dose schedule. 
Proof of pharmacological activity in vivo is ongoing.   
 Finally, the potential of PGA-based conjugates as tissue-
specific smart probes has been fully demonstrated. The combination of 
NIRF enzyme specific smart probes together with the tissue specificity 
provided by PGA as carrier allowed the early detection of disease-
related events in vitro as well as in vivo. In vivo data of selected 
candidates (i.e. MMP13) has pointed out the suitability of these 
polymeric probes in theranostic applications including neuroimaging 
approaches. 
 
  
  
  
 
 
 
 
 
 
                                 Appendices 
 
  
  
 
[Appendix I] 
525 
APPENDIX I. THESIS PROJECT, OBJECTIVES, MAIN 
METHODOLOGY, RESULTS AND CONCLUSIONS IN 
SPANISH. 
1. INTRODUCCIÓN Y MARCO TEMÁTICO DE LA TESIS. 
El creciente aumento tanto en la incidencia como en los costes 
de las enfermedades neurodegenerativas, junto con la falta de 
tratamientos efectivos, pone de manifiesto la necesidad de nuevas 
aproximaciones para hacer frente a la enorme carga que dichas 
enfermedades conllevan. La mayoría de los tratamientos actuales se 
basan en el tratamiento de los síntomas de la enfermedad, pero no en el 
tratamiento del origen para parar su progresión. Además, el 
descubrimiento y desarrollo de nuevos fármacos enfocados a 
enfermedades del sistema nervioso central se ha convertido en una 
ardua y desafiante tarea debido a que dichos fármacos deben ser 
capaces de superar la barrera biológica más infranqueable del cuerpo 
humano: la barrera hematoencefálica (BHE).1-3 Actualmente, se llevan 
a cabo técnicas tanto invasivas como no invasivas para permitir la 
entrada de fármacos a través de la BHE, de manera que se alcancen 
concentraciones de fármaco en el parénquima cerebral que se 
encuentren dentro de la ventana terapéutica para ser efectivos.4, 5 En la 
presente tesis, se han combinado varias estrategias no invasivas basadas 
por un lado, en el uso de nanosistemas para mejorar la acumulación en 
cerebro junto con el uso de “caballos de Troya” moleculares para 
promover la entrada a través de la BHE mediante transporte mediado 
por receptores.6-12 Para ello, se propuso el uso de Polímeros 
Terapéuticos (PT) como nanosistemas para el tratamiento y/o diagnosis 
de enfermedades neurodegenerativas. Con varios productos ya en el 
mercado y un número creciente de ejemplos en desarrollo clínico, 13-16 
los PT exhiben características clave para superar las principales 
limitaciones del uso de fármacos o sondas de bajo peso molecular. Se 
considera que los PT poseen todos los requisitos para ser considerados 
como excelentes candidatos para su uso como plataforma para el 
tratamiento y diagnosis de enfermedades relacionadas con el sistema 
nervioso central (SNC). Entre dichas características se encuentran: (i) 
perfiles farmacocinéticos mejorados y tiempos de vida media en plasma 
prolongados; (ii) la posibilidad de incluir vectores dirigentes 
específicos para trasporte activo; (iii) multivalencia, lo que permite 
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modular la carga de fármaco(s) conjugados y el diseño de polímeros de 
combinación, incluyendo sondas para imagen, (iv) liberación 
controlada y sostenida de los fármacos conjugados a través de enlaces 
biodegradables bajo condiciones específicas; (iv) proporcionan 
estabilidad y reducen la inmunogenicidad del compuesto bioactivo 
conjugado, además de poseer un tamaño óptimo para permitir una 
buena penetración.17 Actualmente se acepta que los futuros retos y 
oportunidades para el avance de esta plataforma tecnológica se basan 
en (i) nuevas dianas moleculares, (ii) la terapia de combinación, (iii) 
control en las estructuras poliméricas y su conformación en solución 
con la ayuda de caracterización físico-química exhaustiva, esencial para 
transformar un conjugado prometedor en un candidato para la 
evaluación clínica, siguiendo las indicaciones reglamentarias 
Existe aún la necesidad dentro del campo de PT de desarrollar 
nuevos polímeros para su uso en sistemas de transporte de fármacos o 
agentes de imagen (Capítulo 1). Nuevos PT basados en aminoácidos se 
postulan como excelentes candidatos para dicho fin, ya que no sufren 
de las limitaciones clásicas de los sistemas actuales (biodegradabilidad, 
multifuncionalidad y biocompatibilidad). Concretamente, los 
poliglutamatos (PGA) constituyen una plataforma versátil que se ha 
utilizado efectivamente como bloques de construcción en los 
conjugados polímero-fármaco y micelas poliméricas para diversas 
aplicaciones médicas que van desde el cáncer18-20 a procesos 
isquémicos.21-23 Por otra parte, se espera su aprobación por la FDA 
después de la aprobación del conjugado PGA-paclitaxel, OpaxioTM para 
el tratamiento de varios tipos de cáncer solos o en combinación 
(OpaxioTM ha sido designado recientemente como fármaco huérfano en 
combinación con radioterapia y temozolomida para el tratamiento de 
glioblastoma multiforme).24-28  
Además, hay un creciente interés en el desarrollo de nuevos 
sistemas poliméricos biodegradables, con arquitecturas y 
conformaciones más definidas y predecibles, pesos moleculares 
superiores (para mejorar el transporte pasivo mediante el efecto EPR), 
menor heterogeneidad, mayor capacidad de carga de fármaco y mayor 
posibilidad de multifuncionalidad. Asimismo, el uso de técnicas físico-
químicas adecuadas, a fin de caracterizar correcta y exhaustivamente 
nuevos sistemas complejos, es un requisito. 
Con todo esto en mente, la tesis tiene como objetivo lograr 
nuevas estructuras basadas en poliglutamatos bien definidos, para ser 
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utilizados como sistemas para el tratamiento y/o diagnóstico de 
enfermedades neurodegenerativas (concretamente Alzheimer (AD)), 
con el fin de atravesar la BHE, utilizando estrategias de transporte 
activo mediante el uso de caballos de Troya moleculares. 
2. OBJETIVOS DE LA INVESTIGACIÓN. 
 El objetivo global de la presente tesis se centra en el diseño y 
desarrollo de una nueva plataforma polimérica basada en el uso de 
polímeros biocompatibles y biodegradables de diversas arquitecturas 
para su aplicación en biomedicina, y en concreto, en el tratamiento y/o 
diagnóstico de patologías tan devastadoras como las enfermedades 
neurodegenerativas. Dicho objetivo general, engloba los siguientes 
objetivos específicos que pueden ser considerados de índole piramidal: 
(i) Diseño y puesta a punto de una metodología versátil de 
polimerización controlada para la obtención de nuevos portadores 
poliméricos biodegradables, biocompatibles, y con alto grado de 
multifuncionalidades, basados en el ácido poliglutámico (PGA). Los 
portadores sintetizados se caracterizarán de forma exhaustiva mediante 
una batería de técnicas físico-químicas. Una vez establecida, dicha 
metodología se usará para conseguir los siguientes objetivos.  
(ii) Diseño, síntesis y caracterización exhaustiva de 
arquitecturas macromoleculares complejas basadas en poliglutamatos, 
obtenidos a través de técnicas de polimerización NCA previamente 
optimizadas. Se llevará a cabo una caracterización físico-química 
completa, así como su evaluación biológica (in vitro e in vivo) para 
validar esta nueva plataforma como portadores poliméricos.  
(iii) Desarrollo de una metodología versátil para la 
modificación post-polimerización de los poliglutamatos sintetizados 
anteriormente, permitiendo alcanzar funcionalizaciones ortogonales 
altamente adecuadas para posteriores bioconjugaciones tanto de agentes 
bioactivos como de sondas de imagen.  
(iv) Obtención de sistemas poliméricos basados en PGA 
para el transporte a través de la barrera hematoencefálica (BHE) como 
pre-requisito para el tratamiento de enfermedades del sistema nervioso 
central.  
(v) Desarrollo de una nueva plataforma de polímeros para 
su uso como sistemas de transporte de fármacos o sondas para 
diagnóstico de enfermedades como el Alzheimer.  
(vi) Obtención de una plataforma polimérica para su uso en 
imagen in vivo, basada en el uso de “sondas inteligentes”, activadas tras 
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actividad proteolítica. Todo ello dentro del marco del proyecto europeo 
del FP7 LIVIMODE. 
Así pues, durante este proyecto se espera construir y evaluar las 
diferentes piezas indispensables para un diseño final basado en el 
concepto de “teranóstico” (del inglés, therapy + diagnostic), en el cual 
se combinen en una sola entidad, todos los bloques desarrollados en la 
tesis: nanovectores para el cruce de la BHE, polímeros-conjugado de 
combinación para el tratamiento de AD, y el uso de sondas inteligentes. 
3. METODOLOGÍA  
3.1. Materiales e instrumentación. 
3.1.1. Materiales. 
Todos los reactivos usados durante la tesis fueron de grado 
analítico o superior, y se usaron sin purificación adicional, a no ser que 
se indique en el correspondiente apartado. Los disolventes usados 
también eran de grado analítico o superior, y se secaron y destilaron 
previamente a su uso. De manera general, las reacciones llevadas a 
cabo en disolventes orgánicos se realizaron bajo atmósfera inerte de 
nitrógeno o argón. 
Los métodos más utilizados de purificación de los polímeros-
conjugados se basaron en el uso de diálisis (usando Vivaspin® con 
membranas de 1, 3, 5 o 10 kDa), o cromatografías por exclusión de 
tamaño, usando resina Sephadex G-25, o las columnas comerciales pre-
empaquetadas PD10.  
Los animales de experimentación usados tanto en CIEMAT, 
Madrid (FVB/NJ) como en Animal Imaging Center, Zúrich (C57Bl/6 y 
ArcAbeta), se mantuvieron en las condiciones y acorde a los protocolos 
de los respectivos comités éticos de experimentación animal. En ambos 
casos, con ciclos de 12 horas de luz y 12 de oscuridad, acceso libre a 
comida y agua, temperatura alrededor de 20-24 °C y humedad relativa 
de un 40 %. 
3.1.2. Instrumentación. 
Espectroscopia por Resonancia Magnética Nuclear (RMN). Los 
espectros de protón y carbono mono y bidimensionales, así como los 
experimentos DOSY y NOESY, se adquirieron en un Bruker AC 300, y 
Bruker Avance III 500 (dependiendo del caso) a temperatura ambiente y 
se analizaron usando el Software MestreNova 6.2.  
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Cromatografía por permeación en gel. Los análisis se realizaron en un 
Triple Detector Array (TDATM) de Viskotek (TDA3 302) 
complementado con un índice de refracción (RI), detector de difracción 
de la luz, detector de viscosidad y un detector UV modelo 2501. Las 
columnas empleadas fueron dos TSK-Gel en serie (Styragel HR3 y 
HR4, tamaño partícula 6 μm, 300 x 7.8 mm). Como fases móviles se 
utilizaron, por un lado, DMF 0.1 % LiBr, con el sistema equilibrado a 
70 °C; y por otro, HFIP (3 g∙L-1 trifluoroacetato potásico) a 40 °C y 
columnas de sílica modificada (PFG, tamaño partícula 7 μm, porosidad 
100 & 1000 Å). Los pesos moleculares se calcularon usando 
calibración interna realizada con estándares de PMMA y tolueno como 
patrón interno. Para el tratamiento de datos, se utilizó en ambos casos el 
software OmniSec 4.1. 
Espectroscopia de infrarrojo (FTIR). Los espectros de IR se obtuvieron 
mediante espectrómetro FT-IR Thermo Scientific Nicolet 380 en un 
rango espectral de 7800-350 cm-1, resolución óptica (apodizada) < 0.9 
cm-1, resolución estándar. Todas las muestras se analizaron disueltas en 
DMF, y a 25 °C.  
Espectroscopia por Dicroísmo circular. Se realizó en un espectrómetro 
J-815 CD Spectrometer (JASCO Corporation) equipado con un soporte 
de celda termostatizado (PTC-423, JASCO Corporation), un 
refrigerante (JULABO F250, JASCO Corporation) y flujo controlado 
de nitrógeno (~2.7 L.min-1) (Afriso Euro-Index). Las muestras se 
midieron en HFIP en el caso de polímeros bencil protegidos y en agua 
desionizada o PBS 7.4 para polímeros en la forma sal sódica. Las 
medidas se realizaron en cubetas de cuarzo, de d= 0.1 cm y por 
triplicado.  
Dispersión de luz dinámica. Las medidas de tamaño de partícula así 
como los experimentos de CAC se realizaron en un dispositivo Malvern 
Zetasizer Nano ZS equipado con un láser (532 nm) a un ángulo de 
dispersión fijo de 90°. Las muestras se midieron en tampón PBS o 
ddH2O a diferentes concentraciones, generalmente a 25 °C, y por 
triplicado. 
Espectroscopia ultravioleta-visible (UV-VIS). Los espectros de UV se 
recogieron en un espectrofotómetro Jasco V-630 UV/Vis a 25 °C con 
celdas de cuarzo de 1 cm y ancho de banda de 0.5 nm. 
Polarimetría. La quiralidad de los polímeros desprotegidos se evaluó 
con un polarímetro Jasco P-1020, midiendo cada muestra por triplicado 
(20 scans por medida) en una celda de vidrio cilíndrica (φ 3.5x100 
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mm). Las muestras se prepararon en ddH2O a 10 mg∙ml-1 y se midieron 
a 25 °C. Los datos se analizaron con el software Spectra Manager.  
Victor2 WallaceTM para medidas de absorbancia o fluorescencia. Para 
determinar absorbancias o fluorescencias en fracciones de purificación 
o ensayos celulares se usó un equipo Victor2 Wallac 1420 Multilabel 
HTS Counter Perkin Elmer (Northwolk, CT, EEUU) utilizando placas 
de 96 pocillos y las correspondientes longitudes de onda 
(emisión/excitación) propias de cada compuesto.  
Microscopía de transmisión electrónica (TEM). Las fotos se 
adquirieron en un microscopio de transmisión electrónica FEI Tecnai 
G2 Spirit (FEI Europe, Eindhoven, Netherlands) usando una cámara 
digital Morada (Olympus Soft Image Solutions GmbH, Münster, 
Germany). Para su preparación, las muestras se adsorbieron en rejillas 
de cobre recubiertas por una película de carbón de 200 mallas. Tras 
ello, se realizó una tinción de contraste negativo con una disolución de 
acetato de uranilo al 2 %.  
Cryo-TEM. Para adquirir las imágenes en un Cryo-TEM, Se vitrificaron 
las muestras en un vitrobot FEI. Posteriormente dichas muestras se 
transfirieron bajo nitrógeno líquido a un soporte de Cryo-TEM (Gatan) 
equipado con un reservorio de nitrógeno líquido. Tras ello, la muestra 
se trasfirió a un equipo Tecnai T20 (FEI company) y se adquirieron las 
fotos a 100 K. 
NanodropTM Para determinar la cantidad de péptidos en las 
conjugaciones se usó un NanodropTM ND-1000 UV-Vis 
Spectrophotometer. Brevemente, las fracciones resultantes de la 
purificación por cromatografía por exclusión de tamaño se analizaron 
en el NanodropTM a una longitud de onda de 280 nm (triptófano).  
Dispersión de neutrones de ángulo pequeño (SANS). Los experimentos 
de SANS se llevaron a cabo en un instrumento D11 en el Institute 
Laue-Langevin (Grenoble, Francia) por nuestros colaboradores de la 
School of Chemistry in Cardiff University (Cardiff, UK). Las muestras 
en disolución fueron preparadas con una concentración de conjugado de 
10 mg∙mL-1 en PBS deuterado 0.1 M y se colocaron en células de 
cuarzo de 2 mm de camino óptico, manteniendo una temperatura de 37 
°C. Para el análisis de datos se usó el modelo FISH. 
Microscopía confocal de fluorescencia en célula viva. Los estudios de 
internalización celular por microscopía confocal se hicieron en el 
Servicio de Microscopía Confocal del CIPF (Valencia). Las imágenes 
se adquirieron con un microscopio (invertido) láser confocal Leica, 
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modelo TCS SP2 AOBS (Leica Microsystems Heidelberg GMBH, 
Mannheim, Alemania) usando un objetivo de inmersión de 63X Plan-
Apochromat-Lambda Blue 1.4 N.A. Se usó longitud de onda de 488 nm 
para el Oregon Green (OG), utilizando para ello un láser de argón 
usando aperturas de canal de 503 a 604 nm. Todas las imágenes se 
adquirieron bajo las mismas condiciones y se analizaron mediante el 
software de Leica “Leica Lite” versión 2.61.  
MaestroTM. Las imágenes de los órganos ex-vivo en 2D se obtuvieron 
usando un Maestro 500 (Cambridge Research Inc, Woburn, USA). La 
fluorescencia se detectó con una cámara CCD. Las imágenes adquiridas 
a diferentes longitudes de onda se sometieron a un “spectral un-mixing” 
para discriminar la autofluorescencia del tejido. Las medidas se 
realizaron en Zúrich, Suiza, en el Animal Imaging Center. 
Ensayos por tomografía de emisión de positrones (PET). Para el 
estudio de biodistribución mediante PET, se utilizó un aparato Argus 
PET/CT (SEDECAL, Madrid) para la monitorización in vivo y se 
cuantificó la radiactividad ex vivo en un contador de centelleo gamma 
Cobra II auto-gamma. Los ensayos se realizaron en la unidad de 
Aplicaciones Biomédicas y Farmacocinéticas del CIEMAT, Madrid.  
3.2. Métodos más relevantes. 
3.2.1. Protocolos de síntesis. 
Síntesis de monómero NCA del ácido glutámico. H-L-Glu(OBzl)-OH 
(17 g, 71.66 mmol) se añadió a un matraz de 250 mL de dos bocas 
equipado con un agitador magnético, una columna de reflujo, un 
embudo de adición compensada y una entrada y salida de Ar. Se purgó 
el sistema por 5 minutos. Después, se añadieron 120 mL de THF 
anhidro y se calentó la mezcla a 60 °C. Tras ello, se añadió limoneno 
(11.6 mL, 71.66 mmol, 1 eq.) y posteriormente difosgeno gota a gota 
(5.2 mL, 8.5 g, 43 mmol, 0.6 eq.), disuelto en 10 mL más de THF. Se 
dejó la mezcla reaccionar durante 3 horas a 60 °C hasta que se convirtió 
en una solución clara. Posteriormente se burbujeó la disolución con 
argón para eliminar el exceso de HCl. Tras ello, se concentró la mezcla 
hasta un cuarto del volumen original y se añadieron 32 mL de acetato 
de etilo. El contenido se precipitó en hexano frío dando lugar a un 
precipitado blanco. Finalmente, el sólido se recristalizó en THF/tolueno 
con la adición lenta de hexano bajo atmósfera inerte. Finalmente, se 
filtró el sólido y se almacenó a -20 °C. La pureza del monómero se 
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analizó por RMN, determinando el punto de fusión, y determinando la 
ausencia de HCl con el test de nitrato de plata. Rendimiento 70-80 %. 
Método general para la síntesis de las sales de BF4 como iniciadores. 
De manera general, se prepararon las sales de las diferentes aminas (n-
butil amina, neopentil amina y MeO-PEG2000-NH2) partiendo de la 
correspondiente amina, disolviendo ésta en THF o dietil éter y usando 
el ácido HBF4∙Et2O. Tras ello, se produce la aparición de un precipitado 
blanco, que es filtrado y recristalizado tres veces en acetato de etilo. 
Tras secarse a vació, su identidad se analizó por RMN (flúor, carbono y 
protón) y se usó como iniciador NCA. Rendimientos cuantitativos. 
Método general para la preparación de iniciadores multifuncionales 
con forma de estrella. La síntesis de los iniciadores de forma estrella se 
llevó a cabo en dos pasos, de manera general, para el iniciador basado 
en etilendiamina: En un matraz de fondo redondo de dos bocas provisto 
de un agitador magnético y entrada y salida de nitrógeno, se disolvió el 
compuesto tricloruro de 1,3,5-bencenotricarbonilo (1.88 mmol, 1 eq.) 
en 12 mL de THF anhidro. Posteriormente, se añadieron 3.3 eq. (6.22 
mmol) de DIEA, seguido de la adición gota a gota de N-Boc-
etilendiamina (6.22 mmol, 3.3 eq). La mezcla se dejó reaccionar 
durante 2 horas. Después de ello, el disolvente se evaporó 
completamente, el producto se disolvió en CHCl3 y se lavó con agua 
desionizada (3x) y con agua ácida a pH 3 (3x). El producto aislado se 
recristalizó 3 veces de THF/metanol/hexano dando lugar a un sólido 
blanco. En un segundo paso, se desprotegió el grupo Boc y se formó la 
sal directamente mediante el uso de 3.3 eq. de HBF4∙Et2O, en 
diclorometano. Se produjo la formación instantánea de un precipitado 
blanco que se filtró y recristalizó 3 veces de THF/metanol/hexano. La 
identidad del producto se estableció por RMN. Rendimiento: 
cuantitativo. 
Procedimiento general para la polimerización NCA. Brevemente, 0.5 g, 
(1.9 mmol) del monómero NCA se añadieron a un tubo Schlenk 
equipado con un agitador magnético y un tapón. Tras purgar tres veces 
con ciclos de vacío/argón, se añadieron 5 mL de DMF (recién 
destilado). Posteriormente, se añadió el correspondiente iniciador y la 
mezcla se dejó reaccionar a 4 °C, 25 o 40 °C (dependiendo de la 
síntesis) durante 3 días, bajo atmósfera de nitrógeno y presión 
constante. Después de 3 días, la disolución se precipitó en un exceso de 
dietil éter frío dando lugar a un precipitado blanco. Rendimiento: 70-90 
%. Los productos se caracterizaron por RMN y GPC. 
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Procedimientos óptimos de desprotección de los grupos bencilo en los 
polímeros. 
a) Desprotección ácida para homopolímeros. En un 
matraz de fondo redondo equipado con un agitador magnético y un 
tapón, se disolvieron 100 mg el polímero PBLG (linear o estrella) 
(0.0035 mmol UAG, unidades de ácido glutámico) en 3 mL de TFA. 
Una vez disuelto, 2 eq. de HBr (48 % v/v, 1.49 g∙cm-3) por grupo 
carboxílico se añadieron gota a gota. La mezcla de reacción se dejó 
agitando 5 horas. *Nota, para cantidades de 600 mg, se necesitaron 16 
horas de reacción. Tras ello, la disolución se precipitó en un exceso de 
dietil éter frio, dando lugar a un sólido blanco. El producto se convirtió 
en la forma sal sódica añadiendo bicarbonato sódico, y se desaló por 
sucesivas precipitaciones ácido-base, o usando G25 o dializando. 
Rendimientos: 75-86%. El producto se caracterizó por RMN. 
b) Desprotección básica para di-bloques híbridos PEG-
PBLG. En un matraz de fondo redondo, se disolvieron 50 mg del di-
bloque protegido (0.184 mmol UAG) en 16 mL de THF a temperatura 
ambiente. Entonces, la disolución se enfrío a 4 °C y se añadieron 2 eq. 
por ácido carboxílico de NaOH (0.369 mmol). Tras ello, la disolución 
se dejó agitando a 4 °C durante 16 horas. Transcurrido ese tiempo, se 
evaporó el THF y el producto se diluyó en agua desionizada para su 
purificación por diálisis (Vivaspin® MWCO 3000 Da). Tras liofilizarse, 
se obtuvo un sólido blanco que se caracterizó por RMN. 
Acoplamientos peptídicos usando reacciones ácido-base. Enlaces 
amida. 
a) Método general para la modificación post-
polimerización de PGAs usando DMTMM∙Cl. 
Protocolo 1. DMTMM∙Cl para soluciones acuosas. En un 
matraz de fondo redondo equipado con un agitador y un tapón se 
disolvieron 200 mg de PGA forma sal (1.55 mmol UAG, 1 eq.) en 10 
mL de agua desionizada. Tras ello, se añadió la correspondiente 
cantidad de DMTMM∙Cl para el % de modificación deseado (para un 
30 % de modificación, 0.3 eq.). Tras 10 minutos, se añadió el doble de 
eq. que de DMTMM∙Cl de la correspondiente amina a introducir (para 
un 30 % de modificación 0.6 eq.). Se ajustó el pH a 8, y la mezcla se 
deja reaccionar durante 16 horas a temperatura ambiente. Tras ello, se 
realizaron purificaciones estándar usando diálisis, o G25, o 
precipitación ácido-base. El producto se caracterizó por RMN. 
Rendimientos: 80-90 %. Eficacias de conjugación 80-100 %. 
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Protocolo 2. DMTMM∙BF4 para soluciones orgánicas. En un 
matraz de fondo redondo de dos bocas equipado con un agitador 
magnético y entrada y salida de nitrógeno se disolvieron 200 mg de 
PGA forma ácida (1.55 mmol, 1 eq.) en 10 mL de DMF anhidro. Tras 
ello, se añadió la correspondiente cantidad de DMTMM∙BF4 para el % 
de modificación deseado (para un 30% de modificación, 0.3 eq.). Tras 
10 minutos de reacción, se añadió el doble de eq. que de DMTMM∙BF4 
de la correspondiente amina a introducir (para un 30 % de modificación 
0.6 eq.). Se ajustó el pH a 8, y la mezcla se deja reaccionar durante 16 
horas a temperatura ambiente. Tras ello, se realizaron purificaciones 
estándar usando diálisis, o G25, o precipitación ácido-base. El producto 
se caracterizó por RMN. Rendimientos: 80-90 %. Eficacias de 
conjugación 90-100 % 
b) Método general mediante DIC/HOBt en soluciones 
orgánicas. En un matraz de dos bocas provisto de un agitador 
magnético y una entrada y salida de nitrógeno, se pesó PGA forma 
ácida (0.225 mmol UAG, 1 eq.) y se disolvió en DMF anhidro bajo 
atmósfera de nitrógeno. A continuación, se añadió DIC (i.e. 0.15 eq. 
para una modificación de un 10 %) y se dejó reaccionar durante 5 
minutos a temperatura ambiente. Tras ello, se adicionó HOBt (0.15 eq. 
para una modificación del 10 %). La reacción se dejó proceder durante 
10 minutos más y se añadió a continuación 0.10 eq. de la amina 
correspondiente. Se ajustó el pH a 8 mediante la adición de DIEA. La 
mezcla se dejó reaccionar durante 48 horas. Finalmente, el disolvente 
se eliminó a vacío, y el producto se convirtió en la forma sal mediante 
la adición de bicarbonato sódico. Tras ello, se procedió a su 
purificación mediante los métodos estándar de diálisis, G25 o 
precipitación ácido-base. Rendimientos 80-90 %. Eficacias de 
conjugación 75-100 %. 
Reacciones Click. 
  a) CuAAC. En un matraz de dos bocas equipado con un 
agitador magnético se disolvió 1 eq. de copolímero (modificado con 
azida o propargilamina) en agua desionizada. Tras ello, se añadió la 
correspondiente cantidad para el % de modificación deseado del agente 
a clicar en DMF. Después, se añadieron 5 eq. de ascorbato sódico en 
disolución acuosa, y la mezcla se desgasificó mediante dos ciclos de 
congelación, vacío y descongelación. Se añadió posteriormente 1 eq. de 
CuSO4 en disolución acuosa y la mezcla final, conteniendo una 
proporción de DMF/H2O de 4:1, se desgasificó de nuevo aplicando otro 
ciclo. La reacción se dejó proceder durante 72 horas protegida de la luz. 
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Los productos se purificaron usando las técnicas estándar de diálisis, 
G25 o precipitación ácido-base. Para el acoplamiento de moléculas 
solubles en agua, se usó el mismo protocolo pero usando sólo agua 
desionizada y desgasificada como disolvente. La eficacia de la reacción 
se valoró por RMN. Dicha reacción se utilizó tanto para la conjugación 
de sondas inteligentes (ver capítulo 8) como para el atrapamiento 
covalente de las estructuras auto-ensambladas (ver capítulo 6).  
  b) Tiol-eno.  
 Protocolo 1. En un matraz de fondo redondo equipado con un 
agitador magnético y un tapón se pesaron 50 mg de PGA modificados 
con tioles activados con el grupo 2TP y se disolvieron en tampón (PBS 
7.4). Tras ello, se añadió el polímero modificado con grupos maleimida 
en una mezcla equimolecular y disuelto también en PBS 7.4 de manera 
que ambos estuvieran a concentración 4 mg∙mL-1. La mezcla se sonicó 
y seguidamente, se añadió el agente reductor TCEP (0.15 eq.), se 
comprobó el pH y la reacción se dejó agitando durante 16 horas. Tras 
ello, el producto se purificó por diálisis usando una membrana de 3.000 
Da. Este protocolo se utilizó para el atrapamiento covalente de 
estructuras auto-ensambladas. 
 Protocolo 2. En un matraz de fondo redondo equipado con un 
agitador magnético y un tapón se pesaron 50 mg de PGA modificados 
con tioles activados con el grupo 2TP y se disolvieron en tampón 
(HEPES 7.4). Tras ello, se añadieron los eq. correspondientes al 
deseado % de modificación del compuesto con grupo maleimida en 
DMF dando lugar a una mezcla (tampón/DMF ratio 5.5/1). Finalmente, 
se añadieron 10 eq. de TCEP disueltos en HEPES y la reacción se dejó 
bajo agitación durante 16 horas a temperatura ambiente y protegida de 
la luz. El producto se purificó utilizando uno de los métodos estándar 
de diálisis, G25 o precipitación ácido-base. Este protocolo se utilizó 
para la conjugación de sondas inteligentes con grupos maleimida. 
c) Química de bisulfuros.  
Protocolo 1. En un matraz de fondo redondo equipado con un 
agitador magnético y un tapón, 100 mg del polímero funcionalizado 
con tioles activados con el grupo 2TP, se disolvieron en tampón PBS 
7.4 a una concentración de 2 mg∙mL-1. Se sonicó la muestra durante 5 
minutos, tras los cuales se añadieron 0.15 eq. de TCEP a la mezcla de 
reacción. Se comprobó el pH y se dejó la muestra reaccionar bajo 
agitación vigorosa, a temperatura ambiente durante 2 horas. 
Transcurrido ese tiempo, el producto se dializó usando Vivaspin® 
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MWCO 3000. Este protocolo se usó para el atrapamiento covalente de 
forma reversible de polímeros auto-ensamblados. 
Protocolo 2. Brevemente, en un matraz de fondo redondo se 
disolvió el polímero modificado con SS-2TP en tampón acetato de 
amonio 150 mM pH 5. En paralelo, se disolvió el compuesto bioactivo 
con grupos SH (mismos eq. que unidades de SS-2TP), en tampón 
HEPES a pH 7.4. Se mezclaron ambas disoluciones, y la mezcla se dejó 
reaccionar a pH 6 durante 16 horas. Tras ello, el producto se purificó 
usando columnas PD10. Este protocolo se usó para la conjugación del 
péptido dirigente ANG entre otros. Eficacia de conjugación 50-70 %. 
Protocolos para el marcaje con sondas de imagen para estudios in 
vitro/in vivo. 
a) Marcaje con Oregon Green (OG) Cadaverina 488 para 
estudios de internalización celular. El marcaje con OG se realizó 
siguiendo el protocolo de modificación con DIC/HOBt (en el caso de 
PGAs en forma ácida: linear y estrella) y siguiendo el protocolo de 
modificación con DMTMM∙Cl para el caso de PGAs en forma sal, 
como es el caso de los di-bloques PEG-PGA. El contenido de OG se 
determinó por fluorescencia usando el lector de placas Victor2 Wallac™ 
con filtro de excitación de 490 nm de longitud de onda y filtro de 
emisión de 535 nm a través de una curva de calibrado previa. 
Rendimientos: 80-95 %. Eficacias de conjugación 80-90 % 
b) Marcaje con Cy5.5 para estudios de biodistribución por 
imagen óptica de fluorescencia in vivo. El marcaje con Cy5.5 se llevó a 
cabo siguiendo los mismos procesos y en los mismos casos que para 
OG. El contenido de Cy5.5 se determinó mediante fluorescencia usando 
el lector de placas Victor2 Wallac™ (λem: 595 nm, λex: 680 nm) después 
de construir una curva de calibrado apropiada. Rendimiento: 60-70 %. 
Eficacias de conjugacion 70-90 %  
c) Marcaje con sondas radioactivas para biodistribuciones 
con PET. DO3A/68Ga y DO3A/111In. Para la introducción de núcleos 
radioactivos en la cadena lateral de los polímeros de diferente 
arquitectura, primero se procedió a la conjugación del agente 
complejante DO3A-tBu-NH2. Dicho agente complejante se conjugó a 
las diferentes arquitecturas de PGA usando, el protocolo estándar de 
DIC/HOBt para aquellos en forma ácida, solubles en disolventes 
orgánicos, y el de DMTMM∙Cl, para aquellos en forma sal, solubles en 
soluciones acuosas. Posteriormente se procedió a la desprotección de 
los grupos ter-butóxido del agente complejante mediante el uso de dos 
protocolos diferentes, dependiendo de la naturaleza del compuesto: (i) 
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Para polímeros con grupos no sensibles a TFA, se desprotegió usando 
una mezcla de CH2Cl2/TFA (3/2, v/v) durante 16 horas a temperatura 
ambiente. (ii) Para polímeros con grupos sensibles a TFA, el polímero 
se disolvió en una mezcla de TFA/H2O/TIPS (95/2.5/2.5, v/v) y se agitó 
a temperatura ambiente durante tres horas. En ambos casos, tras el 
tiempo de reacción, la disolución se precipitó en un exceso de éter frío 
dando lugar a un sólido amarillo pálido. El éxito de la desprotección se 
analizó por RMN. Rendimientos de 80-90 %.  
Una vez desprotegido el agente complejante, se llevó a cabo el 
marcaje con 68Ga o 111In en CIEMAT, Madrid. Brevemente, la 
complejación se llevó a cabo en un tubo de síntesis por microondas, y 
en tampón HEPES a pH 3.5-4. La mezcla de radionúclido y polímero 
marcado con agente complejante se calentó a 90 °C durante 5 minutos 
usando un microondas de laboratorio con radiación monomodal 
(Discover Benchmate, CEM). Tras ello, se enfrió el contenido con 
nitrógeno líquido, se purificó la reacción usando cromatografía por 
exclusión de tamaño (Bio Gel P-6 Biorad) con PBS pH 7 como 
eluyente. La actividad de las fracciones recogidas se midió en un 
activímetro (VDC 405 Veenstra).  
d) Marcaje para MRI con DO3A-Gd3+. El grupo DO3A se 
conjugó a los polímeros de manera idéntica a la anteriormente 
explicada. Tras ello, se procedió a la complejación de gadolinio. 
Brevemente, en un matraz de fondo redondo, se disolvió el 
correspondiente polímero con unidades DO3A en PBS 0.1 M a pH 7.4. 
Tras ello, una cantidad equimolar de GdCl3, se añadió gota a gota 
disuelto en agua desionizada. Durante el proceso, el pH se monitorizó 
en todo momento. El grado de complejación se determinó mediante 
titración con 4-(2-piridilazo)resorcinol. A 5 horas de reacción no se 
detectó Gd libre y se procedió a la purificación del producto mediante 
diálisis usando Vivaspin® MWCO 5000. 
Protocolos para la conjugación de vectores dirigentes capaces de 
atravesar la BHE. 
 Con respecto al diseño de polímeros para el cruce de la BHE, se 
llevaron a cabo dos estrategias básicas: la conjugación de dichos 
residuos dirigentes a la cadena lateral del polímero (es el caso de los 
lineales, estrella, PGA clicados y DB PEG-PGAs), o de forma semi-
telequélica, en uno de los extremos (caso de DB2 PGA-PEG). Ambas 
estrategias se usaron para conjugar Angiopep2-SH (ANG-SH) y cPEP. 
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 a) Conjugación de ANG-SH. Para la conjugación mediante 
bisulfuros de ANG-SH a la cadena lateral de los polímeros, primero se 
modificó el correspondiente polímero con cisteamina-2TP, siguiendo el 
protocolo anteriormente descrito con DMTMM∙Cl. Tras ello, se llevó a 
cabo la conjugación con ANG según lo descrito en el protocolo 2 de la 
química de bisulfuros. Las fracciones de péptido se determinaron por 
absorbancia a 280 nm en NanodropTM. Finalmente, la cantidad de 
péptido se estimó por RMN, y se confirmó mediante análisis de 
aminoácidos, llevado a cabo en la Universidad de Barcelona (Unitat de 
Tècniques Separatives I Síntesi de Pèptids Centres Cientifics I 
Tecnològics). Para la conjugación telequélica del péptido, se llevó a 
cabo el mismo protocolo anterior pero usando PGA-PEG-SS4TP como 
polímero, y un exceso de ANG (2 eq.). Rendimientos 60-75 %. 
 b) Conjugación del péptido cíclico (cPEP). Para la conjugación 
a la cadena lateral de los polímeros, mediante enlace amida a través del 
extremo C-terminal del péptido, primero se modificó el correspondiente 
polímero con N-Boc-etilendiamina, siguiendo el protocolo 
anteriormente descrito con DMTMM∙Cl. A continuación, se 
desprotegieron los grupos Boc, sometiendo al polímero a una 
disolución de CH2Cl2:TFA (3:2) durante 16 horas. El polímero con 
grupos amina libres se purificó por precipitación en acetona fría. Por 
otro lado, se llevó a cabo la activación del grupo ácido carboxílico del 
extremo c-terminal del péptido con DCC/NHS. Brevemente, en un 
matraz de dos bocas provisto de un agitador y una entrada y salida de 
nitrógeno, se disolvieron 30 mg del cPEP (0.032 mmol, 1 eq.) bajo 
atmósfera inerte, en DMSO anhidro. Tras ello, se añadieron 8.7 mg de 
DCC (0.043 mmol, 1.3 eq.) a la mezcla de reacción. 5 minutos después, 
se adicionó NHS (4.8 mg, 0.042 mmol, 1.3 eq.) y la reacción se dejó 
proceder durante 16 horas a temperatura ambiente y bajo atmósfera de 
nitrógeno. Transcurrido el tiempo, la mezcla se precipitó en un exceso 
de dietil éter frío, se filtró y secó. El porcentaje de activación se 
determinó del 100 % de acuerdo a RMN. Finalmente, se llevó a cabo la 
conjugación de cPEP a la cadena lateral de los polímeros mediante 
enlace amida. Para ello, se disolvieron en PBS 0.1 M pH 7.4, el 
correspondiente polímero, y el mismo número de eq. de cPEP activado 
que grupos amina del polímero. La mezcla se dejó reaccionar durante 5 
horas, tras las cuales, se procedió a su purificación usando PD10. El 
contenido del péptido se estimó por RMN, y se corroboró mediante 
análisis de aminoácidos llevado a cabo en la Universidad de Barcelona. 
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En el caso de la conjugación telequélica del péptido, el procedimiento 
llevado a cabo fue el mismo, pero usando en este caso, DB2 PGA-PEG-
NH2 y un exceso de cPEP activado (2 eq.). Rendimientos: 75-80 %.  
Protocolo para la conjugación de Bisdemetoxicurcumina (BDMC) a 
PGA. La conjugación del fármaco BDMC se llevó a cabo a través de 
enlaces éster, usando el protocolo de DMTMM∙BF4 pero con 
modificaciones. Brevemente, en un matraz de dos bocas provisto de un 
agitador magnético y una entrada y salida de nitrógeno, se disolvió el 
correspondiente polímero en 10 mL de DMF anhidro. Tras ello, se 
añadieron 1.5 eq. de DMTMM∙BF4 del tanto por ciento de modificación 
deseado, en 5 mL más de DMF. La reacción se dejó proceder durante 
10 minutos, tras los cuales se añadió BDMC (mismos eq. que de 
DMTMM∙BF4), y una cantidad catalítica de DMAP. Se comprobó que 
el pH de la reacción rondase 7, y se dejó agitando a temperatura 
ambiente y protegida de la luz durante 72 horas. Para la purificación, la 
mezcla se precipitó en un exceso de dietil éter frío, el producto se 
transformó en su forma sal, en agua desionizada y se lavó con éter 
sucesivas veces. Finalmente, se desaló por diálisis usando Vivaspin® 
MWCO 5000. El contenido de BDMC se estimó por UV-VIS a 415 
nm, tras realizar una curva de calibración apropiada. La cantidad de 
fármaco libre se estimó inferior al 1 % de la cantidad de fármaco total 
mediante HPLC, usando un método de gradientes donde: eluyente A: 
agua, eluyente B: acetonitrilo. El gradiente usado fue de 40 % B a 80 % 
B durante 20 min. Tiempo de retención de BDMC: 5.98 
Protocolos para la conjugación de sondas inteligentes (activadas tras 
la acción de proteasas específicas) a PGA. Las sondas se conjugaron 
siguiendo un protocolo u otro en función del grupo funcional 
introducido para ese fin. Así pues, sondas con grupos alquino/azida se 
conjugaron a polímeros modificados con grupos azida/alquino 
respectivamente siguiendo el protocolo de CuAAC descrito 
anteriormente. Por otro lado, sondas con grupos maleimida se 
conjugaron a polímeros modificados con grupos SS-2TP mediante el 
protocolo descrito anteriormente para reacciones tiol-eno en mezclas 
tampón HEPES/DMF. Finalmente, sondas con grupos amina, se 
conjugaron de manera directa (o tras la derivatización con un 
espaciador de etilenglicol), a través del protocolo de DIC/HOBt. La 
derivatización de las sondas con el espaciador FMOC-EG(4)-COOH se 
llevó a cabo mediante la conjugación directa de dicho espaciador a la 
sonda-NH2 usando el protocolo estándar de DIC/HOBt. Se purificó el 
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compuesto usando una columna de fase reversa C18 en metanol. Tras 
ello, se procedió a la desprotección del grupo FMOC, usando 2 mL 
Et2NH/DMF (1/4) durante 45 minutos. El disolvente se evaporó y el 
producto se usó directamente para su conjugación. 
El contenido de sonda en el polímero se determinó mediante 
absorbancia o fluorescencia a sus correspondientes longitudes de onda. 
Protocolos utilizados en la caracterización de los compuestos auto-
ensamblados. 
 a) Determinación de la CAC mediante DLS. Para ello, se 
disolvieron los polímeros basados en PGA en PBS 7.4 a diferentes 
concentraciones dentro de un rango de 0.004-2 mg∙mL-1. Se usó PGA 
lineal como control negativo. Cada solución se preparó fresca para las 
medidas, se sonicó durante 5 minutos y se dejó 24 horas para su 
estabilización. Las medidas de DLS se hicieron por triplicado con 
parámetros fijados para todas las muestras. Los datos se expresaron en 
Kcps vs concentración, donde la intersección entre las curvas nos da el 
valor de CAC. Los estudios de co-ensamblaje de diferentes polímeros 
se llevaron a cabo de igual forma, pero añadiendo a cada serie de 
concentraciones, una cantidad por debajo de su CAC del polímero con 
quien se quiere averiguar el co-ensamblaje.  
 b) Prueba del pireno. Para dichas medidas, se prepararon una 
serie de disoluciones de cada polímero en un rango de concentración de 
0.004-2 mg∙mL-1. Se preparó además una disolución stock de pireno de 
0.02 mg∙mL-1 en acetona, de la cual se añadieron 3 µL a cada una de las 
concentraciones de la gama de polímeros. Tras ello, las disoluciones se 
incubaron a 37 °C durante 2 horas y se midieron 24 horas después en 
un espectrofluorímetro Jasco FP-8300. Las medidas se llevaron a cabo 
a 1 cm de longitud de paso y cada espectro de excitación se adquirió 
desde 300 a 360 nm con emisión a 390 nm. Finalmente, se expresaron 
los datos gráficamente representando el cociente de intensidades 
I338/I333 vs concentración para determinar valores CMC.  
3.2.2. Ensayos In vitro. 
Degradaciones con Catepsina B. Se evaluó la biodegradabilidad de 
varios poliglutamatos en presencia de la enzima lisosomal catepsina B. 
Brevemente, se prepararon disoluciones de 3 mg∙mL-1 de polímero en 
tampón acetato (para 3 mg de polímero, 700 µL de tampón acetato 20 
mM, pH 6, 100 µL de EDTA 2 mM, 100 µL de DTT 5 mM). 
Finalmente, se añadieron 6.25 unidades de Catepsina B disueltas en 100 
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µL de tampón acetato pH 6 20 mM). Las mezclas se mantuvieron a 37 
°C bajo agitación, y se tomaron alícuotas a diferentes tiempos (0, 0.5, 1, 
2, 4, 8, 24, 48 y 72 h). La pérdida de masa molecular del polímero 
durante la degradación se analizó por GPC en tampón PBS 7.4. 
Cultivos celulares. Las células HUVEC se cultivaron en Medium 200 
suplementado con LSGS, mientras que las células SHSY5Y se 
cultivaron en DMEM suplementado con FBS. Las células se 
mantuvieron a 37 °C en atmósfera de 5 % de dióxido de carbono y 95 
% aire. El medio se cambió cada 2-3 días y se pasaron al menos una 
vez por semana cuando se alcanzó el 80 % de confluencia. 
Ensayos MTS de viabilidad celular. Para los ensayos MTS, las células 
se cultivaron en placas estériles de 96 pocillos a una densidad celular de 
35000 cell∙cm-2 para SHSY5Y y 1260 cell∙cm-2 en el caso de HUVEC. 
Las placas se incubaron durante 24 horas y transcurrido ese tiempo se 
añadieron los compuestos (previamente filtrados para su esterilización 
con un filtro de 0.2 μm. Transcurridas 72 horas de incubación, se 
añadió 10 µL de la mezcla, MTS/PMS (20:1) a cada pocillo, y se dejó 
incubar durante 2 horas más. Finalmente, se midió la densidad óptica de 
cada pocillo a 490 nm usando el lector de placas Victor2 Wallac. Los 
valores de absorbancia de las células control (sin tratamientos) se 
tomaron como el 100 % de viabilidad. 
Internalización de polímeros marcados con OG mediante FACS. Para 
ello, se sembraron células SHSY5Y en placas de 6 pocillos a una 
densidad de células de 35000 cell∙cm-2 y se incubaron por 24 horas. El 
experimento se realizó transcurridas dichas 24 horas tanto a 4 °C como 
a 37 °C. Para el experimento a 4 °C, las células se pre-incubaron a esa 
temperatura durante 30 minutos antes de empezar el experimento. En 
ambos casos, 30 minutos antes de añadir el compuesto a estudiar, se 
añadió 0.4 μL de una solución 5 μM de inhibidor de catepsina B CA-
074, para alcanzar una concentración final de 2 μM. A continuación, se 
añadieron 0.01 mg∙mL-1 eq. de OG de los polímeros marcados con OG 
en 10 μL a diferentes tiempos (0 a 300 min) mientras que las células se 
mantenían en incubación tanto 37 °C como a 4 °C. Finalmente, las 
placas se pusieron en hielo, se lavaron las células dos veces con PBS-
BSA 0.1 %, se suspendieron en 0.5 mL de PBS y el pellet se analizó en 
el citómetro de flujo Becton Dickinson FACS Calibur cytometer 
(California, USA) equipado con un láser de argón (488 nm) y filtro de 
emisión de 550 nm.  
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Internalización celular por microscopía confocal de fluorescencia. 
Técnica en célula viva. Se incubaron las células en las mismas 
condiciones que para el análisis por citometría de flujo, sin embargo, la 
siembra se realizó sobre un cristal para poder recoger posteriormente 
las muestras. El experimento se llevó a cabo siguiendo un modo de 
pulso-carga a 37 °C. Primero, se añadió el inhibidor de catepsina B 
(misma cantidad que para citometría) 30 minutos antes de la adición del 
compuesto marcado con OG. De la misma forma, se añadieron 0.01 
mg∙mL-1 eq. de OG de los polímeros marcados con OG en 10 μL y se 
incubaron las células durante 2 horas a 37 °C (pulso). Tras ello, se 
aspiró el medio de las células y éstas se lavaron con PBS conteniendo 2 
μM de inhibidor de catepsina B. Posteriormente, las células se 
incubaron durante 4 horas a 37 °C (carga). 30 minutos antes de 
proceder al lavado de las células con PBS-BSA 0.1%, se añadió el 
marcador nuclear (Hoetch, 1 μL de una disolución 5 mM), y lisosomal 
(Lysotracker Red, 0.75 μL de una disolución 100 μM). Finalmente, se 
lavaron las células con PBS-BSA al 0.1 %, y el cristal se acopló a una 
cámara de microscopio con nuevo medio, conteniendo de nuevo 2 μM 
de CA-074. Se analizaron las muestras en el microscopio del Servicio 
de microscopía confocal del CIPF excitando con los láseres de argón 
(OG 496 nm) HeNe (Lysotracker Red 594 nm), y diodo azul (Hoetch 
405 nm).  
Ensayo de Tioflavina T para la detección de fibrilación de la lisozima 
HEWL. Las fibrillas de HEWL se formaron usando una disolución de 2 
mg∙mL-1 de Hen Egg White Lysozyme en un tampón ácido 12 mM de 
HCl conteniendo 140 nM NaCl y 2.7 mM KCl (pH 2). Las muestras se 
agitaron magnéticamente a 60 °C, durante 24 horas para la formación 
de fibrillas. La cinética de fibrilación se siguió desde el tiempo cero 
mediante un método de titración basado en la fluorescencia de la 
Tioflavina T. Típicamente, se preparó una disolución de 100 μM de 
Tioflavina T en PBS pH 7.4. Se tomaron alícuotas de 20 μL de la 
disolución de HEWL a diversos intervalos de tiempo a las cuales se les 
adicionó 100 μL de disolución de Tioflavina T. Las muestras se dejaron 
estabilizar durante 5 minutos y posteriormente se midió su 
fluorescencia en el lector Victor2 WallaceTM. La evaluación de los 
compuestos de BDMC en la prevención de la fibrilación se llevó a cabo 
de la misma forma descrita, solo que con la adición del compuesto a la 
disolución fibrilante de HEWL. 
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3.2.3. Ensayos in vivo. 
Biodistribución mediante imagen por PET. De manera general, tanto 
para compuestos marcados con 68Ga como con 111In, los animales 
FVJ/N se anestesiaron con isofluorano (1.5 %) y se inyectó el 
compuesto marcado de forma intravenosa a través de la vena de la cola. 
Se obtuvieron muestras de sangre a diferentes tiempos tras la inyección, 
mediante punción cardiaca tras ser anestesiados con isofluorano. 
Finalmente, se extrajeron los órganos (pulmones, corazón, bazo, 
riñones, hígado y cerebro) y algunos tejidos (músculo y grasa), se 
lavaron con suero salino, se pesaron y se midió su radioactividad 
usando un contador Cobra II auto-gamma por triplicado. Las muestras 
de sangre se centrifugaron (3000 rpm, 10 min, 25 °C) y se recogió el 
plasma sobrenadante. Se midió también la radioactividad de plasma y 
sangre para los estudios de farmacocinética. Se calcularon el % de dosis 
inyectada (DI) y % DI∙g-1 mediante comparación con estándares 
tomados de cada disolución inyectada a los animales. Los datos se 
expresaron como media ± DS. 
Biodistribución mediante Imagen Óptica por fluorescencia. La 
biodistribución se llevó a cabo en animales C57Bl/6. Los animales se 
anestesiaron con 1.5 % de isofluorano y una dosis de 4.15 mg∙Kg-1 eq. 
de Cy5.5 se inyectó a través de la vena de la cola. Se extrajeron 
muestras de sangre a diferentes tiempos (1, 3, 7, 14  and 24 h) tras 
anestesiar a los animales con un coctel letal de anestesia (i.e. para un 
animal de 20 g, 200 µL de una disolución de ketamina 100 mg∙Kg-1, 
xylasina 100 mg∙Kg-1, Acepromacida 2 mg∙Kg-1). Tras ello, se 
perfundieron los animales con 10 mL de suero salino, se extrajeron los 
órganos (cerebro, hígado, riñón, corazón, estómago, bazo y pulmones) 
inmediatamente después. Se midió la fluorescencia tanto de la sangre 
como de los órganos en MAESTRO™. Finalmente, para la 
cuantificación de la fluorescencia, se obtuvieron datos normalizados 
tomando siempre la misma región de área en pixeles para todos los 
órganos, expresado en cuentas por segundo. Se realizó una curva de 
calibrado de los compuestos para poder estimar el % DI. 
Determinación de placas Aβ usando el trazador AOI987. El nivel de 
placa Aβ en ratones transgénicos ArcAbeta y wild type se determinó, 
antes de comenzar con los tratamientos, mediante el uso del trazador 
AOI987. Para ello, se anestesió a los animales con isofluorano 1.5 %, 
se afeitó la cabeza de los ratones y se determinó el nivel de 
autofluorescencia (como línea base) de la cabeza del animal. Para medir 
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la fluorescencia in vivo, se transfirió al animal a una plataforma pre-
calentada dentro del sistema de imagen (CriMaestro 500), con anestesia 
constante usando una máscara de anestesia. Tras ello, se les inyectó la 
sonda AOI987 (0.1 mg∙Kg-1).29 Se volvió a medir la fluorescencia de la 
cabeza del animal tres horas post-inyección, en el MaestroTM en el 
rango espectral de 660-800 nm. Para la cuantificación de la 
fluorescencia se procedió del mismo modo que para los estudios de 
biodistribución, tomando siempre la misma área en pixeles. 
Tratamientos para el estudio de actividad en un modelo murino de 
Alzheimer. Se usaron animales transgénicos ArcAbeta y sus 
compañeros de jaula wild type como controles (ratones de la cepa 
C57BI/6). Los animales pesaron entre 27.5 ± 5.5 g. Para la inyección de 
los tratamientos, los animales se anestesiaron con 1.5 % de isofluorano, 
y el compuesto se administró de manera intravenosa a través de la vena 
de la cola a una dosis de 2 mg∙Kg-1 BDMC eq. seis veces, durante un 
período de 2 semanas. Los animales ArcAbeta control se sometieron a 
las mismas condiciones de anestesia pero fueron inyectados con suero 
salino. 24 horas tras la última inyección, se sacrificaron los ratones. 
Previamente se procedió a la extracción de sangre de la vena cava (tras 
anestesiar al animal con un cóctel letal de anestésicos conteniendo 
ketamina 100 mg∙Kg-1, Xylasin 100 mg∙Kg-1, Acepromacide 2 mg∙Kg-
1). La fluorescencia de la sangre se registró en el MaestroTM siguiendo 
protocolos previamente descritos. El animal se perfundió con 10 mL 
suero salino y se extrajeron los cerebros inmediatamente después. 
Dichos cerebros se congelaron inmediatamente después de ser 
embebidos en OCT (Tissue-Teck®; Sakura Finetek USA) a -40 °C 
usando 2-metilbutano y nitrógeno líquido. Para realizar los cortes 
histológicos de los cerebros se usó un criostato Cryostat NX70. Se 
realizaron cortes frontales coronales de 10 µM que se guardaron a -80 
°C para posteriores estudios histológicos. 
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4. RESULTADOS  
4.1. Desarrollo de una nueva metodología versátil para la 
síntesis controlada de polipéptidos. (Capítulo 2).30, 31 
 Se ha expuesto anteriormente la necesidad de nuevos sistemas 
poliméricos con estructuras definidas, altos pesos moleculares, 
multifuncionales y con bajo grado de heterogeneidad. Para ello, y 
centrándonos en la síntesis de poliglutamatos, dadas las ventajas 
inherentes de estos polímeros, en el presente proyecto, se ha 
desarrollado y puesto a punto una metodología nueva basada en la 
polimerización ROP-NCA.32-34 Dicha metodología ha permitido la 
síntesis de polipéptidos bien definidos (homo o polímeros multi-
bloque) con pesos moleculares controlados (hasta un grado de 
polimerización de 800), bajas polidispersidades (menores a 1.2), 
rendimientos cuantitativos, con preservación de la integridad del 
extremo amino, y ausencia de racemización de los centros quirales. 
Todo ello, con alta reproducibilidad lote a lote, en síntesis escalables, 
con ausencia de trazas de impurezas (crucial para aplicaciones 
biológicas) y mediante un método que no requiere del uso de 
equipamiento caro o complejo.  
 En dicha metodología, se ha optimizado tanto, la síntesis del 
monómero NCA del ácido glutámico, como el proceso de 
polimerización en sí y el método de desprotección de los grupos 
bencilo. Todo el proceso ha sido patentado por el laboratorio de 
Polímeros Terapéuticos dirigido por la Dra. Vicent31 cuya patente ha 
dado lugar a la creación de una compañía Spin-Off.  
 Así pues, la metodología de polimerización se basa en el uso, 
por primera vez, de sales de amonio con contraiones no nucleofílicos 
como iniciadores, en concreto, sales de BF4. En primera instancia, se 
llevó a cabo la optimización y escalado de la síntesis del monómero, y 
el ajuste de parámetros como la temperatura, tiempo de reacción, el 
disolvente, la concentración y el ratio [monómero/iniciador]. Tras ello, 
la versatilidad del método se demostró mediante la síntesis de 
diferentes familias de homopolímeros (usando sales de neopentil y n-
butil aminas como iniciadores); después, el método se extendió para la 
síntesis de polímeros funcionalizados en su extremo c-terminal 
mediante el uso de iniciadores funcionalizados con grupos alquino y 
azida, lo que abre la puerta a posteriores conjugaciones específicas de 
moléculas bioactivas, como es el caso de anticuerpos o proteínas, o de 
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agentes de imagen. También se demostró la capacidad del método para 
la obtención de polímeros di-bloque híbridos, mediante el uso de 
macroniniciadores basados en PEG. 
 Una vez optimizada la polimerización, se llevó a cabo el 
estudio de un método adecuado de desprotección de los grupos 
protectores bencilo. El método óptimo debe ser capaz de dar lugar a 
desprotecciones completas, con ausencia de procesos de racemización 
que darían lugar a cambios en la estructura secundaria del polipéptido. 
La relevancia de ello radica en el hecho de que dichos cambios pueden 
dar lugar a modificaciones drásticas en el comportamiento biológico de 
los portadores sintetizados, como alteraciones en las propiedades 
inmunológicas, perfiles de degradación, y en definitiva, alteraciones en 
los perfiles farmacocinéticos y de biodistribución. Teniendo ello en 
cuenta, se pensó en el uso de TFA/HBr como método de desprotección, 
ya que se ha reportado su eficacia, en ausencia de procesos de 
racemización.35 Sin embargo, dichas condiciones no son apropiadas 
cuando se tienen grupos funcionales susceptibles a condiciones ácidas 
drásticas, como es el caso del bloque PEG, en polímeros di-bloque. Por 
ello, se desarrolló y optimizó un nuevo método de desprotección basado 
en el uso de condiciones básicas (NaOH/THF). Dicho método nos 
permite la desprotección total de los grupos bencilo en polímeros di-
bloque, sin cambios estereoquímicos, tras comprobarse al analizar el 
grado de rotación de luz polarizada. 
Los compuestos se caracterizaron mediante el uso de diferentes 
técnicas físico-químicas. Por ejemplo, la identidad de cada compuesto 
se determinó por GPC así como por RMN y la estructura secundaria 
por dicroísmo circular confirmando la existencia de la hélice α, en el 
caso de polipéptidos protegidos, y random coil, en el caso de los 
desprotegidos. 
4.2. Síntesis de poliglutamatos con forma de estrella como 
excelentes candidatos en aplicaciones biomédicas. (Capítulo 3).36 
 Los polímeros ramificados se consideran excelentes aspirantes 
para diversas aplicaciones en biomedicina debido a sus interesantes y 
exclusivas propiedades reológicas, mecánicas y biomédicas, derivadas 
de sus estructuras y que son inaccesibles para polímeros lineales. Por 
ello, la obtención de polímeros con arquitectura ramificada se está 
convirtiendo en un área de creciente interés para el desarrollo de nuevos 
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portadores poliméricos para diferentes aplicaciones dentro de los 
campos de biomedicina y biotecnología, entre otros. 
 Con todo ello en mente, en este proyecto se decidió explorar las 
posibilidades de la nueva metodología de polimerización anteriormente 
optimizada, en la síntesis de poliglutamatos con forma estrella. Todo 
ello, se postuló posible debido al carácter “living” de la polimerización, 
y el control preciso que proporciona sobre la etapa de iniciación, crucial 
para el uso de iniciadores multifuncionales. Así pues, mediante un 
método simple pero poderoso, se llevó a cabo la síntesis de 
poliglutamatos de forma estrella, con tres ramas, estructuras bien 
definidas, pesos moleculares controlados y polidispersidades por debajo 
de 1.2. Para ello, se aplicó un método divergente basado en el uso de 
nuevos iniciadores multifuncionales BF4. Entre los iniciadores usados, 
uno de ellos presenta enlaces bisulfuro reducibles. La relevancia del uso 
de dicho iniciador radica en el hecho de que nos permitió reducir el 
polímero y estudiar los brazos por separado, para confirmar, que 
efectivamente, todos poseían pesos moleculares aproximados, 
verificando la eficacia de la polimerización. 
4.3. Desarrollo de una nueva metodología versátil para la 
modificación post-polimerización de poliglutamatos. (Capítulo 4).37 
 Tal y cómo se ha mencionado anteriormente, la 
multifuncionalidad es necesaria para aumentar la capacidad de carga de 
un polímero, y es por tanto, una característica deseable de los 
poliglutamatos. Esta multifuncionalidad inherente en PGA, se puede 
mejorar con la introducción de funcionalidades diferentes a los grupos 
ácidos, en la cadena lateral del polímero, lo que permitirá 
bioconjugaciones específicas de forma ortogonal. 
 Persiguiendo dicho objetivo, se implementó una metodología 
para la modificación post-polimerización de las cadenas laterales de 
PGA. Esta metodología se basa en el uso de sales de DMTMM como 
activadores de los grupos carboxílicos, necesaria para dar lugar a 
enlaces amida mediante química ácido-base. De esta forma, se 
introdujeron varias funcionalidades entre las que se encuentran 
alquinos, azidas, bisulfuros activados o aminas protegidas, mediante 
condiciones de reacción suaves (necesarias para mantener la integridad 
de la cadena de PGA) y con la versatilidad de un método que permite 
llevar a cabo reacciones tanto en medio acuoso como en disolventes 
orgánicos, simplemente cambiando el contraión de la sal de cloruro a 
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BF4. Dicha versatilidad permite introducir tanto moléculas hidrofílicas 
como hidrofóbicas en las cadenas de PGA. Por lo tanto, el método 
descrito permite introducir todo tipo de funcionalidades que, por 
ejemplo, no podrían introducirse mediante procesos de polimerización 
(usando monómeros funcionalizados), debido a las incompatibilidades 
de ciertos grupos funcionales. 
4.4. Caracterización In vitro de los polímeros sintetizados hasta 
el momento. Validación de los polímeros como portadores de 
fármacos o sondas de imagen. (Capítulos 3-4). 
Por otro lado, la validación de los portadores poliméricos 
mediante su caracterización in vitro es un requisito a cumplir de cara a 
su posterior uso en aplicaciones biológicas. La biocompatibilidad, 
biodegradabilidad y los mecanismos de internalización de los mismos 
son aspectos clave a estudiar. De acuerdo con ello, se llevó a cabo el 
estudio in vitro de diferentes vectores poliméricos con estructura lineal, 
di-bloque PEG-PGA, y polímeros estrella. Así pues, se llevó a cabo la 
degradación en presencia de la enzima lisosomal catepsina B, de varios 
polímeros lineales y estrella, con y sin funcionalizaciones (alquinos y 
azidas). El polímero estrella iniciado con iniciador basado en 
hexilamina, exhibió una velocidad de degradación menor al iniciado 
con iniciador basado en etilamina, para un mismo peso molecular. En el 
caso de los polímeros funcionalizados, se demostró cómo el grado y 
naturaleza de la funcionalización tienen una clara influencia en la 
degradación enzimática del polímero. 
Puesto que el destino final del uso de dichos compuestos se 
prevé para su uso en enfermedades neurodegenerativas, se evaluó la 
citotoxicidad de los compuestos en modelos celulares de células 
endoteliales HUVEC (human umbilical vein endotelial cells) y 
SHSY5Y, de glioblastoma. Los polímeros testados (lineal, di-bloque, 
estrella y funcionalizados) resultaron no tóxicos a las concentraciones 
testadas (hasta 3 mg∙mL-1).  
Para los estudios de internalización celular, se marcaron con 
sondas fluorescentes (OG) diferentes poliglutamatos de diversas 
estructuras (lineal, PEG-PGA y estrella). Dicho estudios realizados por 
citometría de flujo y microscopía confocal revelaron mecanismos de 
internalización dependientes de energía, independientemente del peso 
molecular del polímero, ya que no se encontró internalización a 4 °C, 
en los polímeros testados. En cuanto al peso molecular, se probaron 
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diferentes polímeros lineales de varios pesos moleculares y se observó 
que no existían diferencias significativas en los perfiles de 
internalización. Sin embargo, el grado de internalización encontrado de 
los polímeros estrella fue 4 veces superior al lineal (para un polímero 
de peso molecular similar). Todo ello pone de manifiesto la importancia 
de la arquitectura en cuanto al comportamiento biológico de un 
portador polimérico. Ese hecho puede atribuirse a propiedades 
inherentes de los polímeros ramificados que, de manera general, son 
más compactos, con formas globulares y amplias superficies entre otras 
características que los convierten en candidatos relevantes para su uso 
como vehículos para el transporte y liberación de fármacos, así como 
sondas para imagen, entre otras aplicaciones.38, 39 
4.5.. Estudio exhaustivo de los procesos de auto-ensamblaje de 
nuevos polímeros basados en PGA. (Capitulo 5).40 
  Se sintetizaron nuevos polímeros de PGA con motivos que 
inducen el autoensamblaje. Cuando se llevó a cabo la caracterización 
físico-química exhaustiva de dichos sistemas a través de una batería de 
técnicas físico-químicas (DLS, DOSY y NOESY, CD, TEM, técnicas 
de fluorescencia y SANS) se encontraron resultados interesantes. De 
acuerdo con dichos resultados, se encontró que estos polímeros basados 
en PGA, sufren procesos de auto-ensamblaje dependientes de la 
concentración, de manera tal que, a bajas temperaturas se encuentran 
formando unímeros de 5-10 nm de tamaño y estructuras 
supramoleculares de alrededor de 100-180 nm a altas concentraciones 
(de acuerdo con DLS). Dicho fenómeno ocurre en todos los sistemas 
que incluyen esos motivos inductores de ensamblaje, pero no en PGA 
lineal. Se usó DLS para obtener los valores de concentración crítica de 
agregación (CAC).41-44 Los experimentos de contraste de SANS 
confirmaron la presencia de dominios organizados en la nano-estructura 
ensamblada, lo cual está de acuerdo con lo descrito en literatura.45-48 
Además, los estudios de TEM y SANS revelaron que las nano-
estructuras toman forma de esferas con las ramas de los polímeros 
dirigidas hacia el exterior. Se investigó la influencia de diferentes 
estímulos físico-químicos (temperatura, concentración o fuerza iónica) 
y de diferentes grados y naturalezas de funcionalización en el equilibrio 
dinámico de agregación de las nano-estructuras. Como conclusión de 
todos ellos, se puede decir que el tamaño adoptado por estos sistemas 
depende claramente de las condiciones ambientales así como de la 
[Appendix I] 
550 
funcionalización. De hecho, el proceso de agregación se puede modular 
e incluso prevenir dependiendo de la funcionalización. Aparentemente, 
la presencia de residuos hidrofílicos por encima de un 30 % evitan 
dicha agregación, lo cual puede servir como herramienta para el diseño 
de nuevos portadores poliméricos. 
Con todo ello en mente, se propuso el desarrollo de nuevos 
sistemas para el transporte de fármacos, de alto peso molecular para 
prolongar la circulación in vivo, lo que es un requisito para de manera 
potencial, alcanzar acumulación en cerebro. Esta estrategia está basada 
en el atrapamiento covalente de las estructuras supramoleculares 
descritas, con la ayuda de reacciones de click, dando lugar a nano-
construcciones estables a estímulos físicos. Para ello, se 
funcionalizaron dichos polímeros siguiendo la metodología de post-
polimerización optimizada, de manera que se introdujeron puntos de 
anclaje. Tras confirmarse el co-ensamblaje de los polímeros 
modificados, se llevó a cabo el atrapamiento covalente mediante 
química CuAAC, en primer lugar y posteriormente se extendió a las 
químicas libres de cobre tiol-eno y bisulfuro. El uso de bisulfuros para 
atrapar covalentemente estas estructuras permite construir sistemas de 
gran tamaño, adecuados para aumentar los tiempos de circulación, pero 
capaces de desensamblarse bajo condiciones reductoras.  
La evaluación biológica preliminar de las estructuras atrapadas 
reveló que no son entidades toxicas (MTS) en las condiciones 
estudiadas y que son internalizadas más rápido y en mayor extensión 
que sus análogos unímeros, como se demostró mediante citometría de 
flujo. 
4.6. Diseño, síntesis y evaluación de portadores poliméricos 
capaces de atravesar la BHE (Capítulo 6).40 
 Tras la síntesis y validación de los diferentes portadores 
poliméricos descritos en los capítulos anteriores, se procedió a la 
obtención de sistemas capaces de cruzar la BHE, basando nuestras 
estrategias en el transporte activo mediante transcitosis. Para ello, se 
pensó en primera instancia en la utilización de los péptidos Angiopep-2 
(ANG)49-55 y CRTIGPCSVC (cPEP)56, 57 como vectores dirigentes. Se 
procedió a la evaluación de la plataforma polimérica de 
homopolímeros, di-bloques PEG-PGA y polímeros estrella, en cuanto a 
su capacidad como portadores para el cruce de la BHE. Para ello, se 
sintetizaron conjugados de ambos péptidos con las diferentes 
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estructuras mediante el uso de diferentes químicas de bioconjugación 
(enlace bisulfuro para ANG-2 y amida para cPEP) y se marcaron con 
DO3A-68Ga (en el caso de homo y di-bloques) y DO3A-111In (para el 
caso de polímeros estrella) para su evaluación in vivo mediante técnicas 
de imagen no invasiva (PET, en este caso). Los estudios in vivo son los 
más adecuados para evaluar la capacidad de transporte activo a través 
de la BHE, ofreciendo unos resultados más realistas y fiables. Así pues, 
se llevaron a cabo estudios de biodistribución en FVB/NJ. En todos los 
casos, se inyectaron los compuestos vía intravenosa, a la concentración 
necesaria para un nivel de señal óptimo. Una vez realizada la 
monitorización in vivo, los animales se sacrificaron y se evaluó y 
cuantificó la radioactividad en cada órgano, así como en sangre y 
plasma. La cantidad en plasma nos permitió calcular parámetros 
farmacocinéticos, incluyendo el tiempo de vida medio de los 
compuestos. De los estudios de biodistribución se pudo concluir que 
todos los polímeros testados resultaron ser biocompatibles y no se 
acumularon de forma específica en ningún órgano. Se observaron 
perfiles de eliminación renal en todos los casos. En cuanto a la 
farmacocinética, los polímeros ramificados en general (con vectores 
dirigentes y sin ellos), presentaron tiempos de vida media de entre 12-
16 horas, mucho más superiores a los obtenidos con el PGA lineal (0.59 
horas). Sin embargo, aunque los polímeros estrella mejoraron la 
acumulación en cerebro (si los comparamos con lineales o di-bloque), 
dicha acumulación encontrada resultó no ser significativa. Se pueden 
establecer diversas justificaciones frente a este hecho, entre ellas, una 
falta de exposición de los ligandos para su reconocimiento, o la 
necesidad de tiempos de circulación en sangre superiores, para 
fomentar la acumulación en cerebro. 
 Debido a los resultados obtenidos, quedó patente la necesidad 
de usar nuevas estructuras, de tamaño superior para prolongar los 
tiempos de vida media, a la vez que con superficies de conjugación 
mayores y menos impedidas, que faciliten la exposición de los péptidos 
dirigentes. Las estructuras atrapadas covalentemente, resultado de los 
procesos de auto-ensamblaje descritos en el apartado anterior, se 
presentan como posibles candidatos puesto que reúnen los requisitos 
anteriormente expuestos. Así pues, mediante una estrategia bottom-up, 
se procedió a la modificación en la superficie de dichas estructuras 
clicadas, con la sonda Cy5.5, en este caso para imagen óptica de 
fluorescencia (NIR) y con péptidos dirigentes. De entre los estudios 
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anteriores, se decidió continuar con el péptido ANG-2, puesto que los 
polímeros conjugados del mismo demostraron una mayor acumulación 
en cerebro, cuando se compararon con sus análogos de cPEP. Los 
compuestos sintetizados (con y sin vector dirigente) se analizaron in 
vivo, en términos de biodistribución en ratones C57Bl/6 (Animal 
Imaging Center, Zúrich, Switzerland). Tras su inyección intravenosa a 
través de la vena de la cola, se procedió al sacrificio de los animales a 
diferentes tiempos. La fluorescencia de la sangre y de diferentes 
órganos extraídos tras perfusión, se midió usando un MAESTROTM. En 
este caso, las nano-estructuras testadas también exhibieron perfiles de 
eliminación renal, sin la presencia de toxicidades específicas. Sin 
embargo, la cantidad obtenida en cerebro en estos casos, sí fue 
significativa, llegando a un máximo de un 1.5 % de la dosis inyectada 
para el compuesto con vectores dirigentes. Dicho resultado se encuentra 
dentro de la normalidad para un sistema donde se afirma que “cruza” la 
barrera hematoencefálica.58  
4.7. Diseño, síntesis y evaluación de portadores poliméricos 
para el tratamiento de enfermedades neurodegenerativas. 
(Capítulo 7). 
El siguiente paso fue la síntesis y caracterización exhaustiva de 
conjugados polímero-fármaco para el tratamiento del Alzheimer. Se 
decidió usar las estructuras poliméricas atrapadas covalentemente como 
portadores,  debido a los prometedores resultados previos obtenidos en 
las biodistribuciones. En el diseño de tratamientos eficaces para 
enfermedades del sistema nervioso central, la acumulación en cerebro 
es un requisito. 
Para ello, se seleccionó el curcuminoide, 
bisdemetoxicurcumina (BDMC) como fármaco modelo debido a su 
gran potencial para el tratamiento de la enfermedad del Alzheimer. En 
combinación con residuos de propargilamina, BDMC se conjugó a las 
estructuras clicadas a través de enlaces éster. Dichas estructuras se 
evaluaron in vitro en términos de viabilidad celular, perfiles de 
liberación de fármaco a diferentes pHs, y actividad in vitro como 
inhibidores de la formación de fibrillas. A fin de lograr prueba de 
concepto, la actividad de los compuestos se comprobó mediante un 
modelo aceptado basado en el uso lisozima de clara de huevo de gallina 
(HEWL) con capacidad de formar fibras. Varios conjugados de BDMC 
junto con el fármaco libre se testaron a dos concentraciones diferentes 
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(10 y 50 µM) mediante la incubación, durante 24 horas, con HEWL y 
su poder inhibidor se midió mediante el ensayo de fluorescencia de 
Tioflavina T, a diferentes tiempos. Dichos resultados se confirmaron 
adicionalmente mediante microscopía electrónica de transmisión 
(TEM) donde se observó una prevención significativa de la formación 
de fibras. De manera adicional, se estudió el carácter neuroprotector de 
un sistema clicado con BDMC en cultivos organotípicos de hipocampo 
y entorrinal.59 Para ello, se pre-trataron dichos cultivos con el 
compuesto, antes de inducir neurotoxicidad usando el péptido amiloide 
Aβ1-42. En estas condiciones, los pre-tratamientos con el compuesto, en 
concentraciones de 1 y 5 µM en equivalentes de BDMC produjeron una 
reducción significativa de la muerte celular en cultivos tratados con el 
péptido Aβ1-42. Dado que la concentración de 1 µM resultó suficiente 
para producir un efecto neuroprotector significativo sin llegar a ser 
tóxica, se seleccionó dicha concentración y actualmente se están 
llevando a cabo experimentos para elucidar los posibles mecanismos 
por los cuales estos sistemas producen efectos neuroprotectores. 
De igual forma que para las otras estructuras clicadas, se 
realizaron estudios de biodistribución con nanosistemas cargados con 
BDMC, doblemente etiquetados con las sondas DO3A-Gd3+ y Cy5.5 y 
con unidades dirigentes (Angiopep2) para el cruce de la BHE. Dichos 
estudios se realizaron en ratones C57Bl/6 mediante técnicas de imagen 
óptica de fluorescencia, usando la sonda de Cy5.5 de los portadores. 
Los perfiles de biodistribución obtenidos fueron comparables a los de 
las otras estructuras clicadas (con Angiopep2 y sin Angiopep2), con 
perfiles de excreción renal, acumulación significativa en cerebro (sobre 
1.2 % ID), y acumulación en pulmón a tiempos cortos, debido al mayor 
tamaño de estas estructuras. En resumen, los resultados obtenidos in 
vitro, junto con los estudios de biodistribución de estos compuestos 
mediante imagen óptica, ponen de manifiesto el potencial y prometedor 
uso de estas nanomedicinas para el tratamiento de Alzheimer. Además, 
cuando se administró el compuesto de manera recurrente durante dos 
semanas en animales ArcAbeta (modelo de la enfermedad), dicho 
compuesto no resultó tóxico y se encontró una gran acumulación en la 
cabeza. Estos resultados preliminares nos alientan para investigar más a 
fondo dichos compuestos, tanto in vitro (considerando nuevas dianas de 
la enfermedad donde el fármaco BDMC puede tener un impacto 
favorable), e in vivo, con modelos y diseños experimentales apropiados. 
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4.8. Diseño, síntesis y evaluación de sondas poliméricas 
inteligentes para la detección temprana de eventos moleculares 
relacionados con la enfermedad. (Capítulo 8). 
 Finalmente, y dentro del marco de un proyecto europeo con el 
acrónimo de LIVIMODE, se desarrolló una plataforma para la imagen 
in vivo, basada en el uso de sondas inteligentes activables mediante 
proteasas específicas. Dicha plataforma se desarrolló con el fin de 
permitir la cuantificación, de forma no invasiva, de la expresión de la 
proteasa diana en tejidos enfermos (diagnosis), así como la 
monitorización del progreso de la enfermedad (estado). Dichas sondas 
están basadas en la combinación de un par NIRF (Near Infrarred FRET) 
y secuencias específicas de ciertas proteasas. Tras el procesamiento por 
la enzima en cuestión, se produce la liberación del “quencher” dando 
lugar a la emisión de fluorescencia del fluoróforo. A través de la 
conjugación a los portadores poliméricos basados en PGA, se 
proporcionó especificidad tisular a las sondas sintetizadas por nuestros 
colaboradores. Se conjugaron varias sondas específicas (de MMP-9, 12 
y 13; catepsina B y S; FAP) a derivados de PGA aplicando diferentes 
químicas de bioconjugación. En resumen, los test enzimáticos 
realizados a las sondas poliméricas demostraron que dichas sondas 
mantienen e incluso mejoran su selectividad y especificidad por la 
proteasa en cuestión.  
 Los resultados preliminares in vivo, de algunos de los 
candidatos, en modelos in vivo seleccionados de nuestros 
colaboradores, claramente pusieron de manifiesto el potencial de dichas 
sondas poliméricas. Por ejemplo, en el caso de la sonda polimérica para 
MMP-13,60 se obtuvieron muy buenos resultados con respecto a su 
capacidad para la detección temprana de osteoartritis, en un modelo 
animal basado en la desestabilización del menisco medio. Por otro lado, 
las sondas poliméricas generadas para la detección de catepsina B 
demostraron un gran potencial en los estudios in vitro para su uso en la 
detección temprana de cáncer.61 
Además, dentro del proyecto se exploró el uso de vectores 
dirigentes para mejorar la especificidad tisular de las sondas generadas. 
Con respecto al uso de los conocidos péptidos de Rothenfluh para 
acumulación en cartílago, no mejoró la acumulación que el portador 
polimérico basado en PGA demostró “per se” en la rodilla lesionada del 
modelo murino de OA tras ser administrado i.v. 
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Todos los resultados anteriores ponen de manifiesto el 
potencial de los derivados de PGA para su uso en diagnóstico. Además, 
estas sondas macromoleculares representan excelentes candidatos para 
aplicaciones en “theranostics”. 
5. CONCLUSIONES. 
 Durante el desarrollo del presente trabajo, se ha conseguido 
alcanzar una serie de objetivos que lo convierten en un trabajo 
novedoso y relevante en las áreas de síntesis de polímeros, estudios de 
auto-ensamblajes así como en áreas relacionadas con sus aplicaciones 
biológicas. Así pues, se ha alcanzado: 
 -La puesta a punto de una nueva metodología versátil de 
polimerización que permite la síntesis de poliglutamatos bien definidos, 
con pesos moleculares controlados y bajas polidispersidades mediante 
una nueva aproximación vía ROP-NCA. Además, el uso de diferentes 
iniciadores permite alcanzar poliglutamatos multifuncionales de un solo 
bloque o varios, con diferentes composiciones y estructuras. De hecho, 
la reproducibilidad de esta nueva tecnología, así como la posibilidad de 
realizar escalado, ha dado lugar a la generación de una compañía Spin-
Off (Polypeptide Therapeutic Solutions S.L.). Asimismo, esta sencilla 
pero poderosa metodología se ha extendido a la síntesis de polímeros 
estrella, con numerosas aplicaciones potenciales dentro del campo de la 
biomedicina. Como colofón a la parte de desarrollo de técnicas 
sintéticas, se ha implementado una nueva metodología para la 
introducción de diversos grupos funcionales en las cadenas laterales de 
los poliglutamatos vía modificación post-polimerización. Dichas 
funcionalidades pueden ser usadas en posteriores bioconjugaciones 
dando lugar a síntesis controladas y ortogonales. 
 -El desarrollo, estudio y caracterización de nuevas estructuras 
resultado de procesos de auto-ensamblaje de poliglutamatos, inducido 
por el uso de motivos que promueven dicho ensamblaje. La estructura y 
conformación de dichas construcciones ha demostrado ser altamente 
dependiente de factores y estímulos físico-químicos, así como de la 
naturaleza de los polímeros auto-ensamblados, lo que permite una 
modulación de las mismas. Estos descubrimientos abren la puerta al 
desarrollo potencial de multitud de portadores poliméricos con 
características modulables en función de la aplicabilidad de los mismos. 
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 -El diseño, síntesis y evaluación de una plataforma de 
portadores poliméricos con diferentes arquitecturas para su uso como 
vectores para el trasporte activo a través de la BHE. Se ha desarrollado 
una familia de compuestos (con y sin vectores dirigentes hacia la BHE) 
para alcanzar un cruce significativo a través de la BHE con el fin último 
de ser usados en el tratamiento de enfermedades neurodegenerativas. 
Dentro de ellos, la tercera generación de arquitecturas, sintetizada a 
partir de estrategias ‘bottom-up’ usando las estructuras auto-
ensambladas, ha demostrado ser lo suficientemente eficaz como para 
considerarse candidatos para el ya descrito fin. 
 -El diseño, síntesis y evaluación preliminar de conjugados-
polímero fármaco con actividad neuroprotectora-neurorescatadora para 
ser usados en el tratamiento de enfermedades neurodegenerativas, en 
concreto, Alzheimer. Los primeros resultados corroboran el potencial 
de dichos conjugados, sin embargo, es necesaria una investigación en 
mayor profundidad para verificar su eficacia. 
 -El diseño, síntesis y evaluación preliminar de sondas 
poliméricas para la detección de eventos moleculares que representan 
biomarcadores para la detección temprana de ciertas enfermedades. 
Aunque se ha puesto como ejemplo el diagnóstico de cáncer u 
osteoartritis, el potencial de dichas sondas es extensible al diagnóstico 
de enfermedades neurodegenerativas. 
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APPENDIX II. TABLE OF COMPOUNDS 
REF Chemical Structure Name (Abbreviation) 
1 
 
γ-benzyl L-glutamate N-
Carboxyanhydride 
(OBzl(Glu) NCA) 
2 
 
Poly(-benzyl L-glutamate) 
(PBLG) from different 
initiators 
3  
Tetrafluoroborate n-
butylammonium salt  
(nBu-NH3BF4) 
4 
 
Tetrafluoroborate 
neopentylammonium salt 
(Npt-NH3BF4) 
5 
 
Tetrafluoroborate 
PEGammonium salt 
(MeO-PEG-NH3BF4) 
6 
 
Tetrafluoroborate 
propargylammonium salt 
(Propargyl-NH3BF4) 
7 
 
N3-EG(2)-NH3BF4 
8 
H
N
OO
N
H
O
H
n
O
m
 
Hybrid Di-block polyethylene 
glycol-co-poly(-benzyl L-
glutamate) 
(PEG-PBLG) 
9 
 
α-polyglutamic acid (PGA) 
from different initiators 
10 
 
Hybrid Di-block polyethylene 
glycol-co- polyglutamic acid 
(PEG-PGA or DB) 
11 
 
Mono-Boc cysteamine 
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12 
 
1,3,5-benzene tricarboxamide 
(BTA) based Boc protected 
NCA initiators 
13 
 
1,3,5-benzene tricarboxamide 
(BTA) based BF4 NCA 
initiators 
14 
 
Star-shaped PBLG  
(St-PBLG) from different 
initiators 
15 
 
Star-shaped PGA  
(St-PGA) from different 
initiators 
[Appendix II] 
563 
16 
 
End capped PBLG 
17 
 
17a: Poly(γ-benzyl L-
glutamate-co-N-Boc-
ethylendiamine glutamate) 
17b: Poly(γ-benzyl L-
glutamate-co-N-Boc-
hexaneamine glutamate) 
17c: Poly(γ-benzyl L-
glutamate-co-N-Boc-DOOA 
glutamate) 
18 
 
18a: Poly(γ-benzyl L-
glutamate-co-ethylendiamine 
glutamate) 
18b: Poly(γ-benzyl L-
glutamate-co-hexaneamine 
glutamate) 
18c: Poly(γ-benzyl L-
glutamate-co-DOOA 
glutamate) 
19 
 
4-(4,6-Dimethoxy-1,3,5-
triazin-2-yl)-4-methyl 
morpholinium (DMTMM) 
(19a) Cl or BF4 (19b) 
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20 
 
20a: Poly(glutamic acid-co-
propargyl glutamate) 
20b-d: Poly(glutamic acid-
co-EG(n)N3 glutamate) 
20e: Poly(glutamic acid-co-
EG(6)OMe glutamate) 
20f: Poly(glutamic acid-co-
cysteamine2TP glutamate) 
20g: Poly(glutamic acid-co-
N-Boc-ethylendiamine 
glutamate) 
20h: Poly(glutamic acid-co-
N-Boc-DOOA glutamate) 
20i: Poly(glutamic acid-co-
ethylendiamine glutamate) 
20j: Poly(glutamic acid-co-
DOOA glutamate) 
 
21 
 
Poly(glutamic acid-co-
Oregon Green glutamate) 
 
(linear-PGA-OG, St-PGA-
OG or PEG-PGA-OG) 
22 
-----------------------------------------
-----------------------------------------
----------------------------------------- 
 
D-labeled motif Boc 
Protected 
23 
-----------------------------------------
-----------------------------------------
----------------------------------------- 
 
D-labeled motif 
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24 
 
24a:X-prop 
24b:X-EG(2)N3  
24c:X-SS-2TP  
24d: X-malei 
25 
 
X covalently entrapped (X-
Click) 
25a: X-Click through 
CuAAC 
25b: X-Click through 
disulfide bonding 
25c: X-Click through thiol-
ene click chemistry 
26 
 
DO3A-tBu labeled polymers 
 
26a: PGA-DO3A-tBu 
26b: PEG-PGA-DO3A-tBu  
(DB-DO3A-tBu) 
26c: St-PGA-DO3A-tBu 
26d: PGA-PEG-DO3A-tBu  
(DB2.0-DO3A-tBu) 
26e: X-Click-DO3A-tBu 
[Appendix II] 
566 
27 
 
DO3A labeled polymers 
 
27a: PGA-DO3A 
27b: PEG-PGA-DO3A 
(DB-DO3A) 
27c: St-PGA-DO3A 
27d: PGA-PEG-DO3A  
(DB2.0-DO3A) 
27e: X-Click-DO3A 
28 
 
Radionuclide or MRI labeled 
polymers 
 
28a: PGA-DO3A-68Ga 
28b: PEG-PGA-68Ga 
(DB-DO3A-68Ga) 
28c: St-PGA-DO3A-111In 
28d: PGA-PEG-DO3A -111In 
(DB2.0-DO3A-111In) 
28e: X-Click-DO3A-111In 
28f: X-Click-DO3A-Gd3+ 
29 
 
 
29a: PGA-DO3A-tBu-SS-
2TP 
29b: PEG-PGA-DO3A-tBu-
SS-2TP 
(DB-DO3A-tBu-SS-2TP) 
29c: St-PGA-DO3A-tBu-SS-
2TP 
29d: X-Click-DO3A-tBu-SS-
2TP 
 
z
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30 
 
30a: PGA-DO3A-SS-2TP 
30b: PEG-PGA-DO3A-SS-
2TP 
(DB-DO3A-SS-2TP) 
30c: St-PGA-DO3A-SS-2TP 
30d: X-Click-DO3A-SS-2TP 
 
31 
 
31a: PGA-DO3A-ANG 
31b: PEG-PGA-DO3A-ANG 
(DB-DO3A-ANG) 
31c: St-PGA-DO3A-ANG 
31d: X-Click-DO3A-ANG 
 
32 
 
32a: PGA-DO3A-tBu-N-
Boc-ethylendiamine 
32b: PEG-PGA-DO3A-tBu-
N-Boc-ethylendiamine 
(DB-DO3A-tBu-N-Boc-
ethylendiamine) 
32c: St-PGA-DO3A-tBu-N-
Boc-ethylendiamine 
 
[Appendix II] 
568 
33 
 
33a: PGA-DO3A-
ethylendiamine 
33b: PEG-PGA-DO3A-
ethylendiamine 
(DB-DO3A-ethylendiamine) 
33c: St-PGA-DO3A-
ethylendiamine 
 
34 
AC-CRTIGPSVC-NHS 
(disulfide bridge within) 
CPEP NHS 
35 
 
35a: PGA-DO3A-cPEP 
35b: PEG-PGA-DO3A-cPEP 
(DB-DO3A-cPEP) 
35c: St-PGA-DO3A-cPEP 
 
36 
 
36a: PGA-DO3A-68Ga-ANG 
36b: PEG-PGA-DO3A-68Ga-
ANG 
(DB-DO3A-68Ga-ANG) 
36c: St-PGA-DO3A-111In-
ANG 
36d: X-Click-DO3A-111In-
ANG 
 z
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37 
 
37a: PGA-DO3A-68Ga-cPEP 
37b: PEG-PGA-DO3A-68Ga-
cPEP 
(DB-DO3A-68Ga-cPEP) 
37c: St-PGA-DO3A-111In-
cPEP 
 
38 
 
38a: PBLG-PEG-OMe 
38b: PBLG-PEG-FMOC 
37c: PBLG-PEG-SS-4TP 
39 
 
39a: PGA-PEG-OMe  
(DB2) 
39b: PGA-PEG-FMOC  
(DB2-FMOC) 
39c: PGA-PEG-SS-4TP  
(DB2-SS-4TP) 
40 
 
40a: PGA-PEG-DO3A-tBu  
(DB2-DO3A-tBu) 
40b: PGA-PEG-SS-4TP-
DO3A-tBu  
(DB2-SS-4TP DO3A-tBu) 
40c: PGA-PEG-FMOC-
DO3A-tBu  
(DB2-FMOC DO3A-tBu) 
40d: PGA-PEG-DO3A-tBu-
cPEP  
(DB2 DO3A-tBu-cPEP) 
z
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41 
 
41a: PGA-PEG-DO3A  
(DB2-DO3A) 
41b: PGA-PEG-SS-4TP-
DO3A 
(DB2-SS-4TP DO3A) 
41c: PGA-PEG- DO3A-ANG  
(DB2-DO3A-ANG) 
41d: PGA-PEG-DO3A-cPEP  
(DB2 DO3A-cPEP) 
 
42 
 
42a: PGA-PEG-DO3A-111In  
(DB2-DO3A-111In) 
42b: PGA-PEG-DO3A-111In-
ANG  
(DB2-DO3A-111In-ANG) 
42c: PGA-PEG-DO3A-111In-
cPEP  
(DB2 DO3A-111In-cPEP) 
 
43 
 
X-Click-
DO3A-
tBu-
Cy5.5 
44 
X-Click-
DO3A-
Cy5.5 
45 
 
X-Click-
DO3A-
Gd3+-
Cy5.5 
46 
X-Click-
DO3A-
tBu-SS-
2TP 
47 
 
X-Click-
DO3A-
tBu-SS-
2TP-
Cy5.5 
48 
 
X-Click-
DO3A-
SS-2TP-
Cy5.5 
z
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49 
 
X-Click-
DO3A-
Cy5.5-
ANG 
50 
 
X-Click-
DO3A-
Gd3+-
Cy5.5-
ANG 
51 
------------------- 
------------------- 
X-BDMC 52 
------------------
------------------ 
X-
EG(2)N3-
BDMC 
53 
X-
BDMC-
Click 
(capture 
after 
BDMC 
linking) 
54 
X-Click-
BDMC 
(capture 
before 
BDMC 
linking) 
55 
X-Click-
BDMC-
DO3A 
 
56 
X-Click-
BDMC-
DO3A-
SS-2TP 
 
57 
 
X-Click-
BDMC-
DO3A-
SS-2TP-
Cy5.5 
 
58 
 
X-Click-
BDMC-
DO3A-
Cy5.5-
ANG 
 
59 
 
X-Click-
BDMC-
DO3A-
Gd3+-
Cy5.5-
ANG 
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SP 
 
Compound Probe type Spacer 
Linking 
chemistry (X-Y) 
SP.1 MMP-12 in vitro CH2 CuAAC 
SP.2 MMP-12 in vitro EG(6) CuAAC 
SP.3 MMP-12 in vitro EG(2) CuAAC 
SP.4 MMP-12 in vivo EG(6) CuAAC 
SP.5 MMP-12 in vivo EG(2) CuAAC 
SP.6 MMP-12 in vivo EG(6) CuAAC 
SP.7 MMP-12 in vivo EG(9) CuAAC 
SP.8 MMP-9 in vitro - COOH/NH2 
SP.9 MMP-9 in vitro EG(6) CuAAC 
SP.10 MMP-9 in vivo EG(6) CuAAC 
SP.11 MMP-9 in vivo EG(6) CuAAC 
SP.12 MMP-9 in vivo EG(6) CuAAC 
SP.13 MMP-9 in vivo EG(6) CuAAC 
SP.14 MMP-13 in vivo EG(6) CuAAC 
SP.15 Cat B in vitro EG(6) CuAAC 
SP.16 Cat B in vivo EG(6) CuAAC 
SP.17 Cat S in vitro - COOH/NH2 
SP.18 Cat S in vitro EG(4) COOH/NH2 
SP.19 Cat S in vitro (CH2)2 Thiol-ene 
SP.20 Cat S in vivo (CH2)2 Thiol-ene 
SP.21 FAP in vitro EG(6) CuAAC 
SP.22 FAP in vitro EG(6) CuAAC 
SP.23 FAP in vivo EG(6) CuAAC 
SP.24 FAP in vivo EG(6) CuAAC 
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CT 
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APPENDIX III. SUPPLEMENTARY INFORMATION. 
CHAPTER 2. 
a) 
 
b) 
 
Figure S1. a) 1H-NMR example in DMSO-d6 of Npt-NH3BF4 initiator 
(4). b) 19F-NMR example in DMSO-d6 of Npt-NH3BF4 initiator (4).  
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a) 
 
b) 
 
Figure S2. a) 1H-NMR example in DMSO-d6 of MeO-PEG(2000)-
NH3BF4 initiator (5). b) 19F-NMR example in DMSO-d6 of MeO-
PEG(2000)-NH3BF4 initiator (5). 
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CHAPTER 3. 
a) 
 
b) 
 
Figure S3. NMR spectra of 1,3,5-tri-tert-
butyl((benzenetricarbonyltris(azanediyl)tris(hexane-1,6-diyl)) 
tricarbamate (12b). a) 1H-NMR in DMSO-d6; b) 13C-NMR in CDCl3. 
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a) 
 
b) 
 
Figure S4. NMR spectra in CDCl3 of 1,3,5-tri-tert-butyl 
((((((benzenetricarbonyltris(azanediyl)) tris(ethane-2,1-
diyl))tris(oxy))tris(ethane-2,1-diyl))tris(oxy))tris(ethane-2,1-
diyl))tricarbamate (12c). a) 1H-NMR; b) 13C-NMR. 
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Figure S5. 1H-NMR spectrum of 1,3,5-tri-tert-butyl 
((((benzenetricarbonyltris(azanediyl))tris(ethane-2,1-
diyl))tris(disulfanediyl)) tris(ethane-2,1-diyl))tricarbamate (12d) in 
acetone-d6.  
a) 
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b) 
 
c) 
 
Figure S6. NMR spectra in D2O of 1,3,5-
(benzenetricarbonyltris(azanediyl))trishexan-1-ammonium BF4 salt 
(13b). a) 1H-NMR; b) 13C-NMR; c) 19F-NMR 
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a) 
 
 
b) 
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c) 
 
Figure S7. NMR spectra in D2O of 1,3,5-
(((((benzenetricarbonyltris(azanediyl))tris(ethane-2,1-
diyl))tris(oxy))tris(ethane-2,1-diyl))tris(oxy))triethanammonium BF4 
salt (13c). a) 1H-NMR; b) 13C-NMR; c) 19F-NMR. 
 
Figure S8. NMR spectra in D2O of 1,3,5-
benzenetricarbonyltris(azanediyl))tris(ethane-2,1-
diyl))tris(disulfanediyl))triethanaminium BF4 salt (13c). a) 1H-NMR; b) 
13C-NMR; c) 19F-NMR. 
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CHAPTER 4.  
 
Figure S9. Poly(γ-benzyl L-glutamate-co-N-Boc-DOOA glutamate) 
(17c) characterization. 1H-NMR spectrum in CDCl3 with the 
corresponding assignments. GPC trace in DMF/LiBr is shown in the 
rectangle. 
 
Figure S10. Poly(γ-benzyl L-glutamate-co-N-Boc-hexaneamine 
glutamate) (17b) characterization. 1H-NMR spectrum in CDCl3 with 
the corresponding assignments. GPC trace in DMF/LiBr is shown in the 
rectangle. 
